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Abstract 
 
Abstract 
Human placental villi are covered by a layer of trophoblast epithelia in direct contact 
with maternal blood, which exist in a constant steady-state of turnover and renewal 
ensuring both maternal and fetal health. The process of trophoblast turnover involves 
proliferation, differentiation and fusion of cytotrophoblast cells to form a terminally 
differentiated outer syncytiotrophoblast layer which functions as the active transport 
compartment between mother and fetus. Alterations in the balance between these three 
processes are thought to diminish both the structural and functional integrity of the 
syncytiotrophoblast, potentially leading to placental insufficiency associated with severe 
complications of pregnancy such as pre-eclampsia (PET), intrauterine growth restriction 
(IUGR) and sudden infant death syndrome (SIDS).  
 
Placentas from early (<32 weeks) and late-onset (>33 weeks) pregnancies complicated 
by PET, IUGR, SIDS and gestational age-matched controls were systematically uniform 
randomly sampled to assess the morphological basis of placental villous structure and 
trophoblast turnover (villi, cytotrophoblast, syncytiotrophoblast, apoptotic syncytial 
knots) using unbiased stereological techniques (volumes and numbers). Villous 
cytotrophoblast proliferation was assessed using double immunohistochemistry for 
Ki67 and cytokeratin 7 (CK-7). 
 
Severe early-onset IUGR placentas (n=5) were smaller displaying significant reductions 
in the total number of CT cells, within which the density of proliferating CT was further 
reduced by 50%. Syncytiotrophoblast volume and number was significantly reduced 
with an increase in apoptotic syncytial knots. Late-onset IUGR placentas (n=4) also 
displayed significant reductions in the total number of CT and proliferating CT, but 
were not associated with changes in the density of proliferating CT. SCT numbers were 
significantly reduced with an increase in apoptotic knots.  
 
Placentas from severe early-onset PET (n=11) were similar to preterm controls, except 
for a significant increase in apoptotic syncytial knots. However, late-onset PET (n=6) 
displayed a significant decrease in total CT number, the percentage of which 
undergoing proliferation was significantly increased for structural villi. There were 
increased numbers of apoptotic syncytial knots in peripheral villi.   
Abstract 
 
SIDS-NBW (n=12) and SIDS-LBW (n=12) placentas displayed significant increases in 
the volume density of cytotrophoblast cells, syncytiotrophoblast nuclei and apoptotic 
syncytial knots when compared to term controls (n=12). 
 
These data suggest that IUGR placentas have a severe impairment in the regenerative 
capacity of the villous trophoblast population which may contribute to its small 
placental phenotype, whilst PET is able to maintain overall placental growth with subtle 
alterations in villous trophoblast turnover. SIDS may represent postnatal sequelae of 
placental adaptation to an unfavourable intrauterine environment during early gestation.  
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1 Placental Insufficiency Syndromes 
Pre-eclampsia (PET) and intrauterine growth restriction (IUGR) are broadly defined as 
“placental insufficiency syndromes”, implying that placental development is, in some 
way, inadequate to sustain the health of both mother and infant, but may also have 
severe postnatal consequences i.e. Sudden Infant Death Syndrome (SIDS). Abnormal 
placentation in the first trimester is thought to underpin PET and IUGR, which are 
associated with maldevelopment of the gas-exchanging villi and its accompanying fetal 
vasculature. It is the under-development of these structures that underpins the placental 
pathology of IUGR (1; 2), whilst failure to maintain the villous epithelial layer is 
associated with the maternal symptoms of PET (3). Crucially, these pathological 
abnormalities are thought to arise at the level of the villous trophoblast. The aim of the 
present study is to assess the morphological basis of villous trophoblast turnover in 
placentas from PET, IUGR and SIDS.  
 
1.1 Pre-eclampsia 
Pre-eclampsia still remains one of the leading contributors to maternal and perinatal 
morbidity and mortality and the World Health Organization estimates that over 160,000 
women die from PET each year (4). Pre-eclampsia is a multisystem disorder unique to 
human pregnancy affecting between 5-10% of all births and is diagnosed by the sudden 
onset of hypertension and proteinuria arising de novo after 20 weeks gestation, and is 
characterized by systemic maternal inflammatory response and diffuse endothelial 
dysfunction, leading to damage of various organs including kidneys, lungs and heart, 
and often results in life-long complications (5). Furthermore, approximately 4 million 
babies are born IUGR due to PET (6).  
 
Although PET is the most extensively studied clinical condition in pregnancy, its cause 
still largely remains unclear, but it is generally accepted that the placenta is both 
necessary and sufficient to cause the disorder; pre-eclampsia can occur in the absence of 
a fetus (hydatidiform mole pregnancy) (7) and uterus (abdominal pregnancy) (8), 
supported by the prompt resolution of the disorder upon delivery of the placenta, which 
is the only known cure at present.  
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1.1.1 Definition and Classification 
Pre-eclampsia is a hypertensive disorder of pregnancy defined by the American College 
of Obstetrics and Gynaecology (ACOG) as “new onset of hypertension on two separate 
occasions with proteinuria arising de novo after the 20th week of pregnancy in a 
previously normotensive non-proteinuric woman” (9).  
 
The clinical expression of pre-eclampsia is further subdivided according to the severity 
(mild or severe) indicating the extent of proteinuria and hypertension. Gestational 
hypertension is defined as an elevation in blood pressure ≥ 140/90 mm Hg or higher 
after 20 weeks gestation in a woman with previously normal blood pressure. Only in the 
presence of ≥0.3g of protein in a 24 hour urine specimen, or 1+ proteinuria, classifies 
the hypertension as mild pre-eclampsia. Pre-eclampsia may also be ‘superimposed’ in 
women with pre-existing chronic hypertension i.e. hypertension with or without 
proteinuria diagnosed prior to, during or after pregnancy (10). 
 
Severe pre-eclampsia is defined as an elevation in blood pressure ≥ 160/110 mm Hg or 
higher on two occasions at least six hours apart after 20 weeks gestation with at least 5g 
of protein in a 24 hour urine specimen (3+ proteinuria). Additionally, the presence of 
any signs of maternal organ failure such as HELLP syndrome (haemolysis, elevated 
liver enzymes, and low platelet count), edema, headache, epigastric pain, or eclampsia 
(convulsions), classifies a severely pre-eclamptic woman. Furthermore, the presence of 
a growth restricted fetus (IUGR) classifies pre-eclampsia as severe (9). 
 
Gestational age (GA) is the most important clinical determinant of maternal and 
perinatal outcome and pre-eclampsia is associated with different maternal-fetal 
outcomes depending on its timing-of-onset (early-onset ≤ 34 weeks or late-onset ≥ 35 
weeks) (11). Late-onset pre-eclampsia represents about 80% of all pre-eclampsia cases 
worldwide, and whilst it may present with comparable maternal severity to early-onset, 
it is usually associated with normal (12) or heavier fetal birthweight (13) and therefore 
IUGR does not often co-exist; there is a 50% chance of fetal survival if the fetus is 
delivered > 27 weeks gestation or with a birthweight > 600g (14). In comparison, early-
onset disease (representing 5-20% depending on the statistics (15)) involves 
considerable overlap, whereby pre-eclampsia and IUGR requiring preterm delivery 
often co-exist (16). Because early-onset pre-eclampsia is associated with a 20-fold 
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increase in maternal mortality compared to its late-onset phenotype, it has been 
suggested that early-onset pre-eclampsia represents a different disease to that presenting 
at term (11). 
 
1.1.2 Etiology and Pathophysiology 
The severe pre-eclamptic woman is associated with hypoperfusion and damage of 
various vital organs including the kidneys, liver, brain and heart, which in the most 
severe cases, can result in multi-organ failure or ‘eclamptic’ convulsions (5). These 
pathological changes are due to systemic vasoconstriction resulting from an increased 
sensitivity to pressor agents and activation of the intravascular coagulation cascade, 
secondary to diffuse endothelial dysfunction and a systemic maternal inflammatory 
response- accountable for the clinical syndrome i.e. hypertension and proteinuria. The 
underlying etiological factors responsible for the systemic disease are thought to be 
initiated by the placenta. 
 
In an attempt to describe the pathophysiology of pre-eclampsia, Redman put forward a 
Two Stage Model (17) (Figure 1-1), forming a widely accepted hypothesis within the 
placental scientific community. This model proposes that a poorly perfused placenta, 
secondary to failed spiral artery remodelling in the first trimester of pregnancy, (Stage 
1) produces factor(s) which lead to the maternal syndrome of pre-eclampsia in the third 
trimester (Stage 2) (17; 18).  
 
The link between Stage 1 and Stage 2 remains the ‘holy grail’ of placental research. 
Several placentally-derived factors have been suggested which are thought to lead to 
endothelial dysfunction and systemic inflammatory response leading to 
vasoconstriction. These include pro-inflammatory cytokines (tumour necrosis factor 
(TNF-α) (19; 20), endothelin (ET-1), interleukins (IL-6 and IL-8) (21), anti-angiogenic 
factors (21; 22), syncytiotrophoblast microparticles (STBM) (23), and anti-coagulant 
factors (thrombodulin and von Willebrand factor) and adhesion molecules (VCAM-1, 
ICAM-1 and  E-selectin) (24), which have been shown to be increased in pre-eclamptic 
women. Oxidative stress is an attractive component as part of the linkage (20; 25) which 
would also stimulate release of cytokines, anti-angiogenic factors, microparticles and 
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other potential linkers, many of whose systemic effects would also be mediated by 
oxidative stress (23; 26; 27).   
 
 
Figure 1-1 Two Stage Model of pre-eclampsia 
In the Two Stage Model, reduced placental perfusion in the first trimester (Stage 1) leads to endothelial 
dysfunction which characterises the maternal syndrome of PET in the late second and third trimester of 
pregnancy (Stage 2) (adapted from (17)). 
 
Anti-angiogenic growth factors released by the placenta have received much attention 
as one of the primary causes of endothelial dysfunction in pre-eclampsia providing a 
direct link between Stage 1 and 2 in the pathophysiology of the disease (18). Several 
studies have demonstrated increased circulating levels of placental soluble fms-like 
tyrosine kinase 1 (sFlt1) in serum from pre-eclamptic women (22; 28; 29). SFlt1 is a 
secreted splice variant of Flt1 that antagonizes the potent angiogenic growth factors, 
vascular endothelial growth factor (VEGF) and placental growth factor (PGF), from 
binding and activating endothelial cells of the maternal vascular endothelium. 
Expression of these growth factors has been shown to be subsequently decreased in pre-
eclamptic women (30; 31), suggesting that this imbalance between pro- and anti-
angiogenic factors may result in a prolonged ‘anti-angiogenic state’ in the pre-eclamptic 
woman leading to endothelial dysfunction. Furthermore, when injected into pregnant 
rats, sFlt1 is able to induce pre-eclamptic symptoms including hypertension, proteinuria 
and renal damage, and therefore sFlt1 may play a considerable role in mediating pre-
eclampsia (22). Soluble endoglin is also proving to be another potential pathogenic anti-
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angiogenic protein and predictive marker since its expression is also elevated in women 
who subsequently develop pre-eclampsia (32; 33).  
 
The Two Stage Model was recently challenged by Huppertz, suggesting that pre-
eclampsia has its origins in the first trimester prior to failed transformation of the 
maternal spiral arteries takes place (15). This is supported by the presence of 
placentally-derived proteins (i.e. placental protein 13 (PP13)) (34), long pentraxin 
(PTX3) (35), placenta associated plasma protein A (PAPP-A)) in maternal serum as 
early as 7-8 weeks gestation in those pregnancies that subsequently developed pre-
eclampsia (36). However, failed transformation of the maternal spiral arteries, posited to 
result in reduced placental perfusion, is also observed in pregnancies resulting in IUGR 
without clinical signs of pre-eclampsia and in preterm birth (37). Furthermore, abnormal 
placental protein release is also present in some IUGR pregnancies (i.e. placental 
protein 13 (PP13) (34), long pentraxin 3 (PTX3) (35)), suggesting that these factors 
alone are not sufficient for developing pre-eclampsia (38; 39).  
 
This led to the concept that maternal predisposing factors i.e. genetic, behavioural and 
environmental, modified by the physiological changes of pregnancy were necessary to 
interact with reduced placental perfusion leading to the maternal abnormalities of pre-
eclampsia. Today, the prevailing view is that pathophysiological changes occurring in 
the placental unit begin well before the clinical symptoms; the onset, severity and 
progression of which is related to the maternal response to the underlying pathology. 
Furthermore, many of these factors leading to the maternal syndrome are risk factors for 
cardiovascular disease in later life (39).  
 
1.2 Intrauterine Growth Restriction 
In humans, a newborn may be small for a variety of reasons, and amongst the 
mammalian species, humans have the largest variation in birthweights compatible with 
survival. There are certain overt maternal and fetal factors that may lead to, or are 
strongly associated with poor fetal growth in utero (40; 41). However, there are a group 
of healthy yet ‘small infants’ delivered after an apparently uncomplicated pregnancy 
who are karyotypically and phenotypically normal; this is the small for gestational age 
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infant (SGA) i.e. they are constitutionally small (42). Significantly however, a 
proportion of these fetuses will be intrauterine growth restricted (IUGR) (40).  
 
IUGR is characterized by failure of a fetus to reach its full growth potential as a result 
of suboptimal intrauterine growth conditions (43). IUGR complicates 3-10% of 
pregnancies and 20% of stillbirths are IUGR; perinatal mortality is 5-20 times greater 
for IUGR infants than those infants who are appropriate for gestational age (44). 
Examples of neonatal complications include hypoglycemia, hypoxemia leading to 
polycythemia, hypocalcaemia, pulmonary haemorrhage, hypothermia and toxaemia 
(40). These fetuses are also at an increased risk of significant life-long complications 
such as diabetes, hypertension and cardiovascular disease (45; 46).  
 
1.2.1 Defining an IUGR infant 
IUGR is an important clinical problem and it is therefore necessary for the clinician to 
distinguish between fetuses that are small but otherwise healthy (i.e. constitutionally 
small and not growth restricted) and those that are a consequence of an abnormal 
condition i.e. placental insufficiency. Accurately defining an IUGR infant from an 
apparently healthy infant is therefore crucial to lowering the perinatal and adult 
morbidity and mortality. 
 
At present there is no internationally accepted clinical definition for IUGR (47). The 
classic definition refers to “an infant with a birthweight equal to or less than the 10th 
percentile for gestational age” (40), which in other words, refers to an infant weighing 
less than 90% of the population for gestational age. Population based growth charts 
should be used (in conjunction with an accurately determined gestational age) that are 
adjusted for modifiable factors such as gender, previous births, maternal height, weight 
and ethnicity, all of which are known to influence birthweight (48). 
 
An SGA infant is defined as having a birthweight below a given percentile (usually the 
10th) for gestational age (42). Hence, the above definition for IUGR also includes those 
SGA infants at the extreme lower end of the birthweight spectrum; as many as 70% of 
infants who weigh below the 10th centile for gestational age are constitutionally small 
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(49) and are not at high risk of adverse perinatal outcome. Using this definition on the 
other hand, not all SGA infants will be IUGR. 
 
Birthweight alone should not therefore be used as an indicator of the fetal growth 
trajectory, since it merely represents the result of the growth process itself, and not the 
function (i.e. the fetal growth pattern). For example, an SGA infant grows along a 
consistent albeit lower growth percentile throughout gestation compared to those infants 
born with a birthweight appropriate for gestational age (AGA). An IUGR infant on the 
other hand may grow along the same percentile as an AGA or SGA fetus, but only 
when fetal demands outweigh those of placental supply in the third trimester will the 
infant deviate from its predefined growth trajectory. The severity, duration and nature of 
the insult will determine the extent of the deviation and hence, perinatal survival.  
 
1.2.2 Classifying an IUGR infant 
Birthweight is also generally reflected in longitudinal growth of the fetus, and it has 
been suggested that alterations in the fetal growth pattern at different developmental 
stages will lead to different neonatal phenotypes (50; 51). The common classifications 
are Type I (symmetrical) and Type II (asymmetrical) growth restriction (41).  
 
The asymmetric type of growth restriction develops when oxygen or substrate supply to 
the fetus is reduced during the last trimester of pregnancy due to a reduced functional 
capacity of the placenta i.e. placental insufficiency. These infants display a relatively 
normal head size due to brain sparing in which blood flow is redistributed at the 
expense of the liver, muscle and fat so as to preserve the vital organs. As a result, these 
neonates exhibit scrawny limbs due to decreased muscle mass and thinned skin due to 
decreased body fat (40). This is the most frequent type of growth retardation and is of 
clinical relevance as it is progressive and from the view of the fetus, of an extrinsic 
origin; it might induce intrauterine death and stillbirth (41).  
 
In contrast, in symmetrical growth restriction, the reduction in birthweight is usually 
proportional to reductions in length and head size at birth (51), and is thought to be of 
intrinsic origin present in early gestation. The fact that the growth of the head, femur 
and abdomen is equally affected might lead to a wrong assessment when determining 
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GA by ultrasound. Due to an intrinsic fetal problem, cell division and cell growth is 
limited and independent of substrate supply (41). However, it is likely that Type I and 
Type II phenotypes represent a continuum between the two.  
 
1.2.3 Etiology 
Unlike pre-eclampsia, there are numerous recognized environmental, maternal and 
placental causal factors that may result in an IUGR fetus (Table 1-1). However, in at 
least 40% of all cases of babies born low birthweight, no underlying pathology can be 
identified; in the case of prematurity, which has significant overlap with IUGR, this 
percentage increases to 60–70% (41).  
 
Maternal factors for the risk of IUGR cover approximately 40% of the determinants of 
fetal birthweight. Quantitatively, pregnancy-associated hypertension and/or pre-
eclampsia are the most important maternal factors influencing fetal growth; interestingly 
however a pre-existing hypertensive disorder does not increase the risk of IUGR. The 
most important environmental factor conferring a risk of IUGR is maternal cigarette 
smoking during pregnancy, in which 40% of IUGR infants are born to mothers who 
smoke, and is correlated in a dose-dependent manner. Because fetal causes such as 
congenital abnormalities are relatively rare, any abnormality occurring in the fetal-
placental unit therefore has the capacity to limit fetal growth leading to IUGR (41). 
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Table 1-1 Etiological factors for IUGR 
Maternal/Medical complications Environmental factors 
Hypertension, pre-eclampsia 
Severe chronic infections (inflammatory bowel 
disease, malaria, etc.) 
Hypoxia (asthma,, cyanotic heart disease) 
Other severe diseases (diabetes, 
glomerulonephritis, collagen disease,  
Uterus abnormalities 
Infections 
Viral (TORCH) 
Bacterial (syphilis) 
Protozoal (malaria, toxoplasma) 
Smoking 
Alcohol 
Drugs (antimetabolites, anticoagulants, 
anticonvulsants) 
Narcotics 
High altitude 
Low socioeconomic status  
 
Other conditions Genetic 
Ethnicity 
Pre-pregnancy weight, maternal height 
Pregnancy weight gain 
Prior low-birth-weight infant 
Low maternal age 
Reproductive technologies 
 
Placental abnormalities 
Chromosomal mosaicism 
Infarcts, focal lesions 
Abnormal placentation (placental praevia, placental 
insufficiency) 
Reduced placental blood flow 
 
Chromosomal abnormalities 
Autosomal trisomies, monosomies, deletions 
Errors of metabolism (inborn) 
Malformations 
Cardiovascular defects 
Gastrointestinal defects 
Genitourinary defects 
Skeletal dysplasias, etc. 
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1.3 Sudden Infant Death Syndrome  
Infants born from pre-eclamptic and/or IUGR pregnancies are at an increased risk of 
succumbing to Sudden Infant Death Syndrome (SIDS) (52-55). SIDS refers to the 
unexplained death of an infant between 1 month and 1 year of age and despite the recent 
decline in incidence rates (i.e. the Back to Sleep Campaign (56)), SIDS still remains the 
leading cause of postnatal infant death in industrialized countries (57-59). Furthermore, 
women whose first infant died from SIDS are 2 to 3 times more likely to have a preterm 
delivery or SGA infant in their next pregnancy (52-55).  
 
1.3.1 Definition 
SIDS refers to the unexplained death of an infant. SIDS infants are not associated with 
any overt clinical and/or pathological findings on post-mortem examination. This 
initially led to the misleading assumption that all SIDS infants were normal; judging by 
its close association with obstetric complications, it is likely that not all SIDS victims 
are in fact ‘normal’. Diagnosing SIDS is therefore based on the exclusion of other 
causes of fetal death, such that SIDS is currently defined as “ the death of an infant 
under one year of age which remains unexplained after a thorough investigation, 
including the performance of a complete autopsy, examination of the death scene, 
review of the clinical history, and bacteriology and virology” (60).  
 
1.3.2 Epidemiology 
There are numerous maternal, fetal and environmental factors which may predispose an 
infant to succumb to SIDS (61). Prone sleeping position (infants placed on their front to 
sleep) and cigarette smoking are perhaps the most recognized risk factors for a SIDS 
event, shown by the rapid decline in SIDS events (from 49% in 1980 to 25% in 1999) 
following the public campaign in England and Wales to change the infants sleeping 
position from prone to supine (placing the infant on its back) (62). The majority of SIDS 
events occur at night and during the early hours of the morning, with a peak incidence 
of between 4 and 6 months of postnatal life, which indirectly suggests circadian rhythm 
as a possible contributory pathomechanism for a SIDS event (63). Other risk factors 
include males, multiple pregnancies (also a risk for pre-eclampsia and IUGR), 
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prematurity, low birthweight, low socio-economic status, drug abuse during pregnancy 
and viral/bacterial infections (64; 65).  
 
The first evidence that SIDS may also comprise a genetic component came in 1987 
when twin boys simultaneously succumbed to SIDS within 3 to 4 hours after a 
vaccination against diphtheria-tetanus-pertussis (DTP) (66). More recently, some SIDS 
infants have been shown to display a polymorphism in the IL-10-592*A allele which is 
an important anti-inflammatory anti-immune cytokine, hence it was postulated that 
some SIDS events may result from a genetically determined imbalance in pro- and anti-
inflammatory cytokines, supported by the fact that these particular SIDS infants display 
reduced IL-10 production (67-69).  
 
1.3.3 Pathophysiology 
Rather than a specific disease process SIDS represents a heterogeneous entity. In an 
attempt to explain the pathophysiology of SIDS, Filiano and Kinney (1994) put forward 
the “Triple Risk Hypothesis”. This model proposes that the unexpected death of an 
infant occurs during a lethal situation, when 1) a vulnerable infant is exposed to 2) 
external risk factors during 3) a critical period of physiological development (70; 71).  
 
The concept of a vulnerable infant comes from microscopical and biochemical studies 
into the central nervous system (CNS) (72), cardiovascular system (73) and brain (74-
76) showing that some but not all SIDS infants have neurological, cardiovascular and 
CNS abnormalities. These are postulated to prevent/overwhelm the compromised infant 
from executing normal arousal mechanisms to environmental external stressors, usually 
relating to a hypoxic insult (i.e. cigarette smoking, sleeping prone) (64).  
 
External stressors include viral infections/bacterial toxins, inflammation, biochemical 
disorders and genetic abnormalities, which are thought to be some of the 
pathomechanisms that could be responsible for a SIDS event (64). Autopsy findings 
have revealed evidence of fetal hypoxia prior to death (i.e. increased levels of fetal 
hemoglobulin, immunoglobulins) (166). Several authors believe that SIDS may be a 
predominantly pathophysiologic reaction to bacterial toxins, viruses and/or cigarette 
smoke during the early stages of development in utero when the defence mechanisms of 
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the organs are less effective (63; 64; 77). This is based on the observation that a large 
proportion of SIDS infants exhibit two or more bacteria or viruses on autopsy (78).  
 
However, because not all SIDS infants display the above abnormalities, such changes 
may not necessarily result in a SIDS event, and thus there are likely to be other 
intrinsic/extrinsic factors involved in the context of the triple risk hypothesis. On the 
other hand, these infants may be more vulnerable compared to other SIDS infants i.e. 
varying degrees of vulnerability. 
 
Recently, microscopic investigations using stereological analysis revealed that although 
SIDS infants may appear clinically normal upon pathological analysis, some infants are 
in fact developmentally compromised and are associated with abnormalities in many of 
their organs that are critical for survival ex utero including the lung, kidney, diaphragm, 
phrenic nerve and brain (73; 79; 80). Similar developmental abnormalities are also seen 
in organs from infants who are growth restricted and as such, SIDS and IUGR are 
intricately linked; approximately twice the number of infants who die from SIDS have a 
birth weight below the 10th centile for gestational age (55; 81), hence an IUGR infant is 
twice as likely to die from SIDS. These developmental abnormalities occurring in utero 
may therefore place the infant under increased physiological demand postnatally, and 
when combined with external stressors during a critical developmental period, the 
vulnerable infant may succumb to sudden and unexpected death.  
 
Similar to pre-eclampsia and IUGR, it can be hypothesised that the origin of these 
developmental abnormalities is placental insufficiency (82). Given that fetal 
organogenesis takes place in utero which cannot be compensated for postnatally, any 
detrimental insult occurring in the transfer capacity of the placenta may potentially lead 
to delayed or arrested fetal organogenesis in utero placing the compromised infant at 
risk of SIDS. As such, abnormalities in both placental villous and vasculature are 
observed in both SIDS-NBW and SIDS-IUGR infants, indicating a possible effect of 
SIDS independent of birthweight (82).  
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1.4 Current Placental Hypothesis 
Although the clinical manifestations of pre-eclampsia and IUGR are not evident until 
the second half of pregnancy, early defects in implantation and placentation during the 
first trimester, resulting in defective uteroplacental blood flow in the second and third 
trimester, are thought to underpin the pathological processes of these placentally-
mediated diseases. Despite this common etiology, the placental villi of pre-eclampsia 
respond completely differently to the small, maldeveloped villi characteristic of 
normotensive IUGR. Crucially, this divergence is now thought to result from defects in 
proper differentiation of the trophoblast cell lineage.  
 
1.4.1 Placental Development in Humans 
1.4.2 The Human Placenta 
Successful pregnancy is completely dependent upon successful placental development, 
without the placenta, pregnancy is not viable. Human gestation lasts an average of 40 
weeks and during this time the placenta acts as the only organ of exchange between the 
mother and the fetus, providing nutrition (glucose, amino acids), respiration (oxygen, 
carbon dioxide) and excretion (waste products) (83). The specialized cells of the 
placenta, derived from the trophoblast lineage, are responsible for the production and 
regulation of proteins, peptides and hormones which are necessary for both its own 
growth, but also that of the fetus. The human placenta thus represents a self-sufficient, 
self-renewing organ capable of modulating its own growth and function whilst assisting 
that of the developing fetus.  
 
Placental development is designed to anticipate the exponential growth of the fetus via 
an adequate supply of oxygen and nutrients from maternal blood throughout gestation. 
The human placenta therefore functions as a fetomaternal organ with two components, 
the fetal portion (chorion frondosum) and the maternal portion (decidua basalis) (Figure 
1-2). During the first and second trimester of pregnancy, the placental villi proliferate 
and differentiate to establish both the uteroplacental (anchoring villi), and fetoplacental 
(floating villi) circulations within the villous trees, which is achieved via cells from the 
trophoblast lineage. Floating villi comprise an elaborate network of specialized ‘tree-
like’ structures that are responsible for all fetoplacental exchange; these are the 
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chorionic villi which emerge from the fetal chorionic plate (fetal surface) and float in 
the intervillous space (IVS) filled with maternal blood (84).  
 
Each villus comprises an outer epithelial trophoblast layer (the villous trophoblast) and 
a central core of fetal vascular endothelium (connected to the fetal circulation by two 
umbilical arteries and one vein in the umbilical cord), and a population of stromal cells 
(allantoic mesoderm). In the third trimester, growth of the placenta changes towards the 
development of the gas-exchanging villi, which comprise a large network of 
sinusoidally-dilated terminal villi capillaries through which oxygen and nutrients diffuse 
from the maternal blood into the fetal circulation (85). 
 
The mature placenta comprises approximately 15-20 cotyledons (two or more primary 
stem chorionic villous branches and corresponding secondary and tertiary branches) that 
are suspended in the trophoblast-lined IVS. Each cotyledon is supplied with maternal 
blood from the uterine spiral arteries located in the uterus (85).  
 
 
 
Figure 1-2 Anatomy of the human placenta  
Each fetomaternal circulatory unit is composed of one villous tree with a corresponding centrifugally 
perfused portion of the IVS. This unit is called a placentone. Maternal blood (arrows) enters the IVS near 
the centre of the villous tree (decidual artery) and leaves near the clefts of neighbouring villous trees 
(decidual vein). One or only a few villous trees occupy one placental lobule (cotelydon) (adapted from 
(85)).  
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1.4.3 Early Events in Placentation: the First Trimester 
The human placenta develops from the sperm and the egg that also forms the fetus. 
After fertilization, the human zygote undergoes a series of symmetrical mitotic divisions 
forming a mass of totipotent blastomere cells (the morula) which differentiate into 
embryonic and extra-embryonic tissues. Differentiated cells of the inner cell mass, or 
embryoblast (EB), go on to form the embryo, umbilical cord, amnion, blood vessels and 
connective tissue of the chorionic villi, whilst cells of the outer wall, the trophectoderm, 
surround the blastocyst cavity and go on to form the trophoblast cell lineage and the 
placental villous trees (85).  
 
Placentation begins with implantation of the blastocyst beneath the maternal uterine 
epithelium (at around day 7 post conception, PC), which is achieved through invasion of 
the outer trophoblast cells into the uterine lining (85). Here, trophoblast cells from the 
embryonic pole of the blastocyst rapidly proliferate forming a trophoblastic cell mass 
which differentiates into two distinct layers, an outer syncytiotrophoblast layer (SCT), 
which expands via fusion of underlying proliferating cytotrophoblast cells (CT). The 
syncytiotrophoblast shell invades and interdigitates the maternal endometrial epithelium 
forming a series of lacunae which coalesce to become the forerunner of the maternal 
blood-filled IVS (85).  
 
Proliferating cytotrophoblast cells from the chorionic plate then invade the trophoblastic 
shell forming trophoblastic protrusions into the lacunae, generating primary villi 
composed of an outer syncytiotrophoblast layer and an inner cytotrophoblast core, 
which are then invaded centrally by allantoic mesenchyme (stroma) transforming them 
into secondary villi (Figure 1-3). Formation of the fetoplacental blood vessels within the 
stroma, connected proximally to the umbilical arteries, characterizes their transition to 
tertiary villi which are the forerunners for the development of all floating chorionic villi; 
the first generations of which are the mesenchymal villi (86). These ‘tri-layered’ villi 
are therefore composed of 1) an outer syncytiotrophoblast layer in direct contact with 
maternal blood (hemochorial placentation), 2) an underlying proliferative 
cytotrophoblast layer, and 3) a stromal core containing the primitive fetal vasculature 
and stromal cells (Hofbauer cells and fibroblasts) (84). 
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Figure 1-3 Early placental development 
(A) At around 12-15 days PC, primary villi are formed as columns of cytotrophoblast cells in the centre 
covered by an outer layer of syncytiotrophoblast. (B) These columns are then invaded centrally by extra-
embryonic mesenchyme (around day 15-21 PC) leading to the formation of secondary villi. (C) The 
formation of placental blood vessels (vasculogenesis) within the secondary villi transforms them into 
tertiary villi beginning around day 18 PC (145).  
 
1.4.4 Extravillous Cytotrophoblast Invasion 
Those cytotrophoblast cells that penetrate beyond the syncytiotrophoblast shell, having 
adopted an invasive extravillous cytotrophoblast (EVT) phenotype, move through the 
syncytium at selected sites forming a cytotrophoblast shell thereby physically attaching 
those villi to the maternal uterine wall; the so-called cell columns of the anchoring villi 
(Figure 1-3). 
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Immediately following their invasion through the syncytiotrophoblast shell, 
proliferating cytotrophoblast progenitor cells from the proximal portion of the cell 
columns of the anchoring villi differentiate into two distinct subsets of EVT. These cells 
display invasive phenotypes that enable invasion, penetration and remodelling of the 
maternal spiral arteries thereby rerouting maternal blood to the implantation site. This is 
crucial to successful pregnancy outcome. 
 
There are thought to be two routes of EVT invasion (87). Interstitial EVT invades the 
decidua stroma (and inner third of myometrium) where they surround the spiral arteries 
(they do not invade the arteries) and replace the vascular media with matrix-type 
fibrinoid material converting the spiral arteries into large, dilated vessels of low 
resistance (88). In contrast, in what is thought to be a separate pathway, endovascular 
EVT invade the lumen of the spiral arteries where up until the 12th week of gestation, 
they form an ‘endovascular plug’ thereby preventing maternal blood from entering the 
developing IVS, which then migrate in a retrograde fashion (89). The physiological 
significance of endovascular plugging serves to maintain a ‘hypoxic’ environment 
relative to maternal tissues (90), which is essential for fetoplacental angiogenesis of 
early tertiary villi, the regulation of key cellular events involved in trophoblast 
differentiation and crucially, fetal organogenesis in utero (90-93). Regression of the 
endovascular plug at around 10-12 weeks gestation establishes the maternal-fetal 
circulation (94).  
 
Further differentiation of the EVT occurs and intramural EVT (whether these are 
derived from endovascular or interstitial EVT remains unclear) infiltrate the walls of the 
spiral arteries transforming them into uteroplacental vessels, whilst intra-arterial EVT 
replace the endothelium having adopted a ‘vascular’ endothelial phenotype. 
Transformation of these musculoelastic vessels into distended flaccid vessels, plus 
considerable increase in luminal diameter allows for significantly decreased 
uteroplacental flow resistance allowing maximal maternal blood flow to the feto-
placental unit throughout gestation (95).  
 
Subsequent steps in placentation, and hence fetal viability at the end of the first 
trimester, is therefore dependent upon the commitment of the trophoblast lineage along 
two pathways in the 3rd week PC; the EVT which invade the maternal spiral arteries to 
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promote maternal blood to the intervillous space and the secondly, the villous 
trophoblast responsible for growth and maintenance of the floating chorionic villi 
throughout gestation.  
 
1.4.5 Development of the Chorionic Villi  
The second trimester of pregnancy marks the beginning of the fetal phase of 
development in which uteroplacental and fetal circulations commence in preparation for 
rapid fetal growth. This is accompanied by rapid linear growth and differentiation of the 
different chorionic villi involving both hyperplastic growth of the villous trophoblast 
layer and angiogenesis of the underlying fetal vasculature. Coordinated development of 
the chorionic villi is fundamental to successful pregnancy outcome and subsequently 
perinatal survival since they are the primary site of all fetoplacental diffusive and active 
transport between mother and fetus. 
 
Growth and differentiation of the villous trees is geared towards the exponential 
evolution of the gas-exchanging terminal villi (TV), which are the principal anatomical 
site of maternal-fetal exchange where growth occurs exponentially throughout the third 
trimester. At term, their surface area available for exchange reaches 13m2 and their 
capillaries contain 25% of total fetoplacental blood volume (96). 
 
To achieve this, sufficient generations of dichotomous branches, the so-called stem villi 
(SV), are required to provide the necessary framework leading into these gas-
exchanging villi. Stem villi are formed from immature intermediate villi (IV) in a 
gradual process beginning around the 8th week PC. Here, mesenchymal villi continue to 
develop from tertiary villi and transform into IV up until the end of the second trimester, 
predominating between 14 and 20 weeks when the formation of stem villi is most 
intense. New mesenchymal sprouts form from the tips of IV to continue the cycle of self 
replication (97). IV are transformed proximally through the formation of muscularised 
medium into stem villi, characterized by the differentiation of capillaries into arterioles 
and venules, regression of the capillary network and fibrotic condensation of the loose 
stroma; participation in maternal-fetal exchange is therefore minimal. No defined 
function of IV has yet been elucidated except that they act as the ‘growth zone’ of the 
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developing villous tree, and thus has some involvement in controlling the final size of 
the villous tree (84; 86).  
 
The third trimester of pregnancy marks the period of rapid fetal growth and maturation 
in preparation for the transition from intrauterine to extrauterine environments. During 
weeks 21 to 25 PC, substantial fetal weight gain occurs and as such there is a gradual 
switch in emphasis from formation of conductance vessels in stem villi to the formation 
of gas and nutrient exchanging villi, the mature intermediate (MV) and terminal villi 
(85; 86; 98) (Figure 1-4). 
 
 
 
Figure 1-4 Development of the chorionic villi 
Starting in the ninth week, tertiary stem villi are transformed (via mesenchymal sprouting) into immature 
intermediate villi. Near the end of the second trimester, mature intermediate villi develop from the sides 
of the tertiary stem villi. By week 32, mature intermediate villi produced small nodule like secondary 
branches called terminal villi (99). 
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At around 24 weeks gestation, mesenchymal villi switch from forming IV to form MV. 
Regeneration of the IV thus ceases and those remaining immature intermediate villi 
continue to differentiate into stem villi until term (85). MV do not self-replicate or go on 
to form stem villi, instead they elongate and produce terminal villi by ‘intussusception” 
(non-branching angiogenesis) in which longitudinal growth of the fetal capillaries in the 
MV exceeds longitudinal growth of the villi itself (98). Consequently, the capillary 
loops ‘prolapse’ laterally into the overlying trophoblast layer of the MV resulting in 
thinning of the trophoblastic surface, bringing the fetal circulation close to maternal 
blood separated only by a thin layer of syncytiotrophoblast, the vasculo-syncytial 
membrane (100). Formation of these serial sinusoidal dilations which form the terminal 
villi are of critical importance in achieving low fetoplacental vascular impedance in the 
third trimester allowing for optimal diffusional exchange. It is the maldevelopment of 
these structures that underpins the villous pathology of IUGR. 
 
1.4.6 Angiogenesis  
Numerous investigations report that villous angiogenesis drives villous development 
(101), and it is well established that disruptions in villous angiogenesis result in altered 
villous growth (102; 103). The principle angiogenic regulators of these developmental 
steps are vascular endothelial growth factor (VEGF) (104), placenta-like growth factor 
(PGF) (105) and the angiopoietins (Ang-1, Ang-2) (106), all of which are themselves 
regulated by oxygen availability.  
 
During the first and second trimesters of pregnancy, the fetal vasculature develops 
predominately by branching angiogenesis. Endothelial tube formation (vasculogenesis 
(107)) and proliferation is induced by binding of VEGF to its receptors VEGFR-1 (flt-1) 
and VEGFR-2 (KDR) respectively (108). VEGF is highly expressed in villous 
cytotrophoblast and stromal macrophages (Hofbauer cells) (109) and is induced under 
hypoxic conditions by hypoxia-inducible transcription factor 1 (HIF-1) (110); 
circulating VEGF can be detected in the maternal plasma at 6 weeks of gestation and 
rises to a peak at the end of the first trimester (111).  
 
During the third trimester of pregnancy, a switch occurs in the expression of the 
angiogenic growth factors whereby the fetal vasculature develops via non-branching 
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angiogenesis. Whilst VEGF secretion predominates during the first and second 
trimesters, PGF is the predominant angiogenic growth factor during the third trimester 
(112). In contrast to VEGF, oxygen is a potent stimulator of PGF (113) which induces 
endothelial tube formation through binding to VEGFR-1; synthesis is localized to the 
villous and extravillous trophoblast (105).  
 
The VEGF/PGF interchange coincides with the switch from predominantly branching to 
non-branching angiogenesis at around 25 weeks PC (114). VEGF/PGF directed 
vasculogenesis and angiogenesis may therefore shape villous tree development and its 
morphology may reflect the underlying angiogenic process (115; 116). For example, 
branching angiogenesis drives immature intermediate villi growth, which are 
characteristically large bulbous structures covered by a thick trophoblast layer 
containing central stem vessels. In contrast, non-branching angiogenesis drives mature 
intermediate and terminal villi growth which are filiform structures covered by a thin 
trophoblast layer and tightly coiled capillaries. This suggests that the trophoblast 
displays some degree of ‘plasticity’, which may adapt with, or in response to, the 
underlying angiogenic architecture. 
 
1.5 Defective Placentation in PET and IUGR  
1.5.1 Physiological Conversion of Maternal Spiral Arteries 
Physiological conversion of the maternal uterine spiral arteries is essential in promoting 
effective uteroplacental blood supply to the fetal villi at the end of the first trimester, 
and is achieved by cells from the extravillous cytotrophoblast lineage (85; 87; 95; 117). 
Maternal blood flow to the human placenta does not begin until 10 to 12 weeks 
gestation (118), which is prevented from entering the developing IVS by the 
endovascular plug. Oxygen tension plays a key role in early placental development and 
EVT invasion, and thus, oxygen is important physiological factor for formation of the 
maternal-fetal interface and hence, fetal growth (119).  
 
Studies have shown that cytotrophoblasts have the ability to sense oxygen, whereby 
cytotrophoblasts proliferate under hypoxic conditions. As EVT invade the uterus they 
encounter increasing levels of oxygen which triggers their exit from the cell cycle and 
differentiation into the various EVT phenotypes occurs (91; 119) (Figure 1-5). These 
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cells must continuously invade and physiologically transform the distal myometrial 
portions of the maternal spiral arteries from the non-pregnant state during the first 
trimester, into widely dilated flaccid conduits capable of delivering large quantities of 
maternal blood to the intervillous space in order to meet the exponential demands of the 
rapidly growing fetus during the second and third trimester. Vascular transformation is 
thought to involve all 100-150 spiral arteries in the placental bed (120). 
 
 
Figure 1-5 Extravillous cytotrophoblast invasion of the maternal spiral arteries 
Early placental development occurs in a relatively hypoxic environment (A) that favours CT proliferation 
rather than differentiation along the invasive pathway. (B) Proliferating CT cells invade the uterine wall 
and form an endovascular plug (dark green cells). (C) By 10 to 12 weeks, maternal blood flow to the IVS 
begins and EVT cells continue to migrate along the lumina of the spiral arteries where they replace the 
endothelial cell lining (adapted from (119)). 
 
In those pregnancies destined to develop pre-eclampsia, placental bed biopsies 
(although these may not reflect global changes in the placental bed) demonstrate 
varying degrees (within and between placentas) of defective EVT invasion and failure 
to physiologically convert the maternal spiral arteries (121-123) (Figure 1-6). Failed 
physiological conversion has also been demonstrated in some, but not all IUGR 
pregnancies where IUGR was defined as a birth weight of less than the 10th centile for 
GA (i.e. SGA). However, SGA infants below the 2.3th centile (high risk of IUGR) 
exhibit a strong association with failed conversion (123). In both normal and 
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pathological placentas conversion is maximal in the central bed vessels (124). Failure to 
transform the arteries in the first trimester is thought to result in defective maternal 
blood flow to the IVS (125), which in turn, is evidenced in vitro to result in hypoxic 
damage and ischemia-reperfusion injury to the developing chorionic villi (126) and in 
the most severe cases, chronic fetal hypoxia (127).  
 
 
 
 
 
Figure 1-6 Failed spiral artery remodelling in pre-eclampsia 
Diagrammatic representation of the uterine vasculature in human pregnancy. Normal pregnancy is 
characterised by large arterio-venous shunts, which by contrast are minimal in pre-eclampsia with 
narrower uterine arteries. Depth of trophoblast invasion is also minimal in comparison to normal 
pregnancy (Adapted from (128)). 
 
Whether defective trophoblast invasion is a primary cause of reduced blood flow per se, 
or whether the placenta is at all hypoxic has recently been debated (128). Nonetheless, 
the prevailing placental hypothesis still holds that reduced trophoblast invasion and 
spiral artery transformation, resulting in the clinical entity of ‘uteroplacental 
insufficiency’ (129), are key pathological features underpinning pre-eclampsia and 
IUGR. 
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1.5.2 Defective EVT Differentiation 
Current studies focussed on pre-eclampsia and failed EVT invasion are aimed towards 
elucidating a link between abnormal EVT invasion and the maternal vascular syndrome. 
The currently accepted hypothesis is that pre-eclampsia, (particularly severe early-onset 
disease requiring preterm delivery) is associated with defects in extravillous 
cytotrophoblast differentiation leading to an altered EVT phenotype with subsequent 
reduced uterine invasion. Morphologically, placental bed biopsies typically reveal 
decreased numbers of interstitial EVT around the decidual arteries (130) and 
rudimentary endovascular EVT invasion of the myometrial spiral arteries (124). The 
dominant ‘pre-eclamptic phenotype’ comprises immature, hypoinvasive and pseudo-
proliferative extravillous cytotrophoblast cells (88; 95; 117). 
 
1.5.2.1 Altered EVT Phenotypes in PET 
Migration and invasion of cytotrophoblasts into the decidua and maternal spiral arteries 
requires that cytotrophoblasts differentiate thereby adopting an invasive ‘vascular-like’ 
phenotype, which is controlled by intrinsic EVT factors (enzymology of adhesion 
molecules and extracellular matrix degradation (ECM)) and secondly by extrinsic 
maternal uterine factors (e.g. impaired decidual remodelling, impaired function of 
uterine natural killer cells (NK)) (89). 
 
Zhou et al were the first to describe the failure of cytotrophoblasts to acquire a vascular 
repertoire of adhesion molecules in pre-eclamptic placentas (131). In pre-eclampsia, 
cytotrophoblast progenitor cells at the distal cell columns fail to undergo an epithelial 
(endoderm) to endothelial (mesoderm) transformation. Cytotrophoblasts fail to switch a 
repertoire of adhesion molecules necessary for invasion of the spiral arteries, such as 
failure to down regulate expression of E-cadherin (proliferative phenotype) and α6β4 
integrin, and therefore persist as a more proliferative population compared to normal 
pregnancy. In essence, they fail to replace their epithelial-like receptors and turn on 
receptors that promote invasion through endothelial vascular adhesion molecules 
characteristic of differentiating/invading cytotrophoblasts, such as α5β4 and α1β1 
integrins, VE-cadherin, VCAM-1 and PECAM-1 (88; 132). 
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The expression of various growth factors involved in regulating the invasive pathway is 
also impaired in pre-eclampsia including in vitro over-expression of TGF-β3, an 
inhibitor of migration, and IGFBP-1 in vivo, which led to altered trophoblast invasion 
and differentiation (88). Enzymatic degradation of the ECM necessary for migration is 
also defective in pre-eclampsia as trophoblasts fail to up regulate MMP-9 (matrix 
metalloproteinase 9), a proteinase closely associated with the invasive phenotype of 
trophoblast (88). Furthermore, numbers of invading endovascular (intramural) EVT are 
reduced in early-onset pre-eclampsia with IUGR due to reduced numbers of interstitial 
EVT and excessive endovascular EVT apoptosis; increased numbers of activated 
maternal macrophages expressing pro-apoptotic TNFα and TNF-R1 have been 
described close to the implantation site (117; 122).  
 
However, can this phenotype be linked to the maternal symptoms of pre-eclampsia? 
Consistent with the hypothesis that pre-eclampsia is associated with failure to adopt an 
vascular EVT adhesion phenotype, observations that extravillous cytotrophoblast cells 
down regulate vascular endothelial growth factor (VEGF) in vitro (28; 133), have led to 
the concept that as well as mediating vasculogenesis and angiogenesis during vessel 
remodelling, VEGF also plays a pivotal role in EVT migration and spiral artery invasion 
(94; 133-135).  
 
Invasive cytotrophoblast cells during early gestation express VEGF-A, VEGF-C, and 
PGF, and their receptors VEGFR-1 (flt-1) and VEGFR-3, and at term VEGF-A, PGF 
and VEGFR-1 (136). Significantly, invasion and migration of EVT were suppressed 
when VEGF receptor binding and signal transduction were blocked by receptor fusion 
proteins. Specifically, in pre-eclampsia, VEGF-A is down-regulated in EVT, whilst 
secretion of a truncated form of the receptor VEGFR-1, soluble fms-like tyrosine kinase 
1 (sFlt-1) in vitro is increased (137). In normal pregnancy, circulating sFlt-1 levels 
increase throughout gestation and binds VEGF and PGF with high affinity, thereby 
decreasing availability to the trans-membrane receptors VEGFR-1 and VEGFR-2. 
Presumably, the decrease in EVT VEGF-A expression and increase in the sFlt-1 
receptor that sequesters VEGF reduces the bioavailability of VEGF required for EVT 
migration and invasion of the uterine spiral arteries (138). This provides direct evidence 
supporting the theory that failed cytotrophoblast invasion and pseudovasculogenesis are 
linked through abnormal VEGF production to the maternal vascular pathology. Soluble 
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Flt-1 has therefore become a strong candidate as a pathogenic mediator of the pre-
eclamptic syndrome, and a promising predictive marker of pre-eclampsia in high-risk 
women in the first trimester (139).  
 
1.5.3 Placental Pathology 
The placental bed in early-onset pre-eclampsia and IUGR display a range of arterial 
disease associated with defective maternal blood supply, collectively referred to as 
decidual vasculopathy, including failed transformation of the uteroplacental arteries, 
acute atherosis and luminal thrombosis of the maternal vessels (140). Non trophoblast-
invaded vessels retain their smooth muscle media and fail to undergo further 
vasodilation such that uteroplacental vascular resistance remains high (128). As a result, 
the same volume of maternal blood may enter the IVS but due to the narrowed arteries 
does so at greater velocity in jet-like streams, potentially disrupting the villous branches 
and anchoring villi, which is thought to essentially push the placenta up thereby 
accounting for its “wobbly, jelly-like” appearance (128), which can be seen as early as 
14-15 weeks of gestation (141). The resultant changes in intervillous haemodynamics 
will therefore impair maternal-fetal diffusional exchange and may account for the 
higher than normal oxygen levels in the uterine vein in severe early-onset IUGR 
pregnancies (142).  
 
The reduction in uteroplacental blood flow associated with early-onset pre-eclampsia 
and IUGR can be quantified using colour imaging from pulsed Doppler waveforms as 
an assessment of the blood flow within the proximal uterine arteries (143; 144). In 
normal pregnancy, endovascular EVT regression permits maternal blood flow in the 
uterine arteries by 12 weeks gestation, represented by positive end diastolic flow 
velocity waveforms (PEDFV), indicating adequate trophoblast invasion and spiral artery 
remodelling. In the most severe forms of placental insufficiency (i.e. early-onset pre-
eclampsia and IUGR delivering <32 weeks), end diastolic flow is persistently absent or 
even reversed in the uterine arteries (mean pulsatility index >1.45 and/or early diastolic 
notches) (140), signifying high resistance in the uteroplacental circulation and is 
therefore an indirect sign of inadequate trophoblast invasion which also correlates well 
with decidual vasculopathy (145). Since these pathological conditions do not correlate 
with maternal or fetal thrombophillia disorders, it suggests that the gross pathological 
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changes to the placental gas-exchanging villi in PET and IUGR are a result of the 
reduction in uteroplacental circulation (146).  
 
Conversely, abnormal uterine artery Doppler (UTAD) may not necessarily confer 
malinvasion of the uteroplacental arteries since power Doppler ultrasound and vascular-
enhanced uterine artery MRI have recently shown that most of the uterine artery blood 
flow in the second trimester does not enter the IVS. Instead most of the maternal blood 
is shunted away from the myometrium (147) and although the involvement in 
trophoblast invasion is unclear (146), shunting is thought to represent a physiological 
mechanism to reduce maternal systemic vascular resistance. Hence, in pre-eclampsia 
and IUGR, changes in UTAD may be the result of arterio-venous fistulas within the 
uterine myometrium and not due to malinvasion (146). Moreover, this also suggests that 
EVT promote uterine artery blood flow by additional pathways other than by anatomical 
erosion of the arterioles, supported by observations that interstitial EVT secrete 
angiogenic and vasodilatory factors that increase local blood flow to the uterus but also 
maternal cardiac output, whilst decreasing blood pressure due to systemic vasodilation. 
Thus, increased blood pressure in the second trimester may result from defects in these 
pathways. 
 
Uteroplacental insufficiency also confers a high risk of damage to the placental villi, 
since abnormal UTAD correlates well with thrombotic pathological findings of the 
placental villous trees (148; 149). Narrow and/or diseased spiral arteries may 
thrombose, secondary to failed physiological conversion, which as a secondary 
pathology may lead to poor maternal perfusion of the placenta, leading to focal 
infarction of placental villi (tissue death due to lack of blood supply) necessary for 
maternal-fetal gas and nutrient exchange (141). Furthermore, focal accumulations of 
fibrin around villi (perivillous) and intervillous thrombosis are all typical thrombotic 
pathological features of the placental villous trees associated with severe placental 
insufficiency (129). Reduced uteroplacental blood flow is not however a precondition 
for placental insufficiency as increased fractional oxygen extraction by the chorionic 
villi, as part of a sustained adaptive response, may preserve placental supply and fetal 
demand as pregnancy progresses (116; 150). By contrast, these findings are minimal or 
absent in pre-eclampsia and IUGR at term (140). Furthermore, intermittent spiral artery 
blood flow resulting in ischemia-reperfusion injury may lead to oxidative stress of the 
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fetal endothelium and necrotic shedding of trophoblast within the placental villi 
associated with maternal endothelial dysfunction in pre-eclampsia (126; 151).  
 
1.5.4 Villous Maldevelopment 
It is well established that development of the chorionic villous tree and fetal vasculature 
is abnormal in PET and IUGR (1; 2; 152) compared to normal pregnancy, and more 
recently in placentas from infants succumbing to SIDS (82). Consistent with the clinical 
implications, it has become apparent that the severity, timing-of-onset, and umbilical 
artery Doppler (absent versus positive) are associated with divergent pathways of 
villous maldevelopment in these pregnancy complications. Given that PET and IUGR 
are both associated with uteroplacental insufficiency, the placenta responds differently 
to the expected ‘intra-placental hypoxia’. Oxygen is therefore a key regulator of villous 
development and different pathways of villous maldevelopment have been proposed 
based on the origin of fetal hypoxia (153). 
 
Following analysis of placental villi in complicated pregnancies, the origin of fetal 
hypoxia has been classified as pre-placental, uteroplacental, or post-placental (153). In 
pre-placental hypoxia, the mother, placenta, and fetus are potentially hypoxic due to a 
reduced oxygen content of the maternal blood, such as in pregnancy at high altitude and 
maternal anaemia (103). In contrast, in uteroplacental hypoxia, maternal blood flow is 
normoxic but the placenta and fetus may become hypoxic due to compromised flow into 
the IVS, i.e. malinvasion of the maternal spiral arteries. In post-placental hypoxia, 
maternal blood flow is normal in combination with normal or reduced flow into the 
IVS, but a severe defect in fetoplacental perfusion prevents the fetus from receiving 
sufficient oxygen, and hence is at serious risk of becoming hypoxic (153). 
 
1.5.4.1 IUGR 
In situations of pre-placental hypoxia or uteroplacental hypoxia, the placenta may 
undergo excessive branching angiogenesis and trophoblast proliferation in order to 
produce greater amounts of vascularised terminal villi as part of an adaptive response so 
as to maintain adequate fetoplacental diffusional exchange; maternal supply and fetal 
demand are therefore carefully balanced by the development of the terminal villi. This 
type of villous adaptation is associated with late-onset pre-eclampsia (154), and in some 
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but not all cases of IUGR (150), which have been shown to display increased capillary 
volume fractions, and degree of branching (for review see (155)). Because such changes 
are not observed in severe early-onset IUGR, these placentas are thought to represent 
‘failure to adapt’, since they appear to have lost their ‘hypoxic’ angiogenic drive (153) 
conferring severe functional consequences to the potentially hypoxic fetus (post-
placental hypoxia).  
 
Stereological and morphometric analyses have led to the agreement that the small 
placentas from IUGR pregnancies are associated with a failure in the development of 
the gas-exchanging villi, due to malformation of the fetal capillaries in terminal villi 
secondary to failed branching angiogenesis in the third trimester of pregnancy and the 
predominance of non-branching angiogenesis. Stereological studies reveal consistent 
reductions in the elaboration of mature intermediate and terminal villi (102; 152; 156-
159) (volumes, surface areas, and lengths) and reduced terminal villous capillarisation 
(160; 161). 3D scanning electron microscopy and vessel casts confirmed reductions in 
the numbers of ‘malformed’ (1), congested, elongated, poorly-branched gas-exchanging 
villi and underlying fetal vasculature (2). These observations are evident in placentas 
from both early- (2; 152) and late-onset IUGR (102; 152; 156-159; 161; 162).  
 
The malformed capillaries in severe IUGR placentas confer high vascular impedance 
which is associated with abnormal umbilical artery Doppler (150), representing a severe 
form of reduced fetoplacental blood flow inferred by absent or reverse end-diastolic 
flow velocity waveforms (AREDV). Those pregnancies destined to develop severe 
IUGR are therefore typically associated with severe abnormalities in umbilical artery 
Doppler, which has become an established test of fetal wellbeing in the second trimester 
of pregnancy (19-23 weeks) (129). 
 
The compromised fetoplacental circulation is understood to result in reduced extraction 
of oxygen from maternal blood in the intervillous space leading to poor oxygenation of 
the severe IUGR fetus (hence the term postplacental fetal hypoxia), evidenced by the 
inability of the IUGR placenta to maintain adequate transfer of oxygen/nutrients to the 
fetus (reduced oxygen diffusive conductance, Dp) (159; 163). Consequently, IVS 
oxygen levels remain similar, but not higher than maternal arterial tensions, such that 
the oxygen content of maternal blood exiting the uterine veins is close to arterial values 
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(142). This led to the term placental ‘hyperoxia’, although this is still debated by some 
investigators (Figure 1-7). 
 
Given that angiogenesis shapes villous development, the pathway of villous 
maldevelopment in severe early-onset IUGR is associated with changes in the molecular 
regulation of the principal angiogenic factors, VEGF and PGF. Whilst in normal 
pregnancy VEGF predominates in the first trimester and PGF predominates in the third, 
IUGR placentas demonstrate increased expression of PGF (113) (mRNA and protein) 
and decreased syncytial expression of VEGF (164). Because PGF mediates non-
branching angiogenesis, this imbalance in angiogenic factors is thought to contribute to 
the poorly branched, elongated gas-exchanging villi that characterize IUGR 
pregnancies.  
 
1.5.4.2 PET 
Although pre-eclampsia is the most extensively studied pregnancy complication at term, 
its influence/impact on placental morphology is inconsistent and less well understood in 
early pregnancy. Severe early-onset pre-eclampsia, by definition, often co-exists with 
IUGR, conferring significant risk for perinatal survival compared to term complications. 
Distinguishing the contributions of each disease on the pathway(s) of villous 
maldevelopment is thus hampered by this close association, but is presumed to involve 
considerable overlap. Consequently, the majority of stereological studies addressing the 
pathways of placental dysfunction in pre-eclampsia without IUGR focused on term 
pregnancies which revealed conflicting results.  
 
Initially, stereological studies revealed one distinct pathway of placental dysfunction in 
pre-eclampsia compared to IUGR. At term, pre-eclamptic placentas displayed normal 
(102; 156; 161; 165) or ‘enhanced’ placental villi and vasculature morphology e.g. 
increases in terminal capillarisation (adaptive branching angiogenesis due to intra-
placental hypoxia), placental volume and fetal birth weight in comparison to normal 
term controls. This led to the prevailing hypothesis that ‘pure’ pre-eclampsia at term has 
no overall effect on placental villous and vasculature development in comparison to 
IUGR. Furthermore, these placentas are typically associated with normal Dopplers 
represented clinically by preserved end-diastolic blood flow velocity waveforms 
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(PEDV) conferring minimal vascular impedance (153). IUGR at term is typically, but 
not exclusively, associated with normal umbilical artery Dopplers indicating normal 
fetoplacental blood flow associated with favourable perinatal outcome.  
 
 
 
 
Figure 1-7: Pathways of villous maldevelopment 
Pathways of villous angiogenesis according to villous oxygenation. Three different examples of 
oxygenation, postplacental hypoxia (top), normal pregnancy (middle) and pre-placental as well as 
uteroplacental hypoxia (bottom) are illustrated by their terminal capillarisation patterns (left) and by 
typical cross sections of terminal villi (right). The oblique lines refer to the position of the cross sections 
beneath (153).  
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Molecular evidence for intra-placental hypoxia in pre-eclampsia at term, (representing a 
form of uteroplacental hypoxia), came from the observation that expression of the 
hypoxia inducible transcription factors, HIF-1α and HIF-2α, is significantly increased in 
these placentas. However, due to the difficulty of measuring serum levels of VEGF 
(normal or increased) and PGF (normal or decreased), there are inconsistencies in the 
reported expression of these angiogenic factors in pre-eclampsia at term (155). 
 
This concept was challenged by Egbor et al (152) who identified two distinct pathways 
of villous maldevelopment in pre-eclampsia, illustrating that early-onset pre-eclampsia 
without IUGR shares similar morphological features to the maldeveloped villi that are 
typically observed in both early- and late-onset IUGR placentas . This led to idea that 
the early phenotype of PET may have a different etiology compared to its late-onset 
phenotype, and that they may represent two different diseases.  
 
1.5.4.3 SIDS 
Protracted intrauterine hypoxia occurring during fetal development is also thought to be 
a primary pathophysiologic factor in SIDS (166). SIDS placentas may represent a form 
of pre-placental hypoxia due to the high incidence of maternal smoking associated with 
SIDS. However, previous stereological studies revealed that both SIDS-NBW and 
SIDS-LBW placentas are associated with altered placental villous (162) and vasculature 
(82) morphology. Changes observed include reduced volumes and surface areas of 
placental villi, and reduced surface areas of intermediate and terminal capillaries, which 
are contrary to the expected intra-placental hypoxia as noted in other forms of pre-
placental hypoxia. Because villous development is also driven by the villous 
trophoblast, it hypothesized that different pathways of villous maldevelopment may 
reflect divergent villous trophoblast phenotypes.  
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1.6 Regulation and Maintenance of the Trophoblast Lineage during Pregnancy 
Pre-eclampsia is associated with defective differentiation and invasion of EVT cells, 
whereas by contrast, severe early-onset IUGR is typically characterized by reduced 
branching of the peripheral villi and the underlying vasculature. On the basis of recent 
observations using mouse models, it has become apparent that these human placental 
pathologies may be the result of distinct molecular abnormalities in the differentiation 
of the trophoblast lineage.  
 
1.6.1 Molecular Basis of Placental Development in Mice 
The trophoblast origins of pre-eclampsia and IUGR are difficult to investigate as these 
diseases represent investigative endpoints, and hence, very early gestational samples are 
not available. However, the last ten years has seen a substantial increase in our 
knowledge regarding trophoblast development due primarily to transgenic and knockout 
studies in the mouse (167). Although they differ in their overall structure (Figure 1-8) 
their basic developmental plan is the same and as such, they are thought to be quite 
similar in terms of their molecular regulation (168). Because some genes known to be 
involved in murine placental development are expressed in an analogous manner in 
humans, this indicates that key molecular determinants of placental development in 
mice are also likely to be involved in humans (for full review see (169)). This data, 
albeit limited, suggests that trophoblast subtype-specific function is conserved between 
the two species (reviewed in (168)), and have highlighted the importance of the 
trophoblast and its differentiation into the different lineages in directing the different 
stages of placental development.  
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Figure 1-8 Comparative anatomy of the murine and human placenta 
(a) Structure of the mouse placenta. The inset details the fetal-maternal interface in the labyrinth (b) 
Structure of the human placenta. The inset image shows a cross-section through a chorionic villus; 
trophoblast-derived structures (blue) and mesoderm-derived tissues (orange). The inset images illustrate 
the number and type of cell layers between maternal and foetal blood (169). 
 
1.6.2 Trophoblast Stem Cell Maintenance and Differentiation 
Trophoblast stem cells (TS) arise in the polar trophectoderm (170) and are distributed 
throughout the extra-embryonic ectoderm (chorion) (171). These cells are characterized 
by their ability to 1) retain an undifferentiated proliferative phenotype and 2) 
differentiate into the various trophoblast cell-types in the mouse (i.e. spongiotrophoblast 
(SpT), trophoblast giant cells (TG), or syncytiotrophoblast (SynT) of the labyrinth). 
Differentiation into these various cell-types is characterized by arrest of mitosis and the 
promotion of transcription factor pathways that ultimately determine cell fate decisions 
(Figure 1-9) (172).  
 
Maintenance of the proliferative TS phenotype is dependent on stimulation by fibroblast 
growth factor (FGF) signalling through its ligand (FGF4) (173), (expressed in the early 
embryo, the ICM and the epiblast of the post-implantation embryo (169)) and its 
receptor, FGFR2 (expressed in the trophectoderm and chorion (174)), and the 
downstream transcription factors Cdx2 (175) and Eomes (176) (all are promoted by 
Nodal (170)). Removal of FGF4 from cultured trophoblast stem cells leads to the rapid 
down-regulation of Cdx2 and Eomes and proliferation ceases owing to their exit from 
the cell cycle (173) and subsequent differentiation into the various labyrinth trophoblast 
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cell types via expression of transcription factors (Hand1, Stra13 (TG), Gcm1 (SynT)) 
(172) (For a full review of murine trophoblast genetics, see (169; 170; 177)). 
 
 
 
 
Figure 1-9: Trophoblast stem cell fate in the mouse 
Segregation of the murine trophoblast lineage first occurs at the blastocyst stage prior to implantation. 
Blastomeres on the outside of the conceptus form the trophectoderm destined to become trophoblast, 
whilst the inner cells become part of the ICM; these cells are prevented from differentiating into 
trophectoderm by the expression of Oct4. Subsequent differentiation of trophoblast stem cells into 
syncytiotrophoblast, spongiotrophoblast, trophoblast giant cells and glycogen cells is associated with 
down regulation of Cdx2 and Eomes and upregulation of lineage-specific transcription factors. 
Differentiation into trophoblast giant cells is induced by up-regulation of two basic helix-loop-helix 
(BHLH) transcription factors, Hand 1 and Stra13, whilst differentiation into and maintenance of the 
spongiotrophoblast layer is dependent upon the BHLH Mash 2, a subpopulation of which differentiates 
into trophoblast glycogen cell promoted by the Igf2 gene (adapted from 170). 
 
Significantly however, the developmental potential of TS cells is lost from the murine 
placenta coinciding with the development of the labyrinth layer at E8.5, since TS cells 
can only be derived from the chorion up until E8-8.75 (171; 178). Because the placenta 
continues to grow almost until term, an as yet uncharacterized population of progenitor 
cells must therefore persist throughout gestation which account for the formation of the 
subsequent trophoblast cell types and the labyrinth layer (170). Furthermore, these cells 
may be lineage-restricted, supported by the observation that Eomes and Ehox positive 
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trophoblast cells are detected in the labyrinth layer, and may well represent labyrinth 
trophoblast progenitors (179; 180). Such progenitor cells are also predicted to exist in 
the human placenta as these cells act as the germinal layer of the functional syncytial 
layer of the chorionic villi throughout gestation.  
 
1.6.3 Branching Morphogenesis and Labyrinth Development in Mice 
The villous part of the murine placenta, the labyrinth layer- functionally analogous to 
the chorionic villi in humans, begins to form after embryonic day (E) 8.5 and is 
dependent upon attachment of the chorioallantois to the allantoic mesoderm (derived 
from the embryoblast) (181). Here, the mesoderm gives rise to mesenchymal cells and 
blood vessels within the labyrinth layer, whereas the different trophoblast layers within 
the chorion give rise to the three layers of differentiated trophoblast in the labyrinth 
(post-mitotic mononuclear trophoblast cells, and two syncytial layers formed by cell-
cell fusion). 
 
Branching morphogenesis and syncytiotrophoblast formation in the labyrinth layer 
depends upon the trophoblast transcription factor, glial cell missing 1 (Gcm1), the 
expression of which depends upon signalling from the allantois (182). Gcm1 mutant 
mice fail to initiate branching morphogenesis and syncytiotrophoblast formation 
demonstrating the fundamental role of this transcription factor for labyrinth 
development in the mouse (181). Initially, Gcm1 is expressed in small clusters in post-
mitotic cuboidal trophoblast cells (182) in the flat basal surface of the chorion as early 
as E7.5 (183) at sites where the chorion begins to fold to form the primary villi; GCM1 
positive cells become elongated at the onset of branching morphogenesis (181). Because 
of its restricted chorion expression to labyrinth-committed cells, it suggests that GCM1 
may be critical in maintaining the multi-potent stem cell pool (173) in the early 
placenta. 
 
Gcm1 expression is subsequently restricted to the tips of the primary branches and 
differentiated syncytiotrophoblast begin to form (181) where Gcm1 is localized to the 
SynT-II cells (182). Syncytiotrophoblast formation requires cell-cycle exit and cell-cell 
fusion to form a syncytium, although the underlying fusion mechanism(s) or whether 
this is mediated by Gcm1 is currently not known in the mouse (170). By E9, primary 
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villous branches are apparent which undergo further branching and elongation to form 
the mature labyrinth at around E10.5 (182). However, the cellular processes regulating 
subsequent growth and expansion of the labyrinth layer are largely unknown, since (in 
contrast to the human placenta) proliferating trophoblast cells become rare in the 
labyrinth layer towards the end of gestation after ~E12.5 (182). Instead, mitotically 
active cells are restricted to the basal part of the labyrinth suggesting that growth may 
be seeded from the basal layer to the tips, and given that the labyrinth continues to 
expand in volume towards term (184), growth maybe achieved in part by an increase in 
cell volume (182).   
 
1.6.4 Trophoblast Stem Cells in the Human Placenta 
Despite the knowledge regarding trophoblast stem cell maintenance in murine 
placentas, the localisation, regulation and fate of human trophoblast stem cells still 
remains unclear. However, it is generally accepted that in the human placenta, the 
cytotrophoblast population represents the proliferative stem cell pool. In contrast to the 
mouse, proliferating cytotrophoblast cells can be found in the base of the anchoring villi 
and in the chorionic villi as they are needed to regenerate the syncytium throughout 
gestation. 
 
Studies suggest that cytotrophoblast cells may be a heterogeneous pool, and that these 
different cell phenotypes arise by lineage specific progenitors. It was originally thought 
that the villous cytotrophoblast represents a single stem cell pool, in that they produce 
both syncytiotrophoblast and extravillous trophoblasts during the first trimester. This 
statement is supported by in vitro cell culture studies (185), and the establishment of in 
vitro 3D floating explant models in which villi remain in their native environment. In 
syncytium-denuded models, cytotrophoblast cells adopt an extravillous phenotype 
(upon addition of FGF4) at distal portions of cytotrophoblast outgrowths, whilst in the 
absence of growth factors, cytotrophoblast spontaneously differentiate into 
syncytiotrophoblast. FGF4 initiates cytotrophoblast proliferation (173), and results in 
smooth cytotrophoblast outgrowths, the more proximal cells of which adopt an 
extravillous phenotype (Cx40, α5β1, HLA-G positivity) (132; 186). This is presumably 
because FGF4 recruits FGFR2-positive cytotrophoblasts to divide rapidly, thereby 
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physically separating the outer layers of cells from the underlying basal lamina and 
mesenchymal cells.  
 
Hence what would normally constrain cytotrophoblasts to make syncytiotrophoblast is 
lost and subsequently cells adopt an extravillous phenotype. Interestingly, 
cytotrophoblast cells do not enter the extravillous invasive pathway upon addition of 
FGF4 to syncytium-intact models, suggesting that syncytiotrophoblast may itself be 
necessary to maintain cells in the villous phenotype and to prevent their differentiation 
into an extravillous phenotype (for a full review see (185)). 
 
A counter-argument against cytotrophoblast bi-potentiality is presented by James et al 
(187). These authors indicate that villous and extravillous trophoblast populations arise 
from two separate pools of cytotrophoblast stem cells in the first trimester, in 
comparison to the generally accepted single pool, and that these cells are lineage-
restricted.  
 
The differentiation and/or maintenance of the cytotrophoblast columns, analogous to the 
spongiotrophoblast layer in mice, is dependent upon an upstream assembly of 
transcription factors including Hash2 (188), Stra13 , Id2 and E-factor (189). As 
cytotrophoblast cells adopt an invasive phenotype (trophoblast giant cells in mice), 
Hash2, Id2 and E-factor are down-regulated and Stra13 is up-regulated in vitro (189). 
These expression patterns are analogous to those seen in the mouse, reinforcing the idea 
that these are homologous cell types. However, some species disparity may exist as 
differentiation into invasive extravillous trophoblast in humans is not dependent upon 
Hand1 (190), a BHLH transcription factor essential for trophoblast giant cell 
differentiation in the mouse. Although Hand1 mRNA is not detectable in both first and 
third trimester placenta, expression of Hand1 is detectable in JEG-3 and JAR 
trophoblast cell lines (190). 
 
As in the mouse, recent studies in humans have found that villous morphogenesis and 
syncytiotrophoblast formation is completely dependent upon the trophoblast-specific 
transcription factor, Gcm1 (181; 183; 191). Originally thought of as a homogenous 
population of cells, these studies have shown that in fact villous cytotrophoblast 
represents a heterogeneous stem cell population in which a subset of cells display 
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(likely asymmetrical) expression of GCM1 protein; presumably the post-mitotic 
daughter cells destined for syncytial fusion, and it is speculated that those negative for 
GCM1 may retain the stem cell phenotype. The factor(s) behind this asymmetrical 
expression of GCM1 are at present unknown. Up-regulation of GCM1 in this subset 
drives the cell to exit the cell cycle and subsequently results in de novo formation of 
syncytiotrophoblast, which is supported by numerous observations that Gcm1 up-
regulates Syncytin1 (192), a gene involved in trophoblast fusion (193). Furthermore, 
GCM1 expression is associated with villous sprouts which represent the sites of primary 
villous formation, suggesting GCM1 initiates villous morphogenesis in the human 
placenta (191). 
 
1.7 Villous Trophoblast Turnover in Normal Human Pregnancy 
In the human placenta, the chorionic villi are covered by the epithelial villous 
trophoblast compartment. The outer layer, in direct contact with maternal blood, 
represents a functional post-mitotic multinucleated syncytium (syncytiotrophoblast, 
SCT) displaying both transcriptional and translational activity (194), and is responsible 
for the bulk of placental functions including gas, nutrient and waste exchange, immune 
tolerance and hormone production (85).  
 
Throughout gestation, the syncytium expands in surface area to meet the increasing 
demands of the growing fetus, which is achieved by the process of trophoblast turnover. 
This involves the continuous fusion of underlying villous cytotrophoblast cells (CT), a 
subset of which undergoes asymmetrical proliferation (191) to produce one daughter 
cell that differentiates and fuses to form the terminally differentiated SCT, whilst the 
other remains in an undifferentiated progenitor cell phenotype for further rounds of cell 
division (183). Fusion is not only the basis for growth of the syncytiotrophoblast but is 
also crucial for keeping it alive; fresh organelles, enzymes and nucleic acids are 
transferred into the generative-deficient syncytium. Some weeks later, aged syncytial 
nuclei (syncytial knots) are then removed from the villous membrane by the process of 
apoptosis and are shed into the intervillous space in the form of membrane-bound 
apoptotic bodies (195), where they are engulfed and cleared by macrophages in the 
maternal lungs serving to protect the mother from an imminent inflammatory response 
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(196). Shed nuclei are then replaced by new fusion events from post-proliferative 
daughter cytotrophoblast cells (Figure 1-10). 
 
 
 
 
Figure 1-10 Villous trophoblast turnover 
The events are arranged in a clock-wise manner around the villous starting at one o’clock. Thickness of 
arrows indicates the rate of respective process. The cytotrophoblast daughter cells differentiate and fuse to 
form the syncytiotrophoblast layer. Following differentiation and maturation within the 
syncytiotrophoblast layer the aging nuclei are shed by apoptosis and to a lesser extent, by necrotic 
shedding into the IVS. This process is a continuous cycle that is carefully regulated through out gestation 
(adapted from 228). 
 
Disruptions in the balance of trophoblast turnover suggest alterations in the rates of 
proliferation, fusion and/or apoptosis. These homeostatic alterations may lead to 
potential increases or decreases in the amount of material included or extruded from the 
villous membrane, subsequently affecting membrane function, as seen in pathological 
conditions such as pre-eclampsia (3; 197) and IUGR (198; 199). Therefore, maintaining 
a physiological balance between placental villous cytotrophoblast proliferation, 
apoptosis and shedding is essential for sufficient maternofetal oxygen transfer; 
dysregulation of this balance may affect the functional integrity of the villous membrane 
and ultimately result in compromised fetal growth and development.   
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1.7.1 Proliferation 
Growth and integrity of the placental villous trees is completely dependent upon the 
continuous proliferation and fusion of villous cytotrophoblast progenitor cells 
throughout gestation (200), as their daughter cells are needed for growth and 
regeneration of the overlying syncytium; without fresh input of cytotrophoblastic 
material the syncytium dies necrotically within a few days. Cytotrophoblast 
proliferation is thus a continuous process from the first trimester to term, albeit to a 
lesser degree (195; 201-206).  
 
In the placenta, few markers of trophoblast cell cycle initiation and progression leading 
up to syncytial fusion are known and understanding the molecular regulation of 
cytotrophoblast proliferation/differentiation into syncytiotrophoblast is still in its 
infancy. However, is has recently been shown through semi-quantitative 
immunohistochemical studies to be coordinated with mitotic regulators of the cell cycle 
which change as a function of both differentiation and gestational age (207). 
Furthermore, growth factors such as epidermal growth factor (EGF) (208), transforming 
growth factor alpha (TGFα) (208), and the insulin-like growth factors I and II (IGFI, 
IGFII) (209) are also involved in the trophoblast life cycle.  
 
Oxygen is a key regulator of cytotrophoblast proliferation in vitro such that proliferation 
is inversely related to oxygen tension (210). These studies showed that under hypoxic 
conditions, cytotrophoblast proliferation is increased alongside a necrotic 
syncytiotrophoblast, suggesting that low oxygen levels inhibit syncytial fusion. 
Conversely, increased oxygen levels lead to decreased cytotrophoblast proliferation 
which may also lead to necrotic shedding versus apoptotic shedding (Figure 1-11). 
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Figure 1-11 The effect of oxygen and cytotrophoblast proliferation 
Abnormal oxygenation may alter the balance between apoptotic versus necrotic shedding of trophoblast 
material into the maternal circulation. Stating with the normal turnover in A, figures B-D describe 
alterations of the turnover. Thickness of arrows indicates the rate of the respective process (128). 
 
1.7.2 Differentiation and Syncytial Fusion 
Recruitment of the cytotrophoblast into the syncytium (syncytial fusion) is coupled to a 
highly complex and coordinated differentiation process which to a large extent remains 
unclear, but which is thought to comprise two levels (211). In the first differentiation 
process fusion of cytotrophoblast cells with syncytiotrophoblast is preceded by the 
accumulation of RNA, proteins and organelles within the cytotrophoblast (85) together 
with ongoing changes in nuclear shape, size and contents of heterochromatin and 
nucleoli as fusion progresses (212). This is followed by a second differentiation process 
in which the newly incorporated syncytiotrophoblast undergoes functional maturation 
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thereby adopting a cellular phenotype necessary for a functioning epithelium eventually 
succeeded by terminal differentiation and sequestration into syncytial knots. Both 
processes are known to be associated with the apoptosis cascade (213).  
 
Cytotrophoblast differentiation is characterised by arrest of mitosis. The decision of a 
CT cell to exit the cell cycle, differentiate and fuse with the overlying syncytium is 
mediated by the asymmetric expression of the trophoblast-specific transcription factor, 
GCM1 (183; 191). In humans, up-regulation of GCM1 results in reduced 
cytotrophoblast proliferation and the induction of syncytial fusion subsequently 
resulting in de novo syncytiotrophoblast formation (214)- analogous to its reported 
function in mice (181). The asymmetric expression of GCM1 therefore serves to 
maintain the pool of proliferating cytotrophoblast cells, but also which cells are selected 
for syncytial fusion (191). GCM1 is therefore crucial to syncytiotrophoblast formation.  
 
Syncytin1 is a direct downstream effector of GCM1 (193). Syncytin1, a protein encoded 
by the envelope gene of an endogenous retrovirus of the HERV-W family (192), is 
evidenced to play a direct role in mediating syncytial fusion of villous trophoblast (215), 
although there are inconsistencies within the literature concerning its localization and as 
to how and why syncytin1 can regulate fusion. Its role in trophoblast fusion has been 
demonstrated in numerous studies in which addition of cAMP analogues known to 
stimulate fusion (216), along with forskolin, an agent which increases cAMP 
intracellular levels (217), leads to the up-regulation of syncytin1 mRNA and subsequent 
fusion in BeWo cell lines (192), but also in primary cytotrophoblast cultures (218).  
 
The distribution of the protein however is less defined, with separate reports of 
syncytin1 immunolocalisation to the basal and/or the apical membrane of the 
syncytiotrophoblast layer, weak staining in cytotrophoblast cells and a subset of EVT 
cells. The almost exclusive expression of syncytin1 in the syncytiotrophoblast, implying 
synthesis post-fusion, is a paradoxical finding given the assumption that syncytin1 
initiates fusion (219). This implies that the syncytiotrophoblast is too involved in the 
process of initiating syncytial fusion, in line with studies suggesting that ageing areas of 
the syncytium are preferably involved in fusion. The involvement of 
syncytiotrophoblast in initiating fusion is further supported by the localisation of its 
receptors, ASCT1 and ASCT2 (RDR) to the syncytium (220). 
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Other key fusogenic proteins recognized in the process of syncytial fusion in the human 
placenta include ADAM2, ADAM12 (221), CD98 (222), connexin 43 (223), and the 
adhesion molecules cadherin-11 and E-cadherin (224). Furthermore, proteases involved 
in the apoptosis cascade also appear to initiate fusion, including caspase 8 (225) and 
phosphatidlyserine (195) (for full review see (211; 219)).  
 
1.7.3 Apoptosis 
Fusion of post-proliferative villous cytotrophoblast cells (GCM1-directed) with the 
syncytium is balanced by the removal of terminally-differentiated aged syncytial nuclei 
that have lost their functional importance which subsequently undergo apoptosis (i.e. 
programmed cell death) and packed into ‘syncytial knot’ regions. These nuclei are shed 
from the villous membrane in the form of apoptotic bodies into the maternal circulation 
so as to avoid a maternal inflammatory response. In normal pregnancy the turnover 
from syncytial fusion to shedding of syncytial knots takes around 2-3 weeks (195). 
Typical morphological features of an apoptotic cell include cellular shrinkage, 
membrane blebbing, nuclear condensation and fragmentation (226). 
 
Differentiation and syncytial fusion of villous cytotrophoblasts with the syncytium is 
therefore coupled to the initial stages of the apoptosis cascade (Figure 1-12) (227). 
Studies have shown that the initiator stages of apoptosis are likely activated and 
confined to a subset of differentiating daughter cytotrophoblast cells, and is involved in 
initiating and regulating, both temporally and spatially, fusion of daughter 
cytotrophoblast cells into the syncytium. Once fused, terminal differentiation, functional 
maturation and extrusion of syncytial nuclei from the syncytium is the result of the 
execution stages of the apoptosis cascade (195; 225; 228). Apoptosis thus plays a 
pivotal role in maintaining the balance between the input and output of material within 
villous membrane.  
 
The initiator stages of the apoptosis cascade are thought to be confined to the GCM1-
expressing daughter cytotrophoblast cells that are selected for syncytial fusion (191), 
thereby maintaining the pool of proliferating cytotrophoblast progenitor cells needed for 
further syncytial growth and regeneration throughout gestation. Following syncytial 
Placental Insufficiency Syndromes Chapter 1
 
 
 45
fusion, cytotrophoblasts enter the final stages or ‘execution’ stages of the cascade in the 
syncytiotrophoblast. 
Although induction of apoptosis is not well understood in the placenta (e.g. death-
receptor ligands FasL and TNFα/TNF-R1 (229; 230)), the final pathway leads to the 
induction of initiator caspases 8, 9 and 10, which are responsible for the first proteolytic 
events in the apoptotic cascade, such as cleavage of the cytoskeletal proteins vimentin, 
actin and fodrin, which is partly responsible for membrane blebbing (226). Post-
proliferative cytotrophoblast cells destined for fusion begin to express some of these 
apoptosis-related proteins, some of which have been shown to be a pre-requisite for 
syncytial fusion itself (195). Huppertz et al demonstrated the presence of active caspase 
8 in cytotrophoblast cells prior to syncytial fusion, and that blocking caspase 8 activity 
by either antisense oligonucleotides or peptide inhibition results in considerable 
reduction in trophoblast fusion in villous explant cultures and the accumulation of 
cytotrophoblast cells (225). These authors therefore concluded that caspase 8 functions 
as a pre-requisite for syncytial fusion in the villous cytotrophoblast and blockage of 
caspase 8 leads to the inhibition of fusion and subsequently progression of the apoptosis 
cascade in the syncytiotrophoblast. Subsequently, this leads to the ‘flip’ of 
phosphatidylserine from the inner to the outer plasma membrane of the trophoblast and 
acts as a signal for syncytial fusion (217; 231). These events hallmark early apoptosis, 
and are thus far reversible. 
 
These observations indicate that early apoptosis events are related to the differentiation 
and syncytial fusion of cytotrophoblast cells with the syncytiotrophoblast. Activation of 
the initiator caspases thus leads to the fusion of daughter cytotrophoblast cells into the 
syncytiotrophoblast, and subsequently the transfer of the apoptosis machinery from 
cytotrophoblast to syncytiotrophoblast.  
 
Once syncytial fusion has occurred, these early yet reversible stages of apoptosis do not 
immediately advance to the final execution stages of apoptosis, but instead are halted 
therefore preventing the premature loss of syncytiotrophoblast nuclei. Apoptosis is 
focally retarded due to the translation of the cytoplasmic anti-apoptosis oncoproteins 
Bcl-2, Mcl-1, and Mdm2 (expression of these proteins is greater in the 
syncytiotrophoblast compared to the cytotrophoblast) (228; 232). 
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Figure 1-12 Villous trophoblast apoptosis 
Molecular markers for certain stages of differentiation/apoptosis of the villous trophoblast. The 
machinery for the apoptosis cascade is present in the cytotrophoblast; however prior to fusion only the 
early and still reversible stages of apoptosis takes place. After syncytial fusion, the cascade is halted (e.g. 
Bcl-2) where it is restarted several weeks later so that the end stages of apoptosis can be found in discrete 
areas of the syncytiotrophoblast. Finally, late apoptotic nuclei are packed in syncytial knots and extruded 
into the IVS (adapted from 228). 
 
Progression of the apoptotic cascade may also be regulated at the initiator stage by flice-
like inhibitory protein (Flip) expressed in cytotrophoblast cells, which competes with 
caspase 8 for binding to the activated death-receptors (233). Furthermore, members of 
the X-linked inhibitor of apoptosis protein family (XIAP) (234) have been shown to be 
expressed in both cytotrophoblast and syncytiotrophoblast throughout gestation and can 
inhibit both initiator caspases (caspase 9) (235) and the effector caspases (236). 
 
These focal inhibitions are generally, but not inevitably, followed by activation of the 
effector caspases 3, 6 and 7 leading to the degradation of cytoskeletal proteins e.g. 
cytokeratin 18, forming a neo-epitope that can be detected immunohistochemically 
(M30) (195; 237). Reactivation of the cascade through irreversible activation of the 
execution caspases several weeks later is characterized by down-regulation of 
transcription, fragmentation and condensation of DNA, alteration of nuclear and cellular 
shape and finally formation of syncytial knots (228). 
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Syncytial knots contain densely-packed, pleiomorphic nuclei of high, mainly-annular, 
chromatin condensation and are released from the apical syncytiotrophoblast membrane 
into the IVS in the form of tightly-sealed membrane-bound vesicles serving to protect 
the mother from an inflammatory response. The mechanisms involved in the formation 
of these regions are unknown, however, aged nuclei seem to aggregate and move 
toward the villous tips where they accumulate into syncytial knots, the process of which 
is hypothesized to be driven by sheer mechanical stress from maternal blood flow; 
conversely syncytial knots do not form at sites with arrested maternal circulation in vivo 
(228). Furthermore, their mechanism of clearance after release is unclear, although 
syncytial knot fragments have been detected in the capillary beds of the maternal lungs, 
indicating that they are phagocytosed in the first capillary system after exit from the 
placenta i.e. the maternal lungs (212). 
 
1.7.4 Altering the Balance of Villous Trophoblast Turnover 
Given the previous analyses, syncytial integrity is therefore dependent upon the rate at 
which the three processes, proliferation, fusion and apoptotic extrusion occur. 
Alterations in the rate of only one of these processes will have a direct downstream 
consequence on the rate of other processes disturbing the placental transfer barrier, 
potentially leading to impaired placental function and ultimately compromised fetal 
growth (228). 
 
Proliferation: An increased rate of cytotrophoblast proliferation (provided no change in 
the rate of syncytial fusion), would lead to thickening of the trophoblast layer, resulting 
in an increased oxygen diffusion distance, and hence reduced oxygen uptake into the 
fetal capillaries. Conversely, decreased cytotrophoblast proliferation would result in 
fewer cytotrophoblast cells incorporated into the syncytium, which may shift 
trophoblast apoptosis towards necrosis (non-programmed cell death) due to the lack of 
trophoblast regeneration (210), and limit the growth potential of the chorionic villi.  
 
Fusion: Alterations in the rate of syncytial fusion will have similar effects on the 
syncytiotrophoblast as for cytotrophoblast proliferation but the effects on the 
cytotrophoblast will be different. Reduced syncytial fusion will increase the 
cytotrophoblast layer such that in extreme cases the cytotrophoblast may become 
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multilayered. The syncytium may become necrotic due to the lack of fusion. 
Conversely, increased syncytial fusion may deplete the pool of villous cytotrophoblast 
progenitor cells.  
 
Apoptosis: The effect and the degree to which the subsequent changes in the rate of 
apoptosis will have on villous membrane function are largely determined by the location 
of these changes within the apoptotic cascade. Alterations or disturbances in the 
differentiation-syncytial fusion pathway (i.e. the early stages of the apoptotic cascade) 
will affect incorporation of the cytotrophoblast into the syncytium. A consequence of 
this could be failure to incorporate and transfer the molecular machinery required for 
apoptosis into the syncytiotrophoblast, and so therefore remains in the cytotrophoblast. 
The lack of mRNA and protein transfer to the syncytiotrophoblast may render the 
syncytiotrophoblast unable to complete the apoptosis cascade; a direct response to this 
may be cell-free release of aged syncytial nuclei through non-apoptotic processes such 
as secondary necrosis (if material is shed but apoptosis has not taken place), or 
‘aponecrosis’ (describes a truncated form of apoptosis with an incomplete execution 
followed by degeneration by necrosis). On the other hand, because syncytial fusion 
focally retards the cascade, the rate of syncytial apoptosis may increase. Nonetheless, 
the final consequence would be that ‘late’ apoptosis occurs in the cytotrophoblast prior 
to syncytial fusion (228). Alternatively, if the apoptotic cascade is interrupted during the 
late stages of apoptosis, then apoptotic nuclei may accumulate within the 
syncytiotrophoblast leading to areas of apoptotic nuclei aggregates surrounding the 
villous membrane that will ultimately perturb villous membrane function (3).   
 
Therefore, maintaining a physiological balance between placental villous trophoblast 
proliferation, apoptosis and shedding is essential for sufficient maternofetal oxygen 
transfer; dysregulation of this balance may affect the functional integrity of the villous 
membrane and ultimately result in compromised fetal growth (201).   
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1.7.5 Villous Trophoblast Turnover in PET and IUGR 
Villous trophoblast turnover is evidenced to be altered in pre-eclampsia and IUGR. In 
pre-eclampsia, several studies have shown an increased rate and number of villous 
cytotrophoblast cells undergoing proliferation (201; 238; 239), as well as increased 
syncytiotrophoblast apoptosis and increased syncytial knotting (197; 240; 241). In 
contrast, studies demonstrate reduced villous cytotrophoblast proliferation, increased 
syncytiotrophoblast apoptosis and increased syncytial knotting in IUGR pregnancies 
(198; 240; 242). An altered balance between recruitment and loss of the villous 
trophoblast (i.e. differentiation) may underpin the villous pathology of these placentally-
mediated diseases.   
 
1.7.5.1 Pre-eclampsia  
The currently accepted hypothesis is that in pre-eclampsia, the rate of the entire villous 
trophoblast turnover is accelerated, commencing with increased proliferation of the 
cytotrophoblast followed by an increased rate of apoptosis in the syncytiotrophoblast 
(3). This imbalance is hypothesized to lead to the dysregulated shedding of necrotic 
syncytial nuclei, as opposed to the normal apoptotic release, and the excess release of 
anti-angiogenic factors (i.e. sFlt-1) which may contribute towards the systemic 
inflammatory response and endothelial dysfunction that characterizes the maternal 
syndrome of pre-eclampsia (23). The initiating factor for the alterations in the villous 
trophoblast is thought to be uteroplacental insufficiency (153). In a recent set of 
experiments, Huppertz correlated the pO2 of the uterine vein with the rates of villous 
cytotrophoblast proliferation and apoptosis and found that at any given rate, 
cytotrophoblasts from pre-eclamptic placentas displayed a higher rate of proliferation 
and apoptosis when compared to controls (3).  
 
What remains to be determined from these studies is the link between the increased rate 
of apoptosis and the pathophysiology of the condition. The process of apoptosis 
removes unwanted or old material in a temporally and spatially controlled manner (via 
apoptotic bodies) as to prevent the organism from eliciting an inflammatory response, 
which is the result of otherwise non-programmed cell death such as necrosis. Because of 
this, it seems unlikely that the apoptotic release of material in one case has no effect 
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(IUGR), whereas it should have a detrimental effect in the other case (PET) which is 
characterized by a maternal inflammatory response (213). 
 
Huppertz proposed that the increased rate of villous cytotrophoblast proliferation in pre-
eclampsia may lead to a higher rate of syncytial fusion, since a multilayered 
cytotrophoblast layer is not a feature of these placentas. This in turn, may lead to a 
greater amount of trophoblast material being introduced into the syncytiotrophoblast in 
comparison to the normal situation. Subsequently, syncytiotrophoblast apoptosis may be 
increased to counterbalance the increased cytotrophoblast input so as to maintain 
syncytial integrity. However, the syncytiotrophoblast may be unable to equal the 
increased incorporation rate of material into the syncytium with the rate of exclusion by 
increasing the rate of apoptosis. As a direct result, material is shed into the maternal 
circulation by ‘aponecrosis’; cells enter the apoptotic cascade but undergo incomplete 
execution and are therefore removed and degenerated by necrosis (213); hence the term 
‘aponecrosis’. Necrotic release of apoptotic subcellular fragments into the maternal 
circulation in pre-eclampsia may, in part, be responsible for the clinical manifestations 
of the syndrome such as the maternal inflammatory response (243), endothelial 
dysfunction (27) (Figure 1-13). 
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Figure 1-13: Schematic representation of trophoblast turnover.  
Normal pregnancy (A): (1) final events in cytotrophoblast differentiation (2) syncytiotrophoblast 
differentiation and finally (3) apoptosis takes place where material is extruded via syncytial knots (4). 
Pre-eclampsia (B): enhanced proliferation and syncytial fusion (1) may overwhelm the capacity of the 
syncytiotrophoblast in terms of differentiation (2) and apoptotic release (3) resulting in necrotic release 
(4) (adapted from (3)).  
 
1.7.5.2 IUGR 
Ultrastructural and 3D studies have demonstrated that the malformed terminal villi from 
IUGR pregnancies with abnormal umbilical artery Doppler display decreased numbers 
and mitotic activity of villous cytotrophoblast cells, accompanied by an ageing 
syncytium displaying increased numbers of apoptotic syncytial knots (1; 195; 212). 
These authors concluded that villous trophoblast turnover may be arrested in severe 
early-onset IUGR, and that reduced villous cytotrophoblast proliferation may account 
for reduced growth and elaboration of the gas-exchanging villi in combination with 
failed branching angiogenesis (100). 
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These same authors suggested that arrested trophoblast turnover may be a consequence 
of rising intra-placental oxygen levels due to the inability if the malformed terminal villi 
capillaries to extract it, which in turn may further compromise cytotrophoblast 
proliferation and syncytial fusion. Because syncytial fusion transfers the necessary 
mRNA, proteins and organelles needed for a functioning syncytium, the net result of 
these change may lead to a functional deficit in the active transport capacity of the 
syncytiotrophoblast, which in turn, may lead to fetal growth restriction independent of 
the impaired surface area for diffusional exchange (100). 
 
Other authors have subsequently confirmed reduced villous cytotrophoblast 
proliferation (244; 245) and increased trophoblast apoptosis (198; 240; 242) in IUGR 
pregnancies. Importantly, the increased rate of villous trophoblast apoptosis in IUGR is 
not accompanied by an increase in proliferation and so shedding of aged syncytial 
nuclei occurs via apoptosis, and hence IUGR is not associated with the same clinical 
manifestations as pre-eclampsia.  
 
1.7.5.3 SIDS 
The present investigation comprises a pilot study analyzing villous trophoblast turnover 
in placentas from infants succumbing to SIDS. Although not statistically significant, 
previous in-house studies revealed a trend towards a thicker villous membrane (82) in 
both the SIDS normal birthweight (NBW) and SIDS low birthweight (LBW) placentas 
which have the potential to limit physiological exchange of oxygen and nutrients from 
the maternal blood to the fetal capillaries. 
 
The present study is aimed at further investigating these changes, more specifically, 
potential morphological alterations in placental villous trophoblast; the cytotrophoblast 
and syncytiotrophoblast respectively. Because these placentas represent a form of pre-
placental hypoxia (52; 246; 247), proliferation and apoptosis may be increased in 
comparison to normal pregnancies at term. Such changes may lead to placental 
insufficiency resulting in compromised fetal growth and development through delayed 
or arrested fetal organogenesis in utero, contributing to the sudden and unexpected 
death of an infant ex utero. 
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1.8 Stereology and the Trophoblast 
Much of our current knowledge and understanding of human placental development 
stems from studies employing 3D quantitative stereological techniques. In the context of 
the placenta, stereology has identified and quantified the relevant developmental 
processes, including villous growth and maturation, villous trophoblast turnover, 
fetoplacental angiogenesis and passive diffusion, in both normal and complicated 
pregnancies (248; 249). The ability to count nuclei and obtain absolute numbers is 
however perhaps the most biologically valuable and informative property of stereology. 
These studies that showed that villous trophoblast is a continuously-renewing 
epithelium involving cytotrophoblast proliferation and recruitment, and 
syncytiotrophoblast differentiation and extrusion (212).  
 
However, despite this wealth of information, there remains a complete lack of 
stereological studies investigating trophoblast kinetics (i.e. proliferation, fusion and 
apoptosis) in normal and pathological pregnancies. A major limitation of such studies at 
present is the inability to accurately identify and phenotype subsets of villous 
cytotrophoblasts that either proliferate or are destined to fuse into the overlying 
syncytiotrophoblast. The implication of altered cytotrophoblast proliferation in pre-
eclampsia and IUGR is therefore based on 2D counting methods leads to inaccurate and 
irreproducible results in 2D. The integration of stereological techniques and 
immunohistochemistry in the present study therefore permits the accurate and 
reproducible quantification of proliferating cytotrophoblast cells and 
syncytiotrophoblast structure including evidence of apoptotic shedding via syncytial 
knots.  
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1.9 Hypothesis 
The overall hypothesis is that placentas from severe early-onset pre-eclampsia, IUGR 
and SIDS display divergent phenotypes of villous cytotrophoblast turnover and that 
these also differ from their late-onset phenotypes. 
 
The specific hypotheses are that: 
 
1. The small placentas from severe early-onset IUGR pregnancies display a reduced 
number of proliferating villous cytotrophoblast cells (similar to that of the mouse) with 
a reduced regenerative capacity for sustained villous growth leading to villous 
maldevelopment. This is hypothesized to reflect a reduction in the pool of villous 
cytotrophoblast progenitor cells.  
 
2. In pre-eclampsia, an increase in proliferating cytotrophoblast cells makes sufficient 
numbers of syncytiotrophoblast, but results in dysregulated syncytial shedding 
(necrotic and apoptotic) into the IVS contributing towards the maternal syndrome. 
 
3. In SIDS, cytotrophoblast proliferation and syncytiotrophoblast apoptosis are 
increased due to pre-placental hypoxia, leading to placental insufficiency resulting in 
compromised fetal growth and development through delayed or arrested fetal 
organogenesis in utero, contributing to the sudden and unexpected death of an infant. 
 
1.10 Aim 
Using stereological techniques, the first aim is identify the villous morphology in these 
diseases. Secondly, by integrating immunohistochemistry with stereological techniques, 
the subsequent aim is to estimate the volumes and numbers of proliferating villous 
cytotrophoblast cells, syncytiotrophoblast nuclei and syncytial knots in both early and 
late-onset PET, IUGR and SIDS. 
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2 Clinical Methodology  
Gestational age is the most important clinical variable in predicting maternal and 
perinatal outcomes. Severe early-onset pre-eclampsia and IUGR (<32 weeks) are 
associated with significant risk of maternal and fetal morbidity and mortality, whereas 
late-onset (32> weeks) disease is generally associated with favourable maternal and 
fetal outcome (16). 
 
Late-onset pre-eclampsia and IUGR are typically associated with different maternal and 
fetal phenotypes. Late-onset pre-eclampsia may present with comparable maternal 
severity to early-onset, but is usually associated with normal (12) or heavier fetal birth 
weight (13) and therefore IUGR does not often co-exist. Similarly, IUGR at term is 
usually evident as fetal distress in utero with favourable neonatal outcome. In 
comparison, early-onset disease involves considerable overlap, such that pre-eclampsia 
and IUGR requiring preterm delivery often co-exist (combined disease) (250; 251), and 
are associated with the most severe maternal and fetal phenotypes. Because these two 
diseases often co-exist in early gestation, clinical delineation between pre-eclampsia and 
IUGR is therefore difficult.  
 
There is, however, evidence demonstrating major differences in the placental phenotype 
between early-onset (252) and late-onset pre-eclampsia (152; 253) and IUGR (152), 
which may reflect different disease etiologies and trophoblast phenotypes.   
 
Therefore, the clinical aim was to:  
1. Determine pure disease from combined disease  
2. Distinguish trophoblast phenotypes in early- and late-onset placental disease 
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2.1 Cases 
Placentas were collected at delivery following local ethics approval from two hospitals: 
 
1. Mount Sinai Hospital (MSH), Toronto, Canada 
For high-risk pregnancies complicated by: 
 
Early (n=11) versus late-onset (n=6) PET 
Early (n=5) versus late-onset (n=4) IUGR 
Early (n=19) versus late-onset (n=6) PET-IUGR 
Gestational age-matched preterm (n=12) and term controls (n=13) 
 
2. Rotunda Hospital, Dublin, Ireland 
Placentas were retrieved from archived material from infant deaths as a result of SIDS: 
 
SIDS-NBW (n=12) versus term control (n=12) 
SIDS-LBW (n=12) versus term control  
 
2.1.1  Clinical criteria 
Early-onset was defined as infants delivered ≤ 32+6 weeks gestation. 
Late-onset was defined as infants delivered ≥ 33 weeks gestation. 
 
1. Pre-eclampsia 
Hypertensive disorders were defined according to criteria set by the American College 
of Obstetrics and Gynaecology (9).  
 
Pre-eclampsia was defined as:  
? blood pressure of 140/90 mm Hg or higher occurring ≥ 20 weeks gestation in a 
previously normotensive woman 
? proteinuria of 0.3g (+1) or higher in a 24 hr urine sample occurring ≥ 20 weeks 
gestation in a previously normotensive woman 
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Severe pre-eclampsia was defined as:  
? blood pressure ≥160/110 mm Hg or higher occurring ≥ 20 weeks gestation in a 
previously normotensive woman 
? proteinuria (3+) or higher in a 24 hr urine sample occurring ≥ 20 weeks gestation 
in a previously normotensive woman 
? HELLP syndrome occurring de-novo after 20 weeks gestation 
? co-existent IUGR  
 
Pre-eclampsia without IUGR was defined using the following fetal criteria: 
? normal fetal health tests including: amniotic fluid index (AFI), umbilical artery 
Doppler (PEDV), non-stress test 
? birthweights above the 10th centile for Canadian sex and gestation-specific 
birthweight centiles (254). 
 
No patients developed eclampsia. 
 
2. IUGR 
Small for gestational age (SGA) was defined as a birth weight ≤10th centile using 
Canadian sex and gestation-specific birthweight centiles (254). 
IUGR was defined as a subset of SGA based on (140): 
? serial ultrasound assessment showing falling growth centiles 
- estimated fetal weight <10th centile accompanied by fetal asymmetry  
- (elevated HC/AC ratio) 
? low AFI (<10 cm) 
? abnormal umbilical artery Doppler (AREDV) ultrasound assessment prior to 
delivery 
Hypertensive disorders were excluded. Stillbirths and intrauterine deaths were included 
in all pathological groups representing the most severe disease phenotype. 
 
3. SIDS 
SIDS cases were defined using the definition following the “Back to Sleep” campaign 
(255): “The sudden death of an infant between 1 month and 1 year of age which remains 
unexplained after a thorough investigation, including the performance of a complete 
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autopsy (Dr John Gillan, Ireland) examination of the death scene and a review of the 
clinical history, virology and bacteriology” 
 
SIDS placentas were subdivided into two categories 
? SIDS-NBW: birth weight above the 10th centile for gestational age 
? SIDS-LBW: birthweight below the 10th centile for gestational age 
 
4. Controls 
Controls cases were defined as fetuses that had 
? birthweight above the 10th centile for Canadian sex and gestation-specific 
birthweight centiles 
? normal umbilical Doppler velocimetry 
? no evidence of hypertension, proteinuria, and/or HELLP syndrome or IUGR 
 
Preterm controls were selected from pregnancies resulting from preterm premature 
rupture of the amniotic membranes (pPROM), spontaneous vaginal delivery, or cervical 
incompetence.  
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2.2 Stereology 
Stereology is a morphometric tool. It combines strict sampling rules and simple 
estimation tools that allow the unbiased and efficient estimation of 3D quantities such as 
volumes, surface areas, lengths and numbers of cells/tissues/organs from 2D 
histological sections. It provides global quantities as well as information concerning the 
local characteristics of the organ/object of interest, both of which are crucial to our 
understanding of how biological systems function at the whole organ level (256; 257). 
 
To obtain such information, the object/organ of interest must be sliced/sectioned 
generating thin two dimensional (2D) sections allowing the visualisation of otherwise 
unidentifiable objects. Sectioning however causes loss of dimensionality of geometrical 
information and the 2D profile will undoubtedly deviate from the natural situation in 
3D. By systematically randomising sampling, and the orientation and direction of slices 
through them, the ‘sectioning effect’ is overcome (258). For these reasons, stereology 
generates more reliable and accurate 3D quantities compared to ad hoc 2D 
quantification techniques (259).  
 
2.2.1  The Stereological Design 
The stereological design begins with sampling. The objective of sampling is to obtain 
samples that mimic the biological reality of the tissue/organ of interest; they must be 
representative of the whole tissue/organ. If the final sample of fields is to be 
representative, the selection of items at every stage (individuals, blocks, sections, fields 
of view, and measurements) of a multistage design must be randomised (260).  
 
The human placenta represents a heterogeneous organ which varies in structure both 
spatially and temporally. Due to this inherent variation, the final stereological estimate 
is completely dependent and biased towards how and where samples are obtained from 
the placenta. Restricting sampling to the periphery and maternal aspect will bias 
estimates towards terminal villi. In contrast, restricting sampling beneath the umbilical 
cord and fetal aspect will bias estimates toward stem and immature intermediate villi. 
Since it is the combination of all villous types which ultimately determines placental 
function, an unbiased sample should represent all villous types. Such samples are 
obtained stereologically using systematic uniform random sampling (SUR) (261), 
Clinical Methodology Chapter 2
 
 
 60
ensuring every part of the placenta has the same chance (probability) of being included 
into the final estimation thereby generating unbiased and efficient estimates.  
 
2.2.2  Unbiasedness and Efficiency 
Stereological estimates are unbiased and efficient. Unbiasedness (accuracy) and 
efficiency (precision) represent two statistical attributes used to describe the quality of a 
sample or outcome measure (Figure 2-1). In the context of stereology, accuracy refers to 
‘without systematic deviation from the true value’ (which is unknown) and precision 
refers to ‘with low variability after spending a moderate amount of time’ (262). Both 
depend upon systematic uniform random sampling. 
 
Precision 
A precise estimate is one which is efficient, repeatable and reliable (263). These 
attributes are associated with variation around the ‘true’ value. Variation is introduced 
into a stereological estimate in two ways, (i) biological variation reflecting inter-
individual variance, and (ii) sampling errors involving sampling, measurement precision 
and analytical technique. A stereological design should generate reliable estimates 
regarding the magnitude and variation (the mean and standard deviation) of the 
structural parameters of interest, and do so efficiently (264). 
 
The stereological aim is to ensure that biological variation exceeds sampling error since 
biological variation is so diverse it can rarely be eliminated. Sampling error is reduced, 
and precision increased, by increasing sample sizes and thus reducing the standard error 
of the mean for a group of individuals (264). 
 
Accuracy 
An accurate (unbiased) estimate is one which represents the ‘true value’- which is 
inherently unknown. Deviation from the ‘true’ value is introduced by systematic error 
(bias) leading to over- and under-estimations.  
 
Systematic error or bias consists of an unknown but consistent amount of deviation 
(inaccuracy) in an unknown but consistent direction. If systematic error is introduced 
due to assumptions and models, the bias can never be removed, and it is embedded in 
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the theory of the methodology. Increased sampling leads to more precise estimates, but 
does not result in more accurate estimates. In fact, increased sampling with a biased 
method leads to a greater deviation from the true value. Thus, once bias (e.g. 
methodology) is present, it can never be removed by increasing sampling at any level of 
the stereological investigation. Accuracy is therefore not synonymous with precision 
(257; 264; 265). 
 
The degree of bias is thus determined by the degree of deviation. Stereology calculates 
this deviation, known as the coefficient of error (see section 2.5.4) allowing the 
investigator to assess how accurately the estimate represents the true value. 
 
 
Unbiased and precise  accurate answer reached with relatively few measurements  
 
Biased but precise inaccurate answer reached with relatively few measurements 
 
Biased and imprecise accurate answer never reached even with vast measurements 
 
Unbiased and imprecise  accurate answer reached but required a large number of 
measurements 
 
Figure 2-1 Unbiasedness and efficiency in stereological analysis 
A graphical illustration of the difference between accuracy and precision in an experiment.  The top row 
of targets show high precision, that is the hits are closely clustered together, whereas the bottom row of 
targets show low precision, illustrated by the marked scatter of hits. In the left hand column, the average 
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of the cluster of hits tends towards the bull’s-eye, which means they are accurate. The right hand column 
shows the converse case, these hits are inaccurate or ‘biased’. In a given experiment we want to be in the 
left hand column, which can be achieved by using the correct sampling design and measurement tool. 
Whether the estimate is precise or imprecise depends on the object of interest, and in many cases can be 
controlled by working harder (adapted from 265).  
 
2.2.3  Systematic Uniform Random (SUR) Sampling  
Randomness 
By definition, sampling with equal probability equals random sampling. A deviation 
from randomisation introduces bias (inaccuracy) by increasing the probability that a 
particular outcome will be favoured above others. The fundamental requirement of 
stereological analysis is that all objects within the organ/object of interest have an equal 
probability of being sampled i.e. randomness of position and orientation (266). 
 
In random sampling, the position of every item in the sample is an independent choice, 
and this can lead to a particular area of the specimen being over-sampled, thus 
decreasing the efficiency of the estimate (260). Such clustering would generate 
imprecise estimates which take numerous trials before converging on the true value. 
Random sampling is therefore unbiased but inefficient. 
 
A more efficient way to sample is through systematic uniform random sampling which 
arrives at the theoretically unbiased estimate with less sampling, time, effort and cost. 
 
SUR Sampling 
Systematic uniform random sampling captures most of the biological variation by 
efficiently sampling a small but representative percentage of the total population with 
minimum sampling noise- “do more less well” (261). 
 
In SUR, the position of the first point on the specimen to be sampled is selected at 
random, after which each point has a predefined pattern at equal distances. This pattern 
must be kept uniform to eliminate bias and ensures that all parts of the specimen have 
the same chance of being included in the sample (261).   
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Two examples of uniform random sampling are illustrated in (Figure 2-2). In A, the 
specimen is systematically sampled by uniformly slicing at predefined distances 
throughout the whole of the specimen (x). Randomness of location is achieved by 
allowing the first slice to occur with uniform probability in the interval 0-d (A). Such a 
sample is said to be uniform random in position. It is not acceptable to always locate the 
first slice image at some predetermined distance from zero (e.g. 1cm) as this will not 
give all parts of the specimen the same chance of being sampled, resulting in a biased 
estimate (263). In B, randomness of sample position (0-d) is achieved by randomly 
‘throwing’ a uniform grid of holes of fixed distance apart onto the surface of the 
specimen thereby allowing each part of the specimen the same chance of being sampled 
(263). All placentas in the present study were sampled using SUR sampling in Figure 2-
2 B.  
 
SUR is also applied to 2D histological sections (Figure 2-3). Just as it is not acceptable 
to choose where you select your specimen samples, one cannot simply choose where to 
take your profile measurements. Each part of the section must have the same chance of 
being sampled.  
 
A B
 
Figure 2-2: Systematic uniform random sampling 
(A) The object is uniformly sliced at predefined distances with a random start in the interval (0-d). (B) A 
uniform grid of holes of fixed distance apart is thrown onto the object surface. Both methods generate 
systematic uniform random samples.  
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Figure 2-3: Uniform random sampling within 2D histological sections 
Fields of view (dashed boxes) are sampled SUR using the X and Y axes. The first point on the section is 
chosen at random, and from then on the distance between each point (dashed boxes) along the X-axis is 
kept uniform. The distance between points (dashed boxes) on the Y-axis is also kept uniform, but may 
differ from the distances employed for the X-axis. The values chosen must be kept consistent throughout 
each specimen (individual) to eliminate bias. 
 
2.2.4 Estimating Quantities in 3D 
2.2.4.1 Volume 
Estimation of the reference volume is crucial in stereology in order obtain absolute 
(global or total) quantities (267), which provide information regarding the whole organ 
i.e. the total number of cells in the human placenta. The reference volume represents the 
‘space’ within which the particular stereological measure is to be estimated, it can be 
anything, (e.g. individual, plant, organ, tissue). Failure to estimate the reference volume 
dictates that structure can no longer be related to function; hence this step is 
fundamental to a biological study.   
 
Volumetry can be performed in various ways, for example, the volume of a large object 
can be obtained from its weight or by fluid displacement (e.g. the placenta). The most 
Clinical Methodology Chapter 2
 
 
 65
commonly used method for estimating the reference volume is the Cavalieri Principle 
(261; 268).  
 
Cavalieri demonstrated that the volume of an arbitrary shaped object could be 
determined in a serially sectioned structure by the product of the slice areas and the slice 
thickness. A series of uniform parallel sections is cut through the object of fixed 
distance apart, producing slices of known equal thickness. The area of only one face of 
each section (e.g. anterior) is estimated by randomly superimposing a systematic array 
of test points on each face in turn, and counting the number of points overlying each 
face. Volume can then be estimated by multiplying the total number of points for all 
slices (disregarding the end section) by the area associated with each point and by the 
mean section thickness (268). 
 
2.2.4.2 Volume Density 
The Cavalieri Principle however, cannot provide direct estimates of component volume. 
Instead this is obtained by estimating volume density, or relative volume (Vv), which is 
the mean volume of a particular phase/feature of interest within the reference volume. 
Simply put, the volume fraction of ‘phase Y’ (e.g. trophoblast) within a reference 
volume (e.g. placenta) is the proportion of each unit volume of the reference space taken 
up by Y (269; 270). 
 
Volume density is estimated by the technique of point counting (271), such that volume 
density (fraction) is equal to the number of points falling within the phase of interest 
divided by the total number of points within the reference space. If the number of points 
falling within the reference space varies (heterogeneous morphology), then the 
estimator of volume fraction becomes a ‘ratio estimator’ (272). In this type of estimator, 
the phase of interest and the reference space vary from field to field, and it is not correct 
to simply average the individual estimates of volume fractions over all fields. Instead, 
the sum of all points hitting the phase of interest over all fields analyzed (m) is divided 
by the sum of all points hitting the reference space over all fields analyzed: 
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Total volume (Vtot) is estimated by multiplying volume density (Vv) by the reference 
volume (Vref) of the organ/object of interest: 
 
refvtot VVV ×=  
 
2.2.4.3 Point Sampled Intercept 
In addition to estimating the total volume of an organ/tissue (e.g. the placenta) and the 
volume occupied by trophoblast (volume density), point sampled intercept (PSI) is a 
method for estimating the mean volume of an object (e.g. mean volume of a syncytial 
knot) thereby generating a measure of object/particle size within an organ/tissue (265). 
 
The point sampled intercept (PSI) is a direct method for measuring the mean volume-
weighted particle volume (νv) (273). Objects are selected for analysis based on their 
volume rather than by number, whereby larger objects have more chance of being 
selected than smaller objects i.e. an object will be hit with a probability determined by 
its volume rather than by its mere presence. This is distinct from number-weighted 
mean volume (νN) where selection is based purely on the number of objects within the 
area of interest.  
 
Volume-weighted particle selection is achieved by randomly ‘throwing’ points into 3D 
space (systematic array of test points) and only measuring a particle if it is hit (i.e. 
sampled) by a point. Where a point hits a particle profile (e.g. syncytial knot), a line 
which crosses the profile is drawn through this point at a randomly selected angle to the 
outer edges of the profile, which is repeated for all points hitting particle profiles. 
 
The volume of each of the sampled particles is then estimated by measuring the length 
of the line passing from each of the sampled points. The part of the line intercepting the 
particle constitutes an isotropic point sampled intercept, l0, and its length provides the 
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basis for estimating mean volume-weighted particle volume. The third power of these 
intercept lengths averaged over all intercepts multiplied by π/3 is an unbiased estimator 
of (νv): where 
3
0l  is the mean cubed length of all intercepts. 
 
3
0
^
3
lVv ⋅= π  
 
2.2.4.4 Numerical Density 
The assumptions associated with counting objects in 2D are overcome stereologically 
by counting particles within volumes (3D) rather than areas (2D) (267). The disector 
principle (274) can be applied as a physical or optical technique for the estimation of 
total object number. 
 
2.2.4.4.1 The Disector 
The disector principle of counting objects requires the estimation of object number 
within a known volume. This volume can be generated using physical sections or 
alternatively optical sections. The volume is determined by the disector height (h) and 
the area of an unbiased counting frame (UCF) (258). The disector height is determined 
by the size (height) of the cell to be counted in relation to section thickness i.e. a cell of 
15µm cannot be counted in a 10µm thick section. In the physical disector, the disector 
height is generated by a known (fixed) distance between pairs of perfectly registered 
parallel sections (e.g. sections cut 10 µm apart). Particles are counted in 3D based on 
the presence of object transects within the ‘reference’ section and corresponding 
absence in the ‘lookup’ section (274).  
 
In contrast to the physical disector, the optical disector does not require the comparison 
of a pair of registered sections. Instead, two sections are created optically. This is 
possible if the sections are thin enough, which can only be achieved if using a 
microscope with a lens that has a thin focal plane thus creating the ‘optical section’. 
When the in-focus plane is thin, the in-focus image acts like a section. The observer 
focuses down through the slice. When a particle comes into focus the observer stops. 
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Since the particle has not been into focus up to this point it means that the particle did 
not exist in the look-up section. Particles are counted based on the counting frame rules 
(see section 2.2.4.4.2). 
 
2.2.4.4.2 The Optical Brick 
A more efficient way of generating direct counts of objects in 3D space is to count 
objects in one thick section of a defined volume, using an unbiased counting brick 
(265). Cells are counted within each optical disector using an unbiased optical ‘brick’ 
i.e. the volume of space generated by sweeping a 2D unbiased counting frame down 
through 3D space (Figure 2-4). It consists of three acceptance planes and five forbidden 
planes. Particles are counted only if they are totally inside the brick and do not intersect 
any of the forbidden planes. This removes bias introduced by counting cells with 
assumptions concerning size, shape and orientation. For a full review of unbiased 
counting rules see (258). 
 
In practice, counts are made using a microscope fitted with a microcator, which is used 
to measure depth (µm) in the z direction (the disector height). Objects are counted on 
the basis of the unbiased counting brick (258). An object close to the upper surface of 
the section is brought into sharp focus (e.g. a cytotrophoblast cell), the microcator 
zeroed, and the section is scanned downwards at a defined distance, for example 15 μm; 
this is the optical disector height (h). As each cell comes into sharp focus, two 
considerations need to be made. The first is whether the cell is sampled correctly within 
the unbiased counting brick, and secondly whether the optical section containing the 
particle is within the height of the optical disector. All particles of interest coming into 
sharp focus within these considerations are counted and recorded as ‘new events’.  
 
This is repeated for each uniform randomly selected field of view for the entire 
sample/subject generating a numerical density (NV); number per unit volume (Vf). This 
volume is generated by multiplying the area of the UCF (Af) by the disector height (h): 
 
hAV ff ×=  
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Numerical density (Nv) is then estimated by dividing the number of objects counted (Q) 
by the volume of the tissue sampled multiplied by the number of disectors counted ∑P: 
 
( )∑ ∑ ⋅⋅= hAP
Q
N
f
v  
 
Total number of objects (Ntot) is estimated by multiplying the numerical density (Nv) by 
total volume of the organ/object of interest, i.e. the reference volume (Vref): 
 
refvtot VNN ×=  
 
 
  
(A) 2D unbiased counting frame (B) 3D unbiased counting brick 
 
Figure 2-4: Unbiased counting frame applied to thin (A) and thick histological sections (B).  
(A) The 2D counting frame consists of one acceptance line (dashed blue line) and one forbidden line (red 
line). Objects that intercept the acceptance line or are completely within the counting frame and not 
touching either of the forbidden lines are counted (i.e. purple objects n=5). Those objects that intercept 
the forbidden line are not counted (i.e. orange objects, n=3). (B) The unbiased brick consists of a central 
volume, bounded by three acceptance planes and three forbidden planes, which at the edges of the 
diagram extend to infinity. Any object that is wholly within the brick or cuts the acceptance planes 
without anywhere cutting any forbidden surface is counted (adapted from 265). 
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2.2.4.5 Tissue Deformation of Thick Sections 
Estimating number using the optical disector in thick paraffin sections requires the 
estimation of tissue deformation in the z-axis. Deformation, usually in the form of 
shrinkage, can be introduced from tissue fixation and processing, histological 
preparation and/or immunohistochemical procedures (275). Broadly speaking, 
regardless of the spatial distribution (homogenous or differential), uniformity (uniform 
or non-uniform), or local deformation, the number of particles (the cardinality) is 
preserved. Specific requirements for optical designs dictate that no particles should be 
lost from the disector sample (e.g. the use of guard volumes), the final section thickness, 
t, should be known, and no differential deformation in the z-axis may occur (275). 
 
If, after estimation of Vref, there is homogenous, uniform deformation of sections in the 
z-axis, then local section thickness will differ from the original section thickness, 
meaning number is estimated using: 
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Where t  is the mean final section thickness, BA is the block advance; h is the dissector 
height, a is the area of the counting frame, p is the number of reference points per 
counting frame, ∑P  is the total number of counting frame points hitting the reference 
volume and ∑ −Q  is the total number of particles sampled. 
 
Under these same circumstances, if homogenous, non-uniform deformation is present, 
then local section thickness should be estimated for each field of view, and number 
becomes dependent on number-weighted mean section thickness:  
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Where −Qt  is the particle weighted mean section thickness. 
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The most likely scenario however, is the presence of all three kinds of deformation- 
deformation of the blocks, deformation of the sections in the plane of the section, and 
homogenous non-uniform deformation in the direction of the z-axis, in which case 
number is estimated using: 
 
∑
∑
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ah
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t
ADVDN QV :  
Where VD is the volume deformation before sectioning and AD is the volume 
deformation after sectioning. 
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2.3 Systematic sampling of fresh placental tissues 
All placentas were sampled using strict criteria that fulfil stereological requirements 
(263). Prior to sampling, placental weight and volume (fluid displacement) were 
determined from trimmed placentas (fetal membranes and umbilical cord removed). 
 
A perspex grid of systematic-uniformly arranged holes was randomly overlain onto the 
fetal aspect of each placenta (Figure 2-5). Approximately 4-6 full-depth pieces of tissue 
(fetal through to maternal) were obtained using a steel borer from every overlaying hole. 
Each sample was immediately washed in phosphate buffered saline (PBS) and cut in 
half along the longitudinal axis. One half was retained for molecular analysis and the 
other fixed in 10% neutral buffered formalin (NBF) and subsequently paraffin wax-
embedded (FFPE) for stereological analysis. Placental samples were randomly 
orientated during embedding as a defined orientation is not a requirement of volume or 
number estimation. 
 
 
 
 
Figure 2-5 SUR sampling of the human placenta 
 
 
Clinical Methodology Chapter 2
 
 
 73
2.4 Immunohistochemistry 
2.4.1 Immunolabelling of Cytokeratin 7 
A monoclonal antibody to cytokeratin 7 (CK-7) was used to immunolocalise 
cytotrophoblast cells in 5µm sections, thereby distinguishing them from 
syncytiotrophoblast nuclei and stromal cells. This was required for volume estimation of 
1.) cytotrophoblast cells and 2.) syncytiotrophoblast nuclei 
 
5µm sections were: 
1. Deparaffinised in     Xylene 1: 5 min 
      Xylene 2: 5 min 
2. Rehydrated in      100 % IMS: 2 min 
      95 %   IMS: 2 min 
         75 %   IMS: 2 min 
3. Running tap water for 2 min 
4. Incubated with 10 % hydrogen peroxide (H202) in methanol (MeOH) for 20 min 
5. Washed 3 x 3 min TBS (100mM Trisma Base, 150mM NaCL, pH 7.6) (Sigma) 
6. Incubated with Vector ready-to-use (R.T.U) 2.5 % normal horse serum for 30 min 
7. Incubated with CK-7 mAb (Mouse Monoclonal Anti-Human, clone OV-TL 12/30, 
Dako) diluted [1:150] in TBS for 1hr at room temperature (RT) 
8. Washed 3 x 3 min TBS 
9. Incubated with Vector ImmPress Peroxidase Anti-mouse Ig for 30 min at RT  
10. Washed 3 x 3 min TBS  
11. Incubated with Vector ImmPact DAB (using manufacturer’s instructions) for 10 
min  
12. Immersed in distilled water for 5 min 
13. Counterstained: Harris Haematoxylin 10 sec, Eosin 2 mins 
14. Rinsed in 1 % Acid-alcohol for 3 x 3 sec 
15.  Dehydrated in       75 % IMS for 30 sec 
      95 % IMS for 30 sec 
    100 % IMS for 2 min  
16. Cleared in xylene for 2 x 2 min and mounted 
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2.4.2  Double Immunolabelling of CK-7 and Ki-67  
Antibodies to CK-7 and Ki-67 were used in a sequential double-labelling protocol to 
immunolocalise cytotrophoblast cells and proliferating cytotrophoblast cells in 25µm 
thick paraffin sections, respectively. This protocol allowed the simultaneous estimation 
(in one thick section) of the number of 1.) cytotrophoblast cells 2.) proliferating 
cytotrophoblast cells, and 3.) syncytiotrophoblast nuclei (see Appendix 6). 
 
First antigen: CK-7 
25µm sections were: 
1. Deparaffinised in                     Xylene 1: 10 min 
            Xylene 2: 5 min 
2. Rehydrated in                     100 % IMS: 2 min 
95 %   IMS: 2 min 
75 %   IMS: 2 min 
Running tap water for 2 min 
3. Incubated with 10 % H202 in MeOH for 30 min 
4. Washed 3 x 3 min TBS-T (100mM Tris-HCl, 300mM NaCl, 0.05 % Tween, pH 
7.6) 
5. Incubated with Dako Protein block for 30 min 
6. Incubated with CK-7 mAb (Mouse Monoclonal Anti-Human, clone OV-TL 12/30, 
Dako) diluted [1:300] in TBS for 20 min at RT 
7. Washed 3 x 3 min TBS-T 
8. Incubated with Vector ImmPress Peroxidase Anti-mouse Ig for 20 min at RT.  
9. Washed 3 x 5 min TBS-T 
10. Incubated with Vector ImmPact DAB (using manufacturer’s instructions) for 1 min  
11. Immersed sections in distilled water for 5 min 
 
Second antigen: Ki-67 
12. Slides were incubated in a coplin jar filled with Citrate Buffer antigen retrieval 
solution (20 mM Citrate Trisodium Anhydrous, 2mM EDTA, pH 6.2, 0.05 % 
Tween) heated to 90oC for 15 min and then cooled for 20 min at RT  
13. Washed 3 x 3 min TBS-T  
14. Incubated with Dako protein block for 30 min 
Clinical Methodology Chapter 2
 
 
 75
15. Incubated with Ki-67 mAb (Mouse Monoclonal Anti-Human, clone MIB-1, Dako)   
diluted [1:50] in TBS for 2 hr at RT 
16. Washed 3 x 3 min TBS-T  
17. Incubated with Vector ImmPress Peroxidase Anti-mouse Ig for 30 min at RT 
18. Washed 3 x 5 min TBS-T  
19. Incubated with Vector VIP chromagen (manufacturer’s instructions) for 2 min  
20. Immersed sections in distilled water for 10 min 
21. Counterstained with Methyl Green (Vector) for 2 min at RT 
22. Immersed slides in distilled water to remove excess stain for 10 seconds 
23. Dehydrated immediately in 95% ethanol for 2 min, followed by 100% ethanol 2 for 
2 min 
24. Differentiated in 0.05% acetic acid/acetone for 10 seconds 
25. Cleared in xylene for 2 x 2 min and mounted using permanent non-aqueous media 
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2.5 3D Analysis of the Villous Trophoblast  
The morphological basis of villous trophoblast turnover was quantified stereologically 
by estimating the relative and absolute volume and number of (i) villous cytotrophoblast 
cells, (ii) cytotrophoblast cells positive for Ki-67, (iii) syncytiotrophoblast nuclei, and 
(iv) the relative volume and size (mean individual volume) of syncytial knots (SK). All 
analyses were carried out at the light microscope level aided by Visiopharm Integrator 
System for volume estimation (x40 magnification) and Kinetic Digital Stereology 5.0 
software for number estimation (x100 magnification, NA 1.25), with the aid of a BH2 
Olympus light microscope and a Heidenhain microcator (ND 281A) attached to the z-
axis of the microscope stage. Approximately 50 fields of view were analysed for each 
parameter per placenta.  
 
2.5.1 Volume Estimations 
Volume densities of placental components (the different classes of villi, villous 
cytotrophoblast cells, syncytiotrophoblast nuclei, and syncytial knots) were estimated 
using the technique of point counting (260) employing a quadratic array of coarse and 
fine test points (Figure 2-6, Figure 2-7). 
 
The number of coarse points overlying the different classes of villi were counted for 
each uniformly-random selected field of view (villi were identified using previously 
defined histological criteria (115)). Using the same lattice, the numbers of fine points 
falling within the different classes of villi were used to estimate the proportion occupied 
by cytotrophoblast (CK-7 positivity), syncytiotrophoblast (densely stained H&E nuclei 
at the maternal-fetal interface and corresponding absence of CK-7) and syncytial knots 
(H&E).  
 
Due to sectioning artefacts (276), true syncytial knots, (signifying syncytial 
degeneration in the final stages of normal villous trophoblast turnover) were defined as 
those SCT knot regions containing apoptotic nuclei displaying morphological features 
characteristic of the final stages of apoptosis (small densely stained nuclei, distinct 
annular chromatin). Knots displaying morphologically normal syncytial nuclei were 
subsequently quantified as non-apoptotic knots and were interpreted to contain a 
mixture of villous sprouts, bridges and flat sectioning. Necrotic nuclei were not 
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distinguished from apoptotic nuclei. The sum of all points hitting each of the different 
placental components divided by the sum of all points hitting the area of interest over all 
fields analyzed generated a volume density (Vv), which when multiplied by total 
placental volume, yielded absolute volume (VTOT). Stem and immature intermediate 
villi were grouped as ‘structural villi’ (SV) and mature and terminal villi were grouped 
as ‘peripheral villi’ (PV). For SIDS cases, immature and mature intermediate villi were 
grouped as intermediate villi (INT). 
 
Mean individual volume of syncytial knots (i.e. an indicator of size) was estimated 
using the point sampled intercept, PSI, (a direct measure of mean volume-weighted 
particle volume) (see references (273; 277) for full explanation). Briefly, twelve 
randomly orientated test lines, each containing twenty points per line, were randomly 
superimposed onto each field of view. Syncytial knots were selected based on the 
presence of a test point (from a line) overlying its surface and the length of each 
intercept line within each syncytial knot was measured. The third power of these 
intercept lengths averaged over all intercepts multiplied by π/3 generated PSI. 
 
 
 
Figure 2-6 Volume density estimation of the villous trophoblast.  
The number of points overlying the different villi types were counted (yellow points, 14) for each field of 
view. Points landing in the intervillous space were not counted. The number of points overlying 
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cytotrophoblast cells, C (9 points) and syncytiotrophoblast nuclei, S (7 points) were counted for the 
different villi types within each field of view.  
 
 
 
Figure 2-7 Volume density estimation of syncytial knots 
For volume density estimation, a uniform random grid of 256 points was randomly overlain onto each 
field of view. The number of points overlying non-apoptotic syncytial knots (N) and apoptotic syncytial 
knots (A) was counted. Densities were estimated for the different villous types and converted to total 
volumes by multiplying by total placental volume. For PSI estimation, twelve randomly orientated test 
lines, each containing twenty points per line (not to scale in image), were randomly superimposed onto 
each field of view. Syncytial knots were selected based on the presence of a test point (from a line) 
overlying its surface and the length of each intercept line within each syncytial knot was measured.  
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2.5.2  Numerical Density Estimations 
The double-labelled sections were used to estimate the numerical density of (i) CK-7 
and Ki-67 positive villous cytotrophoblast cells, and (ii) syncytiotrophoblast nuclei, for 
the different classes of placental villi using the optical brick technique as previously 
described (278).  
 
An unbiased counting frame (UCF) (red and green lines) is randomly superimposed 
onto each uniform-randomly sampled field-of view (Figure 2-8). Each field of view was 
focused through in the z-axis as a continuous motion; cells in the first (0-5µm) and last 
(20-25µm) 5µm of the 25µm sections were not counted to avoid the lost cap effect 
(279), generating a disector height of 15µm within which cells/nuclei were counted. As 
the section was scanned through the z-axis within the disector height (i.e. 15µm), each 
labelled cytotrophoblast cell (brown chromagen) that came into sharp focus and did not 
intercept the red forbidden line of the UCF was counted as a ‘new event’. The number 
of proliferating villous cytotrophoblast cells co-localised with Ki-67 (purple and brown 
chromagen) were also counted, as were the number of syncytiotrophoblast nuclei 
(green). 
 
The sum of the counts (per placenta) was then multiplied by the disector volume (i.e. 
15µm x area of the UCF) generating a number per unit volume of placenta, or, 
numerical density. This is then multiplied by total placental volume (estimated using the 
fluid displacement method) generating the total number of cytotrophoblast cells/Ki-67 
positive cytotrophoblast cells for the entire placenta.  
 
Section thickness at each field of view was recorded (µm) for subsequent estimation of 
tissue deformation, measured by focussing through the entire section. 
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Figure 2-8 Numerical density estimation of proliferating cytotrophoblasts 
Counting the number of proliferating cytotrophoblast cells in 25µm sections double immuno-labelled 
with CK 7 and Ki-67 using the optical brick technique (A-C, x1000). An unbiased counting frame (UCF) 
(red and green lines) is randomly superimposed onto each uniform-randomly sampled field-of view. As 
the section is scanned through the z-axis within the disector height (i.e. 15µm), each labelled 
cytotrophoblast cell (brown chromagen) that comes into sharp focus and does not intercept the red 
forbidden line of the UCF (cells marked with an asterisk) is counted as a ‘new event’ (A, no.1, 2, and 3) 
(B, no. 4 and 5) (C, no.6). The number of cytotrophoblast cells co-localised with Ki-67 (purple and brown 
chromagen) is also counted (A, no. 2, C no. 5). Hence, for this field of view, 6 cytotrophoblast cells are 
counted, 2 of which are positive for Ki-67. The sum of the counts (per placenta) is then multiplied by the 
disector height (i.e. 15µm x area of the UCF) generating a numerical density. 
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2.5.3 Statistical Analysis 
2.5.3.1 Co-efficient of Error 
The amount of sampling error produced by a stereological estimate (the difference 
between an estimate and a true value) is unknown. By estimating to co-efficient of error 
(CE), one can determine how accurate the stereological estimate represents the true 
value; the CE is essentially therefore a measure of ‘how good’ the stereological estimate 
is. A CE of less than 5 % is desired i.e. only a 5 % chance the estimate is inaccurate and 
does not represent the true value. 
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where k is the number of fields analysed, u is the number of points hitting the 
intervillous space and v is the number of points hitting the placenta (trophoblast). 
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where n is the total number of intercepts counted per placenta, and l is the intercept 
length estimated for each syncytial knot. 
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where Q is the number of trophoblast, and f is the total number of disectors falling 
within the placenta. 
 
Clinical Methodology Chapter 2
 
 
 82
2.5.3.2 Group Comparisons 
All data in this study was expressed as mean and standard error of the mean (SEM).  
A one-way analysis of variance (ANOVA) was used for: 
 
Pure disease: 
? Early-onset PET versus preterm controls 
? Early-onset IUGR versus preterm controls 
? Early-onset PET-IUGR versus preterm controls  
 
? Late-onset PET versus term controls 
? Late-onset IUGR versus term controls 
? Late-onset PET-IUGR versus term controls 
 
Combined disease: 
? Early-onset PET-IUGR versus early-onset PET = change due to IUGR 
? Early-onset PET-IUGR versus early-onset IUGR = change due to PET 
 
? Late-onset PET-IUGR versus late-onset PET = change due to IUGR 
? Late-onset PET-IUGR versus late-onset IUGR = change due to PET 
 
? SIDS-NBW versus term control 
? SIDS-LBW versus term control 
 
P-values below p=0.05 were considered statistically significant. Statistical analysis was 
carried out using Sigma Stat (2.0) aided by Microsoft Excel 2000.  
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2.6 Western Blotting for Cleaved-Cytokeratin 18 (CK 18) 
Protein expression of apoptosis-specific cleaved CK18 (recognised by the monoclonal 
antibody M30), was semi-quantified by western blotting. Analysis of full-length 
CK8/18 protein was carried out to validate M30 detection of cleaved CK18. This was 
repeated 3 times and the average data was reported. 
 
1. Samples 
Systematic uniform-random samples were used from the following cases:    
Preterm 
control 
Early-onset 
PET 
Early-onset 
PET-IUGR 
(n=3) (n=4) (n=6) 
 
2. Western blotting  
Total protein extraction  
1. Placental tissues were washed twice in ice-cold PBS and homogenised in RIPA 
lysis buffer (50mM Tris, 150mM NaCL, 1% Triton X 100, 1% Sodium 
Deoxycholate, 0.1% sodium dodecyl sulphate (SDS), pH 7.5) supplemented with 
complete protease inhibitor cocktail (Roche)  
2. Samples were left for 30 min to 1hr on ice and centrifuged at 4oC 10,000 rpm for 
15 min.  
3. Supernatants containing total protein were transferred to eppendorfs and protein 
concentration was determined according to the Bradford assay (280).  
4. Equal amounts of extracted protein (85µg) were resuspended in 4x SDS reducing 
loading buffer and denatured by boiling for 5min. 
5. 15µl of total protein was loaded and separated on 10% SDS-PAGE gel (15 well, 
1.5mm) by electrophoresis for 2hrs at 50V and transferred (2hrs) to 
Polyvinylidene Fluoride (PVDF) membrane.  
 
Immuno-detection for M30 and CK 8/18 
1. Membranes were blocked with 5% skimmed milk in 0.1% TBS-T for 1hr at RT  
2. Anti-M30 [1:500] (Peviva, clone M30) or anti-CK8/18 [1:1000] were diluted 
with 5% skimmed milk in TBS-T and incubated at 4oC overnight 
3. Membranes were then washed with TBS-T for 3x10 min 
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4. Incubation with either anti-mouse HRP conjugated Ig [1:1000] or anti-guinea 
pig HRP conjugated Ig [1:3000] respectively, diluted with 5% skimmed milk in 
TBS-T for 1hr at RT 
5. Antibody reactions were visualised using ECL detection kit (Pierce) and 
visualised using X-ray film.  
6. Membranes were then stripped and re-probed with goat polyclonal anti-beta 
actin [1:3000] (Santa Cruz) diluted with 5% skimmed milk in TBS-T and 
incubated at 4oC overnight, allowing for standardisation of data. 
 
Quantification 
Bands were semi-quantified by densitometry (Image J). The optical density (OD) of the 
analysed samples was normalised to an internal control sample run on each blot 
allowing for inter-blot comparisons. This was followed by overall standardisation to 
beta actin OD.  
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3 Placental Pathology 
3.1 Introduction 
Severe early-onset IUGR due to placental insufficiency is characterised by significant 
reductions in uteroplacental and fetoplacental blood flow, represented by abnormal 
uterine and umbilical artery Dopplers respectively (140). Failure to physiologically 
increase uteroplacental blood flow in the early second trimester due to failed trophoblast 
invasion of the maternal spiral arteries leads to a reduced blood supply relative to the 
growth demands of the fetus. Approximately one third of such pregnancies will develop 
abnormal umbilical artery Doppler (140). The underlying causes of abnormal umbilical 
artery Doppler are complex and include both damage to areas of placental tissue due to 
infarction, and increased vascular impedance from poorly developed capillaries in 
terminal villi secondary to a defective angiogenic drive in the late second trimester of 
pregnancy. The inability of the poorly developed capillaries to extract oxygen ultimately 
creates an arterialized or ‘hyperoxic’ intervillous space relative to maternal tissues, 
further limiting placental angiogenesis and trophoblast proliferation (100). These 
changes contribute to the stepwise deterioration in placental function and umbilical 
artery Doppler flow patterns that characterize severe IUGR pregnancies, which often 
co-exist with pre-eclampsia in early gestation.  
 
The pathological changes are associated with are numerous stereological and 
morphometric studies demonstrating reduced elaboration of the peripheral villous tree in 
severe early-onset IUGR (1; 2; 102; 152; 156; 161). Less understood is the impact of 
pre-eclampsia without IUGR on villous development in early gestation, mainly due to 
the lack of clinical delineation between the two. The aim of this chapter is to determine 
stereologically the villous phenotype of these diseases. 
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3.1.1 Hypothesis 
The specific hypotheses are that: 
 
1. Severe early-onset IUGR is associated with reduced volumes of peripheral villi 
compared with gestational age-matched controls. 
 
2. Severe early-onset pre-eclampsia without IUGR is associated with normal or 
increased volumes of villi compared with gestational age-matched controls. 
 
3. The villous phenotype in each early-onset disease differs from that observed in the 
late-onset variants of these pathologies. 
 
4. The villous phenotype of the SIDS placenta is similar to that of the late-onset pre-
eclampsia or IUGR placenta. 
 
3.1.2 Experimental Aim 
Determine the density and total volume of placental villi in placentas from early- and 
late-onset pre-eclampsia, IUGR, and SIDS using the stereological technique of point 
counting.  
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3.2 Results 
Patient profiles of all 76 women involved in the Toronto cohort are presented in 
Appendix 1. (It should be noted that clinical data sets are incomplete and data is 
presented where available). 
 
Placentas were delivered from non-smoking, chromosomally-normal, singleton 
pregnancies. All preterm and term controls showed no clinical or pathological signs of 
pre-eclampsia, IUGR, or any significant maternal co-morbidity.  
 
3.2.1 Early-onset pathologies 
3.2.1.1 Clinical data  
Clinical and placental characteristics for severe early-onset pathologies are summarised 
in Table 3-1. A total of 35 women required delivery before or at 32 weeks of gestation 
(70% caesarean delivery) due to severe pre-eclampsia and/or IUGR. Twenty of these 
women were nulliparous with median maternal age of 30 years (range 17-43 years) and 
gestational age of 29 weeks (range 24-32 weeks). Birthweights were significantly 
reduced (median 840g; range 420-1550g) for both IUGR and pre-eclampsia with co-
existing IUGR (50% <3rd centile and 79% 3-10th centile respectively), as were placental 
weights (43% and 45% respectively).  
 
All infants delivered as a result of maternal pre-eclampsia weighed between the 10-50th 
birthweight centile for gestational age with placental weights comparable to preterm 
controls. Since 58% of preterm controls had a birthweight between the 50-90th centile 
(weighing significantly more than expected), this may account for the significant 
reduction in birthweight in infants delivered as a result of severe early-onset pre-
eclampsia (P=0.013). There were no significant differences in placenta: fetus weight 
ratio for either early-onset pathology. 
 
All women delivering due to PPROM or cervical incompetence (preterm controls) or 
IUGR were normotensive throughout gestation and peripartum. The majority of pre-
eclamptic women presented with severe hypertension (91%> 160/90 mm Hg) and ≥3+ 
proteinuria (82%). Two out of these 11 women had pre-existing chronic hypertension 
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with superimposed pre-eclampsia. This prevalence increased to 32% (6 out of 19 
women) when pre-eclampsia co-existed with IUGR, 78% of whom presented with 
severe hypertension (>160/90 mm Hg) with ≥3+ proteinuria (63%). Thirty-six percent 
of pre-eclamptic women subsequently developed HELLP syndrome, the incidence of 
which fell to 21% when pre-eclampsia co-existed with IUGR.  
 
Complex obstetric and medical histories, including previous pre-eclampsia requiring 
preterm delivery (3 out of 35 women) and well controlled diabetes mellitus (DM) (2 
insulin dependent, 2 diet controlled and 1 gestational diet controlled DM) were 
observed for both pre-eclampsia with and without IUGR. Of the 2 women with diet 
controlled DM, 1 woman with pre-eclampsia with IUGR had a longstanding history of 
retinopathy and nephropathy. Idiopathic thrombocytopenia was observed in 1 woman 
from the preterm control study group.  No previous obstetric or medical complications 
were noted for IUGR.  
 
Infant mortality was low (11%), with perinatal deaths arising as a result of stillbirth (3 
out of 5 mortalities) or intrauterine fetal death (IUD) from pregnancies complicated by 
IUGR with and without pre-eclampsia. 
 
All preterm controls had normal Doppler assessment of umbilical artery blood flow. 
Abnormal uterine artery Doppler (UTAD) was observed in 11 of the 35 severe preterm 
pathologies. Nine of these were documented for women presenting with pre-eclampsia 
with co-existing IUGR; 8 bilateral and 1 unilateral diastolic notching. Only 1 of the 11 
women with pre-eclampsia had abnormal UTAD (unilateral diastolic notching). UTAD 
was mostly normal for IUGR pregnancies with 1 documented case of bilateral diastolic 
notching in the uterine arteries. 
 
Nearly all women (90%) with pre-eclampsia with co-existing IUGR had abnormal 
umbilical artery Doppler. Of the 17 documented abnormal findings, 11 women had 
absent EDF in the umbilical arteries whilst 6 had reversed EDF in the umbilical arteries. 
Three out of the 5 IUGR cases (60%) had documented AREDV in the umbilical 
arteries. The majority of pre-eclamptic women (82%) had positive end diastolic flow in 
the umbilical artery Dopplers (3 cases of ‘acute’ AREDV at delivery).  
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Table 3-1 Clinical and placental characteristics for severe early-onset pathologies 
Characteristic Control  (n=12) 
PET 
(n=11) 
IUGR  
(n=5) 
PET-IUGR  
(n=19) 
     
Gestational age† 
(weeks) 30 (26-32) 29 (26-32) 29 (26-31) 28 (24-32) 
Birthweight╫ (g)  1555 (970-1810) 1210* (710-1550) 700* (475-1260) 770** (420-1370) 
Placental weight† (g) 343 (220-500) 330 (150-410) 198* (150-260) 204• (100-290) 
Placenta:fetus wt ratio 0.241 (0.015) 0.291 (0.026) 0.285 (0.034) 0.263 (0.016) 
BW centile     
     > 50th (n) 7 0 0 0 
     10-50th (n) 5 11 0 0 
     < 10 (n) 0 0 5 19 
     
Caesarean delivery (n) 5 (42%) 9 (82%) 4 (80%) 14 (74%) 
     
Male‡ (n) 8/12 (67%) 5/9 (56%) 2/5 (40%) 10/18 (56%) 
Female‡ (n) 4/12 (33%) 4/9 (44%) 3/5 (60%) 8/18 (44%) 
      
Maternal age† (y) 28 (17-38) 30 (17-43) 28 (24-33) 32 (19-41) 
Nulliparous‡ (n) 6/11 (55%) 7/8 (88%) 3/3 (100%) 10/17 (59%) 
Blood pressure (mm Hg)  
   systolic†  - 166 (140-180) 131 (127-140) 169 (144-200) 
   diastolic†  - 109 (90-123) 89 (74-98) 104 (96-110) 
Proteinuria 0 ≥3+ (73%) 0 ≥3+ (67%) 
HELLP (n) 0 4 (36%) 0 4 (21%) 
     
Obstetric/Medical History     
Pre-eclampsia (n)  0 1 0 2 
Chronic hypertension (n)                 0 2 0 6 
Diabetes Mellitus (n) 1 2 0 2 
     
Abnormal Uterine artery Doppler (n) 1 (9%) 1 (20%) 9 (47%) 
     
Unilateral diastolic 
notching (n) - 1 0 1 
Bilateral diastolic 
notching (n) - 0 1 8 
     
Abnormal Umbilical artery Doppler (n) 3 (27%) 3 (60%) 17 (90%) 
     
Absent end-diastolic 
blood flow (n) - 2 1 11
∞ 
Reversed end-diastolic 
blood flow (n) - 1  2 6 
     
Abnormal AFI (<10) (n)    4 3 2 5 
     
Perinatal mortality (n)                     0 0 1 4 
     
 
† data presented as the mean and range  
╫ data presented as the median and range 
‡ (n) presented as a ratio of available data  
*significant difference compared to control   
**significant difference compared to PET 
• significant difference compared to IUGR 
∞includes 6 cases with absent/ intermittent reverse flow 
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3.2.2 Total Volumes of Placental Villi 
All volumetric data is presented in Appendix 2. 
 
Table 3-2 Volumetric estimates of placental villi for early-onset pathologies 
Parameter 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Total Placental volume 323 ± 23 322 ± 27 158 ± 21* 169 ± 14** 
Total Villous volume (cm3) 147 ± 11 153 ± 18 72 ± 12* 82 ± 7** 
VTOT Structural villi (cm3) 82 ± 12 90 ± 17        49 ± 11 51 ± 5** 
VTOT Peripheral villi (cm3) 64 ± 8 63 ± 7  23 ± 3* 31 ± 4** 
% peripheral villi: total villi 45 ± 6 45 ± 4  36 ± 7 38 ± 3 
Total Villous Density  0.46 ± 0.02 0.47 ± 0.02 0.45 ± 0.03 0.48 ± 0.01 
Vv Structural villi  0.25 ± 0.03 0.27 ± 0.03 0.30 ± 0.05 0.31 ± 0.02 
Vv Peripheral villi 0.21 ± 0.03 0.20 ± 0.02 0.15 ± 0.02 0.18 ± 0.01 
Data are presented as mean and SEM  
*significant difference compared to controls   
**significant difference compared to pre-eclampsia  
 
 
Early-onset PET had no significant effect on total placental or villous volumes (totals 
or densities) compared to preterm controls. 
 
Early-onset IUGR was associated with a significant reduction in total placental 
(P<0.001), total villous (P=0.001), and total volume of peripheral villi (P=0.005). No 
significant differences were observed for volume density estimates. 
 
Early-onset PET-IUGR was associated with significant reductions in the total 
placental (P<0.001), structural (P=0.013) and peripheral villous volume (P<0.001). No 
significant differences were observed for villous densities.  
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3.2.3 Late-onset Cases 
3.2.3.1 Clinical Data 
Table 3-3 summarises the clinical and placental characteristics for late-onset pathologies.  
 
A total of 16 women presented with either pre-eclampsia and/or IUGR in the second 
half of pregnancy requiring delivery (55% caesarean) at a median gestational age of 37 
weeks (range 33-41 weeks) and with a median birthweight of 2640g (range 570-4690g). 
Birthweights were significantly reduced in IUGR with (100% <3rd centile, P<0.001) and 
without pre-eclampsia (75% <3rd centile, P=0.003), as were placental weights (P=0.004, 
P<0.001 respectively). All infants born as a result of maternal pre-eclampsia weighed 
between the 10-50th centile for gestational age with placental weights comparable to 
controls; 46% of infants were between the 50-90th centile for gestational age. Mean 
placenta: fetus weight ratio increased in late-onset pre-eclampsia with co-existing IUGR 
in comparison to controls, pre-eclampsia and IUGR, but failed to reach significance 
(P=0.065). 
 
The majority of infants were male (65%) and born predominantly to second-time 
mothers (75% biparous) at a median maternal age of 33 years (range 26-43). 
Approximately 50% of pre-eclamptic women with and without IUGR presented with 
severe hypertension (>160/90 mm Hg) (50% and 33%) and ≥3+ proteinuria (33% and 
50%). One of these women had pre-existing hypertension and one woman subsequently 
developed HELLP syndrome. All women from control and IUGR pregnancies were 
normotensive before and throughout gestation.  
 
No complex obstetric or medical problems or perinatal mortalities were recorded for 
any of the term pathologies; however a history of DVT was noted in 1 woman in the 
control group.  
 
UTAD was normal for term controls. Abnormal findings were noted for pre-eclampsia 
with (1 case of unilateral diastolic notching) and without IUGR (1 case of documented 
uteroplacental insufficiency). Abnormal umbilical artery Doppler was noted for IUGR 
at term; absent EDF in the umbilical arteries was documented in IUGR with (60%) and 
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without pre-eclampsia (67%). PEDV in the umbilical arteries was associated with all 
pre-eclamptic and control cases.  
 
Table 3-3 Clinical and placental characteristics for late-onset pathologies 
Characteristic Control  (n=13) 
PET 
(n=6) 
IUGR  
(n=4) 
PET-IUGR  
(n=6) 
     
Gestational age† 
(weeks) 38 (33-41) 36 (33-40) 36 (33-37) 36 (34-38) 
Birthweight╫ (g)             3090 (2020-4690) 3000 (1970-4020) 1672* (1160-2400) 1600** (570-2325)
Placental weight† (g) 547 (360-700) 496 (352-603) 273* (180-338) 385** (256-500) 
Placenta:fetus wt ratio 0.172 0.172 0.163 0.296 
BW centile      
        > 50th  (n) 6  0 0 0 
        10-50th (n) 7 6 0 0 
        < 10 (n) 0 0 4 6 
     
Caesarean delivery (n) 9 (69%) 2 (33%) 3 (75%) 3 (50%) 
     
Male‡ (n) 9/13 (69%) 3/3 (100%) 3/4 (75%) 3/4 (75%) 
Female‡ (n) 4/13 (31%) 0 1/4 (25%) 1/4 (25%) 
      
Maternal age† (y) 33 (26-42) 30 (28-38) 32 (27-38) 34 (28-42) 
Nulliparous‡ (n) 6/13 (46%) 2/3 (67%) 1/4 (25%) 2/4 (50%) 
Blood pressure (mm Hg) 
    systolic†  - 157 (150-164) 115  151 (140-160) 
   diastolic† - 99 (91-107) 67 98 (80-110) 
Proteinuria 0 ≥3+ (33%) 1 (1+) ≥3+ (50%) 
HELLP (n) 0 1 (17%) 0 0 
     
Abnormal Uterine artery Doppler  (n) 1 (16%) 0 1 (16%) 
     
Unilateral diastolic 
notching (n)               -             1 utero.insufficiency 0 1 
Bilateral diastolic 
notching (n) - 0 0 0 
     
Abnormal Umbilical artery Doppler (n) 0 2 (50%) 3 (50%) 
     
Absent end-diastolic 
blood flow (n) - 0 2 3
 
Reversed end-diastolic 
blood flow (n) - 0 0 0  
     
Abnormal AFI (<10) (n)                0 1 1 1 
     
Perinatal mortality (n)                 0 0 0 0 
     
† data presented as the mean and range 
╫ data presented as the median and range 
 ‡ (n) presented as a ratio of available data 
*significant difference compared to control  
**significant difference compared to PET 
HELLP= hemolysis, elevated liver enzymes, low platelet syndrome 
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3.2.3.2 Total Volume of Placental Villi 
Table 3-4 Volumetric estimates of placental villi for late-onset pathologies  
Parameter 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Total Placental volume (cm3) 555 ± 33 487 ± 49 275 ± 42* 369 ± 40** 
Total Villous volume (cm3) 248 ± 14 247 ± 37 147 ± 26* 167 ± 14** 
VTOT Structural villi (cm3) 129 ± 14 89 ± 8 80 ± 14 87 ± 15 
VTOT Peripheral villi (cm3) 119 ± 13 157 ± 36 67 ± 18 80 ± 15 
% peripheral villi: total villi 48 ± 4 60 ± 6 44 ± 6 48 ± 9 
Total Villous density 0.45 ± 0.02 0.50 ± 0.04  0.53 ± 0.03* 0.46 ± 0.03 
Vv Structural villi 0.24 ± 0.02 0.19 ± 0.02 0.29 ± 0.03 0.25 ± 0.05 
Vv Peripheral villi 0.22 ± 0.02 0.31 ± 0.05 0.23 ± 0.04 0.21 ± 0.03 
  Data are presented as mean and SEM  
  *significant difference compared to controls    
  **significant difference compared to pre-eclampsia 
 
Late-onset PET had no significant effect on total placental volume or total villous 
volume. However, there was a trend towards an increase in the volume density and 
percentage of peripheral villi compared to term controls (P=0.066). 
 
Late-onset IUGR was associated with significant reductions in total placental (P<0.001) 
and total villous volume (P=0.017). There was no significant difference in the total 
volume of structural or peripheral villi. Total villous density was significantly increased 
(P=0.038) due to a slight increase in stem villous density. 
 
Late-onset PET with IUGR displayed significant reductions in total placental 
(P=0.004), and total villous volume (P=0.003). No significant difference was observed in 
the total volume or density of structural villi or peripheral villi.  
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3.2.4 SIDS Cases 
3.2.4.1 Clinical Data 
Table 3-5 summarises the clinical data from the SIDS cohort. Patient profiles of all 24 
women are presented in Appendix 1. Eight term controls were used from the Toronto 
cohort for comparison. 
 
SIDS infants were born either spontaneously (58%) or by elective caesarean section 
(33%) to predominantly biparous women at a mean gestational age of 40 weeks (range 
38-41 weeks). Postnatal age at death was not documented. SIDS-LBW infants had 
birthweights below the 10th centile for gestational age which were significantly reduced 
(P<0.001) compared to term controls. SIDS-NBW cases were comparable to term 
controls for birthweight. Placental weights were significantly reduced in SIDS-LBW 
(P=0.003) but not in SIDS-NBW. Placenta: fetus weight ratios for SIDS-NBW and 
SIDS-LBW were comparable to controls. 
 
SIDS-NBW infants were born to significantly younger mothers (P<0.009) with a mean 
maternal age of 24 years (range 15-39 years) compared to term controls (mean 32; range 
26-37 years). SIDS-LBW infants had a high incidence of maternal smoking during 
pregnancy (82%); this fell to 58% in SIDS-NBW. All women were normotensive. No 
prevalence of male births was observed for all SIDS cases.  
 
A high prevalence of previous perinatal deaths (cause unknown) were observed for both 
SIDS-LBW (42%) and SIDS-NBW infants (33%).  
 
Uterine and/or umbilical artery Doppler was not documented for SIDS cases due to the 
retrospective study design. No pathological lesions (Dr.J.Gillan, personal 
communication) characteristic of placental insufficiency were noted for all SIDS and 
control cases.  
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Table 3-5 Clinical and placental characteristics for SIDS placentas 
Characteristic 
Control  
(n=12) 
SIDS-LBW 
(n=12) 
SIDS-NBW 
(n=12) 
    
Gestational age† 
(weeks) 
40 (38-41) 39 (37-41) 40 (39-41) 
Birthweight† (g) 3507 (2640-4690) 2609* (1740-3420) 3425  (3110-3910) 
Placental weight† (g) 549 (398-700) 391* (176-676) 511 (280-700) 
Placenta:fetus wt ratio 0.16 (0.010) 0.15 (0.010) 0.15 (0.009) 
BW centile    
> 10th centile (n) 12 0 12 
< 10th centile (n) 0 12 0 
    
Caesarean delivery (n) 5/12 (42%) 4 (33%) 4 (33%) 
Male (n) 10/12 (83%) 6/12 (50%) 5/12 (42%) 
Female (n) 2/12 (17%) 6/12 (50%) 7/12 (58%) 
    
Maternal age† (y) 32 (26-37) 29 (19-46) 24* (15-39) 
Nulliparous‡ (n) 6/12 (50%) 3/12 (25%) 1/12 (8%) 
Smoker (n) 2 (17%) 10 (83%) 7 (58%) 
BMI    
      >24 (n) 2 2 1 
     <19 (n) 0 1 2 
    
History of perinatal 
mortality (n) 
3 5 4 
    
† data presented as the mean and range 
 ‡ (n) presented as a ratio of available data  
*significant difference compared to control 
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3.2.4.2 Total Volume of Placental Villi 
 
Table 3-6 Volumetric estimates of placental villi for SIDS cases 
 
Control  
(n=12) 
SIDS-LBW 
(n=12) 
SIDS-NBW 
(n=12) 
Total Placental volume (cm3) 513 ± 29 381 ± 34* 493 ± 23 
Total Villous volume (cm3) 264 ± 16 262 ± 22 347 ± 19* 
VTOT Stem villi (cm3) 57 ± 6 55 ± 7 66 ± 15 
VTOT Intermediate villi (cm3) 134 ± 14 84 ± 8* 109 ± 10 
VTOT Terminal villi (cm3) 71 ± 19 122 ± 19 174 ± 13* 
% terminal villi: total villi 24 ± 6 43 ± 5* 52 ± 3* 
Data are presented as mean and SEM  
*significant difference compared to controls   
 
SIDS-NBW placentas were comparable to controls in terms of total placental volume. 
However, there was a significant increase in total villous volume (P=0.003). This was 
due to a significant increase in the total volume of terminal villi (P<0.001) and 
percentage occupied by terminal villi (P<0.001). 
 
SIDS-LBW placentas were associated with significant reductions in total placental 
volume (P=0.008) and total volume of intermediate villi (P=0.008). The percentage 
occupied by terminal villi was significantly increased compared to term controls 
(P=0.025). 
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3.3 Discussion 
3.3.1 Volumes 
Volume is a crude measure of growth based on mass and physical composition in 3D. 
Stereological estimates of the volume of the placenta and its villi provide a measure of 
the overall growth and development of these structures, providing an index of placental 
function.  
 
Total placental volume is a global quantity providing an estimate of net functional 
capacity since this organ must attain a certain size to meet the increasing demands of the 
growing fetus as gestation advances. This in turn is dependent upon an exponential 
increase in the total volume of its functional units, the chorionic villi, or more 
specifically the gas-exchanging villi during the third trimester of pregnancy when fetal 
maturation takes place. Both of these estimates are relevant to the pathology of pre-
eclampsia, IUGR and SIDS. 
 
Unbiased estimates of villous volume were obtained using the technique of point 
counting (269), to produce a volume density (ratio of placental villi to total placental 
volume). Changes in volume density may arise from changes in one or both of the 
associated variables; a reference trap appears when these changes are presumed to be 
due to changes in volume without considering the reference space i.e. total placental 
volume (281). Villous densities therefore give no indication of function and total 
placental volume must be taken in account to obtain absolute volumes relating to the 
entire organ. 
 
Global changes in the total volume of villi result from an alteration in the number and/or 
size of placental villi and its subcomponents. Volumes of the underlying vasculature, 
the stromal core and the cytotrophoblastic tissues therefore determine the total volume 
of placental villi. Local changes in the volume density of placental villi (ratio of 
placental villi per unit volume of placenta) may not necessarily result in changes at the 
global level i.e. total placental volumes. For example, human adaptations to pregnancies 
associated with hypobaric hypoxia (282) and maternal anaemia (283) demonstrate total 
placental volumes comparable to normal pregnancy, however, they display increased 
volume densities of peripheral villi. 
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There is some degree of bias when estimating villous volumes inherent to placental 
collection. Blood loss and vasculature collapse as a result of spontaneous vaginal 
delivery may alter vasculature volume density (284) but should have minimal effect on 
villous density and trophoblast volumes. Nonetheless, every effort was made to ensure 
the umbilical cord was clamped immediately following delivery in order to preserve 
villous architecture. Although they may not be an exact representation of the in vivo 
state, estimates in this study are comparable to previous investigators.  
 
Numerous investigations report that villous angiogenesis drives villous development 
(101), and it is well established that disruptions in villous angiogenesis results in altered 
villous growth (102; 103). In this study, volumes of fetal vasculature were not estimated 
which may limit accuracy when assessing villous pathology in severe early-onset pre-
eclampsia, IUGR, and SIDS, since the former are largely determined by the 
oxygenation state of the intervillous space and subsequently the fetal vasculature (153). 
As such, the significance of this limitation stems from the fact that changes in total 
villous volume may not necessarily result from identical changes in the volume of the 
fetal vasculature. For example, whilst there may be a decrease in the total volume of 
villi, capillary volume density may be increased as part of an adaptive response; pre-
eclampsia with IUGR at term is typically associated with reduced total volumes of 
terminal villi and an associated increase in capillary volume density (161).  
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3.3.2 Early-onset PET and IUGR: Divergent Villous Phenotypes? 
The overall aim of this chapter was to determine the villous phenotype in severe early-
onset pre-eclampsia and IUGR on which the trophoblast hypotheses were based. 
Because severe early-onset pre-eclampsia and IUGR often co-exist, few studies have 
‘clinically’ separated the two pathologies. By carefully selecting pre-eclamptic cases 
with normal umbilical artery Doppler, the principal finding from this chapter is that 
severe early-onset pre-eclampsia and IUGR differ in their impact on placental villous 
volume. Whilst pre-eclampsia had no significant effect on villous volume, severe early-
onset IUGR had a major impact on placental morphology. This suggests different 
patterns of villous development, indicative of divergent trophoblast phenotypes, in 
severe early-onset pre-eclampsia and IUGR.  
 
There is general agreement between investigators using both molecular (113) and 
morphometric analyses (2; 152) that IUGR is associated with major defects in the 
development of the gas-exchanging villi, due to defective angiogenesis represented by 
AREDV in the umbilical artery (150). The pattern of villous maldevelopment is referred 
to as ‘failed branching angiogenesis’ associated with intraplacental ‘hyperoxia’, in 
which the oxygen content of maternal blood in the IVS increases (relative to maternal 
tissues) due to the inability of the malformed terminal villi capillaries to extract it (153). 
In the present study, placentas from severe early-onset IUGR with AREDV in the 
umbilical arteries displayed significant reductions in placental weight, total placental 
volume, the total volume of villi and the total volume of peripheral villi. This confirms 
the villous phenotype on which the trophoblast hypotheses are based, and is consistent 
with morphometric data describing villous maldevelopment in severe early-onset IUGR 
(1; 2; 102; 152; 156; 161). Significant reductions in the above parameters were also 
observed in severe early-onset PET-IUGR, plus an additional reduction in the total 
volume of structural villi.  
 
Interestingly, there was a trend towards an increase in the volume density of both stem 
and immature intermediate villi in severe early-onset IUGR placentas (with and without 
pre-eclampsia), which may account for the fact there where no changes in total volume. 
The increase in density may result from an increase in either the number or size of these 
villi and/or accompanying vessels. From a developmental perspective, the decisive 
factors for placental growth and maturation depend upon when and to what extent 
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mature intermediate villi develop out of immature ones. Increased numbers indicates 
failure of immature villi to form mature intermediate villi, such that these vessels 
continue to branch into mainly immature villi resulting in less mature intermediate villi 
and terminal villi; hence, placental immaturity (285).  
 
Equally likely is an increase in size of the vessels. One study reported tertiary-stem villi 
vessel wall hypertrophy with a reduction in luminal circumference in IUGR (between 
28-38 weeks gestation), hypothesised to be due to the release of vasoactive substances 
that cause chronic vasoconstriction and vascular wall hypertrophy (286). Increased stem 
vessel density in this study is inconsistent with numerous investigations (using mainly 
2D histological quantification) demonstrating significant reductions in stem artery 
density, postulated to be due to ‘obliteration’ of pre-formed arterioles, as previously 
reported (287). However, no significant differences in stem villi vascularisation were 
identified using systematic sampling and stereological tools (288).   
 
Villous immaturity is an attractive concept in the placental pathology for severe early-
onset IUGR, but is a rare finding at term (289). It is not clear whether in the severe 
IUGR placenta, the delay in villous maturation is defective from the outset of pregnancy 
or whether there is an “arrest” of development of a previously normal maturing villous 
tree. However, the trend towards an increase in the density of immature intermediate 
and stem villi in the present study support the latter theory, giving even more credence 
to the notion of an ‘early origin’ of ‘early-onset’ IUGR via dysregulated cytotrophoblast 
biology. 
 
A more widely supported villous phenotype has been suggested based on the scarcity of 
the villous pathology as mentioned above, and secondly, on the observed failure in 
VEGF-directed branching angiogenesis and predominance towards PGF mediated non-
branching angiogenesis leading to slender, longer capillaries with fewer loops, 
suggesting premature maturation of fetal vessels in terminal villi (155). 
 
Stereological analyses report an increased severity of the alterations associated with 
IUGR in the presence of co-existing pre-eclampsia; clinically the most severe 
phenotype (161). The data in this study is in disagreement with these observations. 
Severe early-onset IUGR displayed the most severe placental phenotype (in terms of 
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volumetric data) in comparison to early-onset IUGR with pre-eclampsia. Villous 
volumes resembled that of isolated IUGR, but the severities of the alterations were 
lessened by the presence of severe early-onset pre-eclampsia. This suggests a potential 
interaction effect of severe early-onset pre-eclampsia with severe early-onset IUGR. Is 
it therefore possible that pre-eclampsia has a ‘dampening’ effect on IUGR since on its 
own, severe early-onset pre-eclampsia has no overall effect on the volumes of villi in 
this study? 
 
Significantly, placentas from severe early-onset pre-eclampsia without any clinical signs 
of IUGR (normal umbilical artery Dopplers) were comparable to preterm controls in 
terms of placental weight, total placental volume, the total volume and density of villi, 
and the total volume and density of structural and peripheral villi. Umbilical artery 
Doppler is considered an indicator of placental vasculature resistance (290). Severe 
early-onset IUGR is typically associated with abnormal umbilical artery Doppler 
representing increased vascular resistance, associated with malformed terminal villi 
capillaries secondary to defective angiogenesis (290). A clinical criterion of this study 
for separating severe early-onset pre-eclampsia from IUGR was (in comparison to 
IUGR with AREDV) the selection of pre-eclamptic cases with PEDV in the umbilical 
artery, thereby signifying normal fetal growth i.e. birthweights were between the 10-50th 
centile for gestational age indicating adequate oxygen and nutrient exchange and hence 
normal fetal growth. 
 
The finding that severe early-onset pre-eclampsia with normal umbilical artery Doppler 
has no effect on villous volumes in the present study is unique, and is in disagreement 
with the only other published stereological assessment of villous morphology in early-
onset pre-eclampsia without IUGR (152).  
 
The previous study showed that early-onset pre-eclampsia with normal umbilical artery 
Doppler is associated with abnormally developed terminal villi compared to preterm 
controls; similar abnormalities to those observed in severe early-onset IUGR placentas 
with documented AREDV. Significant reductions were noted in the total volume, 
surface area and capillary volume of terminal villi. The discrepancy may be due to the 
fact that the previous study used a smaller, less strictly defined group of pre-eclamptic 
cases with significantly reduced birthweights and placental volumes compared to 
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preterm controls and IUGR. However, the present study used a more homogeneous 
group of strictly defined severe pre-eclamptic cases without any signs of IUGR based 
on normal Dopplers and birthweights above the 10th centile for gestational age. 
Significantly, the fact that the same pathway of villous maldevelopment was 
documented for both early-onset pre-eclampsia and IUGR, but that abnormal umbilical 
artery blood flow was only documented in some IUGR cases and not pre-eclampsia, 
seems confounding. It is therefore possible that some infants in early-onset pre-
eclampsia maybe subject to some degree of growth restriction in utero. 
 
One non-stereological morphometric assessment of villous development in pre-
eclampsia between 29-37 weeks gestation noted a high incidence of placental 
hypermaturity (285). Immature intermediate villi are transformed into mature ones too 
quickly producing vast numbers of terminal branches which is abnormal at every stage 
of gestation. Histologically there are many clusters of terminal villi with excessive 
capillarisation (153; 154) as a result of increased branching angiogenesis secondary to 
uteroplacental hypoxia. This pattern of villous development has been observed in both 
pre-eclampsia and IUGR (150) at term with PEDV in the umbilical arteries (153), which 
disagrees with the data in the present study. This could be due to the fact that a mixture 
of both mild and severe pre-eclamptic cases were used across a wider gestational age, 
and that analyses were based on one full-thickness section obtained from directly 
beneath the umbilical cord. Significantly, there were no cases of terminal villi 
deficiency as was seen in severe early-onset IUGR (stereological studies assessing fetal 
vasculature are reviewed in (155)).  
 
In the present study, fetal birthweights from severe early-onset pre-eclamptic 
pregnancies were between the 10-50th centile for gestational age. A birthweight above 
the 10th centile for gestational age is an indicator of adequate oxygen extraction by the 
‘appropriately-grown’ fetus, such that supply and demand between the placenta and 
fetus has been achieved.  
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Graph 3-1 Birthweight centiles in preterm control and severe early-onset PET  
 
Significantly, mean fetal birthweight was reduced in severe early-onset pre-eclampsia in 
comparison to controls. Importantly, the preterm control population used in this study 
displayed fetal birthweights that were considerably heavier than expected for gestational 
age; over half of the infants born prematurely had fetal birthweights above the 50th 
centile for gestational age. This is likely to account for the significant reduction 
observed in pre-eclamptic (mean) birthweight in this study. Crucially however, 
comparison of birthweights between the 10-50th centile for gestational age from preterm 
control pregnancies with pre-eclamptic birthweights revealed no significant difference 
(Graph 3-1), signifying normal fetal growth.  
 
The reduction in mean fetal birthweight (although not statistically significant when 
accounting for birthweight centiles) in severe early-onset pre-eclampsia lead to an 
increase in placental to fetal weight ratio in comparison to preterm controls 
(approaching statistical significance, P=0.077), which was similar to the increase 
observed for severe early-onset IUGR with fetal birthweights below the 10th centile for 
gestational age. An increase in the placental weight to birthweight ratio has been 
previously observed in pre-eclamptic placentas (between 31-39 weeks of gestation) 
(161); all infants had significantly reduced birthweights.  
 
Placental Pathology Chapter 3
 
 
 104
3.3.2.1 Summary 
? Severe early-onset pre-eclampsia was not associated with alterations in the 
volume if placental villi  
? Severe early-onset IUGR displayed significant reductions in the total volume of 
villi and the total volume of peripheral villi 
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3.3.3 Late-onset PET, IUGR and SIDS: Similar Villous Phenotypes? 
Pre-eclampsia and IUGR in late pregnancy are typically associated with normal 
umbilical artery Doppler indicating normal fetoplacental vascular impedence. Adaptive 
angiogenesis in peripheral villi is thought to reduce capillary resistance leading to 
normal umbilical Doppler velocimetry in late gestation, thereby ‘prolonging’ 
pregnancy. In the present study, placentas from late-onset IUGR and SIDS infants 
demonstrate increased villous volumes indicating possible villous adaptation (161). Pre-
eclampsia had no significant effect on villous volumes in late gestation.  
 
Placentas from late-onset IUGR displayed significant reductions in total placental and 
total villous volume, similar to their severe early-onset IUGR phenotype. However, in 
contrast, the volume density of placental villi was significantly increased in comparison 
to term controls. This increase was more attributable to a trend towards an increase in 
the volume density of stem and immature intermediate villi, rather than peripheral villi, 
a feature also observed for severe early-onset IUGR with AREDV. This is inconsistent 
with previous investigations reporting adaptive angiogenesis in peripheral villi 
(increased capillary volume fraction) from IUGR placentas at term with positive end-
diastolic flow in the umbilical artery (155). Interestingly, 2 of the 4 cases in the late-
onset IUGR group had absent end diastolic flow in the umbilical artery at 33 and 34 
weeks of gestation. From a physiological point of view, failure to detect such changes 
may be logical considering the growth restricted neonates required delivery before 
reaching full term, implying that the peripheral villous tree failed to initiate adaptive 
changes as previously documented. However, it is not possible with the current number 
of cases (n=4) to determine with any degree of accuracy whether this is a true 
morphological characteristic of this pathology at term.  
 
Late-onset pre-eclamptic placentas were comparable to late gestation controls (33-41 
weeks of gestation) in terms of total placental volume and total villous volume. 
Although not statistically significant, there was an apparent shift towards an increase in 
the total volume and density of peripheral villi (increase from 119 cm3 in controls to 
157 cm3 in late-onset pre-eclampsia) and decrease in structural villi (from 129 cm3 in 
controls to 89 cm3 in late-onset pre-eclampsia). However, these estimates displayed 
large variation and coupled with the low number of cases in this group, statistical 
significance was not reached.  
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Interestingly, the above changes were not evidenced in the combined disease. 
Reductions in total placental and total villous volumes were due to the effects of IUGR, 
and similar to severe early-onset cases PET-IUGR, was not the most severe phenotype 
in terms of villous maldevelopment.  
 
SIDS-NBW placentas were comparable to term controls with respect to total placental 
volume, whilst placentas from SIDS-LBW infants were significantly smaller. A novel 
finding from this study is that SIDS placentas display a significant increase in the total 
volume of terminal villi compared to term controls independent of fetal birthweight. 
Both SIDS-LBW and SIDS-NBW were associated with a 42% and 59% increase in the 
volume of terminal villi, respectively. Histologically terminal villi appeared congested 
with dilated capillaries. These observations suggest that the placenta has increased its 
surface area for diffusional exchange which may be a compensatory mechanism for 
‘potential insults’ that may have occurred early in gestation. Secondly, that these 
compensatory mechanisms have been initiated by factors relating to SIDS and not to 
LBW.  
 
The observed increase in the total volume of terminal villi in SIDS is a feature typically 
associated severe maternal anaemia (283), pregnancies at high altitude (282), and in 
some (291) but not all (292; 293) cases of maternal smoking during pregnancy. 
Placentas from these pregnancies are associated with ‘pre-placental’ hypoxia (153) and 
adaptive villous angiogenesis resulting in increased capillary volume density have been 
reported using both stereological (103) and corrosion casting methods (291).  
 
There is a strong correlation between fetal hypoxia and an increased risk of SIDS. The 
origin of fetal hypoxia is proposed to be associated with the high incidence of maternal 
smoking in SIDS events (166). In this study, the majority of SIDS infants were born to 
mothers who smoked throughout gestation; 10 out of 12 SIDS-LBW infants and 7 out 
of 12 SIDS-NBW infants were born to mothers who smoked. This data implies that 
smoking is more associated with LBW than to SIDS, and recent studies report an 
average 377g decrease in fetal birthweight as a result of maternal smoking during 
pregnancy (294).  
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Based on the considerations of placental adaptation to the maternal environment above, 
it may be presumed that the increase in terminal villi volume observed in SIDS 
placentas is due to the effects of maternal smoking, such that adaptive angiogenesis is 
initiated during early pregnancy secondary to ‘pre-placental’ hypoxia, thereby ensuring 
adequate diffusional exchange throughout gestation. However, by separating smoking- 
from non-smoking mothers in SIDS-NBW, there remains a significant increase in 
terminal villi volume in non-smoking SIDS-NBW mothers compared to non-smoking 
term controls (P=0.007). This suggests that the increase in terminal villi volume is 
independent of maternal smoking and LBW due to factors relating specifically to SIDS.  
As maternal smoking during pregnancy has been demonstrated to lead to fetoplacental 
insufficiency, and hence fetal hypoxia, it may be concluded that hypoxia is a 
prerequisite for the occurrence of SIDS. It is unsurprising then that hypoxic perinatal 
risk factors for SIDS include both pre-eclampsia (53) and intrauterine growth 
restriction.  
 
The increase in terminal villi volume in both SIDS-LBW and SIDS-NBW is more 
severe than that observed for late-onset pre-eclampsia and IUGR. Two interpretations 
are possible based on the assumption of increased terminal villi volume as an adaptive 
response to fetal hypoxia. First, that the origin of the presumed fetal hypoxia is 
uteroplacental insufficiency as documented for pre-eclampsia and IUGR. Second, that 
the SIDS placenta is able to compensate fully for the presumed pre-placental hypoxia, 
and thus remove the potential to develop pre-eclampsia and/or IUGR.  
 
These results suggest that SIDS-NBW placentas have sufficient compensatory reserve 
to maintain fetal growth in utero until term e.g. normal birthweights, which SIDS-LBW 
placentas lack. However, since these infants are still victims of SIDS, it suggests that 
these in utero mechanisms are insufficient to compensate for developmental 
abnormalities in organs critical for survival ex utero. Other causally associated 
mechanisms must therefore be present that do not necessarily result in altered placental 
morphology. Hence, while it is assumed that the placental abnormalities are causative 
for SIDS fetal deficiencies, it is also equally likely that these factors are first present in 
the fetus and are causative for placental abnormalities (82). As such, it is possible a 
fetally derived abnormality of the trophoblast may be sequelae of abnormalities in 
villous development.  
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3.3.3.1 Summary 
? Late-onset PET was not associated with any significant changes in villous volumes 
? Late-onset IUGR placentas displayed a significant increase in villous density 
? SIDS placentas displayed a significant increase in the total volumes of terminal villi 
independent of fetal birthweight 
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4 Cytotrophoblast Biology 
4.1 Introduction 
Fetal growth and survival are dependent upon successful villous development. Villous 
growth is proliferative, which is dependent upon the ability of a pool of villous 
cytotrophoblast progenitor cells to continually proliferate, such that the products of cell 
division can differentiate and fuse with the overlying syncytium throughout gestation. 
Studies in mice (181; 187; 191) and human villous explant models (185; 191) show that 
syncytial fusion is required for syncytial integrity and that the asymmetric roles for 
cytotrophoblasts is created by the asymmetric expression of the transcription factor 
GCM1. These studies suggest that the developmental potential of the villous 
cytotrophoblast lineage and its regenerative capacity are dependent upon the relative 
proportions of proliferating and differentiating cytotrophoblasts, and that this balance 
maybe the key player in determining the elaboration and final size (i.e. the physical 
parameters) of the placental villous tree, and subsequently its functional capacity. 
Reduced numbers of villous cytotrophoblast progenitor cells may therefore contribute to 
the small placental phenotype and reduced elaboration of the peripheral villous tree in 
severe early-onset IUGR. 
 
Studies also suggest that maternal health is dependent upon the balance between 
proliferating and differentiating villous cytotrophoblast cells (3). An accelerated 
regenerative capacity of villous cytotrophoblast cells (i.e. preference of villous 
progenitor cells over differentiating cytotrophoblast cells displaying an increased rate of 
proliferation and syncytialisation) is hypothesised to result in abnormal shedding of 
syncytiotrophoblast (e.g. aponecrosis) (210; 214), resulting in the excessive release of 
anti-angiogenic proteins (e.g. soluble Flt-1) (28) which contributes towards the systemic 
endothelial syndrome of pre-eclampsia.  
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4.1.1 Hypothesis 
The overall hypothesis is that severe early-onset PET and IUGR display an altered 
balance between villous cytotrophoblast proliferation and differentiation. 
 
The specific hypotheses are that: 
 
1. Severe early-onset IUGR placentas display reduced total numbers and density of 
proliferating villous cytotrophoblast cells in comparison to preterm controls 
 
2. Severe early-onset pre-eclamptic placentas display normal or increased numbers and 
density of proliferating villous cytotrophoblast cells in comparison to preterm 
controls 
 
3. Villous cytotrophoblast proliferation is normal or increased in late-onset pre-
eclampsia late-onset IUGR in comparison to term controls 
 
4. The villous cytotrophoblast phenotype in SIDS is similar to that observed for late-
onset pre-eclampsia or IUGR placentas 
 
4.1.2 Experimental Aim 
Using stereological analysis, the following parameters will be estimated:  
 
1. The volume of villous cytotrophoblast cells immuno-localised for cytokeratin 7  
 
2. The number of non-proliferating and proliferating villous cytotrophoblast cells by 
simultaneously estimating (i) the density of villous cytotrophoblast cells immuno-
localised with cytokeratin 7 and (ii) the density of villous cytotrophoblast cells co-
localised with the nuclear proliferation marker, Ki-67, in 25µm paraffin sections.   
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4.2 Results 
All volumetric and numerical data for the villous cytotrophoblast is presented in 
Appendix 3. 
 
4.2.1 Early-onset pathologies 
4.2.1.1 Total Volume of Villous Cytotrophoblast 
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Graph 4-1 Total CT volume in early-onset pathologies  
 
There were significant reductions in: 
IUGR    total trophoblast volume (P<0.001)  
total volume of CT (P=0.004)  
total volume of CT for peripheral villi (p=0.018) 
 
PET-IUGR total trophoblast volume (P<0.001) 
total volume of CT (P<0.001) 
  total volume CT for structural villi (p=0.005) 
total volume of CT for peripheral villi (p=0.009) 
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Table 4-1 Volume density of CT in early-onset pathologies 
 
 
 
 
 
 
Data 
presented as mean and ± SEM 
* significant difference compared to controls   
 
There were significant reductions in: 
PET  volume density of CT for structural villi (p=0.027) 
PET-IUGR volume density of CT for structural villi (P=0.013) 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Volume density 
C
0.016 ± 0.001 0.016 ± 0.002 0.014 ± 0.001  0.013 ± 0.002 
Structural villi  0.006 ± 0.001 0.004 ± 0.001* 0.006 ± 0.001  0.004 ± 0.0004* 
Peripheral villi  0.010 ± 0.001 0.011 ± 0.001 0.008 ± 0.001  0.010 ± 0.001 
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4.2.1.2 Total Number of Villous Cytotrophoblast cells 
 
Graph 4-2 Total CT number in early-onset pathologies  
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Total numbers of cytotrophoblast were significantly decreased in  
IUGR   peripheral villi (P<0.001) 
PET-IUGR structural (P=0.045) and peripheral villi (P=0.019) 
 
Table 4-2 Numerical density of CT in early-onset pathologies 
 
There were no significant differences in the numerical density of cytotrophoblast cells. 
There was however a trend for CT density to decrease in PET (P=0.071) (peripheral 
villi). 
 
 
 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Total  
Density (μm-3) 
2.1x10-4 ± 1.2x10-5 1.9x10-4 ± 1.1x10-5 2.1x10-4 ± 1.6x10-5 2.0x10-4 ± 6.7x10-6 
Nv Structural villi  5.4x10
-5 ± 1.0x10-5 5.8x10-5 ± 1.4x10-5 6.2x10-5 ± 1.3x10-5 4.4x10-5 ± 1.3x10-5 
Nv Peripheral villi 1.6x10
-4 ± 1.0x10-5 1.3x10-4 ± 8.1x10-6  1.4x10-4± 1.2x10-5 1.5x10-4 ± 5.5x10-5 
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4.2.1.3 Total Number of Ki-67 positive Villous Cytotrophoblast cells 
 
Graph 4-3 Total number of Ki-67 positive CT in early-onset pathologies 
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Table 4-3 Numerical density of Ki-67 positive CT in early-onset pathologies 
Data presented as the mean and ± SEM (x10-6) 
* significant difference compared to controls 
** significant difference compared to pre-eclampsia 
 
Significant reductions for 
IUGR  total number (p=0.006) and total density of Ki-67 +ve CT (p=0.044) 
density of Ki-67 +ve CT for peripheral villi (p=0.009) 
 
PET-IUGR total number (p<0.001) and total density of Ki-67 +ve CT (p=0.046)  
total number and density of CT for peripheral villi (p=0.009, p=0.007) 
 
 
 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Numerical  
density (μm-3)
6.2x10-5 (± 7.6) 6.1x10-5 (± 5.6)  3.6x10-5 (± 3.8)*    4.5x10-5 (± 2.8)**
Nv Structural villi  1.5x10-5 (± 3.8) 1.7x10-5 (± 3.5) 1.5x10-5 (± 3.9)    1.0x10-5 (± 1.8) 
Nv Peripheral villi  4.7x10-5 (± 5.5) 4.4x10-5 (± 6.4)  2.1x10-5 (± 3.0)*    3.5x10-5 (± 2.6)** 
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Graph 4-4 Percentage (%) of Ki-67 positive CT in early-onset pathologies 
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1:4  1:3  1:7 1:5 Ratio  
Ki-67: CT p value  0. 069  0. 002 0. 025 
 
There were no significant differences in the % or ratio of Ki-67 positive CT in structural 
villi compared to controls 
 
The percentage and ratio of Ki-67 positive CT cells was significantly reduced in 
peripheral villi in: 
 
• IUGR  50% reduction compared to preterm controls (P=0.018) 
• PET-IUGR 25% reduction compared to preterm controls (P=0.041) 
Structural villi 
Peripheral villi 
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4.2.1.4 Summary 
 
Severe early-onset PET 
• significant decrease in the volume density of cytotrophoblast in structural villi (Table 
4-1) 
 
Severe early-onset IUGR and PET-IUGR  
Significant reductions in 
• the total volume of cytotrophoblast cells (Graph 4-1) 
• the total number of cytotrophoblast cells  (Graph 4-2) 
• the total number and density of Ki-67 positive cytotrophoblast cells (Graph 4-3, 
Table 4-3) 
• the percentage of cytotrophoblast cells positive for Ki-67 ( 
•  
•  
• Graph 4-4) 
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4.2.2 Late-onset pathologies 
4.2.2.1 Total Volume of Villous Cytotrophoblast cells 
Graph 4-5 Total volume of CT in late-onset pathologies 
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There was no statistically significant difference in total trophoblast volume or total CT 
volume compared to controls 
 
Table 4-4 Volume density of CT in late-onset pathologies 
 Data presented as mean and ± SEM 
 
There were no statistically significant differences in CT volume density when compared 
to controls. 
 
 
 
 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Volume density 0.018 ± 0.003 0.018 ± 0.004 0.013 ± 0.005  0.017 ± 0.003
Vv Structural villi  0.007 ± 0.002 0.004 ± 0.001 0.005 ± 0.002  0.005 ± 0.001
Vv Peripheral villi 0.011 ± 0.001 0.014 ± 0.004 0.009 ± 0.003  0.012 ± 0.003
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4.2.2.2 Total Number of Villous Cytotrophoblast cells 
 
Graph 4-6 Total number of CT in late-onset pathologies 
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There was a significant decrease in the total number of CT in comparison to controls 
for: 
PET  total CT volume (P=0.048) 
IUGR  total CT volume (p=0.003), total CT volume for peripheral villi (P=0.013) 
PET-IUGR total CT volume (p=0.004), total CT volume for peripheral villi (P=0.004) 
 
Table 4-5 Numerical density of CT in late-onset pathologies 
Data presented as mean and ± SEM  
 
There were no significant differences in the numerical density of CT cells for late-onset 
pathologies in comparison to controls.  
 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Numerical Density 
(µm-3) 
1.8x10-4 ± 8.6x10-6 1.6x10-4 ± 1.6x10-5 1.8x10-4 ± 1.3x10-5 1.6x10-4 ± 1.2x10-5
Nv  Structural villi  4.5x10-5 ± 6.5x10-6 3.0x10-5 ± 7.1x10-6 4.0x10-5 ± 8.4x10-6 4.5x10-5 ± 1.1x10-5
Nv  Peripheral villi 1.3x10-4 ± 8.3x10-6 1.3x10-4 ± 1.5x10-5 1.4x10-4 ± 9.8x10-6 1.1x10-4 ± 6.3x10-6
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4.2.2.3 Total Number of Ki-67 positive Villous Cytotrophoblast cells 
 
Graph 4-7 Total number of Ki-67 positive CT in late-onset pathologies 
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IUGR displayed significant reductions in the total number of Ki-67 positive CT cells 
(P=0.009). This was specific for both structural (P=0.020) and peripheral villi (P=0.015).  
 
Table 4-6 Numerical density of Ki-67 positive CT in late-onset pathologies 
Data presented as mean and ± SEM (x10 -5) 
 
There were no significant differences in the numerical density of Ki-67 positive CT 
when compared to controls. 
 
 
 
 
 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Numerical  
Density (μm-3) 
4.7x10-5 (± 3.3) 4.6x10-5 (± 6.7) 4.8x10-5 (± 2.6) 5.4x10-5 (± 7.8) 
Nv Structural villi  1.1 x10-5 (± 2.0) 1.1x10-5 (± 2.6) 9.3x10-6 (± 2.2) 1.2x10-5 (± 2.4) 
Nv Peripheral villi  3.6x10-5 (± 2.4) 3.5x10-5 (± 5.6) 3.9x10-5 (± 4.1)  4.3x10-5 (± 6.3) 
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Graph 4-8 Percentage of Ki-67 positive CT in late-onset pathologies 
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1:5  1:3  1:5  1:4 Ratio 
Ki-67:CT p value  0. 114  0. 665  0. 394 
 
There was a significant increase in the percentage of Ki-67 positive CT for structural 
villi in PET (P=0.037).  
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1:5 1:5 1:4 1:5 Ratio 
Ki-67:CT p value 0. 625 0. 945 0. 340 
 
There was a significant increase in the percentage of Ki-67 positive cytotrophoblast 
cells in PET-IUGR (P=0.051) 
Peripheral villi 
Structural villi 
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4.2.2.4 Summary 
 
Late-onset PET 
• significant decrease in the total number of cytotrophoblast cells (Graph 4-6) 
• significant increase in the percentage of Ki-67 positive cytotrophoblast cells for 
structural villi (Graph 4-8) 
 
Late-onset IUGR 
Significant reductions in 
• the total volume of trophoblast (Graph 4-5) 
• the total number of cytotrophoblast cells (Graph 4-6) 
• the total number of Ki-67 positive cytotrophoblast cells (Graph 4-7) 
 
Late-onset PET-IUGR 
• significant reduction in the total number of cytotrophoblast cells (Graph 4-6) 
• significant increase in the percentage of cytotrophoblast cells positive for Ki-67 
specifically for peripheral villi (Graph 4-8) 
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4.2.3 SIDS 
4.2.3.1 Total Volume of Villous Cytotrophoblast cells in SIDS 
 
Graph 4-9 Volume density of CT cells in SIDS placentas 
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Table 4-7 Total volume of CT in SIDS 
Total Volume (cm3) 
Control 
(n=12) 
SIDS-LBW 
(n=12) 
SIDS-NBW 
(n=12) 
VTOT  Stem villi  0.60 ± 0.08 1.30 ± 0.26* 1.79 ± 0.32* 
VTOT Intermediate villi  3.32 ± 0.90 4.09 ± 0.59 4.59 ± 0.35 
VTOT Terminal villi 1.37 ± 0.32 2.03 ± 0.29 2.99 ± 0.50* 
Data presented as mean and ±SEM 
Immature and mature intermediate villi are grouped as intermediate villi 
* significant difference compared to control 
 
SIDS-NBW displayed a significant increase in CT volume density (stem p=0.006, 
mature p<0.001, and terminal villi, p=0.042), and total CT volume (stem p=0.002, 
terminal p=0.012). 
 
SIDS-LBW displayed a significant increase in CT volume density (stem p=0.008 and 
mature villi p=0.002) and total CT volume (stem villi p=0.017).  
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4.2.3.2 Summary 
 
SIDS-NBW 
• significant increase in the total volume and volume density of cytotrophoblast (stem, 
mature intermediate terminal villi) (Table 4-7,Graph 4-9) 
• significant decrease in cytotrophoblast volume density for immature intermediate 
villi (Graph 4-9) 
 
SIDS-LBW 
• significant increase in the total volume of cytotrophoblast cells for stem villi (Table 
4-7)  
• significant increase in the volume density of stem and mature intermediate villi 
(Graph 4-9)  
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4.3  Discussion 
4.3.1 Methodology  
Estimating the number of proliferating villous cytotrophoblast cells using stereological 
analysis 
Although stereologically-derived numbers, volumes and surface areas of the villous 
cytotrophoblast compartment have long established the structural parameters of 
syncytial and villous growth (i.e. hyperplastic vs. hypertrophic growth) (200; 295; 296), 
the actual growth fraction of this population (i.e. the number of proliferating 
cytotrophoblast cells) has not, until now, been determined stereologically in either 
normal or pathological pregnancies. The implication of increased villous 
cytotrophoblast proliferation in pre-eclampsia and decreased cytotrophoblast 
proliferation in IUGR is therefore based purely on 2D counting methods (typically using 
the proliferation marker Ki-67) and non-randomised sampling regimes, which are 
generally limited to mild disease presenting in the third trimester (Table 4-8). 
Furthermore, accuracy of these studies is in itself conflicted by comparable 2D studies 
describing no change in cytotrophoblast proliferation in both pathologies (199; 239; 
297). This inconsistency is due to the lack of sampling methodology and ad hoc cell 
counting methods which lead to inaccurate and irreproducible results in 2D.  
 
2D vs. 3D estimation of villous cytotrophoblast proliferation 
Why count in 3D? 
The estimation of the number of cells/nuclei in a histological section generating a 
‘number per unit area’ is to a certain degree valid, but only to the area in which they 
were analysed; the fact that this area does not represent the entire organ is a major 
avenue for misinterpretation of reality, which is inherently 3D. The advantage of using 
stereological analysis is that it estimates the total number of cells in the entire placenta 
(i.e. in 3D), thereby relating structural changes to potential functional changes at the 
whole organ level (256). 
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Table 4-8 Studies of CT proliferation using Ki-67 and 2D counting methods  
Proliferation 
marker 
Pathology GA Results Reference 
Ki-67  IUGR + AREDV 24-41 wks ↓ CT proliferation (244) 
 IUGR + AREDV 28-36 wks ↓ CT proliferation (1) 
Ki-67 IUGR Term No difference (199; 239; 297) 
 IUGR + PET 26-39 wks ↓ CT proliferation (245) 
Ki-67  PET 37-42 wks ↑ MIB-1/BrdU ratio (201) 
 PET  ↑ CT proliferation (238) 
 PET Term No difference (239) 
Ki-67 PET + HELLP Term ↑ CT proliferation (239) 
 
The numerous 2D cross sections of villi that appear in a histological section vary from 
field-to-field, in the number of villous cytotrophoblast cells and in the number of those 
undergoing proliferation, which are both spatially (immature intermediate villi display 
the highest proliferation index (201)) and temporally regulated (the density of 
proliferating cytotrophoblast cells declines with increasing gestational age (212)). Since 
it is the combination of all villi which determines the functionality of the 3D placenta, 
an unbiased representation of all villi should be obtained, which is achieved 
stereologically by uniform-random sampling at the placental and histological levels, 
thus giving all villi and cytotrophoblast cells the same probability of being selected for 
estimation. Restricting estimations to ‘one or two areas’ within a histological section 
from a single ‘chosen’ sample in 2D studies (e.g. many 2D studies use a single sample 
obtained directly beneath the umbilical cord) will lead to extremely inaccurate and 
erroneous conclusions of little biological worth.   
 
2D studies rely on ‘assumption-based’ counting methods 
A further inaccuracy of 2D studies is that cells/nuclei are counted based on their 
frequency within a histological section, which is governed by their size, shape and 
orientation (i.e. assumption-based counting). The number of 2D profiles (a ‘transect’ 
through a 3D cell) appearing in a histological section will therefore rarely mimic the 
number of 3D cells in reality. In practice, the angle and thickness at which the 
histological section is ‘physically’ taken (e.g. microtome sectioning) will ultimately 
determine the number of 2D profiles in a histological section biased to a cells size, 
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shape and orientation. This is likely to result in over/underestimation of particle number 
as: 
Size: large cells have more chance of being cut by a microtome blade than small cells 
possibly resulting in overestimation of cell number. Conversely, smaller cells have a 
higher improbability of being included into any given section thickness resulting in 
underestimation. 
Shape: irregular particles (e.g. ganglion) will be cut in several places by the blade in the 
same plane resulting in multiple profiles appearing in one histological section, making it 
difficult to distinguish whether the multiple profiles belong to the same cell or not, 
leading to overestimation of particle number. 
Orientation: fusiform cells (e.g. smooth muscle cells) will be cut more times using 
transverse sections than by longitudinal sections, therefore cell morphology also needs 
to be taken into account.  
 
Given the dangers highlighted above and the fact that 2D rarely mimics reality, if you 
ass-u-me, you make ass out of u and me (259). To overcome these assumptions, 
stereological counts are made within a defined volume of tissue, using either one thick 
section (optical brick technique (279)) or a pair of thin, perfectly-registered serial 
sections a known distance apart (physical disector technique (274)). Cells are counted 
within an unbiased counting frame (258) ensuring cells are counted only once, 
generating the number of cytotrophoblast cells per unit volume of placenta, or 
numerical density.  
 
Interpreting total numbers in stereological analysis 
The total number of proliferating cytotrophoblasts cells in the human placenta is 
estimated by multiplying numerical density by total placental volume. From a 
stereological perspective, the total number of cytotrophoblast cells in the placenta 
therefore depends upon placental volume and the numerical density of cytotrophoblast 
cells. For there to be no change in the total number of proliferating cells, the reference 
volume and numerical density must remain unchanged compared to a population 
parameter. Alternatively, total numbers would remain unchanged if the reference 
volume increased whereas the numerical density decreased, and vice versa.   
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An increase in numerical density therefore does not dictate a global increase in the total 
number of cells, since the reference space in which the cells are contained may be 
significantly smaller (i.e. reduced placental volume), resulting in no change or a 
significant increase in the total number of cells. Conversely, a decrease in numerical 
density does not automatically result in a global decrease in the total number of cells 
since the reference space in which they are contained may be larger (i.e. increased 
placental volume), resulting in no change or a significant decrease in the total number of 
cells. 
 
A ‘true’ change occurs when the nature of change in both parameters follows suite, i.e. a 
reduction in numerical density is matched by a reduction in the reference space and 
ultimately, the total number of cells, and vice versa. In this scenario, changes in the 
local characteristics of the tissue have resulted in global changes at the whole organ 
level. A more difficult situation to interpret arises when there are no changes in local 
characteristics (i.e. numerical density), yet there is a significant change at the global 
level. For example, if there is no change in numerical density, a reduction in the total 
number of cells can only result from a significantly reduced reference volume. In this 
situation, the reduction in the total number of cells may be loosely regarded as a ‘false-
positive’ because it is the local characteristics of the tissue in question which ultimately 
determine the global characteristics and hence function of the tissue at the whole organ 
level. The question then arises of how and why local characteristics do not imitate 
global changes. Information regarding the physiological/biochemical characteristics of 
the tissue is therefore required.  
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4.3.1.1 Double-immunolabelling of proliferating CT cells in thick sections 
Stereological assessment of the cytotrophoblast population involves the estimation of 
volume and number. The estimation of the total number of cytotrophoblast cells in the 
human placenta has, until now, been estimated using the physical disector technique 
(274) based on morphology and topography using 5µm tinctorially-stained sections. 
Morphological estimation of cytotrophoblast number may introduce bias (albeit 
minimal) into the final estimation by failure to resolve cytotrophoblast nuclei from 
syncytiotrophoblast nuclei and stromal cells. The most efficient way to estimate cell 
number is achieved by applying the disector principle to one thick section (≥25 µm) in 
which cells are counted within a known volume using an optical brick (279). There is, 
however, limited application of the optical brick technique in placental research since 
the use of thick sections reduces the ability to unambiguously identify different cell 
populations (discussed in the following section).  
 
Stereological analysis of cytotrophoblast proliferation is based on the supposition that 
an increase in cell number is synonymous with an increase in the number of 
proliferating cells (200). Whilst these interpretations are valid since an increase in cell 
number can only occur by cell division, these methods do not quantify or distinguish the 
population currently undergoing proliferation, the growth fraction, from non-
proliferating cells. In this study, a novel double-immunolabelling protocol was 
developed in 25µm thick paraffin sections using monoclonal antibodies to cytokeratin 7, 
a cytoplasmic marker of cytotrophoblast cells, and Ki-67, a nuclear marker of 
proliferation, thereby allowing the unbiased estimation of the total number of 
proliferating cytotrophoblast cells using the optical brick technique.  
 
The application of this double-labelling technique for stereological analysis is 
advantageous since 1) the estimation of number using the optical brick technique is 
more efficient than using the physical disector 2) the use of cytokeratin 7 to distinguish 
cytotrophoblast cells from syncytium and stromal cells removes the experimental bias 
introduced when assigning trophoblast nuclei to different compartments based purely on 
morphology, and 3) the use of Ki-67 precludes the assumptions concerning trophoblast 
proliferation based on an increase in cell number.  
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Although immunohistochemistry has previously been achieved in thick paraffin sections 
in the mouse placenta (184), and similarly antibodies to cytokeratin 7 and Ki-67 have 
been employed to identify trophoblast and proliferating cell in double-labelling on 
single sections (239) or individually on parallel sections (204), the superiority of the 
double-stain arises from the adaptation of these two markers into one combined stain in 
thick paraffin section therefore allowing quantification of cell number using the optical 
brick technique.  
 
4.3.1.2 Cytokeratin 7 as an immuno-histochemical marker for quantifying CT  
Present methods to study villous cytotrophoblast cells using light microscopy include 
the use of tinctorial stains (e.g. haematoxylin & eosin) or the immuno-histochemical 
localisation of phenotypic subsets of these cells i.e. progenitor (185), proliferating or 
differentiating cytotrophoblast cells (189; 214). A current limitation in quantifying the 
total complement of cytotrophoblast cells is the lack of a generic immunohistochemical 
marker which identifies all phenotypes of the cytotrophoblast population, thus 
permitting the unambiguous delineation of all cytotrophoblast cells from 
syncytiotrophoblast nuclei and stromal cells. This is a crucial requirement of 
stereological analysis, as failure to accurately distinguish (and count) different cell 
populations increases the risk of stereological bias at the level of the observer, which 
may ultimately lead to under or overestimation of cell number.  
 
In thin tinctorially-stained paraffin sections, cytotrophoblast cells can be readily 
delineated from syncytiotrophoblast nuclei morphologically and topographically. 
Undifferentiated cytotrophoblast cells residing on the basal lamina exhibit a large ovoid 
nucleus with ample chromatin, resulting in weak nuclear staining which is easily 
distinguished from the dense staining pattern of syncytiotrophoblast nuclei (85). 
Conversely, differentiating cytotrophoblast cells which have lost contact with the basal 
lamina, exhibit similar staining patterns to syncytiotrophoblast nuclei, making this 
phenotype more difficult to distinguish histologically without the use of antibodies (85). 
These limitations are greatly amplified when using thick paraffin sections (i.e. 25µm) 
that are required for number estimation using the optical disector technique. Antibody 
criteria for the estimation of cytotrophoblast cell number therefore included 1) the 
constitutional expression of the antigen within the cytoplasm of all cytotrophoblast cells 
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throughout gestation 2) no cross-reactivity with syncytiotrophoblast nuclei or stromal 
cells and 3) the ability to penetrate 25µm thick paraffin sections.  
 
A review of the literature revealed three commercially available markers specifically for 
cytotrophoblast cells. These included antibodies to E-cadherin [6], a cell-cell adhesion 
protein expressed in the cytoplasm of cytotrophoblast cells, hepatocyte growth factor 
activator inhibitor-1 (HAI-1) (298-300), a membrane protein expressed in 
cytotrophoblast cells, and cytokeratin 7, an intermediate filament protein expressed in 
the cytoplasm of epithelial cells (301). HAI-1 localised to a subset of villous 
cytotrophoblast cells displaying inconsistent staining ranging from apical, to basal, to 
whole cytoplasmic localisation and was thus excluded. A recent study showing failure 
of HAI-1 deficient mice to undergo branching morphogenesis (300) suggests a similar 
expression pattern (e.g. asymmetric expression in a subset of villous cytotrophoblast 
cells) and role to GCM1 (191) in directing human villous cytotrophoblast differentiation 
(214). 
 
Cytokeratin 7 is a member of the intermediate filament family of proteins expressed in 
epithelial cells which interact with the basement membrane (via integrins) linking the 
cytoskeleton to the extracellular matrix (302). In the human placenta, different 
populations of cytotrophoblast cells express cytokeratins in a developmental, 
differentiative (301) and functional manner (303). In first trimester placentas, 
cytokeratin 7 is expressed in extravillous (cell islands and columns) and villous 
cytotrophoblast cells, but also in the basal plasma membrane of the syncytiotrophoblast 
layer (301). During the second and third trimester, cytokeratin 7 expression increases 
throughout the whole of the syncytium (301). Because cytokeratin 7 is expressed in 
cytotrophoblast and syncytiotrophoblast, immunolocalisation of cytokeratin 7 
specifically to cytotrophoblast cells (in both second and third trimester placentas) was 
achieved though the omission of antigen retrieval. Staining was localised to the 
cytoplasm of cytotrophoblast cells and no cross-reactivity was observed for the 
syncytiotrophoblast nuclei or stromal cells. A pilot study estimating cytotrophoblast cell 
number at term using the optical brick technique demonstrated a significant increase in 
the number of cytotrophoblast cells counted when using the mAb cytokeratin 7 
(presented at the European Histopathology Meeting, Northampton, UK 2007) in 
comparison to counts made on tinctorially stained sections (H&E).  
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4.3.1.3  Ki-67 as an immunohistochemical marker of proliferating CT 
Ki-67 is an established marker of cell proliferation (304), as the antigen is present in the 
of all active phases of the mammalian cell cycle, G1, S, G2, and M phase, and absent in 
quiescent cells (G0) or non-cycling cells (305). In the human placenta, only a subset of 
villous cytotrophoblast nuclei express Ki-67. Its expression has been semi-quantified in 
numerous 2D analyses in both normal and pathological pregnancies (Table 4-8) but cell 
numbers have not, until now, been accurately quantified stereologically (restricted to 
villous cytotrophoblast cells). There are however recognised caveats when using Ki-67 
as a proliferation marker:  
 
Proliferation is an indicator of growth by means of an increase in cell number; hence, an 
ideal proliferation marker must therefore identify cells which are going to divide. Ki-67 
however is a phase-labelling index, and Ki-67 expression does not declare that a cell is 
unquestionably going to divide as the cell may still decide to exit the cell cycle and 
enter a quiescent or terminally differentiated state (306). Ki-67 positivity should 
therefore be used to indicate the potential of a cell to divide, and not to predict the 
actual division of the cell (306).  
 
Furthermore, Ki-67 positivity gives no indication of the rate of proliferation. The rate of 
cytotrophoblast proliferation is determined by the duration of interphase (G1, S, and G2 
phases), and to a lesser extent, by the time it takes for the cell to divide in mitosis. For 
any given population, cytotrophoblast cells may differ in inter-mitotic times such that 
they exhibit different proliferative activity (G1, S, and G2 phases) but a constant S 
phase, or differ in the duration of S phase but have a constant proliferative phase. Thus, 
Ki-67 only labels those cells actively involved in the cell cycle and provides no 
indication of the rate of proliferation. Further analysis of the different phases of the cell 
cycle (BrdU for S phase and mitotic counts for M phase) would allow identification of 
the growth fraction of cells that is actively dividing (306). 
 
In the human placenta, Ki-67 will be expressed in both villous cytotrophoblast 
progenitor cells and in a population of their daughter cells undergoing transit cell 
divisions prior to syncytial fusion. Its expression therefore is not a direct determinant of 
the progenitor cell pool. In fact, quiescent (G0) villous cytotrophoblast cells (Ki-67 
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negative) may be regarded as ‘true progenitor’ cells per se as they remain in an 
undifferentiated state destined for future mitotic cycles throughout gestation, whilst 
their daughter cells undergo syncytial fusion or further transit cell divisions prior to 
syncytial fusion (Ki-67 positive). Relevant murine immunohistochemical markers to 
Cdx2 and FGF-R2 (170) should be employed in future studies in an attempt to identify 
true progenitor cells representing the villous trophoblast stem cell lineage.  
 
4.4 Results 
4.4.1 Villous Cytotrophoblast Proliferation in Normal Pregnancy 
Between the first and third trimester of pregnancy, the human placenta undergoes a 
significant increase in the total volume and surface area of the chorionic villous trees. 
During the first trimester, linear growth of stem and immature intermediate villi occurs 
via a steady state of proliferating cytotrophoblast, endothelial and stromal cells (200). 
During the second and third trimester of pregnancy, growth of mature intermediate and 
terminal villi is vascular-mediated (115), such that endothelial proliferation prevails 
over cytotrophoblast proliferation resulting in capillary coiling and morphogenesis of 
terminal villi from the surfaces of mature intermediate villi. The functional consequence 
of these changes serve to thin the trophoblast layer thereby decreasing the diffusional 
distance of oxygen and nutrients between maternal and fetal circulations needed to 
maintain adequate fetal growth in the second half of pregnancy. In this context, it may 
be concluded that proliferation is more important during the first half of pregnancy, 
whereas cytotrophoblast differentiation is more relevant in later gestation thus 
regenerating the villous trees. 
 
In the present study, volumetric growth of the cytotrophoblast increased significantly 
from an average 1.18 cm3 to 2.42 cm3 between 26 and 41 weeks of gestation. This 
reflects the increase in total placental and villous volume with increasing gestational 
age, consistent with previous reports (200); however total cytotrophoblast volume 
estimates were considerably lower (307). This is because total villous volume as 
opposed to total placental volume was used as the reference volume, allowing potential 
changes to be related to specific villous types, which are an indicator of gestational 
changes and hence functionality. 
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Gestational changes in villous cytotrophoblast proliferation in the normal human 
placenta between 26 and 41 weeks of gestation are illustrated in Graph 4-10. In 
proportion to the increase in total cytotrophoblast volume, the total number of 
cytotrophoblast cells increased significantly with increasing gestational age (Graph 
4-10, B), consistent with previous stereological data. In contrast, when looking at 
relative numbers, the density (Nv) of cytotrophoblast cells decreased significantly with 
increasing gestational age, which was paralleled by a significant decline in the density 
of proliferating cytotrophoblast cells (Graph 4-10, A). The decrease in numerical density 
is accountable to the fact that villous surface area expands with increasing gestational 
age, thereby dispersing cytotrophoblast cells across the villous surface resulting in a 
reduced number of cytotrophoblast cells per unit volume of placenta. This indicates a 
genuine decline in the density of proliferating cytotrophoblast cells in the normal human 
placenta between 26 and 41 weeks of gestation. 
 
There is however a mismatch between the total number of cytotrophoblast cells and the 
total number of proliferating cytotrophoblast cells (Graph 4-10, B). Whilst the total 
number of cytotrophoblast cells significantly increased between 26 and 41 weeks of 
gestation, the total number of proliferating cytotrophoblast cells remained constant, 
equivalent to approximately 30% of the total complement of cytotrophoblast cells. 
Together, these results confirm that the relative pool of proliferating villous 
cytotrophoblast cells decreases significantly between 26 and 41 weeks of gestation in 
the normal human placenta, but the proportion of proliferating cytotrophoblast cells 
remains constant throughout gestation (Graph 4-10, C). This suggests that a definite 
number of proliferating cytotrophoblast cells is required to maintain the epithelial 
steady state in the second half of pregnancy, which is estimated to be approximately 
30%, or that 1 in 4 villous cytotrophoblast cells are actively cycling in the human 
placenta between 26 and 41 weeks of gestation.  
 
Given the basic considerations of villous physiology in the third trimester of pregnancy 
(i.e. vascular-mediated villous growth), there are likely functional consequences of 
altering the pool/definite number of proliferating cytotrophoblast cells in the second half 
of pregnancy. An increase in the number of proliferating cytotrophoblast cells would 
result in an increased number of cytotrophoblast cells and subsequently villous 
membrane thickness, (providing no change in extrusion), thus impeding diffusional 
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exchange of oxygen and nutrients to the fetus. Alternatively, the reverse holds true in 
that insufficient numbers of proliferating cytotrophoblast cells in the third trimester may 
lead to depletion in cytotrophoblast number and subsequent growth and regeneration of 
the syncytium, thereby limiting active transport and endocrine function needed to 
maintain fetal growth (via the villous tree) in the third trimester of pregnancy. 
 
A single proliferative unit can be expressed as a ratio of the number of cytotrophoblast 
cells to the number of syncytiotrophoblast nuclei. Previous stereological analyses 
estimated a single proliferative unit to be composed of one cytotrophoblast cell 
associated with between 9 and 13 syncytiotrophoblast nuclei. In the present study, these 
estimates in both early and late gestation were considerably higher at 1:5 (range 1:4 to 
1:7). The preterm placenta (between 26 and 32 weeks of gestation) in the present study 
was estimated to contain approximately 6.8x1010 cytotrophoblast cells. However, 
between 27 and 31 weeks of gestation Mayhew estimated there to be 0.36x1010 
cytotrophoblast cells in the human placenta, whilst Simpson estimated these placentas to 
contain 0.34 x1010 cytotrophoblast cells. The disparity is likely due to the fact that the 
previous investigators used the physical disector technique to count cytotrophoblast 
nuclei morphologically, whereas in this study cytokeratin 7 was used to immunolocalise 
cytotrophoblast cells which is likely to increase the number of cells identified. 
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Graph 4-10 Gestational changes in the number of proliferating CT cells in control placentas 
between 26 and 41 weeks  
(A) The numerical density of cytotrophoblast cells and Ki-67 +ve CT significantly declines with 
gestational age (P<0.001, P=0.021) (B) Total numbers of CT cells significantly increase with gestational 
age (P=0.019) whereas Ki-67 +ve CT cells do not (C) Percentage of proliferating cytotrophoblast cells 
remains constant across gestation. 
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4.4.2 Villous Cytotrophoblast Proliferation in Early-onset PET and IUGR 
The present findings confirm the hypothesis that severe early-onset IUGR placentas 
with documented AREDV in the umbilical arteries have reduced numbers of 
proliferating villous cytotrophoblast cells. Conversely, data does not support the 
hypothesis that severe early-onset pre-eclampsia with PEDV in the umbilical arteries is 
associated with increased numbers of proliferating villous cytotrophoblast cells. This 
may indicate divergent villous trophoblast phenotypes in severe early-onset pre-
eclampsia and IUGR.  
 
4.4.2.1 Decreased Villous CT proliferation in Severe Early-onset IUGR 
By 26 weeks of gestation, severe early-onset IUGR placentas show a significant 
reduction in the total number of cytotrophoblast cells in peripheral villi, and that within 
this reduced complement of cells, the percentage undergoing proliferation (i.e. Ki-67 
positive) is also significantly reduced (50%) in comparison to age-matched controls. 
This may indicate a severe impairment in the regenerative capacity of villous 
cytotrophoblast cells, which may reflect premature loss of villous progenitor cells that 
can proliferate, differentiate and fuse with the overlying syncytium throughout 
gestation, thereby contributing to the small placental phenotype of IUGR.  
 
The reduction in cytotrophoblast proliferation in severe early-onset IUGR was spatially 
and temporally regulated. Peripheral villi did not display any significant changes in 
cytotrophoblast density in comparison to control placentas, however 50% fewer cells 
were undergoing proliferation; equivalent to 1 in 7 cytotrophoblast cells undergoing 
proliferation compared to 1 in 4 in controls. Conversely, structural villi were not 
associated with alterations in cytotrophoblast volume, number or those undergoing 
proliferation. This suggests arrest of mitosis immediately prior to or at the onset of 
development of the gas-exchanging villi.  
 
Cytotrophoblast proliferation is upregulated by intra-placental hypoxia and down-
regulated by increasing intra-placental oxygen levels in vitro (100). The observed 
reduction in the number of proliferating cells in this study is therefore consistent with 
the notion of intra-placental ‘hyperoxia’ in severe early-onset IUGR. Increased oxygen 
levels (relative to maternal blood) in placentas from IUGR with AREDV are thought to 
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result from the inability of the poorly developed terminal villi to extract it (153). Since 
these placentas had reduced volumes of peripheral villi, placental ‘hyperoxia’ is a 
plausible, but not an exclusive explanation for reduced cytotrophoblast proliferation in 
severe early-onset IUGR. 
 
Villous cytotrophoblast cells represent a heterogeneous population of cells displaying 
distinct cellular phenotypes, including 1) progenitor cells (185) 2) mitotic or cycling 
cells 3) differentiating/fusing cells (189) and more recently 4) apoptotic/necrotic 
cytotrophoblast cells (308). Based on a simple model of cell division, a decrease in 
cytotrophoblast proliferation should result in a decrease in the number of daughter cells. 
Significantly, this was not observed in severe early-onset IUGR and the reduced density 
of proliferating cytotrophoblast cells was not paralleled by a reduced density of 
cytotrophoblast cells (Ki-67 negative cells). 
 
Cytotrophoblast differentiation is characterised by arrest of mitosis. The decision of a 
cytotrophoblast cell to exit the cell cycle and fuse with the overlying syncytium 
(differentiation) has recently been described in the human placenta to be regulated by 
the trophoblast specific GCM1 transcription factor (214)- analogous to its reported 
function in mice (181). Forskolin-induced up-regulation of GCM1 in BeWo cells and 
first trimester floating villous explants results in reduced cytotrophoblast proliferation 
and the induction of cell-cell fusion (GCM1 induces the fusion protein syncytin1 (193)) 
producing a thick syncytiotrophoblast layer (214). GCM1 therefore promotes cell cycle 
arrest, and hence GCM1 positive cells are post-mitotic (Ki-67 negative). The 
asymmetric expression of GCM1 (191) therefore serves to maintain the pool of 
proliferating cytotrophoblast cells but also which cells are selected for fusion. 
 
Based on these observations, it may be hypothesised that reduced cytotrophoblast 
proliferation in severe IUGR results from an increase in the number of villous 
cytotrophoblast cells expressing GCM1, resulting in a reduced density (per unit area) of 
villous cytotrophoblast cells secondary to increased syncytial fusion as demonstrated in 
vivo (214). In the present study, severe early-onset IUGR placentas are associated with 
reduced GCM1 mRNA yet increased GCM1 protein expression (30%) in comparison to 
preterm controls (personal communication, Sascha Drewlo, Toronto). It can be 
speculated that reduced GCM1 mRNA (presumably in villous cytotrophoblast) is 
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associated with reduced syncytial fusion through failure to upregulate syncytin1, 
resulting in surplus numbers of ‘undifferentiated’ villous cytotrophoblast cells relative 
to proliferating villous cytotrophoblast cells, as shown in the present study. This is 
supported by the recent observation of reduced syncytin1 expression in PET-IUGR 
(309).  
 
The cellular origin of increased GCM1 protein expression in severe IUGR is more 
difficult to explain without further immunolocalisation studies. The mismatch between 
increased GCM1 protein expression, reduced GCM1 mRNA and ‘normal’ 
cytotrophoblast density does suggest however that increased GCM1 protein in severe 
IUGR may not be causally associated but rather an effect of 1) the surplus number of 
undifferentiated cytotrophoblast cells relative to proliferating cytotrophoblast cells in 
comparison to preterm controls (i.e. Ki-67 negative) 2) the presence of the GCM1 
protein within the syncytium (310) and to a lesser extent in stromal and chorionic cells, 
and 3) the continued translation of GCM1 protein within pathological syncytial knots.  
 
4.4.2.2 Normal Villous CT Proliferation in Severe Early-onset Pre-eclampsia 
Severe early-onset pre-eclampsia with PEDV in the umbilical arteries displayed no 
significant difference in the total volume, density and number of cytotrophoblast cells 
and those undergoing proliferation compared to preterm controls. However, despite 
there being no significant difference in numbers, there was a trend towards an increase 
in the percentage of proliferating cytotrophoblast cells. Whilst the global increase was 
negligible (29% in preterm controls versus 32% in severe early-onset pre-eclampsia) 
there was a 32% increase in the number of proliferating cytotrophoblast cells in stem 
and immature intermediate villi. This however did not reach significance due to large 
variation. 
 
Current hypotheses hold that pre-eclampsia is associated with an increase in the rate of 
villous trophoblast turnover (3). Increased cytotrophoblast proliferation is associated 
with an increase in the rate of syncytial fusion, since a multi-layered cytotrophoblast has 
not been described for pre-eclamptic placentas. Consequently, increased apoptotic and 
necrotic shedding of syncytiotrophoblast nuclei is proposed to counterbalance the 
accelerated input of cytotrophoblastic material as part of an adaptive response.  
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The increase in cytotrophoblast proliferation in pre-eclampsia is thought to result from 
intra-placental hypoxia (153) secondary to reduced placental perfusion as a consequence 
of malinvasion of the maternal spiral arteries by extravillous cytotrophoblast cells (124). 
Increased numbers of villous cytotrophoblast cells (inferring increased proliferation) 
have been documented for several pathological conditions related to placental hypoxia, 
including maternal anaemia (204), pre-eclampsia (311), and pregnancies at high altitude 
(312-314). Stereological data from the present study does not support the association 
between intra-placental hypoxia and increased numbers of proliferating cytotrophoblast 
cells.  
 
Intra-placental hypoxia is heterogeneous, and the oxygen content of the intervillous 
space has been shown to be spatially restricted. The inherent variation in intraplacental 
hypoxia may result in areas of increased as well as decreased proliferation and hence 
syncytial fusion, likely resulting in local, rather than global changes in cytotrophoblast 
proliferation. This may account for the failure of the increase in the number of 
proliferating cytotrophoblast cells in stem and immature intermediate villi to reach 
statistical significance. 
 
In addition to focal restrictions, the oxygenation status of the intervillous space is also 
temporally regulated. During normal villous development, hypoxia drives villous 
cytotrophoblast proliferation during early pregnancy which declines with the onset of 
the maternal blood supply in the early second trimester, thereby increasing intra-
placental oxygenation. Severe early-onset pre-eclampsia displayed temporal alterations 
in the number of cytotrophoblast cells undergoing proliferation. Whereas stem and 
immature intermediate villi were associated with a trend towards an increase in 
cytotrophoblast proliferation, mature intermediate and terminal villi displayed normal 
cytotrophoblast proliferation, indicating normalisation of oxygenation in the second 
trimester around the development of the peripheral villous tree. This suggests that 
placental entry and fetal extraction of oxygen is matched by the late second trimester in 
severe early-onset pre-eclampsia.  
 
Despite the above inconsistencies, normal cytotrophoblast numbers and proliferation is 
consistent with the normal villous volumes observed for severe early-onset pre-
eclampsia in this study. Physiologically this makes sense, since a significant increase in 
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cytotrophoblast proliferation, assuming no change in the rate of syncytial fusion, would 
result in increased numbers of cytotrophoblast cells. As a consequence, villous 
membrane thickness would increase serving to limit diffusional exchange, likely 
resulting in a growth-restricted neonate. However, fetal birthweights in severe early-
onset pre-eclampsia were between the 10-50th centile for gestational age indicating 
adequate oxygen extraction by the fetus and hence growth.  
 
The pre-eclamptic placentas in this study are associated with decreased GCM1 protein 
expression (personal communication, Sascha Drewlo, Toronto), consistent with 
previous observations (310). Given that up-regulation of GCM1 is associated with 
reduced cytotrophoblast proliferation in vitro, a decrease in the number of 
cytotrophoblast cells expressing GCM1 in vivo may be inferred to result in an increase 
in the number of cytotrophoblast cells with the potential to proliferate. Of particular 
interest is the observed trend towards a decrease in the density of villous 
cytotrophoblast cells in mature and terminal villi in severe early-onset pre-eclampsia. 
Whilst there was no change in the density of proliferating cytotrophoblast cells, the 
decrease in the density of cytotrophoblast cells suggests increased cytotrophoblast 
fusion consistent with the current trophoblast hypothesis of pre-eclampsia. Thus, 
decreased GCM1 protein expression may be due to a reduction in the number of villous 
cytotrophoblast cells.  
 
4.4.3 Villous Cytotrophoblast Proliferation in Late-onset PET, IUGR, and SIDS 
Present findings confirm the hypothesis that pre-eclampsia and IUGR in late gestation 
display different CT morphologies when compared to its early-onset phenotype.  
 
IUGR presenting in late gestation had no significant effect on the percentage of 
proliferating villous cytotrophoblast cells, but were associated with a 50% reduction in 
the total number and volume of villous cytotrophoblast cells and those undergoing 
proliferation; densities remain similar to age-matched controls. However, the 
combination of the low number of cases (n=4) and the large intra-group variation (two 
33 week cases with abnormal umbilical artery Doppler, and two cases at 37 weeks with 
normal Dopplers) in the late-onset IUGR group means that conclusions regarding 
cytotrophoblast turnover cannot be determined with any degree of accuracy.  
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Late-onset pre-eclampsia was not associated with any significant changes in the volume 
or numerical density of villous cytotrophoblast cells or those undergoing proliferation. 
Interestingly, the total number of cytotrophoblast cells significantly decreased in 
comparison to controls leading to a significant increase in the percentage of 
proliferating cytotrophoblast cells specifically for structural villi. This may indicate that 
a higher proportion of cytotrophoblast cells retain a proliferative phenotype compared to 
controls, supported by the significant reduction in the number of Ki-67 negative cells 
(28%) (non-proliferating cytotrophoblast cells). 
 
The same holds true for late-onset pre-eclampsia with co-existing IUGR. These 
placentas displayed a trend towards a decrease in the numerical density of 
cytotrophoblast cells for peripheral villi, the total number of which significantly 
decreased (40%). In conjunction with the subtle increase in the density of proliferating 
cytotrophoblast cells (14%), the percentage of proliferating cytotrophoblast thus 
significantly increased (26%) in comparison to age-matched controls, indicating that a 
higher proportion of cytotrophoblast cells retain a proliferative/progenitor cell 
phenotype compared to controls.  
 
In contrast to the normal placental phenotype of late-onset pre-eclampsia without IUGR, 
the presence of IUGR is associated with reduced total placental and villous volumes. 
This begs the question as to why these placentas are smaller if they (presumably) retain 
more proliferative/progenitor cells. One hypothesis is that the cytotrophoblast 
progenitor pool may be depleted due to the effects of IUGR therefore impeding villous 
growth potential, but the remaining cytotrophoblast cells adopt a proliferative 
phenotype undergoing ‘faster’ transient cell divisions in comparison to controls, which 
may contribute to the development of pre-eclampsia.  
 
Both SIDS-NBW and SIDS-LBW placentas displayed significant increases in the 
volume density of cytotrophoblast cells for stem (44%, 55%), mature intermediate villi 
(43%, 53%) and terminal villi (39%, 31%) in comparison to term controls, representing 
a SIDS effect independent of infant birthweight (two-way ANOVA). The total volume 
cytotrophoblast cells subsequently increased in SIDS-NBW due to the increase in total 
villous volume, which was not observed for SIDS-LBW displaying no change in villous 
volumes.  
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An increase in the relative volume of cytotrophoblast may arise due to hypertrophy or 
hyperplasia. Although numerical density estimates and proliferation indices are needed 
to clarify this situation, both growth mechanisms are equally plausible. Histologically, 
cytotrophoblast cells appear extremely large (Figure 4-1, A) in terms of nuclear size, 
which could indicate proliferation, or alternatively endoreduplication (315), providing 
no change in nuclear number (although no polyploid nuclei were observed). 
Cytotrophoblast hyperplasia (multi-layering) (Figure 4-1, B, C) was also noted in 
distinct areas of villi displaying intravillous fibrinoid deposition and syncytial 
denudation, indicating a lack of syncytial fusion. This primarily indicates diminished 
syncytiotrophoblast differentiation, but the possibility also exists that these cells have 
adopted an extravillous cytotrophoblast phenotype (185), associated with up-regulation 
of integrin α5β1, a receptor for fibronectin, (a matrix-type fibrinoid) related to 
intracytotrophoblastic deposition (316). This is not an unreasonable explanation as in 
the absence of an intact syncytium, a subset of villous cytotrophoblast cells exposed to 
exogenous FGF4 (which maintains the proliferative state of murine trophoblast stem 
cells (173)), differentiate down the extravillous pathway as shown by positivity for 
integrins α5β1 and α1β1 antibodies, HLA-G and connexin-40 (185).  
 
Implications and possible consequences of these changes for both early and late-onset 
pathologies will be discussed in Chapter 5 in light of results describing syncytial 
integrity.  
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A  
B  
C  
Figure 4-1 Cytotrophoblast morphology in SIDS-NBW placentas immunolocalised for mAb CK-7 
counterstained with H&E  
(A) Cytotrophoblast nuclei appear larger in size with a small cytoplasm, with visible mitotic figures 
(white arrow) (x400) (B) Intravillous fibrinoid (white arrow) and cytotrophoblast deposition (black 
arrow) with syncytial denudation , x200 (C) Multi-layered cytotrophoblast (clear arrow) underlying a 
syncytial knot displaying nuclei with morphological characteristics of necrosis x400. 
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5 Syncytial integrity 
5.1 Introduction 
Fetal growth in utero is primarily determined by nutrient availability (317), which is 
dependent upon the functional and morphological transport capacity of the syncytium 
(SCT), responsible for the bulk of placental function including gas, nutrient and waste 
exchange, immune tolerance, and hormone production (85). Throughout gestation, the 
multinucleate syncytium grows and regenerates via continual syncytial fusion of post-
proliferative villous cytotrophoblast cells, which is coupled to a tightly regulated 
differentiation process involving the initiator stages of the apoptosis cascade (225). 
Initially, fusing “differentiating” villous cytotrophoblast cells, (directed by the 
transcription factor, GCM1) (214), express ‘anti-apoptosis’ proteins (e.g. Bcl-2 and 
Mcl-1) which serve to focally retard syncytial death thereby allowing maturation of a 
cellular phenotype necessary for a functioning epithelium (195). This is eventually 
succeeded by terminal differentiation associated with the execution stages of apoptosis, 
followed by sequestration and extrusion of syncytial knots into the maternal circulation.  
 
Alterations in the balance between villous cytotrophoblast proliferation, differentiation 
and syncytial fusion will therefore exert direct effects on syncytiotrophoblast integrity 
and morphology, and are thought to be primary pathogenic events of pre-eclampsia and 
placental IUGR (85). Under normal conditions, syncytial fusion is counterbalanced by 
extrusion of syncytial nuclei, in the form of syncytial knots. Reductions in the number 
of syncytial nuclei may therefore result from either decreased input via reduced 
syncytial fusion and/or proliferation, or alternatively accelerated shedding/extrusion. 
Conversely, an increase in syncytial nuclei may result from increased syncytial fusion, 
accompanied by increased proliferation, but normal or reduced shedding.  
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5.1.1 Hypotheses  
1. In severe early-onset IUGR, a reduced number of proliferating villous 
cytotrophoblast cells and syncytial fusion events leads to reduced numbers and 
volume of syncytiotrophoblast nuclei and increased syncytial apoptosis in 
comparison to preterm controls 
 
2. In severe early-onset pre-eclampsia, numbers of syncytial nuclei remain similar to 
preterm controls due to sufficient cytotrophoblast input, balanced by accelerated 
terminal differentiation and syncytial extrusion in comparison to preterm controls 
 
3. The late-onset variants of each disease display normal syncytiotrophoblast 
morphology 
 
4. The syncytium in SIDS placentas resembles that of placentas from late-onset pre-
eclampsia or IUGR 
 
5.1.2 Experimental Aims 
The above hypotheses will be tested by estimating the following parameters: 
 
1. The volume and number of SCT nuclei and individual syncytial knot volume 
(i.e. PSI) and morphology (apoptotic vs. non-apoptotic) of syncytial knots  
 
2. The expression of the apoptosis-related protein, cleaved cytokeratin 18, will be 
semi-quantified by western blotting in the severe early-onset pathologies 
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5.2 Early-onset pathologies 
Raw data for SCT volume and number are presented in Appendices 4 and 5 
 
5.2.1 Total Volume of Syncytiotrophoblast 
Graph 5-1 Total volume of SCT in early-onset pathologies 
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Total volume of SCT was significantly reduced in comparison to controls for 
IUGR  peripheral villi (P=0.018) 
PET-IUGR structural and peripheral villi (P=0.019) 
 
Table 5-1 Volume density of SCT in early-onset pathologies 
 
 
 
 
 
 
Data presented as mean and ± SEM 
* significant difference compared to controls  
 
Volume density of SCT was significantly reduced in comparison to controls for: 
PET   structural villi (P=0.013) 
PET-IUGR  structural villi (P=0.052) 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Volume density SCT 0.048 ± 0.002 0.048 ± 0.002 0.048 ± 0.005  0.045 ± 0.002 
Structural villi  0.016 ± 0.001 0.011± 0.001* 0.020 ± 0.004  0.013± 0.001* 
Peripheral villi 0.031 ± 0.003 0.037 ± 0.002 0.028 ± 0.003  0.033 ± 0.002 
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5.2.2 Total Number of Syncytiotrophoblast Nuclei 
 
Graph 5-2 Total number of SCT nuclei in early-onset pathologies  
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Total numbers of syncytiotrophoblast were significantly decreased in  
IUGR    peripheral villi (P<0.001) 
PET-IUGR   structural and peripheral villi (P<0.001) 
 
Table 5-2 Numerical density of SCT nuclei in early-onset pathologies 
Data presented as mean and ± SEM  
* significant difference compared to controls  
 
PET-IUGR displayed a significant decrease in the numerical density of 
syncytiotrophoblast nuclei (P=0.053).  
 
IUGR displayed a trend towards a decrease in syncytial nuclei (P=0.097). 
 
 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Total  
Density (μm-3) 
1.1x10-3 ± 5.2x10-5 9.6x10-4 ± 9.4x10-5 1.0x10-3 ± 1.2x10-4 9.3x10-4 ± 4.1x10-5*
Nv Structural villi  3.4x10-4 ± 4.5x10-5 3.3x10-4 ± 7.9x10-5 4.8x10-4 ± 1.1x10-4 2.9x10-4 ± 2.4x10-5 
Nv Peripheral villi 7.1x10-4 ± 5.3x10-5 6.3x10-4 ± 7.6x10-5 5.6x10-4± 2.4x10-5 6.4x10-4 ± 3.5x10-5 
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5.2.3 Total Volume of Syncytial Knots (SK) 
 
Graph 5-3 Volume density of syncytial knots in early-onset pathologies 
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Significant differences in the volume density of SK were observed in comparison to 
controls: 
PET    ↑ peripheral villi (P<0.001), ↓ structural villi (P=0.036)   
PET-IUGR  ↑ total density (P=0.015),   ↑ peripheral villi (P=0.007)  
 
Table 5-3 Total volume of syncytial knots in early-onset pathologies 
Data presented as the mean and ± SEM * significant difference compared to controls  
   ** significant difference compared to pre-eclampsia     
 
Significant differences in the total volume of SK were observed in comparison to 
controls for: 
 
IUGR   ↓ total volume (P=0.026), ↓ structural villi (P=0.011) 
PET-IUGR ↓ total volume (P<0.001), ↓ peripheral villi (P<0.001) 
 
 
Control 
(n=12) 
PET 
(n=11) 
IUGR 
(n=5) 
PET-IUGR 
(n=19) 
Total volume (cm3) 7.98 ± 0.81 9.22 ± 1.13 4.66 ± 0.68*  4.87 ± 0.37** 
Structural villi  5.00 ± 0.49 3.81 ± 0.68 2.61 ± 0.47*      2.38 ± 0.27 
Peripheral villi 2.99 ± 0.47  5.37 ± 0.68*     2.07 ± 0.28  2.51 ± 0.30** 
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5.2.4 Mean Individual Syncytial Knot Volume (PSI) 
 
Graph 5-4 Individual syncytial knot volume in early-onset pathologies 
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There were no significant differences in the mean volume of syncytial knots in either 
pathology when compared to controls. 
 
However, there was a trend towards an increase in mean syncytial knot volume for 
PET-IUGR, but failed to reach statistical significance (P=0.078). 
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5.2.5 Volume of Apoptotic Syncytial Knots 
 
Graph 5-5 Volume density of apoptotic syncytial knots in early-onset pathologies 
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PET, IUGR and PET-IUGR were associated with a significant increase in the volume 
density of apoptotic knots for peripheral villi when compared to controls 
 
PET also displayed a significant increase in the volume density of non-apoptotic knots 
for peripheral villi when compared to controls 
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5.2.6 Mean Individual Apoptotic Syncytial Knot Volume (PSI) 
 
Graph 5-6 Mean individual apoptotic knot volume in early-onset pathologies 
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There were no statistically significant differences in mean apoptotic syncytial knot 
volume for either pathology when compared to controls 
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5.2.7 Western Blotting for Cleaved Cytokeratin-18 
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Graph 5-7 Relative expression (OD) and representative western blot of cleaved cytokeratin-18 in 
pathological pregnancies.  (A) Relative optical density (OD) of cleaved CK8-18 protein (M30) in 
preterm control (PTC), PET and PET-IUGR placentas in comparison to ß-actin OD. (B) Representative 
western blot of M30 protein expression and cleaved CK8-18 expression in preterm control, PET, IUGR 
and PET-IUGR placentas, and in control and PET placentas at term. M30 was expressed in preterm 
control and PET-IUGR placentas. M30 expression was associated with the corresponding cleavage of 
CK8-18, demonstrating the specificity of the M30 antibody at detecting CK8-18 cleavage. M30 was not 
expressed in control or PET placentas at term. Following an unforeseen clinical re-audit, IUGR placentas 
were reclassified as PET-IUGR placentas and are thus absent in the graphical representation above.  
 
M30 protein expression was assessed using western blot analysis on placental samples 
(repeated 3 times). Relative M30 expression (OD, Image J software) was estimated by 
normalization to beta actin OD (CK8-18 was not semi-quantified) representing the 
house keeping control. M30 was expressed in preterm control, preterm IUGR, and pre-
term PET-IUGR placentas. There were no significant differences in the expression of 
M30 
Control IUGR PET 
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M30 in pre-eclampsia with or without IUGR in comparison to preterm controls. M30 
was not expressed in preterm PET or in control or PET placentas at term. 
 
5.2.8 Summary 
 
Severe early-onset pre-eclampsia 
• significant decrease in the volume density of syncytiotrophoblast in structural villi 
(Table 5-1) 
• significant increase in the volume density and total volume of syncytial knots (Graph 
5-3, Table 5-3) 
• significant increase in the volume density of apoptotic syncytial knots (Graph 5-5) 
 
Severe early-onset IUGR  
• significant decrease in the total volume of syncytiotrophoblast  (Graph 5-1) 
• significant decrease in the total number of syncytiotrophoblast nuclei  (Graph 5-2) 
• significant increase in the volume density of apoptotic syncytial knots (Graph 5-5) 
 
Severe early-onset PET-IUGR  
• significant decrease in the total volume of syncytiotrophoblast  (Graph 5-1) 
• significant decrease in the total number of syncytiotrophoblast nuclei  (Graph 5-2) 
• significant increase in the volume density of syncytial knots (Graph 5-3) 
• significant increase in the volume density of apoptotic syncytial knots (Graph 5-5) 
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5.3 Late-onset pathologies 
5.3.1  Total Volume of Syncytiotrophoblast  
 
Graph 5-8 Total volume of SCT in late-onset pathologies 
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There were no significant differences in the total volume of syncytiotrophoblast for 
either pathology when compared to controls 
 
Table 5-4 Volume density of SCT in late-onset pathologies 
Data presented as mean and ± SEM 
 
There were no statistically significant differences in the volume density of 
syncytiotrophoblast for either pathology when compared to controls. The trend towards 
an increase in the volume density of syncytiotrophoblast for peripheral villi in PET-
IUGR, which just failed to reach statistical significance (P=0.068). 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Volume density SCT 0.042 ± 0.004 0.052 ± 0.010 0.046 ± 0.002  0.051 ± 0.004 
 Structural villi  0.013 ± 0.003 0.010 ± 0.001 0.009 ± 0.001  0.011 ± 0.001 
Peripheral villi 0.029 ± 0.003 0.042 ± 0.010 0.033 ± 0.003  0.041 ± 0.004 
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5.3.2  Total Number of Syncytiotrophoblast Nuclei 
 
Graph 5-9 Total number of SCT in late-onset pathologies 
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There was a significant decrease in the total number of syncytiotrophoblast nuclei in 
comparison to controls for: 
IUGR  structural villi (P=0.042) peripheral villi (P=0.013) 
PET-IUGR peripheral villi (P=0.045) 
 
 
Table 5-5 Numerical density of syncytiotrophoblast nuclei in late-onset pathologies 
Data presented as mean and ± SEM (x10-5) 
 
 
There were no significant differences in the numerical density of syncytiotrophoblast 
nuclei for either pathology when compared to controls. 
 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Total Density (µm-3) 8.7x10-4 (± 6.2) 7.5x10-4 (± 5.2) 8.2x10-4 (± 6.1) 8.9x10-4 (± 9.6) 
Nv  Structural villi  2.8x10-4 (± 4.1) 1.6x10-4 (± 3.5) 2.1x10-4 (± 6.3) 3.1x10-4 (± 6.9) 
Nv Peripheral villi 5.9x10-4 (± 3.5) 5.9x10-4 (± 5.0) 6.1x10-4 (± 4.6) 5.7x10-4 (± 7.2) 
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5.3.3  Volume of Syncytial Knots 
 
Graph 5-10 Volume density of syncytial knots in late-onset pathologies 
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There were no significant differences in the volume density of syncytial knots for either 
pathology when compared to controls  
 
Table 5-6 Total volume of syncytial knots in late-onset pathologies 
Data presented as the mean and ± SEM  
* significant difference compared to controls  
** significant difference compared to pre-eclampsia 
 
Total volume of syncytial knots was significantly reduced compared to controls for: 
IUGR   total volume (P=0.018), peripheral villi (P=0.008) 
PET-IUGR total volume (P=0.029) 
 
Control 
(n=13) 
PET 
(n=6) 
IUGR 
(n=4) 
PET-IUGR 
(n=6) 
Total volume (cm3) 14.52 ± 1.39 13.23 ± 4.73  7.55 ± 0.99*    9.33 ± 0.98** 
Structural villi  7.08 ± 1.13 4.73 ± 0.95 4.52 ± 0.40        4.02 ± 0.89 
Peripheral villi 7.37 ± 0.75  8.52 ± 1.78     3.03 ± 0.73* 5.27 ± 0.90 
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5.3.4  Mean Individual Syncytial Knot Volume (PSI) 
 
Graph 5-11 Mean syncytial knot volume in late-onset pathologies 
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There were no significant differences in the mean volume of syncytial knots in either 
pathology when compared to controls.  
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5.3.5  Volume of Apoptotic Syncytial Knots 
 
Graph 5-12 Volume density of apoptotic syncytial knots in late-onset pathologies 
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PET, IUGR and PET-IUGR displayed a significant increase in the volume density of 
syncytial knots which were apoptotic. 
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5.3.6 Mean Individual Apoptotic Syncytial Knot Volume 
 
Graph 5-13 Mean apoptotic knot volume for late-onset pathologies 
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There were no significant differences in mean apoptotic volume for either pathology 
when compared to controls 
 
There was a significant decrease in mean non-apoptotic volume for PET-IUGR 
(P=0.023) 
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5.3.7  Summary  
 
Late-onset pre-eclampsia 
• significant increase in the volume density of apoptotic knots (Graph 5-12) 
 
Late-onset IUGR and PET-IUGR 
• significant decrease in the total number of syncytiotrophoblast nuclei (Graph 5-9)  
• significant decrease in total volume of syncytial knots (Table 5-6) 
• significant increase in the density of apoptotic syncytial knots (Graph 5-12) 
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5.4 SIDS 
5.4.1 Total Volume of Syncytiotrophoblast 
Graph 5-14 Total volume of syncytiotrophoblast in SIDS 
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There was a significant increase in the total volume of syncytiotrophoblast in 
comparison to controls for 
SIDS-LBW  stem villi (P=0.023) 
SIDS-NBW total volume (P=0.029), stem villi (P=0.002) 
 
Table 5-7 Volume density of syncytiotrophoblast in SIDS  
 
Volume Density 
Control 
(n=12) 
SIDS-LBW 
(n=12) 
SIDS-NBW 
(n=12) 
Vv  Stem villi  0.006 ± 0.001  0.009 ± 0.001*   0.009 ± 0.001* 
Vv Intermediate villi  0.020 ± 0.003  0.038 ± 0.002* 0.029 ± 0.003* 
Vv Terminal villi 0.018 ± 0.003 0.018 ± 0.002  0.020 ± 0.002 
Data presented as mean and ±SEM. Immature and mature intermediate villi are grouped as  
intermediate villi,     * significant difference compared to control 
 
 
There was a significant increase in the volume density of syncytiotrophoblast in 
comparison to controls for 
SIDS-LBW stem villi (P=0.009), intermediate villi (P=0.017) 
SIDS-NBW stem villi (P=0.017) 
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5.4.2 Total Volume of Syncytial Knots 
 
Graph 5-15 Total volume of syncytial knots in SIDS 
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There was a significant increase in the total volume of syncytial knots in comparison to 
controls for 
SIDS-NBW stem villi (P=0.002), terminal villi (P=0.051) 
 
 
Table 5-8 Volume density of syncytial knots in SIDS placentas 
Total Volume (cm3) 
Control 
(n=12) 
SIDS-LBW 
(n=12) 
SIDS-NBW 
(n=12) 
VTOT  Stem villi  0.006 ± 0.001  0.007 ± 0.001 0.007 ± 0.0003 
VTOT  Intermediate villi  0.016 ± 0.002  0.016 ± 0.002 0.012± 0.001* 
VTOT Terminal villi 0.004 ± 0.001 0.005 ± 0.001  0.005 ± 0.001 
Data presented as mean and ±SEM. 
 Immature and mature intermediate villi are grouped as intermediate villi    
  * significant difference compared to control 
 
There was a significant decrease in the volume density of syncytial knots in comparison 
to controls for 
SIDS-NBW intermediate villi (P=0.046)   
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5.4.3 Total Volume of Apoptotic Syncytial Knots 
 
Graph 5-16 Total volume of apoptotic syncytial knots (SK) in SIDS placentas  
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There was a significant increase in the total volume of apoptotic syncytial knots in: 
 
SIDS-LBW total volume (P=0.031), intermediate villi (P=0.045) 
 
SIDS-NBW total volume (P=0.003), intermediate villi (P=0.011), terminal villi 
(P=0.029) 
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5.4.4 Mean Individual Volume (PSI) and Number of Syncytial Knots 
 
Graph 5-17 Mean syncytial knot volume in SIDS placentas  
 
0.E+00
1.E+04
2.E+04
3.E+04
4.E+04
Control SIDS-LBW SIDS-NBW
M
ea
n 
sy
nc
yt
ia
l k
no
t v
ol
um
e 
( µ
m
3 )
PSI Apoptotic knots
PSI Non-apoptotic knots
 
 
There were no significant differences in mean syncytial knot volume for SIDS 
placentas. 
 
SIDS-LBW displayed a trend towards an increase in mean apoptotic syncytial knot 
volume for mature intermediate villi (P=0.075) 
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Graph 5-18 Total number of syncytial knots in SIDS placentas  
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SIDS-NBW displayed a significant increase in the total number of syncytial knots 
(P=0.011) due to an increase in the total number of both apoptotic (P=0.021) and non-
apoptotic syncytial knots (P=0.012).  
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5.4.5  Summary 
 
SIDS-LBW 
• significant increase in the volume density and total volume of syncytiotrophoblast 
(Graph 5-14, Table 5-7)  
• significant increase in the total volume of apoptotic knots (Graph 5-16) 
 
SIDS-NBW 
• significant increase in the volume density and total volume of syncytiotrophoblast 
(Graph 5-15, Table 5-7)  
• significant increase in the total volume of syncytial knots (Graph 5-15) 
• significant increase in the total volume of apoptotic knots (Graph 5-16) 
• significant increase in the total number of syncytial knots (Graph 5-18) 
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5.5 Discussion 
Quantitative data regarding syncytialisation (relative numbers) provides a direct 
measure of the epithelial steady state in human villous trophoblast turnover. Terminally 
differentiated syncytiotrophoblast represent the end stage of this process, the extrusion 
of which (in the form of syncytial knots) balances the input from villous cytotrophoblast 
progenitor cells. A change in the number of syncytiotrophoblast nuclei therefore 
represents either defective input (e.g. cytotrophoblast depletion, failure or down-
regulation of proliferation), or accelerated output of trophoblast material (e.g. altered 
differentiation pathway, extrinsic insults), both of which may perturb syncytial integrity 
and villous growth. 
 
5.5.1 Volume and Number of SCT in Normal Human Pregnancy 
Data from this study supports previous findings (200; 307) showing that the total 
volume and number of syncytiotrophoblast nuclei increases significantly between 26 
and 41 weeks of gestation. This is due to the increase in the total volume of gas-
exchanging villi in the third trimester of pregnancy. Conversely, the numerical density 
of syncytiotrophoblast nuclei decreased significantly between 26 and 41 weeks of 
gestation (supporting previous estimations (318)), due to the expansion of villous 
surface area and subsequent thinning of the trophoblast layer (Figure 5-1). This however 
was not paralleled by a decrease in the volume density of syncytiotrophoblast nuclei, 
which remained constant over gestation (previously reported at term (319)). This is 
because, whilst total trophoblast mass increases with gestational age reflecting villous 
growth, the spatial distribution of syncytiotrophoblast nuclei within this mass also 
changes due to the formation of vasculo-syncytial membranes (thus accounting for the 
decrease in numerical density) and denudation (local injury or mechanical shedding), 
leaving a non-uniform syncytiotrophoblast layer spread over a larger surface area. Thus, 
the proportion occupying villi does not significantly decline; volume density does not 
change. 
 
Although values were higher than previously estimated (318), the ratio of 
cytotrophoblast cells to syncytiotrophoblast nuclei remained constant at approximately 
1 to 5 between 26 and 41 weeks gestation. This indicates a steady balance between 
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recruitment and loss of trophoblast throughout the second and third trimester of normal 
pregnancy. 
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Figure 5-1 Volume and number of SCT in control placentas between 26 and 41 weeks of gestation.  
The total volume and number of SCT significantly increased with GA (A, P=0.031; C, P=0.031). The 
volume density of SCT did not change over gestation (A). Numerical density of SCT significantly 
declined with increasing gestational age (B, P=0.004). 
A. 
B. 
C. 
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5.5.2 Quantifying Syncytial Knots and Apoptosis  
‘Syncytial knotting’ (SK) (or Tenney-Parker changes (320)) is a broad histo-
pathological term used to describe the histological appearance of a focal aggregation, or 
clumping, of syncytiotrophoblast nuclei on the outer surface of placental villi (276; 
321). It encompasses those knots arising as part of a normal physiological event i.e. 
‘true syncytial knots’ (i.e. villous trophoblast turnover, villous sprouting), but mostly 
those arising as a consequence of tangential sectioning of irregularly shaped and 
branched villous trees i.e. ‘flat sectioning’ (276). 
 
Previous non-stereological studies describing increased syncytial knotting and apoptotic 
shedding in pre-eclampsia and IUGR (85; 320; 322) are confounded by (i) the 
assumption that all syncytial knots represent the final stages of villous trophoblast 
turnover, (i.e. syncytial degeneration), when in fact they will contain a mixture of knots, 
and (ii) the inherent bias associated with counting the ‘number of syncytial knots per 
unit area’ in 2D. Thus, there is always a degree of error and inaccuracy attached to 
morphological assessment of syncytial knots- the advantage of quantifying syncytial 
knots stereologically is that it permits the estimation of this error which can therefore be 
kept to a minimum.  
 
Due to sectioning artefacts, true syncytial knots, (signifying syncytial degeneration in 
the final stages of normal villous trophoblast turnover) were defined as those SK 
regions containing apoptotic nuclei displaying morphological features characteristic of 
the final stages of apoptosis (small densely stained nuclei with distinct annular 
chromatin). Knots displaying normal syncytial nuclei were subsequently quantified as 
non-apoptotic knots and were interpreted to contain a mixture of villous sprouts, bridges 
and flat sectioning.  
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(A)  
 
(B)  
 
Figure 5-2: Syncytial Knot Morphology 
Distinguishing between apoptotic and non-apoptotic syncytial knots. (A). At a low magnification it is 
impossible to determine the morphology of syncytial knots, and whether or not some of these contain 
apoptotic nuclei i.e. true syncytial knots (x100). (B). In contrast, apoptotic syncytial knot (white arrow) 
and non-apoptotic knot (black arrow) can be determined at a higher magnification (x400). The latter was 
used to identify apoptotic syncytial knots for this thesis.  
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5.5.3 Morphology of Syncytial Knots is Spatially and Temporally Regulated 
The volume, mean individual volume and morphology of syncytial knots between 26 
and 41 weeks gestation is described in the following section with the use of Figure 5-3. 
 
 
 
Figure 5-3 Syncytial knot (SK) volume, size and morphology between 26 and 41 weeks of gestation 
in control placentas.  
The volume of villi, syncytial knots and apoptotic syncytial knots (volume and size) increase between 26 
and 41 weeks of gestation. (Vv = Volume Density, VTOT = Total Volume, Apop = Apoptotic SK. 
Structural villi = stem and immature intermediate villi, Peripheral villi = mature intermediate and terminal 
villi).  
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5.5.4 Volume of Syncytial Knots 
Total volume of syncytial knots 
Both structural and peripheral villi were associated with a significant increase in the 
total volume of syncytial knots (P=0.025, P<0.001) between 26 and 41 weeks of 
gestation. Whilst the volume density of SK on structural villi did not change over 
gestation, peripheral villi displayed a trend towards an increase, which just failed to 
reach statistical significance, (P=0.055). The former is an expected observation, as stem 
villi are continuously transforming into mature intermediate villi from around 22 weeks 
of gestation, thus the relative volume of SK on stem and immature intermediate villi 
will remain linear between 26 and 41 weeks of gestation.   
 
Mean individual volume of syncytial knots 
Although there were no significant changes in mean individual SK volume for structural 
villi between 26 and 41 weeks of gestation, preterm controls (26-32 weeks) were 
associated with a significant increase in mean SK size in comparison to peripheral villi 
(P=0.021). This likely contributes to the increased volume density of SK in comparison 
to peripheral villi, indicating that structural villi are associated with “fewer larger 
knots”; although “more knots of equal or greater volume” is equally likely. In contrast, 
peripheral villi displayed a trend towards an increase in mean SK size between 26 and 
41 weeks, which just failed to reach statistical significance (P=0.066). This is indirect 
evidence for accelerated extrusion of syncytial nuclei in the third trimester of 
pregnancy, consistent with the redistribution of syncytial mass thinning the villous 
membrane via the formation of vasculo-syncytial membranes (212); a high incidence of 
SK regions are associated with a low incidence of vasculo-syncytial membranes (323). 
 
Morphology of syncytial knots 
Approximately half the total volume of syncytial knots were comprised of “true 
syncytial knots” i.e. those containing apoptotic syncytial nuclei, showing that apoptosis 
is a normal component of villous trophoblast turnover. The overall volume density of 
apoptotic SK nuclei on structural villi was significantly increased compared to 
peripheral villi. In the mature placenta, knots formed on villi during early gestation (i.e. 
structural villi) will likely show increased numbers of ageing nuclei (i.e. apoptosis), 
whereas in comparison those formed in later gestation (i.e. peripheral villi) will contain 
relatively little apoptotic nuclei (321). Hence, even though peripheral villi outweigh 
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structural villi in terms of total volume in late gestation, they actually contain less 
apoptotic nuclei per se.  
 
Over gestation, the total volume of apoptotic nuclei increased in both structural and 
peripheral villi reflecting the increase in villous volume. The volume density of 
apoptotic nuclei displayed a trend towards an increase (P=0.055) with gestational age in 
peripheral villi. 
 
5.6 Syncytial Integrity in Early-onset Pathologies 
5.6.1 Volume and Number of SCT in Severe Early-onset PET and IUGR  
Severe early-onset IUGR displayed a 50% reduction in the total volume and number of 
syncytiotrophoblast nuclei, specifically for peripheral villi, in comparison to age-
matched controls. Whilst the volume density of syncytiotrophoblast was unaffected, the 
numerical density of syncytiotrophoblast displayed a trend towards a decrease (20% less 
nuclei per unit volume of placenta). The discordance between volume and number 
densities is indirect evidence for an increase in the average ‘size’ of syncytiotrophoblast 
nuclei in severe early-onset IUGR. In contrast, severe early-onset pre-eclampsia was not 
associated with any changes in the total volume or number of syncytiotrophoblast nuclei 
when compared to age-matched controls. Volume density of syncytiotrophoblast was 
however significantly reduced in structural villi.  
 
Severe early-onset pre-eclampsia with IUGR (combined group) displayed significant 
reductions in the total volume and number of syncytiotrophoblast nuclei. There was a 
decrease in the numerical density of syncytiotrophoblast nuclei which just failed to 
reach statistical significance (P=0.053). Since these changes were not observed in severe 
early-onset PET, reductions in the total volume and number of syncytiotrophoblast 
nuclei in the combined group were due to the effects of IUGR. In contrast, the reduction 
in volume density of syncytiotrophoblast in structural villi for the combined group was 
due to the effects of pre-eclampsia.  
 
Clinically, severe early-onset pre-eclampsia with IUGR is the most severe phenotype. 
The combination of PET with IUGR is therefore predicted to represent the most severe 
phenotype in terms of abnormal trophoblast biology. Accordingly, the reductions in the 
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total number and density of syncytiotrophoblast were more severe in the combined 
group (compared to pure IUGR or PET) demonstrating a potential synergistic 
interaction of PET and IUGR on numbers of syncytiotrophoblast nuclei. This is in direct 
contrast to villous cytotrophoblast, whereby pre-eclampsia reduced the severity of 
alterations in the combined group; consequently pure IUGR displayed the most severe 
villous cytotrophoblast phenotype. 
 
The functional consequence of reduced syncytiotrophoblast nuclei is predicted to 
severely impair the transport (i.e. of amino acids) and endocrine activity of the 
syncytium upon which fetal growth and viability depend in the second half of 
pregnancy. Diminished growth of the IUGR fetus thus occurs not only by reduced 
volumes and surface area of gas-exchanging villi responsible for diffusional exchange 
of oxygen and nutrients, but is exacerbated by reduced numbers of syncytiotrophoblast 
nuclei available for active transport of amino acids and protein production necessary for 
fetal and subsequent placental growth. Based on these considerations, it is logical that 
‘pure’ severe early-onset pre-eclampsia with normal fetal birth weights and normal 
umbilical artery Dopplers display similar volumes of placental villi and numbers of 
syncytiotrophoblast nuclei to age-matched controls.  
 
5.6.2 Increased Volumes of Apoptotic Syncytial Knots in Early-onset PET and 
IUGR 
Results from this study confirm stereologically that severe early-onset pre-eclampsia 
and IUGR are associated with increased numbers of apoptotic syncytial knots. 
Furthermore, the average size of these knots increases when pre-eclampsia co-exists 
with IUGR.  
 
Severe early-onset pre-eclampsia displayed a significant increase (45%) in the total 
volume and density of apoptotic and non-apoptotic syncytial knots specifically for 
peripheral villi. Conversely, volume density was significantly decreased for structural 
villi. Although severe early-onset IUGR displayed the largest volume density of 
syncytial knots compared to all study groups, statistical significance was not reached 
likely due to the small number of cases. Nonetheless, a significant proportion of these 
knots contained apoptotic nuclei in comparison to controls, shown by a 36% increase in 
the volume density of apoptotic knots in peripheral villi. When combined with pre-
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eclampsia, severe early-onset IUGR displayed a significant increase in the volume 
density of syncytial knots (apoptotic only) for peripheral villi. These were 57% larger 
than apoptotic knots in control placentas, but did not reach significant due to the large 
variation between placentas.  
 
Volume density is a measure of the percentage of the reference volume Y, i.e. the 
placenta, taken up by X, i.e. syncytial knots. An increase in volume density of syncytial 
knots can therefore result from an increase in the number or size of syncytial knots, or 
both. In severe early-onset pre-eclampsia and IUGR, volume density was significantly 
increased but there was no change in individual SK volume (PSI), indicating a genuine 
increase in the number of syncytial knots in these placentas. Conversely, in pre-
eclampsia co-existing with IUGR, both the PSI (trend) and volume density of knots 
increased. This situation may result from the presence of fewer larger knots, or 
alternatively, more knots of equal or larger size. 
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5.6.3 Impaired Syncytialisation in Severe Early-onset IUGR with and without 
PET 
Growth, regeneration and functional integrity of the syncytiotrophoblast layer is 
completely dependent upon the continuous fusion of post-proliferative villous daughter 
cytotrophoblast cells throughout gestation; a lack of cytotrophoblast input via syncytial 
fusion leads to necrotic shedding and rarefaction of syncytiotrophoblast nuclei in vivo 
(214). Reduced numbers of villous cytotrophoblast cells therefore reflects proliferation 
below what is normally required to maintain growth, maintenance and integrity of the 
syncytiotrophoblast layer. The reduction in syncytiotrophoblast volume and number in 
severe early-onset IUGR was thus hypothesised to result from a reduced number of 
syncytial fusion events, secondary to reduced numbers and density of villous 
cytotrophoblast cells (due to premature depletion of progenitor cells), and reduced 
numbers of proliferating cytotrophoblast cells responsible for regenerating the 
syncytiotrophoblast layer.  
 
The reduction in syncytiotrophoblast density is indirect evidence for absence of 
cytotrophoblast fusion in severe early-onset IUGR with and without co-existing pre-
eclampsia. Globally, severe early-onset IUGR placentas are associated with a 50% 
reduction in the total volume and number of villous cytotrophoblast cells, 30% 
reduction in in those undergoing proliferation, subsequently resulting in 50% fewer 
syncytiotrophoblast nuclei in comparison to age-matched controls, confirming the 
hypothesis. However, given that the number of syncytiotrophoblast nuclei is positively 
correlated with the number of cytotrophoblast fusion events, the fact that the reduction 
in syncytiotrophoblast density was not paralleled by a similar reduction in the density of 
villous cytotrophoblast cells implies impaired syncytial fusion (Figure 5-4). 
 
This suggests that ‘impaired recruitment’ of villous cytotrophoblast cells into the 
syncytium, in preference to ‘depletion of cytotrophoblast progenitor cells’ cells per se, 
is causative for reduced syncytiotrophoblast density in severe early-onset IUGR.   
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Figure 5-4 Impaired syncytialisation in severe early-onset IUGR  
In normal placentas (A), four proliferating villous cytotrophoblast cells exit the cell cycle (GCM-1 
directed), giving rise to four syncytial nuclei indicating proper syncytial fusion. In comparison, in severe 
early-onset IUGR, in addition to the 30% global reduction in the total number of proliferating villous 
cytotrophoblast cells (B), the density of syncytial nuclei is further reduced by 50% in comparison to 
preterm controls (C), which in conjunction with the ‘normal’ density of villous cytotrophoblast cells, 
indicates impaired syncytialisation of villous cytotrophoblast cells.  
 
Syncytial fusion is coupled to cytotrophoblast differentiation and the ‘initiator’ stages of 
apoptosis (213; 225). Impaired syncytial fusion and reduced syncytiotrophoblast density 
in severe early-onset IUGR therefore indicates defective villous cytotrophoblast 
differentiation; a similar observation to that reported in vitro for Trisomy 21 affected 
placentas in Down’s syndrome (324).  
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The decision of a cytotrophoblast cell to exit the cell cycle, differentiate and fuse with 
the overlying syncytium is shown to be mediated by the trophoblast-specific 
transcription factor, GCM1 (182; 214). GCM1 induces the expression of the gene 
syncytin (193), specifically expressed in the syncytiotrophoblast (192; 215), which 
transcribes a fusogenic membrane protein, syncytin1 (192), that mediates fusion of 
cytotrophoblast cells into the syncytiotrophoblast (193; 218; 219); both syncytin1 and 
GCM1 expression increase from the first trimester to 37 weeks gestation (310; 325). 
The cellular action of syncytin1 is however unidentified. The reduced 
syncytiotrophoblast density and ‘normal’ cytotrophoblast density in severe early-onset 
IUGR (Figure 5-4) may therefore be associated with dysregulated syncytin1 expression. 
Accordingly, a recent study using primary cytotrophoblast cultures and tissues showed 
that syncytin mRNA and protein expression is significantly reduced in IUGR with co-
existing pre-eclampsia at mean gestational age of 32 weeks, resulting in reduced 
numbers of SCT nuclei (per unit area) inferring impaired syncytial fusion (309). 
 
Given that GCM1 is a trans-activator of syncytin, reduced syncytin1 protein expression 
in IUGR with PET is inconsistent with the increased GCM1 protein expression 
observed for severe early-onset IUGR in this study (personal communication, Sascha 
Drewlo, Toronto); increased GCM1 protein expression would be expected to increase 
syncytin1 expression in vivo. This inverse relationship suggests that initiation of 
syncytial fusion by syncytin1 is expression level-dependent. Huppertz et al 
demonstrated reduced numbers of cytotrophoblast cells upon antisense oligonucleotide 
inhibition of syncytin1, contrary to the expected increase, suggesting that decreased, 
rather than increased syncytin1 expression may stimulate syncytial fusion (211). It may 
be reasoned that increased syncytin1 expression (via upregulation of GCM1 and 
subsequently reduced Ki-67 expression) therefore leads to delayed/impaired syncytial 
fusion, further diminishing cytotrophoblast cell differentiation.(214). Furthermore, the 
presence of an intact syncytium is a precondition for cytotrophoblast fusion and 
syncytialisation (185; 214). First trimester floating villi denuded of syncytiotrophoblast 
in vivo fail to undergo de novo syncytiotrophoblast formation following forskolin 
treatment or up-regulation of GCM1. An alternative viewpoint is that decreased 
syncytiotrophoblast density in severe early-onset IUGR perpetuates the already 
delayed/impaired syncytial fusion secondary to defective cytotrophoblast 
differentiation.  
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Premature death of villous cytotrophoblast cells in severe early-onset IUGR? 
Whilst villous cytotrophoblast progenitor cells feed growth and regeneration of the 
syncytiotrophoblast, the daughter cells are responsible for executing its programmed 
cell death. As cytotrophoblast cells fuse with the overlying syncytium, they transfer the 
necessary apoptotic machinery confining the “execution stages” to syncytiotrophoblast 
nuclei, which are extruded in the form of syncytial knots some 3-4 weeks later (195). In 
normal placental villi, apoptotic cell death is thus almost exclusively (308) confined to 
discrete areas of the syncytiotrophoblast, predominantly aggregated within syncytial 
knot regions (321). Semi-quantitative immuno-histochemical studies have shown an 
increased expression of pro-apoptotic proteins and correspondingly reduced expression 
of anti-apoptotic proteins in the syncytiotrophoblast layer, in both term (198; 240; 242; 
326) and preterm IUGR placentas (327) (reviewed in detail in (328)). More recently, 
increased apoptosis (assessed using terminal dUTP end-labelling, Annexin V binding 
potential, and the measurement of ADP: ATP levels) has been demonstrated in isolated 
villous cytotrophoblasts from pre-eclampsia and IUGR at term (329). Similarly results 
from the present study suggest that (albeit indirectly) in severe early-onset IUGR, 
villous cytotrophoblast cells may well undergo the execution stages of apoptosis prior to 
entering the syncytiotrophoblast, consequently reducing syncytiotrophoblast density.  
 
Although the stimulus is unknown, ultra-structural studies in normal human pregnancy 
between 6 and 15 weeks gestation confirmed that a small percentage of villous 
cytotrophoblast cells do in fact undergo the execution stages of apoptosis, and to an 
even lesser extent, primary necrosis (308). Given that the process of syncytial fusion 
transfers the necessary apoptotic machinery to execute the final stages of apoptosis in 
syncytiotrophoblast (195; 225), it may be postulated that the ‘fusion-disabled’ villous 
cytotrophoblast cells thus undergo the execution stages of apoptosis prior to entering the 
syncytiotrophoblast. Interestingly, over-expression of syncytin1 in choriocarcinoma 
cells (CHO) transfected with the apoptosis inducer staurosporine, significantly reduced 
the rate of apoptotic cell death (reduced caspase-3 activation and increased Bcl-2 
expression), demonstrating the anti-apoptotic effects of syncytin1 in fusing CHO cells 
(330). By inference, reduced syncytin1 expression in IUGR (309) may therefore exert 
pro-apoptotic cellular effects in non-fusing cytotrophoblast cells. Moreover, because the 
process of syncytial fusion transfers anti-apoptotic proteins (e.g.Bcl-2 expression is 
reduced in severe IUGR (240)) which focally retard the apoptosis cascade (195), the 
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lack of syncytial fusion in severe early-onset IUGR may also result in accelerated 
syncytiotrophoblast apoptosis, supported by the significant increase in number of 
apoptotic syncytial knots.  
 
Although numbers of apoptotic nuclei (cytotrophoblast or syncytiotrophoblast) were not 
quantified in the present study, expression of the apoptosis-induced cleaved cytokeratin-
18 was semi-quantified by western blotting. During the ‘irreversible’ stages of caspase-
mediated apoptosis, caspases -3 and -7 proteolytically cleave the intermediate filament 
protein, cytokeratin-18 (CK-18) producing a neo-epitope (42kDa protein) which is 
recognised specifically in epithelial cells by the apoptosis-specific monoclonal antibody, 
M30 (237); M30 does not detect necrosis (303). In normal placentas undergoing 
apoptosis, cleaved CK-18 is predominantly immuno-localised to the syncytiotrophoblast 
cytoplasm, syncytial knots, and to a lesser extent in villous cytotrophoblast cells, which 
under experimentally-induced hypoxia, reverses this expression pattern (210). 
 
In the present study, cleavage of CK-18 (M30 mAb) was detected in equal amounts in 
preterm controls and severe early-onset pre-eclampsia, and was elevated in severe early-
onset IUGR with co-existing pre-eclampsia (35% increase). This however was not 
statistically significant due to large inter-placental variation and small study groups. The 
corresponding absence of the full-length CK-18 protein verified CK-18 cleavage and 
M30 specificity. Neither M30 nor full-length CK-18 expression were quantified in 
severe early-onset IUGR without pre-eclampsia due to unforeseen circumstances.  
 
Despite these limitations, the results still provide reasonable evidence that villous 
cytotrophoblast cells may undergo premature death in severe early-onset IUGR. This 
can be explained for the following reasons. Firstly, since both severe early-onset pre-
eclampsia and IUGR display increased numbers of apoptotic syncytial knots, the fact 
that cleaved CK-18 was not increased in pre-eclampsia but increased in IUGR with PET 
indicates that syncytial knots are not responsible for elevated cleaved CK-18 expression. 
Secondly, syncytiotrophoblast density was significantly reduced in IUGR with PET and 
not pre-eclampsia, which given the above considerations, should reduce the expression 
of cleaved CK-18. Thirdly, severe early-onset IUGR with pre-eclampsia is associated 
with increased numbers of non-dividing cytotrophoblast cells relative to pre-eclampsia. 
For these reasons, increased cleaved CK-18 expression in IUGR with pre-eclampsia can 
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be inferred to result from an increased number of villous cytotrophoblast cells 
undergoing the execution stages of the apoptosis cascade in comparison to preterm 
controls. Furthermore, given that the morphological and molecular pathology of IUGR 
with pre-eclampsia typically resembles that of isolated IUGR, increased cleaved CK-18 
expression, and hence villous cytotrophoblast apoptosis, may be a presumed feature of 
severe early-onset IUGR placentas.  
 
Increased numbers of apoptotic syncytial knots in severe early-onset IUGR 
In line with the above observations, the decrease in syncytiotrophoblast density and 
increase in the number of apoptotic syncytial knots in severe early-onset IUGR and 
PET-IUGR placentas may reflect accelerated formation of syncytial knots. During the 
second and third trimester of normal pregnancy, fetal maturation is accompanied by 
redistribution of syncytial mass into knot regions corresponding to the formation of thin 
vasculo-syncytial membranes, which serve to decrease the diffusional distance of 
oxygen and nutrients between maternal and fetal circulations. As such, a high incidence 
of syncytial knots has been shown to be associated with a low incidence of vasculo-
syncytial membranes. Thus, from a physiological perspective, the reduction in 
syncytiotrophoblast nuclei and increase in syncytial knots may serve to thin villous 
membrane thickness thus compensating for impaired cytotrophoblast fusion.  
 
Apoptotic syncytial knots are undoubtedly physiological, and are thought to represent 
the end stage in the turnover of villous trophoblast. Although the exact mechanism of 
extrusion is unknown, sheer mechanical stress from ‘fast-flowing’ maternal blood in the 
intervillous space is postulated to remove such knots. Increased numbers of apoptotic 
syncytial knots are unlikely to be directly involved in the pathophysiology of severe 
early-onset IUGR, as increased numbers are also observed in pre-eclampsia displaying 
normal fetal birth weights, indicating that syncytial knots do not impede diffusional 
exchange. An alternative explanation is that in IUGR pregnancies with reduced uterine 
artery Dopplers, sluggish and/or intermittent uteroplacental blood flow results in less 
mechanical shedding leading to large accumulations of syncytial nuclei. As a 
consequence, such knots may become apoptotic post-formation. Concordantly, 
experimentally-induced hyperoxia (20% oxygen) (presumed to represent intervillous 
oxygen content in severe early-onset IUGR), increased the number of apoptotic 
syncytial knots per mm2 of terminal villi (322).  
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5.6.4 Accelerated Terminal Differentiation in Severe Early-onset Pre-eclampsia? 
There is general agreement that hypoxia/re-oxygenation injury promotes (331) the 
increased release of placental factors (e.g. cytokines (19), eicosanoids (332), peroxides 
(333), soluble Flt-1 (22), soluble endoglin (334), and trophoblast debris such as 
syncytiotrophoblast microparticles (STBM) (335) and necrotic and/or apoptotic 
syncytial material (210)), from a ‘dysfunctional’ syncytium which are both necessary 
and sufficient (23) to reproduce the maternal syndrome of pre-eclampsia, i.e. maternal 
endothelial dysfunction, clinically evident as maternal hypertension and proteinuria. 
Despite the pathogenic evidence (24), the stimuli(s) for their release is currently 
undefined, but is generally ascribed to dysregulated cytotrophoblast biology (3). 
Findings from the present study indicate that the rate of the entire turnover of villous 
trophoblast is increased in severe early-onset pre-eclampsia, likely contributing to 
abnormal syncytial shedding.  
 
The hypothesis under investigation was that in pre-eclampsia, an increased rate of 
cytotrophoblast proliferation and syncytial fusion makes sufficient numbers of 
syncytiotrophoblast, but results in dysregulated shedding of syncytial nuclei (necrotic 
and apoptotic) into the intervillous space constituting the maternal syndrome. The fact 
that severe early-onset pre-eclampsia was not associated with any significant changes in 
the number or volume of syncytial nuclei when compared to age-matched controls, 
partly confirms this hypothesis. 
 
Sufficient numbers of syncytial nuclei signifies ‘matched’, or even ‘accelerated’ 
cytotrophoblastic input providing this is matched by accelerated extrusion; failure to 
extrude would increase syncytial thickness which is not a feature of pre-eclampsia. 
Although there was no significant increase in the number of proliferating 
cytotrophoblast cells, peripheral villi displayed a trend towards a decrease in 
cytotrophoblast density (P=0.071) whereas syncytiotrophoblast density was unchanged. 
Given that the number of syncytiotrophoblast nuclei is directly correlated with the 
number of cytotrophoblast fusion events, this mismatch between cytotrophoblast and 
syncytiotrophoblast density indirectly indicates increased syncytial fusion and 
accelerated terminal differentiation of villous cytotrophoblast cells in severe early-onset 
pre-eclampsia. This concept is explained in (Figure 5-5). 
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Figure 5-5 Rudimentary model of accelerated trophoblast turnover in peripheral villi in severe 
early-onset pre-eclampsia 
In control placenta (A), trophoblast turnover is balanced such that the number of syncytiotrophoblast 
nuclei is paralleled by an equal number of proliferating and fusing cytotrophoblast cells i.e. four post-
mitotic cytotrophoblast cells (GCM1-positive) differentiate and fuse producing four terminally-
differentiated syncytial nuclei. In (B), an increase in cytotrophoblast proliferation with reduced 
cytotrophoblast fusion leads to a multilayered cytotrophoblast layer and rarefaction of syncytiotrophoblast 
nuclei. This scenario is described for severe early-onset pre-eclampsia in vivo via inhibition of GCM1 
(214). In contrast (C), whilst there are an equal number of proliferating cytotrophoblast cells and syncytial 
nuclei to controls, there are less cytotrophoblast cells. The reduction in cytotrophoblast density is 
therefore indirect evidence for an increase in the rate of cytotrophoblast fusion. The imbalance between 
proliferation and fusion (leading to an increase, although not statistically significant, in the percentage of 
proliferating cytotrophoblast cells) indicates accelerated villous cytotrophoblast differentiation, 
demonstrating a shorter transition time between cytotrophoblast and syncytiotrophoblast phenotypes.  
 
Crucially, for there to be an increase in the rate of cytotrophoblast fusion, the rate of 
cytotrophoblast proliferation must also increase or else the pool of syncytially-fusing 
cytotrophoblast cells would be exhausted, leading to rarefaction of syncytiotrophoblast 
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nuclei. The accelerated turnover of cytotrophoblast proliferation and fusion may 
therefore preclude detection of the hypothesised increase in the number of proliferating 
villous cytotrophoblast cells.  
 
Morphological data in this study is consistent with the molecular pathology of severe 
early-onset pre-eclampsia (in vitro and in vivo). Placentas in the present study are 
associated with decreased protein and mRNA expression of GCM1 (Personal 
communication, Sascha Drewlo, Toronto), as previously described (310). GCM1 is 
differentially expressed in post-mitotic daughter villous cytotrophoblast cells destined 
for syncytial fusion (183; 191). Inhibition of GCM1 in non-denuded first trimester 
villous explants prevents de novo syncytiotrophoblast formation leading to a 
multilayered cytotrophoblast layer and rarefaction of a necrotic syncytium (214), 
signifying the vital role of GCM1 in regulating human villous cytotrophoblast 
differentiation. Concordantly, expression of the fusogenic protein syncytin1, a direct 
downstream effector of GCM1, is significantly reduced in severe early-onset pre-
eclampsia (336-338). Thus, the alterations in GCM1 and syncytin1 are presumed to 
contribute to reduced cytotrophoblast differentiation and fusion, subsequently impairing 
syncytiotrophoblast formation. However, the morphological consequences of GCM1 
inhibition in vivo (representing decreased GCM1 expression in pre-eclampsia) oppose 
the stereological data indicating accelerated cytotrophoblast differentiation and fusion, 
alongside normal syncytiotrophoblast formation.  
 
This may be explained by the fact that the reduction in cytotrophoblast density (via 
presumed accelerated fusion) diminishes the number of GCM1-positive syncytially-
fusing cytotrophoblast cells. Given that up-regulation of GCM1 induces arrest of 
mitosis (counter-expression to Ki-67), the above explanation is justified by an observed 
20% reduction (trend) in the number of Ki-67-negative (i.e. differentiating) 
cytotrophoblast cells (P=0.088). Although this does create a circular argument since in 
vivo, reduced GCM1 expression retards syncytial fusion. Nonetheless, together this data 
indicates ‘under-differentiation’ of villous cytotrophoblast cells which as a consequence 
have to increase the rate of syncytial fusion to maintain syncytial morphology at the 
expense of functional integrity i.e. abnormal shedding.  
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Severe experimental hypoxia (1% O2), presumed to represent an acute model of 
placental ischemia in severe early-onset pre-eclampsia, also reduces GCM1 and 
syncytin1 transcripts and fusion of primary term human trophoblasts (339). A practical 
explanation is that these and the above ‘acute models’ fail to mimic the local changes in 
oxygen tension and intervillous haemodynamics, which change both spatially and 
temporally. Hence, stereological analysis of pre-eclamptic placentas might identify 
more subtle changes in trophoblast morphology, which may well originate from a less 
severe, yet comparable defect/insult initiated during early placental development.  
 
Is accelerated villous trophoblast turnover sufficient to cause dysregulated syncytial 
shedding?  
Circulating syncytiotrophoblast microparticles (i.e. loss of brush border membranes, 
cytoplasmic protrusions, microvillous blebs (340)) arise as part of the normal turnover 
of syncytiotrophoblast, evidenced by their detection in maternal plasma of normal 
pregnancy, and are present in significantly increased amounts in pre-eclampsia (335). 
Such particles are the hallmark of apoptosis (341), which is proposed to coordinate the 
extrusion of aged syncytial nuclei into the IVS, allowing for continuous renewal of the 
syncytial surface (195).   
 
It has recently been shown that diminished villous cytotrophoblast differentiation 
(GCM1-silenced) in vitro and in vivo leads to the increased release and expression of 
the anti-angiogenic factor, soluble sFlt-1 (22), in culture media and syncytiotrophoblast 
respectively, establishing a link between abnormal villous cytotrophoblast 
differentiation and the release of pathogenic placental factors (342). 
 
 
 
 
 
 
 
 
Syncytial integrity Chapter 5
 
 
 186
5.7 Late-onset Pathologies 
5.7.1 Volume and Number of SCT in Late-onset Pathologies 
Although there was no significant decrease in the total volume of syncytiotrophoblast in 
late-onset IUGR, the total number of syncytial nuclei significantly decreased by 50% 
(both structural and peripheral villi) in comparison to age-matched controls. This 
however reflects the small placental phenotype, as volume and number densities of 
syncytiotrophoblast nuclei remained similar to controls. Whilst the overall volume 
density of syncytial knots did not increase, the proportion of them containing apoptotic 
nuclei significantly increased (42%) in structural villi, with a propensity to be larger 
(average volume) than controls. 
 
In contrast, late-onset pre-eclampsia was associated with a 31% increase in the density 
and total volume of syncytial nuclei in peripheral villi, which failed to reach 
significance due to large variation. Conversely, the numerical density of syncytial nuclei 
remained unchanged, indirectly indicating an increase in the average size of individual 
syncytial nuclei in peripheral villi. Structural villi on the other hand displayed a 40% 
reduction in numerical density of syncytiotrophoblast. This resulted in a trend towards a 
decrease in total numbers of syncytiotrophoblast nuclei (27% reduction). Peripheral villi 
displayed a trend towards an increase in the volume density of syncytial knots, a 
significant proportion of which were apoptotic in comparison to age-matched controls 
but of similar size (52% increase).   
 
In comparison to early-onset pre-eclampsia co-existing with IUGR displaying a 
dominant role of IUGR in reducing syncytiotrophoblast volumes and number, pre-
eclampsia played a dominant role in increasing syncytiotrophoblast volumes in the 
combined disease in late gestation; 30% increase in the volume density of syncytial 
nuclei in peripheral villi, which just failed to reach significance (P=0.068). The 
numerical density of syncytial nuclei remained unchanged, whereas total numbers 
declined by 35% in peripheral villi. Similar to the ‘pure’ pathologies, the volume 
density of syncytial knots remained unchanged but a significant proportion of them 
were apoptotic and larger in comparison to controls (32% increase). Furthermore, the 
severity of the above changes was lessened by the presence of pre-eclampsia in late 
gestation, whereby ‘pure’ IUGR displayed the most severe phenotype.  
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5.7.2 Accelerated Syncytialisation in Late-onset Pre-eclampsia 
Results from this study reveal that accelerated syncytialisation and villous trophoblast 
turnover is a shared feature of both early- and late-onset pre-eclampsia. To avoid 
repetition, data for late-onset pre-eclampsia will be briefly described; for a full 
explanation of these observations refer to section 5.6.4 
 
Similar to early-onset cases, the epithelial steady state is dysregulated in late-onset pre-
eclampsia, shown by a global loss (24%) of (Ki-67 negative) cytotrophoblast cells 
alongside preserved numbers of syncytiotrophoblast. Such a loss of cytotrophoblast 
indicates an increased rate of differentiation and fusion into the ‘normal’ syncytium 
(numbers of nuclei). There is also indirect evidence for an increase in the size of 
syncytial nuclei in late-onset pre-eclampsia, since the increase in volume density of 
syncytiotrophoblast (peripheral villi only) was not accompanied by an increase in 
number, which remained similar to controls. This may result from the failure of the 
‘freshly incorporated’ syncytiotrophoblast nuclei to undergo terminal differentiation 
(and hence reduction in size) prior to extrusion, supporting the notion of aponecrotic 
release of syncytial nuclei in pre-eclampsia (3). Because numbers of syncytial nuclei are 
maintained, the increased rate of recruitment (i.e. fusion) must therefore be matched by 
extrusion, since a thicker syncytial membrane is not a feature of these placentas. Whilst 
the number of proliferating villous cytotrophoblast cells remain similar to controls, the 
rate of proliferation must be increased, otherwise villous membrane thickness would 
gradually decline due to the lack of trophoblast input. An increased rate would preclude 
detection of the hypothesised increase in number of proliferating cytotrophoblast cells 
due to accelerated syncytiotrophoblast differentiation. As such, the increase in the 
percentage of proliferating cytotrophoblast cells observed for structural villi was due to 
a decline in cytotrophoblast numbers rather than an increase in the density of Ki-67 
positive cells per se. Together, these results demonstrate that pre-eclampsia is 
associated with an increase in the rate of the entire turnover of villous trophoblast, 
independent of gestational age.  
 
Although there was no significant increase in the volume density of syncytial knots in 
late-onset pre-eclampsia, peripheral villi displayed a significant increase in percentage 
of apoptotic syncytial knots. This is unlikely to reflect defective mechanical shedding 
which would be expected to increase the volume density of syncytial knots. A plausible 
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explanation is the increased extrusion of syncytial knots via accelerated trophoblast 
turnover.  
 
5.7.3 Normal Syncytialisation in Late-onset IUGR 
A combination of the low number of cases (n=4) and the large intra-group variation 
(two 33 week cases with abnormal umbilical artery Doppler, and two cases at 37 weeks 
with normal Dopplers) in the late-onset IUGR groups means that conclusions regarding 
syncytiotrophoblast cannot be determined with any degree of accuracy. Therefore, only 
the stereological data is described.  
 
The placental phenotype of late-onset IUGR resembles that of early-onset disease such 
that the ‘small’ placenta contains 50% less proliferating cytotrophoblast cells, 50% less 
villous cytotrophoblast cells and consequently 50% less syncytiotrophoblast nuclei in 
comparison to term controls. However, in contrast to early-onset pathology, the density 
of syncytial nuclei remained similar to controls indicating normal syncytialisation, and 
thus normal villous cytotrophoblast differentiation. Furthermore, proliferating villous 
cytotrophoblast cells are not depleted, which may account for normal growth of the 
peripheral villous tree seen in late-onset IUGR. Similar to late-onset pre-eclampsia, the 
volume density of syncytial knots remained unchanged but the proportion of apoptotic 
syncytial knots significantly increased. This may reflect failed or retarded extrusion 
resulting in an ageing syncytium in late-onset IUGR.  
 
Contrary to expectations, the epithelial steady state in late-onset pre-eclampsia with 
IUGR resembled that of isolated pre-eclampsia and not IUGR as was acknowledged for 
early-onset disease. Villous cytotrophoblast differentiation was dysregulated in an 
almost identical manner to that described above for late-onset pre-eclampsia. This 
includes (i) a trend towards a decrease in the density of (non-proliferating) villous 
cytotrophoblast cells (P=0.067) and normal numbers of syncytial nuclei indicating 
accelerated syncytialisation (ii) an increase in volume density of syncytiotrophoblast 
with no change in number indicating their increased size, (iii) a significant increase 
(26%) in the percentage of proliferating cytotrophoblast cells for peripheral villi.  
 
This is a paradoxical finding since the ‘small’ placental phenotype of late-onset pre-
eclampsia with IUGR was similar to isolated IUGR, with reductions (albeit less severe) 
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in total placental and villous volumes, and total numbers of trophoblast. This 
discrepancy may be explained by the fact that, whilst rates of differentiation and loss 
seem to be accelerated in pre-eclampsia, rates of proliferation are higher in pre-
eclampsia than IUGR, thereby maintaining appropriate ‘growth pattern’ of the villous 
trees, but which may have began with less developmental potential (i.e. progenitor 
cells).  
 
5.7.3.1 Increased Volumes of SCT and Apoptotic Syncytial Knots in SIDS  
Data from this study shows that SIDS is associated with a thickened syncytiotrophoblast 
layer in comparison to term controls, the severity of which is increased in SIDS-LBW. 
SIDS-NBW placentas displayed a significant increase in the volume density of 
syncytiotrophoblast nuclei (specifically for stem and mature intermediate villi; 37%, 
29%), which was exemplified in the presence of a low birthweight infant (42%, 45%), 
indicating the effect of LBW on syncytiotrophoblast volume. Although SIDS had no 
overall effect on the total volume or density of syncytial knots, the percentage of 
apoptotic syncytial knots increased in the presence of both normal (23%) and low 
birthweight infants (25%), which tended to be smaller in size (30% smaller but not 
significantly). This indicates that SIDS placentas are associated with increased numbers 
of ‘smaller’ apoptotic syncytial knots in comparison to term controls, independent of 
fetal birthweight.  
 
Pre-placental fetal hypoxia and the syncytium in SIDS placentas  
There is a growing concept that SIDS represents a developmental disorder which 
originates during fetal development in utero. It is generally believed that biochemical 
and microscopic developmental abnormalities evidenced in ‘hypoxic’ SIDS infants (64), 
especially in the brainstem (80; 80; 343) and central nervous system (70), are the result 
of protracted or recurrent exposure to ‘intrauterine hypoxia’, culminating in the sudden 
death of an infant during a vulnerable postnatal period (i.e. the triple risk hypothesis 
(71)). Cigarette exposure, either passively or directly during pregnancy is considered the 
principle cause of intrauterine hypoxia (of the pre-placental type) and SIDS; hematocrit 
levels suggestive of hypoxia are elevated in both mothers and fetuses of smokers 
compared to non-smokers.  
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Maternal smoking during pregnancy is associated with a thicker villous membrane, 
evidenced to result from the direct effect of tobacco constituents on reducing 
cytotrophoblast proliferation, differentiation and syncytiotrophoblast apoptosis in vitro, 
in a dose-dependent manner (247; 344). The increased thickness, and hence increased 
volumes of cytotrophoblast and syncytiotrophoblast, may be expected to compromise 
diffusional exchange to the fetus from an early stage in pregnancy resulting in a LBW 
infant. Concordantly, 83% of SIDS-LBW infants were born to heavy smokers (average 
of 20 cigarettes per day) whilst only 42% of SIDS-NBW infants were born to mild 
smokers (average of 10 cigarettes per day). This supports previous observations that 
heavy smoking reduces infant birthweight (246). However, by separating smokers from 
non-smokers in SIDS-NBW infants, there still remains a significant increase in the 
volume of syncytiotrophoblast in non-smoking SIDS-NBW placentas compared to non-
smoking controls. Furthermore, these alterations were more severe in non-smokers than 
smokers. Together, these results indicate that SIDS-specific factors and not those 
relating to maternal smoking, account for the increase in syncytiotrophoblast volume.  
 
The increase in relative syncytiotrophoblast volume is inconsistent with a recent 
stereological study demonstrating no relative syncytial changes in placentas from 
pregnancies at high altitude. Mothers at high altitude experience hypobaric hypoxia, 
representing a natural model for studying ‘pre-placental’ fetal hypoxia. Experimentally-
induced hypoxia (2% O2) has been shown to stimulate cytotrophoblast proliferation 
(MIB-1 index) and inhibit syncytial fusion thus reducing syncytiotrophoblast formation 
in vitro (210; 345). Relative volumes of cytotrophoblast are also increased in placentas 
from high altitude pregnancies alongside a normal syncytium (346). The increase in 
cytotrophoblast volumes in both SIDS-NBW and SIDS-LBW is therefore consistent 
with pre-placental hypoxia. However, analysis of cytotrophoblast proliferation and 
numerical data is needed to confirm whether the increase in volume is due to increased 
cytotrophoblast proliferation or hypertrophy.  
 
The increase in the number of apoptotic knots indicates that SIDS placentas are 
associated with an ageing syncytium. Syncytial ageing may result from defective 
cytotrophoblast differentiation, or alternatively failure to mechanically shed aged nuclei 
into the intervillous space. The latter explanation is supported by the compact 
histological appearance of increased volumes of mature intermediate and terminal villi 
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in SIDS-NBW placentas (Figure 5-6). The ‘clusters’ of mature and terminal villi (likely 
due to adaptive angiogenesis secondary to an early hypoxic insult (103)) will be 
physically unable to shed their nuclei, thus increasing syncytiotrophoblast volume. 
Furthermore, focal restrictions in maternal blood supply will undoubtedly lead to a 
relatively hypoxic environment surrounding the villi, shown in vitro to increase the 
incidence of apoptotic syncytial knots (322).   
 
The association of increased syncytiotrophoblast volume in both SIDS-LBW and SIDS-
NBW seems confusing, since based on the considerations above this would be expected 
to compromise diffusional exchange to the fetus resulting in a low birthweight infant. In 
similar situations of pre-placental hypoxia, infant birthweights are reduced despite 
physiological compensatory adjustments aimed at increasing diffusional exchange such 
as increased intervillous space, reduced trophoblast thickness (346), and increased 
capillary volume fraction of terminal villi (154). Thus, increased relative volumes of 
syncytiotrophoblast and cytotrophoblast are unlikely to represent compensatory 
mechanisms, and importantly, these structural alterations are not necessarily detrimental 
to placental function i.e. leading to a low birthweight infant. Other mechanisms must 
therefore be initiated by SIDS-NBW placentas thus maintaining adequate fetal growth 
in utero. 
 
One plausible explanation is that SIDS-NBW have compensated for increased 
trophoblast volume by increasing the volume of terminal villi (45% increase), and hence 
enlarging the total surface area available for diffusional exchange to the fetus. However, 
this raises the “chicken-and-egg” question as to whether these infants have a normal 
birthweight because of increased volumes of terminal villi, or alternatively why would 
the normal birthweight infant require increased volumes of terminal villi. Although 
SIDS-LBW placentas displayed an increase in the proportion of terminal villi compared 
to term controls, it was insufficient to compensate for the small placental phenotype 
perhaps by failure to elicit mechanistic and functional modifications which SIDS-NBW 
subsequently display. This gives some credence to the interpretation that SIDS-NBW 
have initiated a compensatory reserve which SIDS-LBW lack.  
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A  
B  
C  
Figure 5-6 Syncytial morphology in SIDS-NBW  
(A) Histologically villi are compact with large amounts of fibrin deposition (pink eosin staining) (long 
white arrows = apoptotic knots, arrowhead =non-apoptotic knot) (x200) (B, C). Multi-layered 
cytotrophoblast cells (cytokeratin 7, brown chromagen) overlying a thin or absent syncytium (x200). 
General Discussion Chapter 6
 
 
 193
 
6 General Discussion 
Results presented in this thesis comprise the first stereological report integrating 
accurate immunohistochemical identification to study the morphological basis of villous 
cytotrophoblast turnover in placentas from pregnancies complicated by early- and late-
onset pre-eclampsia and IUGR, and uniquely, in sudden infant death syndrome. 
 
The significant findings from this study are that: 
 
Severe pre-eclampsia presenting before 32 weeks gestation maintains total placental and 
villous volume, and the total volume and number of the villous trophoblast 
compartment. However, the relative volume of cytotrophoblast cells and 
syncytiotrophoblast nuclei is significantly reduced in structural villi, whereas the 
relative volume of syncytial knots and those displaying apoptotic nuclei is significantly 
increased in peripheral villi.   
 
Pre-eclampsia presenting in late gestation is associated with a significant reduction in 
the total number of cytotrophoblast cells, the percentage of which undergoing 
proliferation is significantly increased for structural villi. There are an increased number 
of apoptotic syncytial knots in peripheral villi.  
 
Severe early-onset IUGR with and without pre-eclampsia is associated with significant 
reductions in total placental and villous volume, and total trophoblast volume and 
number. The percentage of villous cytotrophoblast cells undergoing proliferation is 
significantly reduced, accompanied by a significant increase in the number of syncytial 
knots (PET-IUGR) and in those displaying apoptotic nuclei (IUGR, PET-IUGR).  
Late-onset IUGR with and without pre-eclampsia is associated with significant 
reductions in total placental and villous volume, total trophoblast volume and number, 
and in the total number of proliferating cytotrophoblast cells. Significant increases were 
observed in the volume of placental villi (IUGR), in the percentage of proliferating 
cytotrophoblast cells in peripheral villi (PET-IUGR), along with the number of 
apoptotic syncytial knots (IUGR, PET-IUGR). 
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SIDS-NBW is associated with a significant increase in the volume density and total 
volume of terminal villi, the cytotrophoblast, syncytiotrophoblast, and in the total 
number and volume of syncytial knots (both non-apoptotic and apoptotic). 
 
SIDS-LBW is associated with a significant decrease in total placental and intermediate 
villous volume, whereas the percentage of terminal villi was significantly increased. 
These are associated with a significant increase in the total volume of cytotrophoblast 
cells, the relative and total volume of syncytiotrophoblast, and in the total volume of 
apoptotic syncytial knots.  
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6.1 IUGR and the Villous Trophoblast 
In humans, the major determinant of intrauterine fetal growth is the supply of oxygen 
and nutrients to the developing fetus. This in turn is dependent upon 1) the maternal and 
fetal nutritional status 2) the delivery of maternal and fetal blood to the placenta by 
adequate uteroplacental and fetoplacental circulations respectively 3) the size and 
morphology of the placenta, and 4) the morphology and integrity of the villous 
trophoblast compartment lining the chorionic villi (83). Fetal growth has the potential to 
be directly affected by abnormalities in any of these pathways. 
 
The small placentas from severe early-onset IUGR pregnancies in this study display 
reduced fetoplacental blood flow as shown by abnormal umbilical artery Doppler, 
signifying increased resistance to blood flow due to defective formation of the fetal 
capillaries in the gas-exchanging villi (290). These fetuses are at high risk of 
intrauterine death or stillbirth due to chronic fetal hypoxia and acidosis, secondary to 
defective transplacental gas-exchange conferred by these malformed capillaries; four 
stillbirths and one intrauterine death were noted in IUGR pregnancies. Villi also 
displayed fetal thrombotic lesions, intervillous thrombosis, perivillous fibrin deposition 
and villous infarction, all of which can compromise maternal-fetal exchange, and are 
thought to be secondary to poor maternal perfusion of the placenta demonstrated by 
abnormal uterine artery Doppler, of which there is a strong correlation (140). The net 
result of reductions in uteroplacental and fetoplacental circulations (along with gross 
pathological changes) will severely compromise maternal-fetal exchange.  
 
In addition to the dominant vascular pathology, the gas-exchanging villi in severe early-
onset IUGR placentas display arrested villous trophoblast turnover, showing reduced 
villous cytotrophoblast proliferation, decreases in syncytial nuclei, as a consequence of 
impaired syncytial fusion, and increased numbers of apoptotic syncytial knots. 
Furthermore, in relation to its altered villous anatomy, these placentas demonstrate 
increased protein expression of the trophoblast transcription factor, GCM1.  
 
The imbalance in the epithelial steady state between formation (decreased proliferation) 
and loss of trophoblast material (increased numbers of apoptotic knots) provides a 
plausible and sufficient explanation for reduced linear growth of the gas-exchanging 
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villi in severe early-onset IUGR pregnancies with and without pre-eclampsia, with 
AREDV in the umbilical arteries. Poor villous growth as a consequence of arrested 
trophoblast turnover, in conjunction with failed non-branching angiogenesis (113), is 
hypothesized to lead to increased intraplacental oxygen levels relative to the fetus, so-
called post-placental fetal hypoxia (153) further perpetuating arrested trophoblast 
turnover. Furthermore, a focal impairment in syncytial fusion will lead to insufficient 
numbers of syncytial nuclei (which are the active carrier system in the placenta), likely 
contributing to the observed reduction in both placental and fetal levels of amino acids 
and ion transporters in IUGR pregnancies (51; 317; 347; 348), which may be one of the 
primary factors for growth restriction in utero independent of the reduced surface area 
for diffusional exchange. 
 
Because the net loss of trophoblastic material was specific for mature intermediate and 
terminal villi only, this suggests arrest of mitosis at the onset of development of the gas-
exchanging villi. A logical explanation follows that in IUGR placentas, there is a failure 
in differentiation from immature intermediate villi into their mature counterparts, likely 
involving defective signals from both the villous trophoblast and allantoic mesoderm. 
This is because in mice, differentiation of trophoblast chorionic cells and chorion 
morphogenesis (GCM1-mediated (181; 182)) is critically dependent upon signals from 
the allantois, implying that bi-directional interactions are needed for proper 
morphogenesis of the chorion involving both fetal endothelial cells and trophoblast; 
morphogenesis ceases to occur if the allantois fails to attach (182).  
 
In humans, given that fetal vascular proliferation predominates over that of the villous 
trophoblast suggesting that angiogenesis drives growth of the peripheral villous tree 
(115), reduced endothelial proliferation of the fetal vasculature in IUGR can be 
speculated to impact on reduced villous cytotrophoblast proliferation. Interestingly, 
GCM1 has recently been shown in vitro to be involved in the positive regulation of 
PGF, which mediates non-branching angiogenesis in the third trimester. Since over-
expression of GCM1 in trophoblast cell lines significantly increased PGF mRNA levels 
(349), increased GCM1 protein expression therefore correlates well with increased 
placental expression of PGF (stimulated by oxygen) over VEGF (113), which is thought 
to account for the poorly branched villous tree leading to intraplacental hyperoxia in 
severe early-onset IUGR with AREDV in the umbilical arteries (153). 
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Given that early placental growth and differentiation determines functional maturation 
of the placenta in late gestation, why it is that arrested villous trophoblast turnover is 
effective only in the third trimester, given that some cases display defective extravillous 
trophoblast differentiation (95; 123) in the first trimester? Premature differentiation of 
the villous cytotrophoblast provides a plausible explanation: 
 
By definition, an IUGR fetus is one that has been subjected to a pathological failure to 
reach its predetermined growth potential in utero. Because placental insufficiency is 
often cited as the major cause in early gestation, one might expect this to be reflected in 
fetal: placental growth curves. Placental size (weight or volume) has been used as an 
indicator of placental development and a determinant of fetal growth; the fetal: placental 
weight ratio is therefore used as a gross measure of placental efficiency.  
 
In normal pregnancy, placental weights correlate with fetal weights throughout 
gestation, signifying that growth, in terms of mass, is matched throughout gestation, 
despite the fact that their individual growth trajectories differ whereby placental growth 
follows an S-curve regression whilst fetal growth follows an exponential pattern with 
maximal fetal growth in the third trimester (350). In IUGR, placental and fetal weights 
would be expected to follow the same growth pattern during the first and second 
trimester of normal pregnancy, but due to arrested trophoblast turnover and failed non-
branching angiogenesis, placental supply can no longer match fetal demand in the third 
trimester, and hence the fetus deviates from its normal growth pattern leading to IUGR.  
 
One explanation is premature differentiation of the villous cytotrophoblast population. 
Here, if it assumed that the defect(s) in severe early-onset IUGR is intrinsic to the 
villous trophoblast during the first trimester, then premature differentiation of 
proliferating villous cytotrophoblast cells into syncytiotrophoblast during the first and 
second trimester (hypoxia-induced up-regulation of GCM1? (351)) would therefore 
prematurely deplete the pool of villous progenitor cells, such that sustained trophoblast 
turnover is impaired and subsequently the regenerative capacity of the villous 
cytotrophoblast essentially “burns out”, resulting in reduced linear growth of the gas-
exchanging villi, and hence surface area for exchange, in the third trimester. 
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In this situation, the development of the placenta and fetus will not be compromised by 
impaired development of the uteroplacental circulation in the first and early second 
trimester (secondary to defective trophoblast invasion), because the nutritional demands 
of the fetus, in absolute terms, are small. Hence, if the villous trophoblast cannot sustain 
turnover in the third trimester due to premature differentiation when fetal demands for 
energy are highest, this may cause a severe derailment from its predetermined growth 
trajectory, even though this may have been lower to begin with i.e. an SGA versus AGA 
fetus that has fallen from its growth trajectory in the third trimester.  
 
The concept of premature differentiation is reflected in the relationship between fetal 
weight and placental weight in IUGR pregnancies between 26 and 37 weeks gestation 
(Figure 6.1) (352). Cetin et al demonstrated that although overall placental and fetal 
weights are reduced in IUGR pregnancies compared to controls, there is a steeper 
relationship between lower placental weights and decreases in fetal weight, particularly 
in the most severe IUGR cases associated with abnormal umbilical artery Doppler 
(352). This implies that for the same decrease in placental weight, there is a greater 
decrease in fetal weight compared to controls, signifying that in fact placental growth, 
in terms of mass, is inefficient to match that of the fetal demand.  
 
In this situation, the steepness of this relationship may also denote an accelerated rate of 
growth. For example, if the slope of the line in normal pregnancy represents a normal 
villous tree that is appropriate for gestational age e.g. 26 weeks of gestation (Figure 
6.1), then for the IUGR placenta to have achieved the same villous maturity but on a 
steeper growth trajectory (Figure 6.1), then the rate of villous growth must be increased 
(i.e. premature differentiation), the degree of which is determined by the difference 
between the two slopes. Conversely, this then begs the question (assuming an intrinsic 
first trimester defect) as to whether villous growth has been accelerated in an attempt to 
maintain fetal growth.   
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Figure 6-1 Premature trophoblast differentiation in IUGR 
Schematic representation of fetal and placental weight growth curves between the first and third trimester 
of pregnancy.  In normal pregnancy (thick blue line) fetal mass is matched to placental mass, indicating 
that supply and demand between the fetus and the placenta are met. In IUGR, (dashed blue line), fetal 
mass is matched to placental mass but the slope of the curve is higher. This indicates that for the same 
decrease in placental weight, there is a greater decrease in fetal weight compared to normal pregnancy, 
signifying that in fact placental growth, in terms of mass, is inefficient to match fetal demand. 
 
However, overall there were no such changes in fetal: placental weight ratios in both 
early- and late-onset IUGR when compared to appropriate age-matched controls in this 
study (4.4 ± 0.3 versus 4.3 ± 0.7; 6.0 ± 0.3 versus 6.3 ± 0.6). Based on these criteria, 
this demonstrates that although placental and fetal weights are significantly reduced 
compared to controls, placental supply and fetal demand are met, in terms of mass, 
regardless of gestational age.  
 
Premature differentiation is partly supported by placental pathologic findings showing 
that 3 out of the 5 severe early-onset IUGR cases display advanced villous maturity for 
gestational age (85), such that by 28 weeks of gestation these placentas display an 
increased presence of mature and terminal villi than is expected for gestational age. 
However, it cannot be excluded that this may simply be a consequence (or exacerbation) 
of their prematurity since fully mature villous trees are also observed in a vast number 
of placentas from spontaneous preterm deliveries (85). 
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A more accurate way to assess placental efficiency is through its ability to transfer 
oxygen to the fetus, which can be physiologically expressed as its diffusing capacity, 
known as the oxygen diffusive conductance (Dp) (353). This morphometric model 
represents a measure of the volume of gas transferred per minute per gas partial pressure 
(cm3 min-1 mmHg-1), which is estimated by measuring the resistance across the five 
basic compartments of the maternal-fetal interface (maternal erythrocytes, maternal 
plasma membrane, the villous trophoblast, fetal plasma and fetal erythrocytes), the 
reciprocal of which is conductance. This model estimates local structural changes in the 
villous membrane and how they may impact on overall placental function at the whole 
organ level.  
 
The greatest resistance to the diffusion of oxygen is the villous trophoblast (353), which 
depends on surface area and thickness. Trophoblast thickness declines between 10 
weeks and term in normal pregnancy due to the expansion in villous surface area and 
formation of vasculo-syncytial membranes in terminal villi (249). These structural 
changes are brought about so that placental supply and fetal demand are met in the third 
trimester when fetal demands for energy are highest, hence, total placental conductance 
increases commensurately with fetal mass between 10 weeks and term (354). However, 
when corrected for fetal weight gain, little change in specific Dp is observed over the 
same period (354), suggesting that there is a constancy between placental supply and 
fetal demand throughout gestation.  
 
In turn, trophoblast thickness is determined by the spatiotemporal changes in the 
epithelial steady state, such that a greater recruitment of trophoblast over loss would 
increase thickness, and vice versa; by decreasing the thickness of the villous membrane 
however, conductance may be maintained (159). Therefore, it may be hypothesized that 
the harmonic mean thickness (morphometric measure of membrane thickness 
accounting for local thickness variation (354)) in severe early-onset IUGR and PET-
IUGR placentas may be increased thereby reducing the diffusive capacity of the villous 
membrane, ultimately leading to IUGR. From another perspective, as soon as the 
maternal blood supply is unable to meet the demands of the fetus in the third trimester, 
the placenta may increase vascularisation and/or thin the villous membrane to maintain 
diffusive capacity, and where this fails, severe early-onset IUGR may result.   
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To date, there are no published studies investigating oxygen diffusive conductance in 
placentas from severe early-onset pregnancy pathologies. However, in-house data 
shows that severe early-onset IUGR placentas are not associated with alterations in 
villous membrane thickness; however they do display significant reductions in all 
partial conductances across the villous membrane leading to a reduction in total oxygen 
diffusive conductance. Accordingly, Macara et al noted an increased thickness of the 
basal lamina in severe early-onset IUGR placentas with abnormal umbilical artery 
Doppler, although this was not determined using stereological analysis (1). 
 
It may be possible in future studies to determine whether the villous membrane is 
uniformly affected by estimating the thickness uniformity index (mean arithmetic 
thickness divided by mean harmonic thickness) (314); a value of 1.0 representing 
uniformity. Hence, this would be hypothesized to be reduced in severe early-onset 
IUGR (with and without pre-eclampsia) with AREDV in the umbilical arteries.  
 
In comparison to early-onset disease, IUGR presenting in late gestation is typically 
associated with fetal growth asymmetry (brain sparing due to redistribution of cerebral 
blood flow (355)), and normal uterine and umbilical artery Dopplers. Increased 
capillary volume fraction (356) is thought to be a morphological adaptive response 
secondary to uteroplacental hypoxia due to failed spiral artery invasion in the first 
trimester, which in turn may account for the normal umbilical artery Doppler, provided 
there is no secondary pathology damaging the chorionic villi (i.e. villous infarcts, fetal 
thrombotic vasculopathy).  
 
In the present study, a group of late-gestation IUGR cases were analyzed with a wide 
range in their gestational age at delivery, including 33 and 34 week placentas displaying 
AREDV in the umbilical arteries and two delivered at 37 weeks with normal umbilical 
artery Doppler. Despite this clinical variation, a significant increase in the relative 
volume of placental villi was observed, and in contrast to early-onset disease, they did 
not display morphological alterations in villous trophoblast turnover.  
 
These placentas, similar to their early-onset phenotype, are compromised in terms of 
overall growth and surface area for exchange, yet in comparison, they continue to 
sustain fetal growth until late gestation. If it is accepted that late-onset IUGR also has its 
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origins in the first trimester due to uteroplacental insufficiency, then these placentas are 
in basic terms more ‘efficient’ in comparison to early-onset phenotypes, suggesting that 
the placenta can adapt its nutrient and gas exchange capacity to help meet fetal demands 
for growth, even when its own growth is compromised.  
 
Animal studies show that when placental growth is compromised experimentally in late 
gestation (e.g. glucocorticoid administration, under- or over-nutrition, and restriction of 
maternal uterine blood flow), often more fetus is produced per gram of placenta, 
signifying an increase in placental efficiency to meet fetal demands (357). Coan et al 
elegantly highlighted the placentas ability to maintain a functional reserve capacity 
whereby the smallest placenta within a mice litter displayed significant morphological 
and functional adaptations to increase the active transport of amino acids per gram of 
placenta to maintain maximal fetal growth in late gestation despite the overall reduction 
in placental mass (357). The increase in relative volume of villous tissue in late-onset 
IUGR may therefore represent such an adaptive response in order to maintain overall 
surface area for transplacental exchange. In these cases, it is very likely that placental 
supply and fetal demand for diffusional exchange are met.  
 
In an original study, Mayhew et al demonstrated an increase in arithmetic mean 
trophoblast thickness (overall membrane thickness) in IUGR at term which would likely 
impact on Dp (161), however in a more recent study the same author showed that in fact 
no such changes are present in IUGR pregnancies (presumably at term although 
gestational age was not stated) where both arithmetic and harmonic distances of the 
trophoblast remained similar to controls (163). Overall conductance was reduced by 
33% compared to controls (although non-significantly owing to large intra-group 
variation), however when fetal weight was accounted for no significant changes in 
mass-specific conductance was observed for IUGR (163).  
 
In a similar study, a shorter harmonic mean distance across the villous trophoblast was 
observed in SGA infants (thought to represent placental hypoxia due to maternal 
smoking) at term, which can be interpreted as an adaptive response so as to maintain 
conductance. However, in this instance, such an adaptive response was inefficient to 
maintain overall conductance which was significantly reduced, despite the fact that 
mass-specific conductance was maintained (159).  
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In this situation, it is therefore difficult to determine whether the slowing of the fetal 
growth trajectory is a positive adaptation to placental insufficiency or whether early 
fetal growth defines placental physiology by demand (i.e. undergone changes in their 
fetal programming). The latter is supported by the suggestion that in IUGR pregnancies, 
the placenta may register a lack of an appropriate increase in maternal blood flow (i.e. 
failed spiral artery conversion) and/or nutrition, and as a consequence, may down-
regulate essential placental transporter systems in order to decrease growth in late 
gestation (348).  
 
Although they differ in trophoblast morphology, the question remains however as to 
whether the divergence between the early- and late-onset pathologies is the result of 
different developmental pathways or mechanisms.  
 
The turnover of villous trophoblast in the combined disease (PET-IUGR) in early-
gestation resembles that of pure early-onset IUGR showing reduced villous 
cytotrophoblast proliferation, impaired syncytial fusion and increased apoptotic 
syncytial knotting, which are plausible explanations for reduced linear growth of the 
peripheral villous tree as previously described. An interesting observation to arise from 
this study is that the combined disease did not display the most severe alterations in 
trophoblast morphology, which may be a consequence of the fact that pre-eclampsia in 
early gestation had no significant effects on trophoblast morphology. Hence, the 
changes seen in the combined group may relate more to IUGR than pre-eclampsia.  
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6.2 Pre-eclampsia and the Villous Trophoblast 
Several studies have demonstrated that pre-eclampsia presenting in early gestation 
typically resembles IUGR in terms of villous and trophoblast morphology and that these 
changes are more severe when the two diseases co-exist (152). The variable clinical 
disease classifications in these studies has, however, made it difficult to identify 
individual contributions (152; 156). By carefully selecting a subgroup of early-onset 
pre-eclamptic pregnancies displaying normal fetal birthweights and normal umbilical 
artery Dopplers, the present study shows that early-onset pre-eclampsia without any 
clinical signs of fetal growth restriction has no significant effect on villous or 
trophoblast morphology. However, where there are trends towards changes in these 
parameters (i.e. increased rate of turnover), they oppose those for IUGR indicating 
divergent trophoblast pathologies. 
 
Similar to IUGR, uteroplacental insufficiency is thought to be the ‘root cause’ of pre-
eclampsia regardless of gestational age, and that early- and late-onset disease may 
represent divergent end points of different developmental pathways reflected in the 
different fetal phenotypes. Either way, increased villous cytotrophoblast proliferation 
and syncytial fusion is hypothesized to lead to dysregulated syncytial shedding of 
aponecrotic syncytial nuclei and the excess release of anti-angiogenic factors into IVS 
constituting the maternal syndrome of pre-eclampsia (3). 
 
In the present study, whilst there are trends towards such changes (signifying an 
imbalance between proliferation and differentiation), losses are matched by recruitment 
because the overall surfaces and volumes of villi are maintained, and hence in 
comparison to IUGR, they maintain overall diffusing capacity.  
 
Both severe early-onset and late-onset pre-eclamptic placentas display normal placental 
and fetal weights (between 10-50th centile for gestational age) in comparison to 
gestational aged-matched controls, indicating that placental supply and fetal demand are 
met throughout gestation. Because the placental villi are normally grown in terms of 
overall volume, one would not expect to see any detrimental effects on the villous 
trophoblast (i.e. thickening of villous membrane) which would perturb the diffusional 
exchange of oxygen to the fetus with the potential to cause growth restriction in utero.  
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Given the previous analyses, early-onset pre-eclamptic placentas would be expected to 
maintain overall conductance, since fetal birthweights are with the normal range for 
gestational age. Interestingly however, in-house data shows that early-onset pre-
eclamptic placentas maintain villous membrane thickness, but not diffusive capacity. 
This is reflected by the fact that total Dp was significantly reduced from a total Dp of 
4.14 cm3 min-1 mmHg-1 in gestational-age-matched controls to 2.35 cm3 min-1 mmHg-1 
in early-onset PET, what’s more, this reduction persisted even when corrected for fetal 
birthweight in which specific Dp declined from 2.39 cm3 min-1 mmHg-1 in gestational-
age-matched controls to 1.85 cm3 min-1 mmHg-1 in early-onset PET. However, fetal 
birthweights in this cohort were significantly reduced (i.e. SGA), in comparison to 
controls and severe early-onset IUGR pregnancies, making the contribution of pre-
eclampsia alone difficult to interpret. This suggests that in this particular group of early-
onset pre-eclamptic placentas, the dominant pathology is vascular in nature. However, 
that is not to say that the placenta cannot respond to stress in utero by increasing its 
diffusion capacity, but that its capability to do so is limited.  
 
The latter is also reflected by a significant reduction in the fetal: placental weight ratio, 
in severe early-onset pre-eclamptic placentas, signifying that for every gram of placenta, 
there is less gram of fetus. Hence, the placenta is unable to match fetal demand for 
oxygen in the third trimester of pregnancy, but must display some functional reserve 
capacity since these infants were not ‘clinically’ growth restricted. Conversely, SGA 
infants have been shown to have a reduced placental to fetal weight ratio compared to 
normal infants of the same birthweight (350), which based on the above considerations, 
signifies that the placenta in terms of mass is inefficient at meeting fetal demands. This 
seems confounding since these fetuses are, by definition, constitutionally small in 
comparison to their growth restricted counterparts.  
 
A novel finding from this study is that placentas from late-onset pre-eclampsia display 
significant reductions in the total number of villous cytotrophoblast cells. These 
placentas are typically regarded as normal in terms of villous and vascular morphology 
(102; 152; 156; 161; 163). In contrast, this study shows that whilst overall villous 
growth is maintained, the turnover of villous trophoblast may be altered in pre-
eclampsia in late gestation.  
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A reduction in the total complement of villous cytotrophoblast cells indicates an altered 
balance in villous trophoblast turnover. This may represent a loss of progenitor cells, 
similar to that which is hypothesized to IUGR, or alternatively, increased syncytial 
fusion. Because the total number of syncytiotrophoblast was maintained, fusion must 
therefore be increased. Significantly, the percentage of proliferating cytotrophoblast 
cells was increased for stem and immature intermediate villi. Such changes may 
therefore contribute to the maternal syndrome of pre-eclampsia.  
 
Pre-eclampsia at term represents a form of uteroplacental hypoxia. In similar situations 
such as pregnancies at high altitude and pre-existing maternal diabetes, placentas 
display increased capillary volume fraction (314) and branching(154), increased 
endothelial proliferation and both the number and proliferation of villous 
cytotrophoblast is increased (340). Kingdom and Kaufmann (1997) propose that the net 
result of these structural changes serve to thin the villous membrane thereby 
maintaining oxygen transfer (153; 358). Although endothelial proliferation may account 
for the formation of vasculo-syncytial membranes, increased numbers of villous 
cytotrophoblast cells may increase local membrane thickness.  
 
The reduction in the total number of cytotrophoblast cells may therefore represent 
placental adaptation to the maternal environment in order to maintain diffusional 
exchange. This is supported by in-house data showing that late-onset pre-eclamptic 
placentas display a significant reduction in the harmonic mean thickness of the villous 
membrane and therefore maintained total and mass-specific oxygen diffusive 
conductance. Similarly, Mayhew et al demonstrated that pre-eclampsia in late gestation 
has no detrimental effects on villous membrane thickness or its variability; subsequently 
these placentas maintained their total and mass-specific oxygen diffusive conductance 
(163).  
 
Furthermore, whilst the placental phenotype of late-onset pre-eclampsia with IUGR was 
similar to isolated IUGR, the trophoblast phenotype resembled that of pre-eclampsia 
with an increase in the percentage of proliferating cytotrophoblast cells. Hence, whilst 
rates of differentiation and loss seem to be higher in pre-eclampsia, rates of proliferation 
are higher in pre-eclampsia than IUGR, thereby maintaining appropriate ‘growth 
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pattern’ of the villous trees, but which may have started with less developmental 
potential (i.e. less progenitor cells).   
 
This shows that placentas from early- and late-onset pre-eclamptic pregnancies differ in 
their trophoblast morphology and in their ability to maintain overall diffusing capacity, 
whereby late-onset placentas displays functional reserve capacity in the face of 
uteroplacental insufficiency.  
 
Is it possible that such a divergence reflects differences in the severity and duration of 
the initial insult in the first trimester? 
 
The suggestion that the response of the villous tree in the second and third trimester is 
linked to malinvasion of the spiral arteries in the first trimester is supported by the 
observation that abnormal uterine artery Doppler (UTAD) (representing a failure  in the 
physiological conversion of the maternal spiral arteries) is significantly correlated with 
altered cytotrophoblast turnover in severe early-onset IUGR pregnancies with co-
existing pre-eclampsia (combined disease) (no correlation with the syncytium).  
 
This showed that in those cases with abnormal UTAD the numerical density of villous 
cytotrophoblast cells was significantly reduced in comparison to those cases displaying 
normal UTAD, and that this was primarily attributed to a 30% decline for stem and 
intermediate villi; consequently the percentage of proliferating cytotrophoblast cells 
increased, although not significantly. Interestingly these changes resembled pure early-
onset pre-eclampsia, and not IUGR. This shows that alterations in villous trophoblast 
occur early in gestation before they are clinically evident in late gestation supporting the 
association between abnormal UTAD and placental pathologic condition (140).  
 
Whilst this is not a primary causal factor for developing pre-eclampsia in the combined 
disease since those women with normal UTAD also developed pre-eclampsia, it shows 
that the severity of the abnormal uteroplacental blood flow is directly related to the 
severity of alterations in cytotrophoblast morphology, but not determined by it.  
 
Interestingly, women displaying abnormal UTAD had significantly lower blood 
pressures than those with normal UTAD (159 ± 4 /102 ± 1.5 versus 177 ± 4 / 107 ± 1.5; 
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systolic p=0.020, diastolic p=0.035) which may be a maternal consequence of 
rheological changes in the uteroplacental circulation, i.e. high pressure/velocity/rate of 
maternal blood flow entering the spiral arteries, which as shown by Burton et al is 
primarily determined by their terminal dilation (128). Despite there being a good 
correlation between abnormal UTAD and malinvasion of the maternal spiral arteries, 
women with normal UTAD have been shown to exhibit failed physiological conversion 
on biopsy (145).  
 
Whether such correlations exist for isolated IUGR or pre-eclampsia could not be 
determined due to the lack of clinical information and small study groups. Nonetheless, 
these data suggest that extrinsic as well as intrinsic defects in the villous trophoblast are 
critical for pregnancy outcome.  
 
6.3 SIDS and the Villous Trophoblast 
SIDS placentas are thought to represent a form of pre-placental hypoxia (due to 
cigarette exposure), similar to pregnancy at high altitude (hypobaric hypoxia) which 
display increased capillary volume fraction and increased capillary branching (154; 
358), (although whether or not the capillaries become dilated is still debated), 
representing typical cases of placental adaptation to pre-placental hypoxia so as to 
maintain diffusional exchange to the fetus (153). However, the latter group of placentas 
and those associated with maternal smoking also display increased volumes and density 
of villous cytotrophoblast cells and syncytial knotting likely increasing villous 
trophoblast thickness, which would be expected to impact on diffusional exchange.  
 
The association of increased trophoblast volumes in both SIDS-LBW and SIDS-NBW 
seems confusing, since based on the considerations above, would be expected to 
compromise diffusional exchange to the fetus resulting in a low birthweight infant. In 
similar situations of pre-placental hypoxia, infant birthweights are reduced despite 
physiological compensatory adjustments aimed at increasing diffusional exchange such 
as increased intervillous space, reduced trophoblast thickness (346), and increased 
capillary volume fraction of terminal villi (154). Thus, increased relative volumes of 
syncytiotrophoblast and cytotrophoblast are unlikely to represent compensatory 
mechanisms, and importantly, these structural alterations are not necessarily detrimental 
to placental function i.e. leading to a low birthweight infant. The structural alterations in 
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the villous trophoblast however were not associated with changes in either the total or 
specific oxygen diffusive conductance in both SIDS-NBW and SIDS-LBW placentas 
(82), indicating that in both situations, placental supply and fetal demand for oxygen are 
maintained at term. Other mechanisms must therefore be initiated by SIDS-NBW 
placentas thus maintaining adequate fetal growth in utero. 
 
One plausible explanation is that SIDS-NBW have compensated for increased 
trophoblast volume by increasing the volume of terminal villi (45% increase), and hence 
enlarging the total surface area available for diffusional exchange to the fetus. However, 
this raises the “chicken-and-egg” question as to whether these infants have a normal 
birthweight because of increased volumes of terminal villi, or alternatively why would 
the normal birthweight infant require increased volumes of terminal villi. Although 
SIDS-LBW placentas displayed an increase in the proportion of terminal villi compared 
to term controls, it was insufficient to compensate for the small placental phenotype 
perhaps by failure to elicit mechanistic and functional modifications which SIDS-NBW 
subsequently display. This gives some credence to the interpretation that SIDS-NBW 
have initiated a compensatory reserve which SIDS-LBW lack.  
 
In the context of the triple risk hypothesis, SIDS occurs when a vulnerable infant is 
exposed to external risk factors during a critical period of physiological postnatal 
development (70; 71). However, there is now a growing concept that SIDS represents a 
developmental disorder which originates during fetal development in utero placing the 
vulnerable infant at risk postnatally.  
 
Fetal development is an active process, and hence normal fetal development requires 
continuing normal activity. During fetal development, there are critical periods of 
vulnerability to suboptimal conditions and these vulnerable periods occur at different 
developmental epochs for different tissues i.e. cells dividing rapidly are at greatest risk 
(hyperplastic cell growth during the second trimester), and each phase of development 
provides the required conditions for subsequent development. Because SIDS infants 
display specific abnormalities in organs critical for survival ex utero which can only 
have occurred in the second trimester during fetal organogenesis in utero, it suggests 
that the placental adaptations observed in SIDS-NBW (increased terminal villi) 
compensate for detrimental insult(s) occurring in maternal-placental unit in early 
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gestation. Hence, whilst overall diffusional exchange is maintained, these changes are 
insufficient to compensate for compromised organ development in utero, since these 
vulnerable infants have subsequently succumbed to SIDS.  
 
The above explanation is a classic example of fetal programming in utero, such that 
programming has permanent effects that alter responses in adult life. If it is assumed, as 
the data suggests above, that SIDS infants develop in an unfavourable intrauterine 
environment, then the developing fetus may also attempt to compensate for deficiencies, 
(i.e. insults in the maternal-placental unit). Following compensation, birthweight may be 
normal or only slightly decreased. However, postnatally the compensatory effort carries 
a price such that the infant attempts made after birth to severe the consequences of 
programming may have their own unwanted consequences. When postnatal conditions 
prove to be other than those for which the fetus is prepared (i.e. external stressors), 
problems may arise.   
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7 Conclusions 
The principal conclusions from the present study are that:  
 
• Severe early-onset IUGR with AREDV in the umbilical arteries is associated with 
arrested trophoblast turnover due to a reduced regenerative capacity of the villous 
cytotrophoblast population likely contributing to maldevelopment of the peripheral 
villous in the third trimester of pregnancy.  
 
• In contrast, placentas from severe early-onset pre-eclampsia without any clinical 
signs of IUGR do not share any similarities in the villous trophoblast with severe 
early-onset IUGR and shows preliminary morphological evidence for a divergent 
trophoblast pathway showing an increased rate of villous trophoblast turnover, which 
may contribute to the maternal endothelial syndrome.  
 
• Late-onset pre-eclamptic placentas display structural alterations which likely 
represent placental adaptation to the maternal environment which early-onset 
placentas lack 
 
• The data suggests that the severe early-onset pathologies are associated with 
defective villous trophoblast differentiation, whereby the relative proportions of 
proliferating and differentiating cytotrophoblast cells is altered, indicating intrinsic 
defects in the villous cytotrophoblast lineage which likely originate during early 
placental development. 
 
• Because early- and late-onset IUGR do not share any similarities in trophoblast 
morphology, this suggests different disease etiologies for early- and late-onset IUGR, 
whereas this is likely to be the same for pre-eclampsia since morphological 
alterations are very similar.  
 
• SIDS infants may represent postnatal consequences of IUGR, or any detrimental 
hypoxic insult, since they display evidence of placental adaptation by increasing their 
volumes of gas-exchanging villi.  
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7.1 Future Goals 
With regard to the newly developed stereological-immunohistochemistry methods 
presented in this thesis, it should now be possible to quantify other areas of villous 
cytotrophoblast biology in order to understand the morphological basis of these and 
other placentally-mediated diseases. 
 
These include: 
? Determine the accurate localisation and quantification of GCM1 protein and 
mRNA and in the villous cytotrophoblast and syncytiotrophoblast population. 
 
? Identification of villous cytotrophoblast progenitor cell phenotypes using murine 
genes that are thought to be expressed in an analogous manner in humans (e.g. 
Cdx2, Fgfr2). 
 
? Investigate further the role of villous cytotrophoblast apoptosis in both pre-
eclampsia and IUGR. 
 
? Find potential immunohistochemical markers of syncytial shedding to link 
alterations in villous cytotrophoblast biology with pathophysiology of PET. 
 
? Revisit the role of oxygen (HIF proteins) and placental development in PET, 
IUGR and SIDS. 
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Appendix 1: Clinical Data 
1. Toronto Cohort 
Case Diagnosis PM No. ID GA BW
BW 
Centile MA Parity Sex
Highest 
BP
Uterine 
Doppler
Umbilical 
art PI
Umbilical 
EDF
Obstetric 
Hist
Medical 
Hist. MOD
1 PT control P4677 3828 26 970 50-90 17 0 M NA ND ND ND No No vag
2 PT control P4320 CD7 27.4 990 10-50 27 G3P2 M NA ND ND ND vag
3 PT control P4661 3414 28 1150 10-50 0 M NA 0 ND ND No No vag
4 PT control P4675 3685 28 1510 90-95 29 0 M NA ND ND ND No No c/s
5 PT control P4322 CD11 29 1400 50-90 29 M NA ND ND ND vag
6 PT control P4893 4183 30 1615 10-50 34 0 M NA ND ND ND vag
7 PT control P4323 CD1 30 1600 50-90 33 G1P0 M NA ND ND ND vag
8 PT control P4321 1159 30 1810 90-95 2 F NA ND ND ND PT IDDM c/s
9 PT control P4319 1226 31 1780 50-90 38 G5P0 F NA ND ND ND c/s
10 PT control P4665 3428 31 1800 50-90 34 0 F NA 0 ND ND No No vag
11 PT control P4663 3416 32 1500 10-50 23 2 F NA ND ND ND No ITP c/s
12 PT control P3853 756 32 1630 10-50 19 G2P0 M NA ND ND ND c/s
13 Term control P4672 3698 33 2300 50-90 30 0 F NA ND 0.8 0 No No c/s
14 Term control P4899 4736 33 2020 10-50 32 1 M NA ND ND ND No No vag
15 Term control P4324 1183 35 2700 50-90 34 G4P3 M NA ND ND ND c/s
16 Term control P4666 3412 37 2640 10-50 42 0 F NA ND ND ND No DVT c/s
17 Term control P4676 3867 38 3090 10-50 30 1 F NA ND ND ND No No c/s
18 Term control P4892 4006 38 3910 90-95 36 1 F NA ND ND ND No No c/s
19 Term control P5182 5076 38 3020 10-50 35 0 M NA ND ND ND No No c/s
20 Term control P5178 4827 39 2960 10-50 33 0 M NA ND ND ND No No c/s
21 Term control P5179 4835 40 3260 10-50 26 0 M NA ND ND ND No No vag
22 Term control P5183 5077 40 4110 10-50 26 2 M NA ND ND ND No No vag
23 Term control P3903 N/A 41 3520 50-90 37 1 M 120/80 normal ND ND No No c/s
24 Term control P4895 4333 41 4690 95-97 33 0 M NA ND ND ND No No c/s
25 Term control P4901 4791 41 4070 50-90 37 1 M 120/80 ND ND ND No No vag
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Case Diagnosis ACOG GA BW
BW 
Centile MA Parity Sex
Highest 
BP
Protein-
uria
Uterine 
Doppler
Umbilica
l art PI
Umbilical 
EDF
Obstetric 
Hist
Medical 
Hist. MOD PD
1 PET + HELLP severe 26 710 10-50 23 0 M 180/100 3 ND normal normal No No c/s
2 PET severe 27 790 10-50 28 0 M 180/123 4 normal normal normal No No c/s
3 PET severe 33 940 10-50 33 1 F 180/118 4 normal  PI 1.7 1 (0) PET, PTChr.HTN c/s
4 PET severe 29 1210 10-50 35 0 F 150/110 4 1 normal normal No No c/s
5 PET + HELLP severe 29 1130 10-50 43 0 F 160/90 540mg/24hr normal 1 (0) ND ND c/s
6 PET + HELLP severe 29 1200 10-50 35 ND M 160/110 4 ND normal normal No IDDM c/s
7 PET severe 30 1280 10-50 17 0 M 170/120 2 normal normal normal ND ND c/s
8 PET severe 30 1280 10-50 22 160/110 2 normal normal normal
9 PET + HELLP severe 31 1400 10-50 37 G1P0 M 170/110 3 normal normal normal c/s
10 PET severe 31 1300 10-50 26 G3P2 F 180/120 3 ND 1 ND ND c/s
11 PET severe 32 1550 10-50 ND 140/92 3 ND  normal normal
12 PET mild 33 1970 10-50 28 0 M 150/105 2 normal normal normal ND ND c/s
13 PET severe 35 2250 10-50 27 1 M 164/107 3 0 normal normal No No vag
14 PET + HELLP severe 36 2640 10-50 30 0 M 164/94 3 ND normal normal No No c/s
15 PET mild 36.5 3360 10-50 146/98 trace utero.insuf
16 PET severe 38 4020 10-50 38 ND ND 160/95 normal normal normal ND ND ND
17 PET mild 40 3400 10-50 28 ND ND 155/100 normal normal normal ND ND ND
1 IUGR severe 26 475 <3 24 0 F nil 2 ND No No vag IUD
2 IUGR severe 28 680 <3 33 0 F 140/95 nil c/s
3 IUGR severe 30 900 3'-5 28 0 M nil 0 2 No No c/s No
4 IUGR severe 31 700 <3 M 128/74 nil 20 1
5 IUGR severe 31.4 1260 5-10th F 127/98 nil 1
6 IUGR severe 33 1160 <3 27 1 M nil 0 1 No No c/s No
7 IUGR severe 34.3 1304 <3 38 G2P1 M nil 1*2 c/s No
8 IUGR 37 2040 <3 34 G2P1 F 115/67 1+ 0 ND c/s
9 IUGR 37 2400 5-10 30 0 M nil 0 0 No No vag No
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Case Diagnosis
ACO
G GA BW
BW 
Centile MA Parity Sex
Highest 
BP PU
Uterine 
Doppler
Umbilica
l art. PI
Umbilical 
EDF
Obs. 
Hist
Medical 
Hist. MOD PD
1 IUGR + PET severe 24 420 < 5 38 G1P0 180/100 2 ND normal normal vag SB
2 IUGR + PET + HELLPsevere 25 500 <3 31 1 M 150/100 3 normal normal normal PET,PT No c/s No
3 IUGR + PET 26 560 <3 30 G10P0 M normal  PI 1.7 1 (0) vag SB
4 IUGR + PET severe 26 680 5-10 40 G1P0 M 190/110 4 1 normal normal c/s
5 IUGR + PET severe 26 790 5-10th 36 3 M 160/100 3 normal 1 (0) PET, PT Chr.HTN c/s
6 IUGR + PET severe 26 740 5-10th 28 M 150/100 3 ND normal normal No Chr.HTN c/s No
7 IUGR + PET severe 26 480 5 30 1 F 170/106 3 normal normal normal No Chr.HTN vag IUD
8 IUGR + PET severe 29 820 5-10 33 G2P1 F 160/100 3 normal normal normal c/s SB
9 IUGR + PET severe 28 750 3-5 35 0 F 180/110 4 normal normal normal No No vag No
10 IUGR + PET + HELLPsevere 28 750 3-5 39 G2P1 M 180/110 4 ND 1 Chr.HTN c/s
11 IUGR + PET + HELLPsevere 28 720 <3 20 G1P0 M 150/100 3 ND  normal normal vag
12 IUGR + PET + HELLPsevere 29 960 5-10 29 G1P0 M 160/110 3 normal normal normal c/s No
13 IUGR + PET severe 29 860 5-10 41 G3P0 F 175/105 2 0 normal normal c/s No
14 IUGR + PET severe 29 820 <3 24 G1P0 M 180/110 3 ND normal normal c/s No
15 IUGR + PET 29 770 <5 39 0 F 200/110 nil utero.insuf c/s
16 IUGR + PET severe 30 860 3-5 19 0 F 144/96 2 normal normal normal No No c/s No
17 IUGR + PET 31 1160 5-10 30 0 F 190/100 nil normal normal normal c/s
18 IUGR + PET severe 31 1080 5-10 22 0 F 160/110 2 2 ND No No c/s No
19 IUGR + PET severe 32 1370 5'-10 36 1 M 160/100 3 No DDM c/s No
20 IUGR + PET severe 34 570 <3 43 1 F 150/80 2 0 2 No Ess.HTN c/s No
21 IUGR + PET severe 35 1560 <3 160/90 3 20 1
22 IUGR + PET severe 37 2160 <3 34 0 M 160/110 4 1 No No vag No
23 IUGR + PET severe 34.5 1640 <3 32 G2P0 M 150/100 4 0 1 c/s No
24 IUGR + PET severe 37 1440 <3 150/110 1*2 No
25 IUGR + PET severe 38 2325 <3 28 0 M 140/100 2 0 ND No No vag No  
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2. SIDS Cohort 
Case Diagnosis GA BW MA Parity Sex
Highest 
BP Smoker MOD PM
1 Term Control 40 3080 0+2 F ND 0 svd 2
2 Term Control 40 4026 3+0 M ND 0 svd 0
3 Term Control 41 3360 27 3+1 F 5-12 svd 1
4 Term Control 41 4070 37 1 M 120/80 0 svd 0
5 Term Control 41 4690 33 0 M ND 0 c/s 0
6 Term Control 41 3520 37 1 M 120/80 0 c/s 0
7 Term Control 41 3260 M 10 svd 0
8 Term Control 38 2730 36 1 M ND 0 c/s 0
9 Term Control 40 3260 26 0 M ND 0 svd 0
10 Term Control 40 4110 26 2 M ND 0 svd 0
11 Term Control 39 2960 33 0 M ND 0 c/s 0
12 Term Control 38 3020 35 0 M ND 0 c/s 0
1 SIDS NBW 38 3110 24 1 M 10-20 svd 3
2 SIDS NBW 40 3210 19 1+0 F 20 svd 0
3 SIDS NBW 40 3910 19 1 F 20 svd epi 1
4 SIDS NBW 40 3595 15 0 M 30 lscs 0
5 SIDS NBW 40 3585 27 2 F 20 svd 0
6 SIDS NBW 41 3360 18 2 M 0 lscs 0
7 SIDS NBW 40 3620 20 1+0 F 10 bfd 0
8 SIDS NBW 40 3130 31 2 F 0 svd 0
9 SIDS NBW 39 3600 25 2+0 F 120/60 5 svd 0
10 SIDS NBW 37 3540 39 5 M 130/80 20 LSCS 1
11 SIDS NBW 39 3220 22 G2P1 F 120/74 10 SVD 0
12 SIDS NBW 38 3220 33 0+1 M 120/85 20 lscs 0
13 SIDS LBW 39 2320 25 3+0 F 0 lscs 0
14 SIDS LBW 39 3420 30 1 F 25 svd 0
15 SIDS LBW 39 2375 26 1+1 M 5 lscs em 0
16 SIDS LBW 40 2800 32 1 M 0 svd 0
17 SIDS LBW 40 2570 21 1 F 5-10 svd 0
18 SIDS LBW 41 2655 31 0 F 7 svd 0
19 SIDS LBW 41 3070 19 0 M 0-10 svd 0
20 SIDS LBW 41 3115 33 0 M 10 svd 0
21 SIDS LBW 41 3000 22 1 M 0 lscs 2
22 SIDS LBW 41 1740 41 0+1 M 0 lscs em 0
23 SIDS LBW 41 2320 24 1+0 F 120/70 10 vacuum 1
24 SIDS LBW 39 1920 46 1+0 F ND svd 1  
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Appendix 2: Villous Volumes 
1. Toronto Cohort 
CASE DIAGNOSIS PLACENTAL WT. (g)
PLACENTAL 
VOL
ALL 
VILLI  SV & IMV MV & TV 
ALL 
VILLI  SV & IMV MV & TV 
1 PT control 350 320 144 129 15 0.45 0.40 0.05
2 PT control 220 220 107 35 72 0.49 0.16 0.33
3 PT control 280 300 115 83 32 0.38 0.28 0.11
4 PT control 230 220 107 74 32 0.48 0.34 0.15
5 PT control 300 280 144 89 55 0.51 0.32 0.20
6 PT control 387 480 215 167 48 0.45 0.35 0.10
7 PT control 450 345 150 81 69 0.43 0.23 0.20
8 PT control 500 425 219 132 86 0.51 0.31 0.20
9 PT control 360 350 175 77 98 0.50 0.22 0.28
10 PT control 350 360 147 56 90 0.41 0.16 0.25
11 PT control 360 350 120 30 89 0.34 0.09 0.26
12 PT control 330 230 118 34 83 0.51 0.15 0.36
13 Term control 500 501 287 135 152 0.57 0.27 0.30
14 Term control 360 360 153 65 88 0.43 0.18 0.24
15 Term control 477 702 264 64 200 0.38 0.09 0.29
16 Term control 550 540 209 112 97 0.39 0.21 0.18
17 Term control 640 630 312 196 115 0.49 0.31 0.18
18 Term control 640 620 304 87 216 0.49 0.14 0.35
19 Term control 650 620 281 183 98 0.45 0.29 0.16
20 Term control 450 450 187 90 97 0.42 0.20 0.22
21 Term control 480 490 226 95 132 0.46 0.19 0.27
22 Term control 600 620 279 210 69 0.45 0.34 0.11
23 Term control 398.4 340 182 127 55 0.54 0.37 0.16
24 Term control 660 640 271 144 126 0.42 0.23 0.20
25 Term control 700 700 265 165 100 0.38 0.24 0.14
VOLUME DENSITY TOTAL VOLUME (cm3)
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CASE DIAGNOSIS PLACENTAL WT. (g)
PLACENTAL 
VOL
ALL 
VILLI  SV & IMV MV & TV 
ALL 
VILLI  SV & IMV MV & TV 
1 PET + HELLP 150 130 58 26 32 0.45 0.20 0.25
2 PET 410 420 262 233 30 0.62 0.55 0.07
3 PET 300 250 107 72 35 0.43 0.29 0.14
4 PET 300 290 148 73 75 0.51 0.25 0.26
5 PET + HELLP 410 260 111 49 62 0.43 0.19 0.24
6 PET + HELLP 310 350 184 120 64 0.53 0.34 0.18
7 PET 300 320 109 46 63 0.34 0.15 0.20
8 PET 300 320 120 52 68 0.37 0.16 0.21
9 PET + HELLP 400 400 205 126 79 0.51 0.32 0.20
10 PET 350 425 204 103 101 0.48 0.24 0.24
11 PET 400 380 170 89 81 0.45 0.23 0.21
12 PET 352 300 146 80 66 0.49 0.27 0.22
13 PET 400 600 249 85 164 0.42 0.14 0.27
14 PET + HELLP 580 380 142 76 66 0.37 0.20 0.17
15 PET 505 550 254 125 129 0.46 0.23 0.23
16 PET 603 575 362 97 265 0.63 0.17 0.46
17 PET 534 515 327 73 254 0.64 0.14 0.49
1 IUGR 260 220 106 85 21 0.48 0.39 0.09
2 IUGR 200 126.5 65 50 15 0.52 0.39 0.12
3 IUGR 150 180 81 52 30 0.45 0.29 0.16
4 IUGR 185 100 34 15 19 0.34 0.15 0.19
5 IUGR 195 165 75 43 31 0.45 0.26 0.19
6 IUGR 180 150 72 46 26 0.48 0.30 0.17
7 IUGR 270 300 162 113 49 0.54 0.38 0.16
8 IUGR 338 338 162 79 82 0.48 0.24 0.24
9 IUGR 302 312 193 83 110 0.62 0.27 0.35
VOLUME DENSITY TOTAL VOLUME (cm3)
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CASE DIAGNOSIS PLACENTAL WT. (g)
PLACENTAL 
VOL
ALL 
VILLI  SV & IMV MV & TV 
ALL 
VILLI  SV & IMV MV & TV 
1 IUGR + PET 100 127.5 59 35 24 0.46 0.28 0.19
2 IUGR + PET + HELLP 150 150 74 50 24 0.49 0.33 0.16
3 IUGR + PET 270 160 59 20 39 0.37 0.13 0.24
4 IUGR + PET 160 130 73 62 11 0.56 0.48 0.09
5 IUGR + PET 240 220 117 86 30 0.53 0.39 0.14
6 IUGR + PET 220 99 42 28 15 0.43 0.28 0.15
7 IUGR + PET 109 150 74 52 22 0.49 0.35 0.15
8 IUGR + PET 220 150 84 62 22 0.56 0.42 0.14
9 IUGR + PET 170 130 51 18 32 0.39 0.14 0.25
10 IUGR + PET + HELLP 170 145 74 49 25 0.51 0.34 0.17
11 IUGR + PET + HELLP 163 150 56 21 35 0.37 0.14 0.23
12 IUGR + PET + HELLP 264 325 141 103 39 0.43 0.32 0.12
13 IUGR + PET 170 130 72 58 14 0.55 0.44 0.11
14 IUGR + PET 300 200 110 73 37 0.55 0.37 0.18
15 IUGR + PET 200 220 96 61 35 0.44 0.28 0.16
16 IUGR + PET 190 160 73 42 31 0.45 0.26 0.19
17 IUGR + PET 180 200 104 60 44 0.52 0.30 0.22
18 IUGR + PET 290 89 47 34 14 0.53 0.38 0.15
19 IUGR + PET 314 276 152 63 89 0.55 0.23 0.32
20 IUGR + PET 420 250 127 87 41 0.51 0.35 0.16
21 IUGR + PET 475 410 149 21 128 0.36 0.05 0.31
22 IUGR + PET 400 455 207 89 118 0.45 0.20 0.26
23 IUGR + PET 260 400 182 104 79 0.46 0.26 0.20
24 IUGR + PET 256 240 135 89 47 0.56 0.37 0.19
25 IUGR + PET 500 460 199 130 69 0.43 0.28 0.15
VOLUME DENSITY TOTAL VOLUME (cm3)
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2. SIDS Cohort 
CASE DIAGNOSIS PLACENTAL WT. (g)
PLACENTAL 
VOL
ALL 
VILLI SV INT TV
1 Term Control 458 540 224 62 141 20
2 Term Control 598 450 178 90 58 39
3 Term Control 480 488 295 37 130 129
4 Term Control 700 510 360 18 197 145
5 Term Control 660 490 226 92 99 36
6 Term Control 398 620 279 52 214 12
7 Term Control 462 413 281 55 188 38
8 Term Control 656 496 324 42 87 194
9 Term Control 480 464 288 45 90 154
10 Term Control 600 340 182 67 109 6
11 Term Control 450 700 265 74 164 27
12 Term Control 650 640 270 55 168 47
1 SIDS NBW 280 596 444 59 126 258
2 SIDS NBW 462 434 322 42 103 176
3 SIDS NBW 608 556 394 83 132 178
4 SIDS NBW 444 535 350 52 96 196
5 SIDS NBW 466 454 365 39 130 196
6 SIDS NBW 580 399 216 23 47 145
7 SIDS NBW 570 432 333 29 144 190
8 SIDS NBW 560 502 325 65 90 184
9 SIDS NBW 458 573 353 109 71 173
10 SIDS NBW 524 373 251 42 80 129
11 SIDS NBW 700 460 359 40 131 188
12 SIDS NBW 480 607 449 211 161 77
13 SIDS LBW 434 391 271 37 98 135
14 SIDS LBW 376 645 362 81 74 208
15 SIDS LBW 443 445 275 52 65 157
16 SIDS LBW 406 365 210 38 44 128
17 SIDS LBW 412 248 178 80 62 35
18 SIDS LBW 360 392 315 30 105 181
19 SIDS LBW 676 449 318 64 106 148
20 SIDS LBW 456 405 280 53 98 129
21 SIDS LBW 408 420 345 44 128 174
22 SIDS LBW 176 361 290 34 120 136
23 SIDS LBW 254 159 98 44 42 12
24 SIDS LBW 290 297 196 107 68 21  
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Appendix 3: Cytotrophoblast Volume and Number 
1. Toronto Cohort 
CASE DIAGNOSIS
VOL. CT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.CT SV & IMV MV & TV NO. Ki-67 +VE CT MV & TV SV & IMV VOL. CT SV & IMV MV & TV NO.  CT SV & IMV MV & TV
NO. Ki-67 
+VE CT SV & IMV MV & TV 
1 PT control 1.87 1.72 0.15 9.2E+10 4.5E+10 4.7E+10 4.0E+10 1.6E+10 2.4E+10 0.023 0.013 0.010 2.9E-04 1.4E-04 1.5E-04 1.2E-04 4.9E-05 7.5E-05
2 PT control 1.00 0.28 0.72 5.2E+10 5.3E+09 4.7E+10 1.1E+10 1.1E+09 1.0E+10 0.018 0.008 0.010 2.4E-04 2.4E-05 2.1E-04 5.2E-05 4.9E-06 4.7E-05
3 PT control 1.08 0.86 0.22 7.0E+10 2.8E+10 4.2E+10 1.7E+10 7.2E+09 9.6E+09 0.017 0.010 0.007 2.3E-04 9.4E-05 1.4E-04 5.6E-05 2.4E-05 3.2E-05
4 PT control 0.56 0.36 0.19 5.1E+10 1.1E+10 4.0E+10 1.8E+10 3.5E+09 1.5E+10 0.011 0.005 0.006 2.3E-04 5.1E-05 1.8E-04 8.3E-05 1.6E-05 6.7E-05
5 PT control 1.25 0.52 0.72 7.8E+10 1.3E+10 6.6E+10 1.3E+10 9.6E+08 1.2E+10 0.019 0.006 0.013 2.8E-04 4.5E-05 2.3E-04 4.5E-05 3.4E-06 4.1E-05
6 PT control 1.40 0.75 0.65 8.5E+10 3.6E+10 4.9E+10 2.9E+10 1.4E+10 1.5E+10 0.018 0.005 0.014 1.8E-04 7.5E-05 1.0E-04 6.1E-05 2.9E-05 3.2E-05
7 PT control 1.02 0.40 0.61 6.3E+10 7.0E+09 5.5E+10 1.8E+10 3.3E+09 1.4E+10 0.014 0.005 0.009 1.8E-04 2.0E-05 1.6E-04 5.2E-05 9.7E-06 4.2E-05
8 PT control 1.59 0.89 0.71 7.8E+10 1.9E+10 6.0E+10 1.3E+10 2.9E+09 1.0E+10 0.015 0.007 0.008 1.8E-04 4.5E-05 1.4E-04 3.1E-05 6.9E-06 2.4E-05
9 PT control 1.39 0.46 0.94 7.3E+10 1.5E+10 5.8E+10 2.5E+10 3.2E+09 2.2E+10 0.016 0.006 0.010 2.1E-04 4.4E-05 1.6E-04 7.1E-05 9.1E-06 6.2E-05
10 PT control 0.94 0.20 0.74 6.5E+10 1.1E+10 5.6E+10 3.2E+10 2.7E+09 2.9E+10 0.012 0.004 0.008 1.8E-04 3.0E-05 1.6E-04 8.8E-05 7.5E-06 8.0E-05
11 PT control 0.69 0.06 0.63 5.7E+10 1.2E+10 4.5E+10 1.2E+10 2.5E+09 9.8E+09 0.009 0.002 0.007 1.6E-04 3.5E-05 1.3E-04 3.5E-05 7.0E-06 2.8E-05
12 PT control 1.33 0.13 1.21 4.6E+10 9.7E+09 3.6E+10 1.1E+10 2.0E+09 8.9E+09 0.018 0.004 0.015 2.0E-04 4.2E-05 1.6E-04 4.7E-05 8.8E-06 3.9E-05
13 Term control 2.87 0.64 2.23 1.1E+11 1.5E+10 9.4E+10 2.0E+10 8.6E+08 1.9E+10 0.019 0.005 0.015 2.2E-04 3.1E-05 1.9E-04 4.0E-05 1.7E-06 3.8E-05
14 Term control 1.33 0.37 0.96 8.6E+10 3.1E+10 5.5E+10 2.3E+10 5.8E+09 1.7E+10 0.017 0.006 0.011 2.4E-04 8.6E-05 1.5E-04 6.4E-05 1.6E-05 4.8E-05
15 Term control 1.65 0.07 1.58 1.2E+11 1.6E+10 1.0E+11 3.1E+10 5.5E+09 2.5E+10 0.009 0.001 0.008 1.7E-04 2.3E-05 1.4E-04 4.4E-05 7.8E-06 3.6E-05
16 Term control 1.37 0.49 0.87 1.1E+11 1.7E+10 9.1E+10 3.0E+10 5.3E+09 2.5E+10 0.013 0.004 0.009 2.0E-04 3.2E-05 1.7E-04 5.6E-05 9.7E-06 4.6E-05
17 Term control 1.10 0.55 0.55 1.1E+11 1.6E+10 1.0E+11 2.5E+10 2.4E+09 2.3E+10 0.008 0.003 0.005 1.8E-04 2.6E-05 1.6E-04 4.0E-05 3.8E-06 3.6E-05
18 Term control 2.07 0.10 1.97 9.0E+10 1.4E+10 7.4E+10 3.4E+10 4.2E+09 3.0E+10 0.010 0.001 0.009 1.5E-04 2.3E-05 1.2E-04 5.4E-05 6.8E-06 4.8E-05
19 Term control 5.37 4.20 1.17 1.1E+11 3.6E+10 7.0E+10 3.7E+10 9.5E+09 2.7E+10 0.035 0.023 0.012 1.7E-04 5.8E-05 1.1E-04 5.9E-05 1.5E-05 4.4E-05
20 Term control 1.86 0.26 1.60 5.6E+10 8.8E+09 4.7E+10 1.4E+10 2.9E+09 1.1E+10 0.019 0.003 0.017 1.3E-04 2.0E-05 1.1E-04 3.1E-05 6.5E-06 2.4E-05
21 Term control 3.80 1.06 2.74 6.7E+10 2.6E+10 4.1E+10 1.6E+10 4.5E+09 1.1E+10 0.032 0.011 0.021 1.4E-04 5.4E-05 8.3E-05 3.2E-05 9.2E-06 2.3E-05
22 Term control 5.94 5.19 0.75 1.1E+11 2.1E+10 8.8E+10 2.3E+10 4.0E+09 1.9E+10 0.036 0.025 0.011 1.8E-04 3.4E-05 1.4E-04 3.6E-05 6.4E-06 3.0E-05
23 Term control 0.92 0.44 0.47 5.8E+10 2.3E+10 3.5E+10 2.1E+10 6.6E+09 1.4E+10 0.012 0.004 0.009 1.7E-04 6.8E-05 1.0E-04 6.1E-05 1.9E-05 4.2E-05
24 Term control 2.01 0.52 1.49 1.1E+11 3.0E+10 8.2E+10 2.4E+10 5.0E+09 1.9E+10 0.015 0.004 0.012 1.8E-04 4.7E-05 1.3E-04 3.7E-05 7.8E-06 2.9E-05
25 Term control 1.18 0.56 0.62 1.4E+11 6.0E+10 7.6E+10 4.1E+10 2.0E+10 2.1E+10 0.010 0.003 0.006 2.0E-04 8.6E-05 1.1E-04 5.8E-05 2.8E-05 3.0E-05
TOTALS  DENSITIES (µm-3)
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CASE DIAGNOSIS
VOL. CT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.CT SV & IMV MV & TV NO. Ki-67 +VE CT MV & TV SV & IMV VOL. CT SV & IMV MV & TV NO.  CT SV & IMV MV & TV
NO. Ki-67 
+VE CT SV & IMV MV & TV 
1 PET + HELLP 0.41 0.10 0.31 2.4E+10 3.7E+09 2.0E+10 7.0E+09 1.2E+09 5.8E+09 0.014 0.004 0.010 2.4E+10 3.7E+09 2.0E+10 7.0E+09 1.2E+09 5.8E+09
2 PET 1.21 1.02 0.18 1.2E+11 6.8E+10 4.5E+10 2.3E+10 1.5E+10 8.5E+09 0.011 0.004 0.006 1.2E+11 6.8E+10 4.5E+10 2.3E+10 1.5E+10 8.5E+09
3 PET 0.84 0.36 0.48 4.4E+10 1.6E+10 2.9E+10 1.7E+10 5.0E+09 1.2E+10 0.019 0.005 0.014 4.4E+10 1.6E+10 2.9E+10 1.7E+10 5.0E+09 1.2E+10
4 PET 1.24 0.20 1.04 5.7E+10 5.2E+09 5.2E+10 2.9E+10 3.3E+09 2.6E+10 0.017 0.003 0.014 5.7E+10 5.2E+09 5.2E+10 2.9E+10 3.3E+09 2.6E+10
5 PET + HELLP 0.35 0.04 0.30 3.9E+10 8.4E+08 3.8E+10 1.7E+10 8.0E+08 1.6E+10 0.006 0.001 0.005 3.9E+10 8.4E+08 3.8E+10 1.7E+10 8.0E+08 1.6E+10
6 PET + HELLP 1.42 0.65 0.77 7.8E+10 3.6E+10 4.1E+10 2.7E+10 1.2E+10 1.5E+10 0.018 0.005 0.012 7.8E+10 3.6E+10 4.1E+10 2.7E+10 1.2E+10 1.5E+10
7 PET 0.89 0.16 0.73 5.7E+10 8.6E+09 4.8E+10 1.3E+10 1.7E+09 1.1E+10 0.015 0.003 0.012 5.7E+10 8.6E+09 4.8E+10 1.3E+10 1.7E+09 1.1E+10
8 PET 0.60 0.14 0.46 4.6E+10 1.5E+10 3.1E+10 1.3E+10 3.2E+09 1.0E+10 0.010 0.003 0.007 4.6E+10 1.5E+10 3.1E+10 1.3E+10 3.2E+09 1.0E+10
9 PET + HELLP 1.97 0.55 1.42 7.8E+10 1.6E+10 6.1E+10 2.9E+10 4.5E+09 2.4E+10 0.022 0.004 0.018 7.8E+10 1.6E+10 6.1E+10 2.9E+10 4.5E+09 2.4E+10
10 PET 1.74 0.32 1.42 9.0E+10 2.6E+10 6.5E+10 1.6E+10 8.8E+09 6.9E+09 0.017 0.003 0.014 9.0E+10 2.6E+10 6.5E+10 1.6E+10 8.8E+09 6.9E+09
11 PET 2.11 1.19 0.93 7.3E+10 3.5E+10 3.8E+10 2.2E+10 1.1E+10 1.1E+10 0.025 0.013 0.011 7.3E+10 3.5E+10 3.8E+10 2.2E+10 1.1E+10 1.1E+10
12 PET 0.77 0.21 0.56 5.3E+10 7.0E+09 4.6E+10 9.4E+09 1.0E+09 8.4E+09 0.011 0.003 0.009 1.8E-04 2.3E-05 1.5E-04 3.1E-05 3.5E-06 2.8E-05
13 PET 0.90 0.25 0.66 8.0E+10 9.3E+09 7.1E+10 2.7E+10 6.2E+09 2.1E+10 0.007 0.003 0.004 2.1E-04 2.4E-05 1.9E-04 7.1E-05 1.6E-05 5.5E-05
14 PET + HELLP 0.48 0.22 0.26 8.1E+10 2.3E+10 5.8E+10 3.2E+10 5.3E+09 2.6E+10 0.007 0.003 0.004 1.3E-04 3.8E-05 9.7E-05 5.3E-05 8.8E-06 4.4E-05
15 PET 3.20 1.08 2.13 1.0E+11 3.4E+10 6.9E+10 2.6E+10 1.1E+10 1.5E+10 0.025 0.009 0.017 1.9E-04 6.2E-05 1.3E-04 4.8E-05 2.0E-05 2.7E-05
16 PET 7.33 0.32 7.01 7.3E+10 8.0E+09 6.5E+10 2.7E+10 4.0E+09 2.3E+10 0.030 0.003 0.027 1.3E-04 1.4E-05 1.1E-04 4.6E-05 6.9E-06 3.9E-05
17 PET 6.14 0.29 5.85 5.6E+10 1.1E+10 4.5E+10 1.3E+10 4.2E+09 8.4E+09 0.027 0.004 0.023 1.1E-04 2.0E-05 8.8E-05 2.4E-05 8.2E-06 1.6E-05
1 IUGR 0.85 0.72 0.13 5.8E+10 2.3E+10 3.5E+10 7.9E+09 4.0E+09 4.0E+09 0.015 0.008 0.006 2.7E-04 1.1E-04 1.6E-04 3.6E-05 1.8E-05 1.8E-05
2 IUGR 0.31 0.19 0.12 2.5E+10 4.4E+09 2.1E+10 3.0E+09 9.9E+08 2.0E+09 0.012 0.004 0.008 2.0E-04 3.5E-05 1.6E-04 2.4E-05 7.8E-06 1.6E-05
3 IUGR 0.61 0.39 0.22 3.4E+10 1.1E+10 2.3E+10 8.5E+09 4.4E+09 4.0E+09 0.015 0.008 0.007 1.9E-04 6.3E-05 1.3E-04 4.7E-05 2.5E-05 2.2E-05
4 IUGR 0.30 0.08 0.21 2.0E+10 3.6E+09 1.6E+10 3.6E+09 3.6E+08 3.2E+09 0.017 0.006 0.011 2.0E-04 3.6E-05 1.6E-04 3.6E-05 3.6E-06 3.2E-05
5 IUGR 0.42 0.20 0.21 2.9E+10 1.2E+10 1.7E+10 6.1E+09 3.3E+09 2.9E+09 0.011 0.005 0.007 1.7E-04 7.2E-05 1.0E-04 3.7E-05 2.0E-05 1.7E-05
6 IUGR 0.20 0.09 0.10 3.1E+10 9.6E+09 2.1E+10 6.8E+09 2.4E+09 4.5E+09 0.006 0.002 0.004 2.0E-04 6.4E-05 1.4E-04 4.6E-05 1.6E-05 3.0E-05
7 IUGR 0.79 0.54 0.24 5.2E+10 1.2E+10 4.1E+10 1.3E+10 2.3E+09 1.1E+10 0.010 0.005 0.005 1.7E-04 4.0E-05 1.4E-04 4.3E-05 7.5E-06 3.5E-05
8 IUGR 0.81 0.24 0.58 6.8E+10 1.1E+10 5.7E+10 1.8E+10 2.0E+09 1.6E+10 0.010 0.003 0.007 2.0E-04 3.1E-05 1.7E-04 5.5E-05 5.9E-06 4.9E-05
9 IUGR 2.83 0.83 2.00 4.7E+10 8.1E+09 3.8E+10 1.5E+10 2.6E+09 1.3E+10 0.028 0.010 0.018 1.5E-04 2.6E-05 1.2E-04 4.9E-05 8.2E-06 4.1E-05
TOTALS  DENSITIES (µm-3)
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CASE DIAGNOSIS
VOL. CT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.CT SV & IMV MV & TV NO. Ki-67 +VE CT MV & TV SV & IMV VOL. CT SV & IMV MV & TV NO.  CT SV & IMV MV & TV
NO. Ki-67 
+VE CT SV & IMV MV & TV 
1 IUGR + PET 0.32 0.17 0.15 2.6E+10 6.2E+09 2.0E+10 3.9E+09 2.6E+08 3.6E+09 0.011 0.005 0.006 2.0E-04 4.9E-05 1.5E-04 3.1E-05 2.0E-06 2.9E-05
2 IUGR + PET + HELLP 0.46 0.22 0.24 2.8E+10 4.2E+09 2.4E+10 7.0E+09 1.1E+09 5.9E+09 0.014 0.004 0.010 1.9E-04 2.8E-05 1.6E-04 4.7E-05 7.4E-06 3.9E-05
3 IUGR + PET 0.40 0.07 0.33 2.4E+10 5.9E+09 1.8E+10 8.6E+09 1.9E+09 6.7E+09 0.012 0.004 0.008 1.5E-04 3.7E-05 1.1E-04 5.3E-05 1.2E-05 4.2E-05
4 IUGR + PET 0.26 0.20 0.06 2.3E+10 8.4E+09 1.4E+10 3.9E+09 1.8E+09 2.1E+09 0.008 0.003 0.005 1.8E-04 6.5E-05 1.1E-04 3.0E-05 1.4E-05 1.6E-05
5 IUGR + PET 0.96 0.75 0.21 4.7E+10 7.4E+09 3.9E+10 1.0E+10 1.6E+09 8.9E+09 0.016 0.009 0.007 2.1E-04 3.3E-05 1.8E-04 4.8E-05 7.3E-06 4.0E-05
6 IUGR + PET 0.12 0.06 0.06 2.2E+10 3.8E+09 1.8E+10 4.8E+09 6.4E+08 4.1E+09 0.007 0.002 0.004 2.3E-04 3.8E-05 1.9E-04 4.8E-05 6.4E-06 4.2E-05
7 IUGR + PET 0.48 0.28 0.20 3.8E+10 1.1E+10 2.8E+10 6.2E+09 2.9E+09 3.3E+09 0.015 0.005 0.009 2.5E-04 7.1E-05 1.8E-04 4.2E-05 2.0E-05 2.2E-05
8 IUGR + PET 0.58 0.30 0.28 3.4E+10 7.6E+09 2.6E+10 6.0E+09 2.6E+08 5.8E+09 0.018 0.005 0.013 2.3E-04 5.1E-05 1.7E-04 4.0E-05 1.8E-06 3.9E-05
9 IUGR + PET 0.17 0.04 0.13 2.3E+10 5.1E+09 1.8E+10 4.6E+09 8.1E+08 3.8E+09 0.006 0.002 0.004 1.8E-04 3.9E-05 1.4E-04 3.5E-05 6.2E-06 2.9E-05
10 IUGR + PET + HELLP 0.38 0.09 0.30 2.6E+10 1.3E+09 2.4E+10 5.7E+09 2.6E+08 5.4E+09 0.014 0.002 0.012 1.8E-04 9.0E-06 1.7E-04 3.9E-05 1.8E-06 3.7E-05
11 IUGR + PET + HELLP 0.38 0.11 0.27 3.7E+10 1.7E+10 2.0E+10 7.2E+09 4.6E+09 2.6E+09 0.013 0.005 0.008 2.5E-04 1.1E-04 1.3E-04 4.8E-05 3.1E-05 1.8E-05
12 IUGR + PET + HELLP 0.60 0.30 0.30 7.2E+10 1.6E+10 5.6E+10 2.0E+10 5.6E+09 1.5E+10 0.011 0.003 0.008 2.2E-04 5.0E-05 1.7E-04 6.3E-05 1.7E-05 4.6E-05
13 IUGR + PET 0.35 0.23 0.12 2.4E+10 5.1E+09 1.9E+10 2.8E+09 5.1E+08 2.3E+09 0.013 0.004 0.009 1.8E-04 3.9E-05 1.4E-04 2.1E-05 3.9E-06 1.8E-05
14 IUGR + PET 0.46 0.20 0.26 4.4E+10 1.6E+10 2.9E+10 8.6E+09 3.0E+09 5.6E+09 0.010 0.003 0.007 2.2E-04 7.8E-05 1.4E-04 4.3E-05 1.5E-05 2.8E-05
15 IUGR + PET 0.47 0.15 0.33 2.8E+10 3.3E+09 2.4E+10 1.2E+10 2.9E+09 9.5E+09 0.012 0.002 0.009 1.8E-04 2.1E-05 1.5E-04 7.7E-05 1.8E-05 5.9E-05
16 IUGR + PET 0.38 0.09 0.29 3.7E+10 6.6E+09 3.1E+10 1.0E+10 2.2E+09 8.0E+09 0.012 0.002 0.010 1.9E-04 3.3E-05 1.6E-04 5.1E-05 1.1E-05 4.0E-05
17 IUGR + PET 0.41 0.14 0.26 1.8E+10 4.0E+09 1.4E+10 4.0E+09 1.2E+09 2.8E+09 0.008 0.002 0.006 2.0E-04 4.5E-05 1.6E-04 4.5E-05 1.3E-05 3.1E-05
18 IUGR + PET 0.43 0.27 0.16 4.0E+10 1.6E+09 3.8E+10 1.0E+10 0.0E+00 1.0E+10 0.020 0.008 0.012 1.8E-04 7.2E-06 1.7E-04 4.7E-05 0.0E+00 4.7E-05
19 IUGR + PET 3.24 0.28 2.97 4.2E+10 1.1E+10 3.0E+10 1.1E+10 1.2E+09 9.6E+09 0.038 0.004 0.034 1.5E-04 4.0E-05 1.1E-04 3.9E-05 4.4E-06 3.5E-05
20 IUGR + PET 0.77 0.57 0.20 4.1E+10 8.0E+09 3.3E+10 1.7E+10 3.0E+09 1.4E+10 0.012 0.007 0.005 1.6E-04 3.2E-05 1.3E-04 6.8E-05 1.2E-05 5.6E-05
21 IUGR + PET 3.11 0.10 3.01 5.6E+10 2.0E+10 3.7E+10 8.5E+09 3.2E+09 5.4E+09 0.028 0.005 0.024 1.4E-04 4.9E-05 9.0E-05 2.1E-05 7.7E-06 1.3E-05
22 IUGR + PET 2.71 0.76 1.94 9.5E+10 4.3E+10 5.0E+10 3.3E+10 9.9E+09 2.3E+10 0.025 0.009 0.017 2.1E-04 9.5E-05 1.1E-04 7.2E-05 2.2E-05 5.0E-05
23 IUGR + PET 0.99 0.33 0.66 6.4E+10 1.4E+10 5.0E+10 2.1E+10 3.1E+09 1.8E+10 0.012 0.003 0.008 1.6E-04 3.4E-05 1.2E-04 5.3E-05 7.6E-06 4.6E-05
24 IUGR + PET 0.91 0.37 0.54 3.0E+10 5.0E+09 2.5E+10 1.1E+10 1.7E+09 9.4E+09 0.016 0.004 0.012 1.2E-04 2.1E-05 1.0E-04 4.6E-05 6.9E-06 3.9E-05
25 IUGR + PET 1.01 0.42 0.59 6.4E+10 1.8E+10 4.6E+10 3.1E+10 7.1E+09 2.4E+10 0.012 0.003 0.009 1.4E-04 3.9E-05 1.0E-04 6.7E-05 1.5E-05 5.2E-05
TOTALS  DENSITIES (µm-3)
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2. SIDS Cohort 
CASE DIAGNOSIS VOL. CT SV INT TV VOL. CT SV INT TV
1 Term Control 2.98 0.52 1.59 0.90 0.013 0.0023 0.0071 0.0040
2 Term Control 3.38 0.52 1.37 1.57 0.019 0.0029 0.0077 0.0088
3 Term Control 3.54 0.92 1.51 1.12 0.012 0.0031 0.0051 0.0038
4 Term Control 3.60 0.83 1.33 1.33 0.010 0.0023 0.0037 0.0037
5 Term Control 7.23 0.79 5.45 0.99 0.032 0.0035 0.0241 0.0044
6 Term Control 10.04 0.17 9.60 0.17 0.036 0.0006 0.0344 0.0006
7 Term Control 9.84 0.34 8.21 1.26 0.035 0.0012 0.0292 0.0045
8 Term Control 8.74 0.42 3.82 4.63 0.027 0.0013 0.0118 0.0143
9 Term Control 5.48 1.12 2.33 1.90 0.019 0.0039 0.0081 0.0066
10 Term Control 2.20 0.56 0.80 0.84 0.012 0.0031 0.0044 0.0046
11 Term Control 2.52 0.24 1.51 0.80 0.010 0.0009 0.0057 0.0030
12 Term Control 4.16 0.84 2.38 0.95 0.015 0.0031 0.0088 0.0035
1 SIDS NBW 12.42 2.17 4.97 5.28 0.028 0.0049 0.0112 0.0119
2 SIDS NBW 8.04 1.35 4.99 1.71 0.025 0.0042 0.0155 0.0053
3 SIDS NBW 6.30 2.09 2.99 1.38 0.016 0.0053 0.0076 0.0035
4 SIDS NBW 8.40 1.02 5.50 1.86 0.024 0.0029 0.0157 0.0053
5 SIDS NBW 6.21 0.77 3.47 1.93 0.017 0.0021 0.0095 0.0053
6 SIDS NBW 5.40 0.63 2.48 2.24 0.025 0.0029 0.0115 0.0104
7 SIDS NBW 11.32 1.80 5.60 3.80 0.034 0.0054 0.0168 0.0114
8 SIDS NBW 11.37 2.31 5.62 3.44 0.035 0.0071 0.0173 0.0106
9 SIDS NBW 10.60 1.17 4.63 4.88 0.030 0.0033 0.0131 0.0138
10 SIDS NBW 5.26 0.98 3.28 1.03 0.021 0.0039 0.0131 0.0041
11 SIDS NBW 11.84 4.70 5.20 1.97 0.033 0.0131 0.0145 0.0055
12 SIDS NBW 15.26 2.47 6.33 6.33 0.034 0.0055 0.0141 0.0141
13 SIDS LBW 13.82 3.82 6.77 3.20 0.051 0.0141 0.0250 0.0118
14 SIDS LBW 5.44 1.41 2.21 1.85 0.015 0.0039 0.0061 0.0051
15 SIDS LBW 5.22 1.95 2.12 1.13 0.019 0.0071 0.0077 0.0041
16 SIDS LBW 5.46 1.18 3.11 1.20 0.026 0.0056 0.0148 0.0057
17 SIDS LBW 4.09 0.87 1.76 1.53 0.023 0.0049 0.0099 0.0086
18 SIDS LBW 7.86 0.63 4.59 2.77 0.025 0.0020 0.0146 0.0088
19 SIDS LBW 8.59 0.64 5.38 2.67 0.027 0.0020 0.0169 0.0084
20 SIDS LBW 11.20 1.34 8.34 1.46 0.040 0.0048 0.0298 0.0052
21 SIDS LBW 7.94 0.97 3.94 3.07 0.023 0.0028 0.0114 0.0089
22 SIDS LBW 9.27 1.39 4.37 3.42 0.032 0.0048 0.0151 0.0118
23 SIDS LBW 2.64 0.69 1.87 0.06 0.027 0.0070 0.0191 0.0006
24 SIDS LBW 7.46 0.75 4.62 2.02 0.038 0.0038 0.0235 0.0103
TOTAL VOL (cm3) VOL. DENSITIES
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Appendix 4: Syncytiotrophoblast Volume and Number 
1. Toronto Cohort 
CASE DIAGNOSIS
VOL. SCT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.SCT SV & IMV MV & TV VOL. SCT SV & IMV MV & TV
NO.  SCT  
(µm-3)
SV & IMV 
(µm-3)
MV & TV 
(µm-3)
1 PT control 3.05 2.78 0.27 3.9E+11 2.0E+11 1.9E+11 0.039 0.022 0.018 1.21E-03 6.30E-04 5.82E-04
2 PT control 3.13 0.57 2.55 2.9E+11 1.0E+11 1.8E+11 0.052 0.016 0.036 1.32E-03 4.74E-04 8.21E-04
3 PT control 2.65 2.13 0.52 3.3E+11 1.5E+11 1.8E+11 0.042 0.026 0.016 1.10E-03 4.88E-04 6.14E-04
4 PT control 1.78 1.15 0.64 2.4E+11 6.6E+10 1.8E+11 0.035 0.015 0.020 1.10E-03 3.02E-04 8.00E-04
5 PT control 3.94 1.78 2.16 3.4E+11 1.0E+11 2.3E+11 0.059 0.020 0.039 1.21E-03 3.74E-04 8.13E-04
6 PT control 4.56 2.77 1.79 3.7E+11 2.0E+11 1.7E+11 0.054 0.017 0.038 7.79E-04 4.17E-04 3.62E-04
7 PT control 3.24 1.26 1.98 3.2E+11 1.1E+11 2.1E+11 0.044 0.016 0.029 9.27E-04 3.12E-04 6.14E-04
8 PT control 4.98 2.35 2.62 4.0E+11 1.8E+11 2.3E+11 0.048 0.018 0.030 9.47E-04 4.17E-04 5.30E-04
9 PT control 5.81 1.48 4.33 4.2E+11 5.8E+10 3.7E+11 0.063 0.019 0.044 1.21E-03 1.66E-04 1.04E-03
10 PT control 3.32 0.60 2.72 4.4E+11 9.4E+10 3.3E+11 0.041 0.011 0.030 1.21E-03 2.62E-04 9.18E-04
11 PT control 3.55 0.33 3.22 2.8E+11 2.4E+10 2.5E+11 0.047 0.011 0.036 7.87E-04 6.83E-05 7.19E-04
12 PT control 3.42 0.23 3.19 2.2E+11 5.0E+10 1.7E+11 0.045 0.007 0.038 9.75E-04 2.15E-04 7.30E-04
13 Term control 5.75 1.43 4.31 6.1E+11 2.4E+11 3.7E+11 0.039 0.011 0.028 1.21E-03 4.76E-04 7.37E-04
14 Term control 4.13 0.69 3.44 3.3E+11 8.8E+10 2.4E+11 0.050 0.011 0.039 9.20E-04 2.44E-04 6.76E-04
15 Term control 7.39 0.20 7.19 5.5E+11 5.5E+10 5.0E+11 0.039 0.003 0.036 7.90E-04 7.90E-05 7.10E-04
16 Term control 3.68 1.19 2.49 6.0E+11 2.2E+11 3.7E+11 0.036 0.011 0.026 1.10E-03 4.14E-04 6.88E-04
17 Term control 4.84 1.30 3.54 5.4E+11 2.3E+11 3.1E+11 0.037 0.007 0.031 8.51E-04 3.60E-04 4.91E-04
18 Term control 10.72 0.62 10.10 5.7E+11 1.2E+11 4.5E+11 0.054 0.007 0.047 9.18E-04 1.91E-04 7.27E-04
19 Term control 9.78 7.36 2.42 4.5E+11 1.8E+11 2.7E+11 0.065 0.040 0.025 7.25E-04 2.90E-04 4.34E-04
20 Term control 0.85 0.43 0.42 2.6E+11 4.1E+10 2.2E+11 0.009 0.005 0.004 5.79E-04 9.04E-05 4.85E-04
21 Term control 6.03 1.74 4.29 2.5E+11 4.7E+10 2.1E+11 0.051 0.018 0.033 5.18E-04 9.59E-05 4.19E-04
22 Term control 6.46 6.01 0.45 3.9E+11 8.9E+10 3.0E+11 0.035 0.029 0.007 6.23E-04 1.43E-04 4.85E-04
23 Term control 3.19 1.38 1.80 3.1E+11 1.1E+11 2.0E+11 0.044 0.011 0.033 9.18E-04 3.25E-04 5.84E-04
24 Term control 6.21 0.95 5.25 6.0E+11 2.8E+11 3.1E+11 0.048 0.007 0.042 9.34E-04 4.43E-04 4.91E-04
25 Term control 5.24 2.17 3.07 8.5E+11 3.1E+11 5.3E+11 0.044 0.013 0.031 1.21E-03 4.44E-04 7.58E-04
TOTALS  DENSITIES (µm-3)
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CASE DIAGNOSIS
VOL. SCT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.SCT SV & IMV MV & TV VOL. SCT SV & IMV MV & TV
NO.  SCT  
(µm-3)
SV & IMV 
(µm-3)
MV & TV 
(µm-3)
1 PET + HELLP 1.3 0.2 0.27 1.1E+11 1.1E+10 1.0E+11 0.041 0.007 0.033 8.67E-04 8.21E-05 7.85E-04
2 PET 5.4 4.5 2.55 5.6E+11 4.1E+11 1.4E+11 0.049 0.019 0.030 1.32E-03 9.84E-04 3.38E-04
3 PET 2.4 0.9 0.52 2.6E+11 8.4E+10 1.8E+11 0.055 0.013 0.042 1.04E-03 3.37E-04 7.07E-04
4 PET 3.8 0.5 0.64 3.2E+11 4.5E+10 2.7E+11 0.051 0.007 0.043 1.10E-03 1.55E-04 9.46E-04
5 PET + HELLP 2.6 0.3 2.16 2.4E+11 3.5E+10 2.1E+11 0.043 0.006 0.037 9.31E-04 1.34E-04 7.98E-04
6 PET + HELLP 2.7 0.9 1.79 2.4E+11 1.3E+11 1.1E+11 0.037 0.007 0.030 6.99E-04 3.76E-04 3.23E-04
7 PET 2.8 0.5 1.98 3.0E+11 6.4E+10 2.3E+11 0.047 0.010 0.037 9.23E-04 2.00E-04 7.23E-04
8 PET 3.2 0.6 2.62 2.4E+11 7.6E+10 1.6E+11 0.050 0.012 0.038 7.43E-04 2.37E-04 5.06E-04
9 PET + HELLP 4.9 1.3 4.33 6.6E+11 2.5E+11 4.2E+11 0.057 0.011 0.046 1.65E-03 6.14E-04 1.04E-03
10 PET 5.1 0.8 2.72 2.6E+11 7.6E+10 1.8E+11 0.050 0.008 0.042 6.10E-04 1.79E-04 4.31E-04
11 PET 4.0 1.6 3.22 2.6E+11 1.2E+11 1.4E+11 0.048 0.018 0.030 6.82E-04 3.09E-04 3.75E-04
12 PET 2.4 0.6 1.8 2.8E+11 8.2E+10 1.9E+11 0.034 0.008 0.026 9.21E-04 2.75E-04 6.47E-04
13 PET 4.4 0.8 3.6 3.4E+11 3.5E+10 3.1E+11 0.031 0.009 0.022 8.98E-04 9.24E-05 8.05E-04
14 PET + HELLP 2.2 0.7 1.5 4.5E+11 1.6E+11 3.0E+11 0.031 0.009 0.022 7.55E-04 2.62E-04 4.93E-04
15 PET 6.4 1.6 4.8 3.5E+11 8.5E+10 2.7E+11 0.050 0.013 0.037 6.41E-04 1.54E-04 4.85E-04
16 PET 20.0 1.1 18.9 3.7E+11 4.0E+10 3.3E+11 0.083 0.012 0.071 6.50E-04 7.01E-05 5.80E-04
17 PET 19.2 0.5 18.7 3.4E+11 6.9E+10 2.7E+11 0.080 0.007 0.074 6.52E-04 1.35E-04 5.18E-04
1 IUGR 1.8 1.4 0.4 2.7E+11 1.4E+11 1.2E+11 0.036 0.016 0.020 1.21E-03 6.40E-04 5.61E-04
2 IUGR 0.8 0.5 0.4 9.7E+10 2.2E+10 7.5E+10 0.033 0.009 0.024 7.66E-04 1.77E-04 5.90E-04
3 IUGR 2.4 1.6 0.8 2.6E+11 1.4E+11 1.1E+11 0.057 0.031 0.026 1.43E-03 8.02E-04 6.31E-04
4 IUGR 0.9 0.3 0.7 9.2E+10 4.3E+10 4.9E+10 0.052 0.018 0.034 9.16E-04 4.29E-04 4.89E-04
5 IUGR 2.2 1.0 1.1 1.5E+11 5.8E+10 8.8E+10 0.060 0.024 0.036 8.84E-04 3.49E-04 5.35E-04
6 IUGR 1.1 0.5 0.6 1.4E+11 6.0E+10 8.2E+10 0.035 0.012 0.023 9.51E-04 4.02E-04 5.49E-04
7 IUGR 2.5 1.4 1.2 2.0E+11 4.4E+10 1.5E+11 0.036 0.012 0.024 6.59E-04 1.48E-04 5.11E-04
8 IUGR 3.5 0.7 2.7 2.8E+11 5.0E+10 2.3E+11 0.042 0.009 0.033 8.39E-04 1.47E-04 6.91E-04
9 IUGR 7.2 1.8 5.4 2.6E+11 4.9E+10 2.1E+11 0.071 0.022 0.049 8.43E-04 1.57E-04 6.86E-04
TOTALS  DENSITIES (µm-3)
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CASE DIAGNOSIS
VOL. SCT 
(cm3)
SV & IMV 
(cm3)
MV & TV 
(cm3)
 NO.SCT SV & IMV MV & TV VOL. SCT SV & IMV MV & TV
NO.  SCT  
(µm-3)
SV & IMV 
(µm-3)
MV & TV 
(µm-3)
1 IUGR + PET 1.3 0.6 0.7 1.2E+11 3.8E+10 7.9E+10 0.048 0.018 0.029 9.20E-04 2.96E-04 6.23E-04
2 IUGR + PET + HELLP 1.9 0.9 1.0 1.8E+11 4.7E+10 1.3E+11 0.060 0.018 0.041 1.21E-03 3.15E-04 8.97E-04
3 IUGR + PET 1.7 0.2 1.4 1.1E+11 4.3E+10 6.5E+10 0.049 0.011 0.037 6.72E-04 2.66E-04 4.06E-04
4 IUGR + PET 1.5 1.2 0.3 1.2E+11 6.4E+10 5.8E+10 0.047 0.020 0.027 9.39E-04 4.95E-04 4.44E-04
5 IUGR + PET 1.9 1.2 0.7 1.9E+11 5.9E+10 1.4E+11 0.036 0.014 0.022 8.86E-04 2.69E-04 6.17E-04
6 IUGR + PET 0.6 0.3 0.3 7.4E+10 2.3E+10 5.1E+10 0.033 0.012 0.021 7.52E-04 2.33E-04 5.19E-04
7 IUGR + PET 1.5 0.8 0.8 1.4E+11 1.9E+10 1.2E+11 0.049 0.015 0.034 9.12E-04 1.24E-04 7.87E-04
8 IUGR + PET 1.4 0.6 0.8 1.2E+11 4.0E+10 7.9E+10 0.046 0.010 0.036 7.91E-04 2.65E-04 5.26E-04
9 IUGR + PET 0.8 0.1 0.6 1.2E+11 3.3E+10 8.6E+10 0.027 0.008 0.019 9.12E-04 2.52E-04 6.60E-04
10 IUGR + PET + HELLP 1.9 0.7 1.2 1.5E+11 2.6E+10 1.2E+11 0.062 0.014 0.048 1.04E-03 1.81E-04 8.59E-04
11 IUGR + PET + HELLP 1.7 0.4 1.4 1.4E+11 5.5E+10 8.9E+10 0.056 0.017 0.039 9.65E-04 3.69E-04 5.96E-04
12 IUGR + PET + HELLP 2.1 1.0 1.0 1.9E+11 3.9E+10 1.5E+11 0.037 0.010 0.027 5.88E-04 1.20E-04 4.69E-04
13 IUGR + PET 1.3 1.0 0.4 1.6E+11 4.6E+10 1.1E+11 0.044 0.017 0.028 1.21E-03 3.55E-04 8.57E-04
14 IUGR + PET 1.8 0.7 1.1 2.1E+11 8.9E+10 1.2E+11 0.039 0.010 0.030 1.04E-03 4.46E-04 5.97E-04
15 IUGR + PET 2.1 0.6 1.5 1.8E+11 6.1E+10 1.2E+11 0.054 0.010 0.044 1.10E-03 3.83E-04 7.19E-04
16 IUGR + PET 1.4 0.4 1.0 1.8E+11 5.1E+10 1.3E+11 0.042 0.010 0.032 8.98E-04 2.54E-04 6.44E-04
17 IUGR + PET 1.2 0.4 0.8 9.8E+10 3.8E+10 6.0E+10 0.025 0.007 0.018 1.10E-03 4.26E-04 6.76E-04
18 IUGR + PET 1.1 0.7 0.4 2.4E+11 5.4E+10 1.9E+11 0.050 0.020 0.030 1.10E-03 2.46E-04 8.56E-04
19 IUGR + PET 5.2 0.3 4.9 1.8E+11 4.9E+10 1.3E+11 0.060 0.004 0.056 6.62E-04 1.76E-04 4.85E-04
1 IUGR + PET 2.2 1.2 1.0 2.8E+11 1.5E+11 1.2E+11 0.039 0.013 0.025 1.10E-03 6.07E-04 4.95E-04
2 IUGR + PET 6.3 0.1 6.1 2.3E+11 7.8E+10 1.5E+11 0.054 0.007 0.048 5.68E-04 1.90E-04 3.78E-04
3 IUGR + PET 5.5 1.2 4.4 4.0E+11 1.6E+11 2.5E+11 0.050 0.013 0.037 8.79E-04 3.42E-04 5.40E-04
4 IUGR + PET 3.6 0.7 2.9 3.2E+11 1.2E+11 1.9E+11 0.043 0.007 0.037 7.96E-04 3.11E-04 4.85E-04
5 IUGR + PET 3.7 1.0 2.7 1.8E+11 2.6E+10 1.6E+11 0.069 0.012 0.057 7.70E-04 1.10E-04 6.60E-04
6 IUGR + PET 4.4 1.6 2.8 5.6E+11 1.5E+11 4.1E+11 0.053 0.012 0.041 1.21E-03 3.30E-04 8.82E-04
TOTALS  DENSITIES (µm-3)
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2. SIDS Cohort 
CASE DIAGNOSIS VOL. SCT SV INT TV VOL. SCT SV INT TV
1 Term Control 8.06 1.12 3.65 3.36 0.036 0.0050 0.0163 0.0150
2 Term Control 10.15 0.85 4.38 4.95 0.057 0.0048 0.0246 0.0278
3 Term Control 18.32 3.49 9.42 5.32 0.062 0.0118 0.0319 0.0180
4 Term Control 21.97 2.02 9.83 10.16 0.061 0.0056 0.0273 0.0282
5 Term Control 11.53 1.72 7.71 2.10 0.051 0.0076 0.0341 0.0093
6 Term Control 9.77 0.53 9.26 0.00 0.035 0.0019 0.0332 0.0000
7 Term Control 18.27 0.45 15.29 2.53 0.065 0.0016 0.0544 0.0090
8 Term Control 19.42 0.97 8.19 10.26 0.060 0.0030 0.0253 0.0317
9 Term Control 17.29 2.33 7.20 7.69 0.060 0.0081 0.0250 0.0267
10 Term Control 8.01 1.80 2.88 3.26 0.044 0.0099 0.0158 0.0179
11 Term Control 11.66 1.03 6.86 3.74 0.044 0.0039 0.0259 0.0141
12 Term Control 13.01 1.22 8.07 3.73 0.048 0.0045 0.0299 0.0138
1 SIDS NBW 27.05 1.95 9.67 15.48 0.061 0.0044 0.0218 0.0349
2 SIDS NBW 19.95 3.93 10.72 5.31 0.062 0.0122 0.0333 0.0165
3 SIDS NBW 15.35 3.15 8.70 3.42 0.039 0.0080 0.0221 0.0087
4 SIDS NBW 21.35 1.44 13.93 6.02 0.061 0.0041 0.0398 0.0172
5 SIDS NBW 26.28 5.73 12.63 7.96 0.072 0.0157 0.0346 0.0218
6 SIDS NBW 12.09 1.81 4.47 5.70 0.056 0.0084 0.0207 0.0264
7 SIDS NBW 15.99 2.90 5.60 7.46 0.048 0.0087 0.0168 0.0224
8 SIDS NBW 16.24 2.14 8.38 5.78 0.050 0.0066 0.0258 0.0178
9 SIDS NBW 18.02 3.15 6.86 8.13 0.051 0.0089 0.0194 0.0230
10 SIDS NBW 17.30 2.11 11.98 3.28 0.069 0.0084 0.0478 0.0131
11 SIDS NBW 13.99 4.09 7.00 2.91 0.039 0.0114 0.0195 0.0081
12 SIDS NBW 44.00 5.30 20.56 18.18 0.098 0.0118 0.0458 0.0405
13 SIDS LBW 20.86 4.06 12.73 4.06 0.077 0.0150 0.0470 0.0150
14 SIDS LBW 21.02 3.26 10.51 7.61 0.058 0.0090 0.0290 0.0210
15 SIDS LBW 14.29 3.30 8.52 2.47 0.052 0.0120 0.0310 0.0090
16 SIDS LBW 10.91 1.26 5.88 3.57 0.052 0.0060 0.0280 0.0170
17 SIDS LBW 16.73 2.14 9.08 5.52 0.094 0.0120 0.0510 0.0310
18 SIDS LBW 17.93 1.73 8.24 7.96 0.057 0.0055 0.0262 0.0253
19 SIDS LBW 22.27 1.11 14.45 6.59 0.070 0.0035 0.0454 0.0207
20 SIDS LBW 18.48 3.86 12.82 1.68 0.066 0.0138 0.0458 0.0060
21 SIDS LBW 27.97 3.83 13.16 10.84 0.081 0.0111 0.0381 0.0314
22 SIDS LBW 20.86 2.98 11.50 6.32 0.072 0.0103 0.0397 0.0218
23 SIDS LBW 6.95 1.59 4.84 0.51 0.071 0.0162 0.0494 0.0052
24 SIDS LBW 11.59 0.79 6.56 4.22 0.059 0.0040 0.0334 0.0215
TOTAL VOL (cm3) VOL. DENSITIES
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Appendix 5: Syncytial Knots 
1. Toronto Cohort 
CASE DIAGNOSIS  VOL. SK
SV      
&      
IMV 
MV     
&      
TV 
 VOL 
APOP. SK
SV        
&         
IMV 
MV       
&         
TV
 VOL NON-
APOP. SK
SV      
&       
IMV 
MV       
&        
TV
VOL. SK
SV        
&         
IMV 
MV        
&         
TV
VOL. 
APOP.SK
SV        
&         
IMV 
MV             & 
TV
 VOL NON-
APOP. SK
SV       
&        
IMV
MV       
&        
TV
TOTAL PSI TOTAL APOP. PSI
SV        
&         
IMV
MV      
&        
TV
TOTAL NON-
APOP. PSI
SV        
&         
IMV
MV       
&         
TV
1 PT control 6.72 4.26 2.40 3.42 2.88 0.54 3.23 1.38 1.86 0.021 0.013 0.008 0.011 0.009 0.002 0.010 0.004 0.006 1.9E+04 5.9E+03 5.3E+03 5.9E+02 1.3E+04 1.1E+04 1.5E+03
2 PT control 4.80 3.41 1.39 1.72 0.99 0.73 3.08 2.42 0.66 0.022 0.016 0.006 0.008 0.005 0.003 0.014 0.011 0.003 1.6E+04 5.0E+03 2.9E+03 2.1E+03 1.1E+04 5.2E+03 5.7E+03
3 PT control 7.11 6.39 0.72 2.37 2.19 0.18 4.74 4.20 0.54 0.024 0.021 0.002 0.008 0.007 0.001 0.016 0.014 0.002 2.7E+04 1.0E+04 9.1E+03 1.3E+03 1.6E+04 1.1E+04 5.8E+03
4 PT control 4.00 3.65 0.35 2.05 2.02 0.02 1.96 1.63 0.33 0.018 0.017 0.002 0.009 0.009 0.000 0.009 0.007 0.002 1.4E+04 3.9E+03 3.3E+03 6.4E+02 9.6E+03 6.5E+03 3.1E+03
5 PT control 8.82 5.29 3.53 6.38 4.20 2.18 2.44 1.09 1.34 0.032 0.019 0.013 0.023 0.015 0.008 0.009 0.004 0.005 3.2E+04 8.6E+03 2.7E+03 5.9E+03 2.3E+04 1.7E+04 6.2E+03
6 PT control 12.34 7.73 4.61 7.06 4.61 2.45 5.28 3.12 2.16 0.026 0.016 0.010 0.015 0.010 0.005 0.011 0.007 0.005 2.6E+04 1.1E+04 5.8E+03 5.0E+03 1.6E+04 8.9E+03 6.6E+03
7 PT control 7.56 5.04 2.52 3.90 3.11 0.79 3.66 1.93 1.73 0.022 0.015 0.007 0.011 0.009 0.002 0.011 0.006 0.005 6.6E+04 1.1E+04 7.4E+03 3.5E+03 5.6E+04 4.8E+04 7.4E+03
8 PT control 9.35 5.31 4.17 4.00 2.76 1.23 5.53 2.55 2.93 0.022 0.013 0.010 0.009 0.007 0.003 0.013 0.006 0.007 2.1E+04 7.8E+03 4.9E+03 2.9E+03 1.3E+04 9.6E+03 3.3E+03
9 PT control 10.29 6.58 3.71 6.23 3.78 2.45 4.06 2.80 1.26 0.029 0.019 0.011 0.018 0.011 0.007 0.012 0.008 0.004 2.7E+04 7.1E+03 4.0E+03 9.7E+03 2.0E+04 1.4E+04 6.3E+03
10 PT control 6.98 2.74 4.25 2.09 1.44 0.65 4.90 1.30 3.60 0.019 0.008 0.012 0.006 0.004 0.002 0.014 0.004 0.010 1.9E+04 4.5E+03 3.5E+03 1.0E+03 1.4E+04 6.8E+03 7.5E+03
11 PT control 12.64 7.00 5.64 4.94 3.26 1.68 7.70 3.75 3.96 0.036 0.020 0.016 0.014 0.009 0.005 0.022 0.011 0.011 1.8E+04 1.0E+04 7.2E+03 2.8E+03 8.0E+03 2.7E+03 5.3E+03
12 PT control 5.18 2.60 2.58 3.57 2.39 1.17 1.61 0.21 1.40 0.023 0.011 0.011 0.016 0.010 0.005 0.007 0.001 0.006 6.6E+04 2.2E+04 7.1E+03 1.5E+04 4.4E+04 5.9E+03 3.8E+04
13 Term control 14.03 4.01 9.97 3.51 1.55 1.90 10.52 2.45 8.07 0.028 0.008 0.0199 0.007 0.003 0.004 0.021 0.005 0.016 4.8E+04 2.7E+04 1.6E+04 1.1E+04 2.7E+04 1.1E+04 1.0E+04
14 Term control 8.75 4.28 4.46 3.85 2.23 1.62 4.90 2.05 2.84 0.024 0.012 0.0124 0.011 0.006 0.005 0.014 0.006 0.008 2.5E+04 1.4E+04 4.4E+03 9.1E+03 1.1E+04 4.1E+03 6.9E+03
15 Term control 12.00 4.77 7.23 3.93 2.60 1.33 8.07 2.18 5.90 0.017 0.007 0.0103 0.006 0.004 0.002 0.012 0.003 0.008 2.5E+04 7.3E+03 3.9E+03 3.4E+03 1.8E+04 1.2E+04 6.0E+03
16 Term control 12.80 6.70 6.10 6.37 3.78 2.59 6.43 2.92 3.51 0.024 0.012 0.0113 0.012 0.007 0.005 0.012 0.005 0.007 2.9E+04 1.5E+04 1.1E+04 3.8E+03 1.4E+04 3.4E+03 1.1E+04
17 Term control 15.75 9.70 5.67 6.30 4.03 2.27 9.07 5.67 3.40 0.025 0.015 0.0090 0.010 0.006 0.004 0.014 0.009 0.005 3.7E+04 1.6E+04 6.2E+03 1.0E+04 2.0E+04 1.3E+04 7.0E+03
18 Term control 16.99 6.82 10.17 9.42 4.34 5.08 7.56 2.48 5.08 0.027 0.011 0.0164 0.015 0.007 0.008 0.012 0.004 0.008 3.1E+04 1.3E+04 9.5E+03 3.7E+03 1.8E+04 7.1E+03 1.1E+04
19 Term control 23.31 10.97 12.34 4.03 2.29 1.74 19.28 8.68 10.60 0.038 0.018 0.0199 0.007 0.004 0.003 0.031 0.014 0.017 4.9E+04 6.9E+03 3.5E+03 3.4E+03 4.2E+04 2.9E+04 1.3E+04
20 Term control 13.64 2.30 11.34 4.19 1.94 2.25 9.45 0.36 9.09 0.030 0.005 0.0252 0.009 0.004 0.005 0.021 0.001 0.020 2.4E+04 8.9E+03 4.2E+03 4.8E+03 1.5E+04 1.6E+03 1.4E+04
21 Term control 8.72 3.19 5.54 3.92 2.35 1.57 4.80 0.83 3.97 0.018 0.007 0.0113 0.008 0.005 0.003 0.010 0.002 0.008 2.6E+04 6.3E+03 4.1E+03 2.2E+03 2.0E+04 1.4E+04 6.1E+03
22 Term control 11.47 5.70 5.77 5.08 3.22 1.86 6.39 2.48 3.91 0.019 0.009 0.0093 0.008 0.005 0.003 0.010 0.004 0.006 6.7E+04 4.7E+03 2.5E+03 2.2E+03 6.2E+04 2.7E+04 3.5E+04
23 Term control 8.50 4.62 3.84 4.05 2.79 1.26 4.42 1.84 2.58 0.025 0.014 0.0113 0.012 0.008 0.004 0.013 0.005 0.008 3.3E+04 1.4E+04 9.6E+03 4.8E+03 1.8E+04 8.0E+03 1.0E+04
24 Term control 21.12 14.27 6.66 11.07 8.38 2.69 9.60 5.89 3.97 0.033 0.022 0.0104 0.017 0.013 0.004 0.015 0.009 0.006 4.3E+04 2.2E+04 8.6E+03 1.3E+04 1.8E+04 4.4E+03 1.6E+04
25 Term control 21.70 14.70 6.79 13.16 10.01 3.15 8.33 4.69 3.64 0.031 0.021 0.0097 0.019 0.014 0.005 0.012 0.007 0.005 3.5E+04 1.7E+04 1.4E+04 3.6E+03 1.8E+04 1.0E+04 8.1E+03
TOTALS (cm3) PSI (µm3)VOL. DENSITIES
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CASE DIAGNOSIS  VOL. SK
SV       
&       
IMV 
MV      
&        
TV 
 VOL 
APOP. SK
SV       
&        
IMV 
MV      
&        
TV
VOL     
NON-
APOP. SK
SV      
&       
IMV 
MV       
&        
TV
VOL. SK
SV       
&        
IMV 
MV      
&        
TV
VOL. 
APOP.SK
SV        
&         
IMV 
MV        
&         
TV
 VOL     
NON-
APOP. SK
SV       
&        
IMV
MV       
&        
TV
TOTAL 
PSI
TOTAL 
APOP. PSI
SV        
&         
IMV
MV      
&        
TV
TOTAL 
NON-
APOP. PSI
SV        
&         
IMV
MV       
&         
TV
1 PET + HELLP 3.80 1.37 2.43 2.80 1.09 1.70 1.00 0.27 0.73 0.029 0.011 0.019 0.022 0.008 0.013 0.008 0.002 0.006 1.9E+04 9.6E+03 6.0E+03 3.6E+03 9.8E+03 6.0E+03 3.8E+03
2 PET 14.70 9.16 5.54 6.85 5.29 1.55 7.85 3.86 3.99 0.035 0.022 0.013 0.016 0.013 0.004 0.019 0.009 0.010 3.4E+04 1.0E+04 8.2E+03 1.9E+03 2.4E+04 1.5E+04 8.4E+03
3 PET 5.75 3.65 2.00 1.50 0.90 0.65 4.10 2.75 1.35 0.023 0.015 0.008 0.006 0.004 0.003 0.016 0.011 0.005 1.9E+04 4.7E+03 2.0E+03 2.7E+03 1.4E+04 1.3E+04 1.9E+03
4 PET 9.28 3.34 5.80 3.51 1.22 2.29 5.51 2.12 3.51 0.032 0.012 0.020 0.012 0.004 0.008 0.019 0.007 0.012 2.5E+04 8.1E+03 4.7E+03 3.5E+03 1.7E+04 3.4E+03 1.3E+04
5 PET + HELLP 6.19 2.37 3.95 4.68 2.00 2.81 1.51 0.36 1.14 0.024 0.009 0.015 0.018 0.008 0.011 0.006 0.001 0.004 2.9E+04 1.2E+04 3.6E+03 7.9E+03 1.7E+04 1.3E+04 3.9E+03
6 PET + HELLP 14.70 4.97 9.66 10.15 3.99 6.23 4.55 0.98 3.43 0.042 0.014 0.028 0.029 0.011 0.018 0.013 0.003 0.010 2.8E+04 1.3E+04 3.3E+03 9.9E+03 1.4E+04 5.8E+03 8.5E+03
7 PET 8.26 3.55 4.70 4.19 1.98 2.21 4.06 1.57 2.50 0.026 0.011 0.015 0.013 0.006 0.007 0.013 0.005 0.008 2.9E+04 1.2E+04 6.5E+03 5.7E+03 1.7E+04 9.0E+03 7.6E+03
8 PET 7.94 1.73 6.21 5.34 1.12 4.22 2.59 0.61 1.98 0.025 0.005 0.019 0.017 0.004 0.013 0.008 0.002 0.006 2.6E+04 1.0E+04 2.6E+03 7.7E+03 1.6E+04 3.1E+03 1.3E+04
9 PET + HELLP 12.24 5.76 6.48 6.28 3.44 2.84 5.96 2.32 3.64 0.031 0.014 0.016 0.016 0.009 0.007 0.015 0.006 0.009 2.1E+04 7.3E+03 4.6E+03 2.7E+03 1.3E+04 6.5E+03 6.8E+03
10 PET 12.33 4.34 8.03 6.38 2.85 3.61 5.95 1.49 4.42 0.029 0.010 0.019 0.015 0.007 0.009 0.014 0.004 0.010 4.8E+04 2.7E+04 1.8E+04 9.1E+03 2.1E+04 1.4E+04 6.7E+03
11 PET 6.19 1.67 4.29 2.28 0.57 1.47 3.91 1.10 2.81 0.016 0.004 0.011 0.006 0.002 0.004 0.010 0.003 0.007 2.8E+04 6.2E+03 3.6E+03 2.6E+03 2.1E+04 3.1E+03 1.8E+04
12 PET 4.89 1.29 3.60 1.38 0.39 0.99 3.51 0.90 2.61 0.016 0.004 0.0120 0.005 0.001 0.003 0.012 0.003 0.009 1.5E+04 4.4E+03 9.6E+03 3.0E+03 1.0E+04 7.0E+03 3.4E+03
13 PET 15.60 8.28 7.68 6.60 4.50 2.46 9.00 3.78 5.22 0.026 0.014 0.0128 0.011 0.008 0.004 0.015 0.006 0.009 4.8E+04 1.3E+04 8.0E+03 4.9E+03 3.5E+04 2.5E+04 1.0E+04
14 PET + HELLP 9.88 5.36 4.37 4.22 2.01 2.20 5.70 3.34 2.17 0.026 0.014 0.0115 0.011 0.005 0.006 0.015 0.009 0.006 5.1E+04 1.1E+04 7.2E+03 3.7E+03 4.0E+04 2.0E+04 2.0E+04
15 PET 14.30 4.51 9.74 8.25 1.76 6.49 6.05 2.75 3.25 0.026 0.008 0.0177 0.015 0.003 0.012 0.011 0.005 0.006 2.5E+04 1.6E+04 8.3E+03 7.6E+03 9.4E+03 2.7E+03 6.7E+03
16 PET 18.98 3.45 15.53 9.32 1.38 7.94 9.66 2.07 7.59 0.033 0.006 0.0270 0.016 0.002 0.014 0.017 0.004 0.013 3.7E+04 1.4E+04 4.6E+03 9.5E+03 2.2E+04 1.1E+04 1.1E+04
17 PET 15.71 5.51 10.20 8.50 2.11 6.39 7.21 3.40 3.81 0.031 0.011 0.0198 0.017 0.004 0.012 0.014 0.007 0.007 5.7E+04 2.2E+04 1.4E+04 7.5E+03 3.5E+04 2.0E+04 1.5E+04
1 IUGR 5.32 2.64 2.68 2.42 1.10 1.32 2.90 1.54 1.36 0.024 0.012 0.012 0.011 0.005 0.006 0.013 0.007 0.006 2.7E+04 5.6E+03 3.6E+03 2.0E+03 2.2E+04 1.8E+04 3.1E+03
2 IUGR 3.71 2.19 1.52 2.88 1.68 1.20 0.82 0.51 0.32 0.029 0.017 0.012 0.023 0.013 0.010 0.007 0.004 0.003 1.7E+04 6.3E+03 3.5E+03 2.9E+03 1.1E+04 8.1E+03 2.7E+03
3 IUGR 4.36 2.70 1.66 1.91 1.42 0.49 2.45 1.28 1.17 0.024 0.015 0.009 0.011 0.008 0.003 0.014 0.007 0.007 2.0E+04 7.8E+03 4.5E+03 3.2E+03 1.2E+04 7.1E+03 5.0E+03
4 IUGR 3.00 1.32 1.69 2.00 1.05 0.98 1.00 0.27 0.71 0.030 0.013 0.017 0.020 0.011 0.010 0.010 0.003 0.007 3.6E+04 1.6E+04 9.6E+03 6.8E+03 2.0E+04 6.7E+03 1.3E+04
5 IUGR 6.93 4.19 2.79 5.12 2.49 2.62 1.82 1.70 0.17 0.042 0.025 0.017 0.031 0.015 0.016 0.011 0.010 0.001 2.7E+04 1.5E+04 9.5E+03 5.2E+03 1.3E+04 6.8E+03 5.8E+03
6 IUGR 5.09 3.78 1.31 4.22 3.63 0.59 0.87 0.15 0.72 0.034 0.025 0.0087 0.028 0.024 0.004 0.006 0.001 0.005 3.5E+04 1.4E+04 5.2E+03 9.1E+03 2.1E+04 7.0E+03 1.4E+04
7 IUGR 6.87 4.14 2.73 3.81 2.16 1.65 3.06 1.98 1.08 0.023 0.014 0.0091 0.013 0.007 0.006 0.010 0.007 0.004 1.3E+04 3.0E+03 1.5E+03 1.5E+03 1.0E+04 4.8E+03 5.6E+03
8 IUGR 8.82 5.61 3.21 6.56 4.63 1.93 2.26 0.98 1.28 0.026 0.017 0.0095 0.019 0.014 0.006 0.007 0.003 0.004 5.2E+04 3.5E+04 7.5E+03 2.7E+04 1.7E+04 1.6E+04 1.6E+03
9 IUGR 9.42 4.56 4.87 4.49 2.34 2.15 4.93 2.22 2.71 0.030 0.015 0.0156 0.014 0.008 0.007 0.016 0.007 0.009 6.7E+04 1.1E+04 5.5E+03 5.2E+03 5.6E+04 3.5E+04 2.1E+04
PSI (µm3)VOL. DENSITIESTOTALS (cm3)
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CASE DIAGNOSIS  VOL. SK
SV       
&       
IMV 
MV      
&        
TV 
 VOL 
APOP. SK
SV       
&        
IMV 
MV      
&        
TV
VOL     
NON-
APOP. SK
SV      
&       
IMV 
MV       
&        
TV
VOL. SK
SV       
&        
IMV 
MV      
&        
TV
VOL. 
APOP.SK
SV        
&         
IMV 
MV       
&        
TV
 VOL     
NON-APOP. 
SK
SV       
&        
IMV
MV       
&        
TV
TOTAL PSI TOTAL APOP. PSI
SV        
&         
IMV
MV      
&        
TV
TOTAL 
NON-
APOP. PSI
SV        
&         
IMV
MV       
&         
TV
1 IUGR + PET 3.65 2.61 1.10 1.48 1.11 0.37 2.17 1.50 0.73 0.029 0.021 0.009 0.012 0.009 0.003 0.017 0.012 0.006 3.0E+04 2.0E+04 1.8E+04 1.4E+03 7.9E+03 7.3E+03 3.5E+03
2 IUGR + PET + HELLP 5.96 3.17 2.79 3.14 1.77 1.37 2.82 1.40 1.43 0.040 0.021 0.019 0.021 0.012 0.009 0.019 0.009 0.010 5.7E+04 1.2E+04 6.2E+03 5.5E+03 4.5E+04 2.9E+04 1.6E+04
3 IUGR + PET 4.78 1.17 3.62 3.50 1.17 2.34 1.28 0.00 1.28 0.030 0.007 0.023 0.022 0.007 0.015 0.008 0.000 0.008 2.2E+04 1.5E+04 9.8E+03 5.2E+03 7.4E+03 0.0E+00 7.4E+03
4 IUGR + PET 4.02 3.32 0.70 1.92 1.92 0.00 2.09 1.39 0.70 0.031 0.026 0.005 0.015 0.015 0.000 0.016 0.011 0.005 1.5E+04 3.1E+03 2.4E+03 6.6E+02 1.2E+04 6.1E+03 6.1E+03
5 IUGR + PET 6.18 4.44 1.74 2.53 1.94 0.59 3.65 2.51 1.14 0.028 0.020 0.008 0.012 0.009 0.003 0.017 0.011 0.005 3.2E+04 1.0E+04 5.3E+03 5.0E+03 2.2E+04 8.4E+03 1.3E+04
6 IUGR + PET 2.77 0.95 1.95 2.08 0.80 1.41 0.69 0.15 0.54 0.028 0.010 0.020 0.021 0.008 0.014 0.007 0.002 0.006 2.8E+04 1.1E+04 3.0E+03 7.6E+03 1.7E+04 7.4E+03 9.8E+03
7 IUGR + PET 4.13 1.02 3.11 2.61 0.69 1.92 1.52 0.33 1.19 0.028 0.007 0.021 0.017 0.005 0.013 0.010 0.002 0.008 2.4E+04 1.7E+04 1.3E+04 3.5E+03 6.7E+03 2.9E+03 3.8E+03
8 IUGR + PET 3.75 2.78 1.01 2.06 1.50 0.56 1.73 1.28 0.45 0.025 0.019 0.007 0.014 0.010 0.004 0.012 0.009 0.003 2.2E+04 8.7E+03 3.0E+03 5.7E+03 1.3E+04 9.0E+03 3.8E+03
9 IUGR + PET 3.13 1.13 2.00 1.89 0.79 1.09 1.25 0.34 0.91 0.024 0.009 0.015 0.015 0.006 0.008 0.010 0.003 0.007 3.7E+04 6.0E+03 2.8E+03 3.2E+03 3.1E+04 2.2E+04 9.4E+03
10 IUGR + PET + HELLP 5.84 3.09 2.76 2.41 0.97 1.44 3.44 2.12 1.32 0.040 0.021 0.019 0.017 0.007 0.010 0.024 0.015 0.009 2.7E+04 6.1E+03 4.4E+03 1.7E+03 2.1E+04 1.9E+04 1.7E+03
11 IUGR + PET + HELLP 4.67 2.00 2.67 3.72 1.65 2.07 0.95 0.35 0.60 0.031 0.013 0.018 0.025 0.011 0.014 0.006 0.002 0.004 1.8E+04 8.4E+03 3.8E+03 4.6E+03 9.5E+03 5.8E+03 3.8E+03
12 IUGR + PET + HELLP 8.91 5.30 3.61 4.42 2.05 2.37 4.49 3.25 1.24 0.027 0.016 0.011 0.014 0.006 0.007 0.014 0.010 0.004 2.7E+04 1.2E+04 5.3E+03 6.3E+03 1.5E+04 9.7E+03 5.6E+03
13 IUGR + PET 3.15 1.92 1.22 1.13 0.74 0.39 2.02 1.18 0.83 0.024 0.015 0.009 0.009 0.006 0.003 0.016 0.009 0.006 4.1E+04 8.3E+03 7.0E+03 1.3E+03 3.3E+04 1.0E+04 2.3E+04
14 IUGR + PET 5.32 1.58 3.74 1.16 0.74 0.42 4.16 0.84 3.32 0.027 0.008 0.019 0.006 0.004 0.002 0.021 0.004 0.017 8.8E+04 8.1E+03 5.6E+03 2.6E+03 8.0E+04 7.2E+04 7.9E+03
15 IUGR + PET 6.07 3.08 2.99 2.55 1.83 0.73 3.52 1.25 2.27 0.028 0.014 0.014 0.012 0.008 0.003 0.016 0.006 0.010 3.6E+04 9.0E+03 5.4E+03 3.6E+03 2.7E+04 1.2E+04 1.5E+04
16 IUGR + PET 5.30 2.11 3.18 2.94 1.23 1.71 2.35 0.88 1.47 0.033 0.013 0.020 0.018 0.008 0.011 0.015 0.006 0.009 1.1E+05 1.1E+05 1.0E+05 6.5E+03 5.1E+03 2.6E+03 2.6E+03
17 IUGR + PET 4.88 2.74 2.14 3.06 1.92 1.14 1.82 0.82 1.00 0.024 0.014 0.011 0.015 0.010 0.006 0.009 0.004 0.005 3.3E+04 1.2E+04 5.1E+03 7.0E+03 2.1E+04 1.4E+04 6.7E+03
18 IUGR + PET 2.67 1.49 1.17 2.23 1.23 0.98 0.45 0.26 0.19 0.030 0.017 0.013 0.025 0.014 0.011 0.005 0.003 0.002 6.3E+04 1.7E+04 1.2E+04 4.6E+03 4.6E+04 2.1E+04 2.5E+04
19 IUGR + PET 7.45 1.27 6.29 3.59 0.66 2.79 4.14 0.61 3.51 0.027 0.005 0.023 0.013 0.002 0.010 0.015 0.002 0.013 3.6E+04 1.0E+04 1.4E+03 8.9E+03 2.6E+04 1.7E+04 8.5E+03
1 IUGR + PET 7.98 2.55 5.43 4.68 1.45 3.23 3.30 1.10 2.20 0.032 0.010 0.022 0.019 0.006 0.013 0.013 0.004 0.009 3.2E+04 1.2E+04 4.5E+03 7.4E+03 2.0E+04 1.6E+04 3.7E+03
2 IUGR + PET 9.84 2.34 7.34 3.73 1.39 2.34 6.15 0.94 5.00 0.024 0.006 0.018 0.009 0.003 0.006 0.015 0.002 0.012 1.7E+04 8.2E+03 2.4E+03 5.8E+03 8.8E+03 3.6E+03 5.1E+03
3 IUGR + PET 10.01 5.87 4.10 6.37 4.73 1.50 3.64 1.14 2.59 0.022 0.013 0.009 0.014 0.010 0.003 0.008 0.003 0.006 4.2E+04 2.0E+04 8.2E+03 1.2E+04 2.2E+04 8.1E+03 1.4E+04
4 IUGR + PET 6.26 1.94 4.32 5.74 1.70 4.03 0.53 0.24 0.29 0.026 0.008 0.018 0.024 0.007 0.017 0.002 0.001 0.001 3.7E+04 2.3E+04 1.2E+04 1.1E+04 1.3E+04 6.9E+03 6.5E+03
5 IUGR + PET 8.56 4.08 4.48 4.48 2.36 2.12 4.08 1.72 2.36 0.021 0.010 0.011 0.011 0.006 0.005 0.010 0.004 0.006 1.2E+04 7.5E+03 3.5E+03 4.0E+03 4.2E+03 2.6E+03 1.6E+03
6 IUGR + PET 13.34 7.36 5.98 8.46 4.74 3.73 4.88 2.62 2.25 0.029 0.016 0.013 0.018 0.010 0.008 0.011 0.006 0.005 3.2E+04 2.1E+04 1.6E+04 4.8E+03 1.1E+04 7.9E+03 2.6E+03
PSI (µm3)VOL. DENSITIESTOTALS (cm3)
 
 
 
2. SIDS Cohort 
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CASE DIAGNOSIS  VOL. SK SV INT TV
 VOL 
APOP. 
SK
SV INT TV
VOL    
NON-
APOP. 
SK
SV INT TV VOL. SK SV INT TV
VOL. 
APOP. 
SK
SV INT TV
VOL     
NON-
APOP. 
SK
SV INT TV TOTAL PSI
TOTAL 
APOP. 
PSI
SV INT TV
TOTAL 
NON-
APOP. PSI
SV INT TV
1 Term Control 6.2 1.77 2.45 2.01 3.81 1.36 1.30 1.15 2.42 0.41 1.15 0.86 0.021 0.006 0.0083 0.007 0.013 0.005 0.004 0.004 0.008 0.001 0.004 0.003 1.3E+04 3.9E+03 1.8E+04 1.3E+03 1.4E+03 9.4E+03 5.3E+03 2.0E+03 2.1E+03
2 Term Control 6.1 1.62 2.45 2.05 4.14 1.48 1.62 1.04 1.98 0.14 0.83 1.01 0.017 0.005 0.0068 0.006 0.011 0.004 0.005 0.003 0.006 0.000 0.002 0.003 1.7E+04 4.3E+03 6.2E+03 1.3E+03 1.3E+03 1.3E+04 7.3E+03 2.2E+03 3.3E+03
3 Term Control 7.5 1.82 3.89 1.67 2.51 0.43 1.53 0.55 4.87 1.38 2.36 1.12 0.026 0.006 0.0135 0.006 0.009 0.002 0.005 0.002 0.017 0.005 0.008 0.004 2.9E+04 1.5E+04 9.8E+03 6.1E+03 1.9E+03 1.5E+04 6.8E+03 5.6E+03 2.3E+03
4 Term Control 8.2 2.86 4.85 0.42 4.98 2.60 2.01 0.37 3.15 0.27 2.84 0.05 0.031 0.011 0.0183 0.002 0.019 0.010 0.008 0.001 0.012 0.001 0.011 0.000 3.5E+04 1.7E+04 2.4E+03 5.0E+03 1.0E+03 1.8E+04 4.5E+03 1.2E+04 2.1E+03
5 Term Control 8.9 2.21 4.97 1.65 4.67 1.76 2.24 0.68 4.16 0.46 2.73 0.97 0.033 0.008 0.0184 0.006 0.017 0.007 0.008 0.003 0.015 0.002 0.010 0.004 4.3E+04 2.2E+04 5.3E+03 4.1E+03 1.1E+04 2.1E+04 2.4E+03 8.4E+03 9.8E+03
6 Term Control 4.6 1.35 2.73 0.25 2.17 1.35 0.56 0.25 2.17 0.00 2.17 0.00 0.025 0.007 0.0150 0.001 0.012 0.007 0.003 0.001 0.013 0.000 0.012 0.000 3.3E+04 1.4E+04 3.0E+03 8.8E+03 2.2E+03 1.8E+04 8.3E+02 9.9E+03 7.7E+03
7 Term Control 9.7 1.68 5.34 2.65 4.24 1.52 1.81 0.91 5.44 0.16 3.53 1.75 0.030 0.005 0.0165 0.008 0.013 0.005 0.006 0.003 0.017 0.001 0.011 0.005 4.5E+04 2.0E+04 1.3E+04 3.5E+03 4.5E+03 2.5E+04 1.5E+04 4.3E+03 6.2E+03
8 Term Control 7.2 1.16 5.20 0.76 4.55 0.65 3.29 0.60 2.58 0.52 1.90 0.16 0.032 0.005 0.0232 0.003 0.020 0.003 0.015 0.003 0.011 0.002 0.009 0.001 4.2E+04 1.2E+04 3.0E+03 5.0E+03 5.9E+03 3.0E+04 2.2E+04 3.2E+03 4.5E+03
9 Term Control 4.1 0.84 2.24 0.95 1.81 0.68 0.95 0.18 2.21 0.16 1.29 0.77 0.018 0.004 0.0099 0.004 0.008 0.003 0.004 0.001 0.010 0.001 0.006 0.003 2.6E+04 6.3E+03 2.8E+03 4.3E+03 3.7E+02 2.0E+04 6.0E+03 1.1E+04 2.7E+03
10 Term Control 5.3 0.42 4.63 0.11 2.29 0.42 1.87 0.00 2.87 0.00 2.76 0.11 0.019 0.002 0.0166 0.000 0.008 0.002 0.007 0.000 0.010 0.000 0.010 0.000 6.7E+04 4.7E+03 4.4E+03 4.2E+03 0.0E+00 6.2E+04 0.0E+00 3.2E+04 3.0E+04
11 Term Control 5.3 0.91 3.56 0.93 1.66 0.77 0.59 0.30 3.74 0.14 2.97 0.62 0.030 0.005 0.0200 0.005 0.009 0.004 0.003 0.002 0.021 0.001 0.017 0.004 2.4E+04 8.9E+03 3.8E+03 2.2E+03 2.6E+03 1.5E+04 1.6E+03 7.0E+03 6.5E+03
12 Term Control 10.7 2.14 7.56 0.87 1.83 0.76 0.87 0.20 8.74 1.38 6.69 0.67 0.038 0.008 0.0269 0.003 0.006 0.003 0.003 0.001 0.031 0.005 0.024 0.002 4.9E+04 6.9E+03 5.3E+03 4.2E+03 1.4E+03 4.2E+04 2.2E+04 1.8E+04 2.7E+03
1 SIDS NBW 9.3 2.84 4.88 1.37 6.34 2.31 3.19 0.84 2.75 0.53 1.69 0.53 0.021 0.006 0.0110 0.003 0.014 0.005 0.007 0.002 0.006 0.001 0.004 0.001 1.5E+04 7.2E+03 1.7E+03 2.5E+03 3.0E+03 7.3E+03 3.4E+03 2.1E+03 1.9E+03
2 SIDS NBW 7.7 2.70 3.67 1.45 3.67 1.67 1.77 0.23 4.15 1.03 1.90 1.22 0.024 0.008 0.0114 0.005 0.011 0.005 0.006 0.001 0.013 0.003 0.006 0.004 2.2E+04 6.3E+03 1.9E+03 3.2E+03 1.2E+03 1.6E+04 1.8E+03 7.3E+03 6.9E+03
3 SIDS NBW 10.2 2.99 4.84 2.20 3.98 1.42 1.73 0.83 6.06 1.57 3.11 1.38 0.026 0.008 0.0123 0.006 0.010 0.004 0.004 0.002 0.015 0.004 0.008 0.004 1.8E+04 8.3E+03 3.4E+03 2.7E+03 2.3E+03 9.5E+03 4.2E+03 2.8E+03 2.4E+03
4 SIDS NBW 7.4 2.10 4.38 0.74 5.25 1.75 2.98 0.53 1.96 0.35 1.40 0.21 0.021 0.006 0.0125 0.002 0.015 0.005 0.009 0.002 0.006 0.001 0.004 0.001 3.3E+04 6.9E+03 2.7E+03 1.5E+03 2.6E+03 2.6E+04 3.1E+03 2.7E+03 2.1E+04
5 SIDS NBW 8.8 2.19 4.71 1.93 6.06 2.19 2.66 1.20 2.77 0.00 2.04 0.73 0.024 0.006 0.0129 0.005 0.017 0.006 0.007 0.003 0.008 0.000 0.006 0.002 3.4E+04 9.8E+03 4.2E+03 1.1E+03 4.4E+03 2.4E+04 0.0E+00 9.1E+03 1.5E+04
6 SIDS NBW 5.8 1.23 3.28 1.38 4.38 1.10 2.27 1.01 1.51 0.13 1.01 0.37 0.027 0.006 0.0152 0.006 0.020 0.005 0.011 0.005 0.007 0.001 0.005 0.002 2.7E+04 1.1E+04 6.0E+03 3.1E+03 1.7E+03 1.6E+04 7.7E+03 2.1E+03 5.9E+03
7 SIDS NBW 7.3 1.60 2.70 2.96 4.73 1.20 2.07 1.47 2.53 0.40 0.63 1.50 0.022 0.005 0.0081 0.009 0.014 0.004 0.006 0.004 0.008 0.001 0.002 0.005 2.7E+04 9.7E+03 3.5E+03 2.2E+03 4.0E+03 1.7E+04 6.3E+03 6.4E+03 4.4E+03
8 SIDS NBW 8.4 2.21 4.55 1.72 7.66 2.21 4.06 1.40 0.81 0.00 0.49 0.32 0.026 0.007 0.0140 0.005 0.024 0.007 0.013 0.004 0.002 0.000 0.002 0.001 1.7E+04 8.2E+03 3.9E+03 2.7E+03 1.5E+03 8.4E+03 0.0E+00 4.3E+03 4.1E+03
9 SIDS NBW 8.5 2.37 3.78 2.16 6.75 2.19 2.51 2.05 1.56 0.18 1.27 0.11 0.024 0.007 0.0107 0.006 0.019 0.006 0.007 0.006 0.004 0.001 0.004 0.000 5.0E+04 6.3E+03 2.6E+03 1.4E+03 2.3E+03 4.4E+04 7.6E+03 1.4E+03 3.5E+04
10 SIDS NBW 8.0 1.63 4.79 1.58 4.64 1.38 2.41 0.85 3.36 0.25 2.38 0.73 0.032 0.007 0.0191 0.006 0.018 0.006 0.010 0.003 0.013 0.001 0.010 0.003 1.9E+04 9.7E+03 1.9E+03 7.0E+03 7.9E+02 9.6E+03 2.8E+03 2.5E+03 4.3E+03
11 SIDS NBW 6.8 2.83 2.76 1.36 2.22 1.04 1.04 0.14 4.74 1.79 1.72 1.22 0.019 0.008 0.0077 0.004 0.006 0.003 0.003 0.000 0.013 0.005 0.005 0.003 1.6E+04 8.6E+03 1.8E+03 4.2E+03 2.6E+03 7.3E+03 3.4E+03 2.4E+03 1.5E+03
12 SIDS NBW 10.8 3.73 4.22 2.83 5.93 2.38 2.60 0.94 4.85 1.35 1.62 1.89 0.024 0.008 0.0094 0.006 0.013 0.005 0.006 0.002 0.011 0.003 0.004 0.004 2.5E+04 1.4E+04 6.4E+03 4.0E+03 3.6E+03 1.1E+04 5.0E+03 2.5E+03 3.6E+03
13 SIDS LBW 8.7 3.33 5.20 0.22 6.37 2.98 3.39 0.00 2.38 0.35 1.81 0.22 0.032 0.012 0.0192 0.001 0.023 0.011 0.013 0.000 0.009 0.001 0.007 0.001 2.5E+04 4.9E+03 8.0E+02 4.1E+03 0.0E+00 2.0E+04 6.8E+03 3.6E+03 9.9E+03
14 SIDS LBW 7.2 2.43 3.91 1.01 5.07 2.43 2.43 0.22 2.28 0.00 1.49 0.80 0.020 0.007 0.0108 0.003 0.014 0.007 0.007 0.001 0.006 0.000 0.004 0.002 2.0E+04 8.8E+03 6.1E+03 1.6E+03 1.1E+03 1.1E+04 0.0E+00 7.7E+03 3.6E+03
15 SIDS LBW 6.3 1.98 3.60 0.88 2.01 1.29 0.71 0.00 4.45 0.69 2.89 0.88 0.023 0.007 0.0131 0.003 0.007 0.005 0.003 0.000 0.016 0.003 0.011 0.003 3.9E+04 1.2E+04 5.3E+03 6.8E+03 0.0E+00 2.7E+04 4.3E+03 2.0E+04 2.0E+03
16 SIDS LBW 4.4 0.90 2.04 1.34 3.78 0.90 1.80 1.07 0.50 0.00 0.23 0.27 0.021 0.004 0.0097 0.006 0.018 0.004 0.009 0.005 0.002 0.000 0.001 0.001 1.0E+04 7.9E+03 7.9E+03 6.0E+03 1.9E+03 2.2E+03 0.0E+00 1.0E+03 1.1E+03
17 SIDS LBW 6.6 1.44 4.18 0.93 5.87 1.44 3.70 0.73 0.68 0.00 0.48 0.20 0.037 0.008 0.0235 0.005 0.033 0.008 0.021 0.004 0.004 0.000 0.003 0.001 1.7E+04 7.7E+03 3.7E+03 2.5E+03 1.8E+03 9.6E+03 0.0E+00 3.4E+03 6.2E+03
18 SIDS LBW 8.2 1.10 1.95 4.44 3.08 0.57 1.23 1.29 4.40 0.53 0.72 3.15 0.026 0.004 0.0062 0.014 0.012 0.002 0.004 0.004 0.014 0.002 0.002 0.010 2.8E+04 1.4E+04 6.0E+03 4.7E+03 3.2E+03 1.4E+04 1.9E+03 8.9E+03 3.4E+03
19 SIDS LBW 6.4 2.29 2.39 1.75 5.60 2.29 1.88 1.43 0.83 0.00 0.51 0.32 0.020 0.007 0.0075 0.006 0.018 0.007 0.006 0.005 0.003 0.000 0.002 0.001 3.1E+04 1.6E+04 1.9E+03 9.5E+03 4.8E+03 1.5E+04 9.0E+03 4.0E+03 1.5E+03
20 SIDS LBW 7.3 1.51 4.96 0.70 4.87 1.34 3.22 0.31 2.30 0.17 1.74 0.39 0.026 0.005 0.0177 0.003 0.017 0.005 0.012 0.001 0.008 0.001 0.006 0.001 3.2E+04 1.2E+04 5.6E+04 4.9E+03 1.6E+03 2.0E+04 4.7E+03 1.3E+04 3.0E+03
21 SIDS LBW 10.4 2.42 5.73 2.31 4.70 1.76 2.18 0.76 5.77 0.66 3.56 1.55 0.030 0.007 0.0166 0.007 0.014 0.005 0.006 0.002 0.017 0.002 0.010 0.005 4.2E+04 1.8E+04 1.1E+04 2.3E+03 4.5E+03 2.5E+04 1.4E+04 5.2E+03 5.1E+03
22 SIDS LBW 9.0 1.91 4.98 2.00 5.36 1.59 2.78 0.99 3.53 0.32 2.20 1.01 0.031 0.007 0.0172 0.007 0.019 0.006 0.010 0.003 0.012 0.001 0.008 0.004 4.2E+04 7.1E+03 2.3E+03 2.5E+03 2.3E+03 3.5E+04 1.4E+03 3.1E+04 2.7E+03
23 SIDS LBW 4.1 1.16 2.70 0.22 3.00 1.02 1.88 0.10 1.08 0.14 0.82 0.12 0.042 0.012 0.0276 0.002 0.031 0.010 0.019 0.001 0.011 0.001 0.008 0.001 4.0E+04 1.9E+04 4.5E+03 1.3E+04 1.8E+03 2.1E+04 8.8E+03 9.6E+03 2.5E+03
24 SIDS LBW 6.1 1.18 3.61 1.22 3.65 0.98 2.10 0.57 2.36 0.20 1.51 0.65 0.031 0.006 0.0184 0.006 0.019 0.005 0.011 0.003 0.012 0.001 0.008 0.003 2.7E+04 1.5E+04 8.0E+03 3.4E+03 3.3E+03 1.3E+04 2.6E+03 3.3E+03 6.7E+03
PSI (µm3)VOL. DENSITIESTOTALS (cm3)
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In order to understand the pathological basis of abnormal villous trophoblast development in diseased
placentas, the organ must be sampled by non-biased methods and subject to analysis by stereological
tools. This approach permits quantiﬁcation of cytotrophoblast density and syncytiotrophoblast structure
including evidence of apoptotic shedding via syncytial knots. The stereological quantiﬁcation of cells
(or their) nuclei requires that each should be unambiguously identiﬁed and counted within a deﬁned
volume of tissue. A major limitation of such studies at present is the inability to accurately identify and
phenotype subsets of villous cytotrophoblasts that either proliferate or are destined to fuse into the
overlying syncytiotrophoblast.
We describe the development of a novel double immuno-labelling protocol to selectively identify
proliferating villous cytotrophoblast cells in human placental villi using thick (25 mm) parafﬁn sections
suitable for stereological quantiﬁcation. Cytotrophoblast cells were selectively stained using a mono-
clonal anti-cytokeratin 7 (CK 7) antibody without antigen retrieval, followed by nuclear Ki-67 co-
localisation. Both antibodies displayed full depth penetration with sharp, clearly deﬁned staining
precipitates and no cross-reactivity. This double immuno-labelling protocol is reproducible, cost effective
and time efﬁcient (8 h). Use of a variety of antibodies following antigen retrieval will be a signiﬁcant
advancement in the ability to accurately quantify sub-populations of villous cytotrophoblast in normal
and pathological placentas.
Crown Copyright  2009 Published by Elsevier Ltd. All rights reserved.1. Introduction
The regulation of villous trophoblast turnover in human preg-
nancy is of increasing importance especially in pathological preg-
nancies [1–3]. Considerable molecular knowledge in normal
trophoblast development and pathologically mediated dysregula-
tion is available [4]. Yet to date few studies have been able to
integrate speciﬁc changes occurring at a molecular level with
predicted structural changes in the syncytiotrophoblast layer
responsible for fetal growth and maternal well-being. This dual
approach of integrating molecular techniques with stereological
quantiﬁcation within a single placenta therefore provides a physi-
ologically integrated model to study trophoblast development andh, NPIMR, Block Y, Level 3,
: þ44 (0) 20 8869 3270.
009 Published by Elsevier Ltd. Alldysregulation. The numerical correlation between proliferation,
fusion and apoptotic shedding within the trophoblast compart-
ment is paramount and can be achieved using stereological
methods.
In order to investigate trophoblast kinetics using stereological
techniques two factors need to be met 1) each cell or nucleus to be
counted must be unambiguously identiﬁed and 2) cells or nuclei
must be counted within a deﬁned volume of tissue (i.e. the area of
the counting frame multiplied by the disector height, see equation
(1)) within which they reside. Counting within a deﬁned volume of
tissue at this level provides a numerical density estimate (Nv),
which then multiplied by total placental volume, provides an
estimate for the total number of cells within the entire placenta
(Ntot).
The ability to accurately identify and phenotype the villous
cytotrophoblast population from the overlying syncytiotrophoblast
histologically has been attempted using morphological features or
various antibody markers. Reliable identiﬁcation based onrights reserved.
K. Widdows et al. / Placenta 30 (2009) 735–738736morphology alone is difﬁcult, especially as villous cytotrophoblast
changes from a cuboidal-like continuous layer of cells to a discon-
tinuous layer at term. Identiﬁcation based on antibody markers, for
example, E-cadherin [5], hepatocyte growth factor inhibitor
(HAI-1) [6] and cytokeratin 7 [7] have all been used in a variety of
applications. Despite their speciﬁcity for cytotrophoblasts, these
markers are not exclusive displaying some cross-reactivity with the
syncytium and stromal cells. Since no generic marker with the
ability to consistently and accurately label cytotrophoblasts exists,
attempts were made to modify the staining procedure using
a monoclonal cytokeratin 7 antibody [8].
Stereological techniques have previously been employed to
quantify the number of cytotrophoblast cells and syncytiotropho-
blast nuclei based on their morphology and topography. Mayhew
and colleagues used a Gomori trichrome tinctorial stain to identify
different trophoblast populations using thin histological sections
[9]. By using the physical disector technique [10,11], which employs
two thin sections a known distance apart, these authors were able
to quantify the different population of nuclei within a deﬁned
volume of tissue. Although unbiased, this method is time
consuming since each pair of sections requires registration (see
Sterio 1984 [11] for a detailed explanation). A more efﬁcient
method for generating a deﬁned volume is the optical brick/dis-
ector technique [12,13], which employs a single thick (25 mm)
section. This can be achieved using resin sections; however, full
depth antibody penetration in thick resin sections is not possible.
To overcome these limitations, a method for the reliable and
consistent identiﬁcation of double immuno-histochemically
labelled proliferating cytotrophoblast cells in a thick (25 mm)
parafﬁn section, which fulﬁlled the criteria for stereological quan-
tiﬁcation was conceived. The ability to accurately and consistently
identify subsets of trophoblast cells in a deﬁned volume of
placental villous tissue is an important technical advance for future
quantitative analysis andwill provide invaluable insight into villous
trophoblast kinetics in pathological pregnancies.
2. Materials and methods
2.1. Tissue collection and preparation
Placental tissues from normal third trimester pregnancies were obtained from
Mount Sinai Hospital, Toronto, Canada, following local ethical approval and
informed patient consent. Uniform/systematic random placental samples were
taken as previously described [1,14], ﬁxed in 10% neutral buffered formalin for 48 h
processed and embedded into wax blocks. Parafﬁn sections were cut at 5 mm and
25 mm thickness and mounted onto 3-aminopropyltriethoxysilane (APTS) coated
slides (Sigma, UK) and dried at 60 C overnight.
2.2. Antibodies
Cytotrophoblast cells were immuno-localised using an anti-human mouse
monoclonal cytokeratin 7 [1:300] (clone OV-TL) antibody. Proliferating cyto-
trophoblast cells were visualised using amousemonoclonal antibody to Ki-67 [1:50]
(clone MIB-1). Both antibodies were obtained from Dako, Cambridge, UK.
2.3. Double-labelling of cytokeratin 7 and Ki-67
All incubations were carried out at room temperature (RT) and all reagents were
obtained from Vector labs, Peterborough, UK unless otherwise stated. A high salt
TBS-Twash buffer (100 mMTris, 300 mMNaCl, 0.05% Tween, pH 7.6) was used for all
washes during the double-labelling procedure to ensure minimal background
staining.
Localisation of cytokeratin 7 exclusively to the cytotrophoblast required omission
of antigen retrieval, necessitating it as the ﬁrst antibody in the double-labelling
procedure. Sections were dewaxed in xylene for 15 min and rehydrated through
descending alcohol concentrations following routine procedure. Endogenous
peroxide activitywas quenched by incubationwith 10% hydrogen peroxide (H2O2) in
methanol for 30 min, followed by washing with TBS-T (Sigma, UK) for 3 3 min.
Non-speciﬁc protein binding sites were blocked using 2.5% ready-to-use normal
horse serum for 20 min, immediately followed by a 20 min incubation with mAb CK
7. Sections were then incubated with Vector ImmPRESS anti-mouse polymerdetection reagent for 20 min, followed by extensive washing in TBS for 3 5 min.
Cytokeratin 7 was visualised using ImmPACT DAB (diaminobenzidine) incubated for
2 min, producing a brown end product; sections were then washed in deionised
water for 5 min.
Immediately after staining with CK 7, antigen retrieval was carried out on the
same sections to allow for labelling of the second antibody Ki-67. Slides were placed
in a coplin jar containing 20 mM citrate buffer, 2 mM EDTA, 0.05% Tween (Sigma,
UK), pH 6.2, heated to 90 C for 15 min, followed by cooling at RT, for a further
20 min. After washing in TBS-T for 3 3 min, non-speciﬁc proteins were blocked
using 2.5% ready-to-use normal horse serum for 30 min, followed by incubation
with mAb Ki-67 diluted in TBS for 2 h, and subsequently a 30 min incubation with
Vector ImmPRESS anti-mouse Ig polymer reagent. Sections were thoroughlywashed
with TBS-T for 3 5 min to remove unwanted polymer. Ki-67 was visualised using
a contrasting purple chromagen, Vector VIP, incubated for 2 min, followed by
immersion in deionised water for 10 min. Sections were then counterstained using
methyl green for 2 min at RT, differentiated in 0.05% acetic acid/acetone for 10 s,
rinsed in deionised water for 10 s, dehydrated in 95% and 100% ethanol (2 min each),
and ﬁnally cleared in xylene and mounted in DPX; excess DPX was used to avoid
sections ‘drying out’ due to their increased thickness.
2.4. Estimating numerical density using the optical brick technique
The double-labelled sections were used to obtain the numerical density of CK 7
and Ki-67 positive cytotrophoblast cells. Numerical density estimation was per-
formed with the aid of a BH2 Olympus light microscope (magniﬁcation 100 NA
1.25), a Heidenhain microcator (ND 281A) attached to the z-axis of the microscope
stage, and Kinetic Digital Stereology 5.0 software. An unbiased counting frame (UCF)
was applied under software control to each uniformly–randomly selected image
(ﬁeld of view) and the microcator set to zero. Each section was focused through in
the z-axis in a continuous motion; cells in the ﬁrst (0–5 mm) and last (20–25 mm)
5 mm of the 25 mm sections were not counted to avoid the lost cap effect [13],
generating a disector height of 15 mmwithin which cells were counted (veriﬁed by
the microcator). Cells positive for CK 7 (non-proliferating), and CK 7 with Ki-67
(proliferating), were counted provided they obeyed the rules of the UCF and were
within maximum focus within the 15 mm disector height (see Fig. 2). Approximately
10 ﬁelds of view per slide were sampled using a uniform random sampling approach
resulting in an average 50 ﬁelds of view per placenta.
Numerical density estimates were calculated using the following formula
(equation (1)):
Nv ¼
P
Q
P
P

Afh
 (1)
where (Nv) is numerical density,
P
Q is the total number of cells counted divided by
the total number of disectors
P
Pmultiplied by the volume of each disector i.e. area
of the unbiased counting (Af) and the disector height (h).
The total number of cells (Ntot) was estimated by multiplying numerical density
with total placenta volume (equation (2)):
Ntot ¼ Nv  Vref (2)
where (Vref) is the volume of the placenta estimated by ﬂuid displacement.3. Results and discussion
Cytokeratin 7 is an intermediate ﬁlament protein expressed in
epithelial cells. Although this monoclonal antibody stains both
villous cytotrophoblast cells and the overlying syncytiotrophoblast
in antigen-retrieved sections [15] we demonstrate the speciﬁc
localisation of CK 7 exclusively to the cytotrophoblast cytoplasm
when the antigen retrieval step is omitted (Fig. 1). Ki-67 was co-
localised to the nucleus of labelled villous cytotrophoblast cells
following antigen retrieval in this double-labelling protocol in
25 mm thick parafﬁn sections (Fig. 1). Both antibodies displayed full
depth penetration of the tissue sections permitting accurate iden-
tiﬁcation and future quantiﬁcation of proliferating cytotrophoblast
cells from other proliferating cell populations in the stromal
compartment of chorionic villi.
Each antibody in the double-labelling protocol was ﬁrst opti-
mised as a single stain on thin 5 mm parafﬁn sections and then
tested for full penetration and cytotrophoblast speciﬁcity in 25 mm
thick sections; once individually optimized, they were combined in
a sequential double-labelling protocol. This approach ensured
complete penetration of each antibody, minimal background
Fig. 1. Speciﬁc immuno-localisation of anti-cytokeratin 7 to the cytoplasm of cyto-
trophoblast cells (brown chromagen) displaying no cross-reactivity with overlying
syncytiotrophoblast nuclei (counterstained with methyl green) in term placenta.
White asterisk denotes proliferating cytotrophoblast cells (purple chromagen); yellow
asterisk denotes non-proliferating cytotrophoblast cells (5 mm sections, 400). Cross-
reactivity with the syncytium was not observed (arrow shows the clear delineation
between the labelled cytotrophoblast cell and syncytiotrophoblast nuclei).
Fig. 2. Counting the number of proliferating cytotrophoblast cells in 25 mm sections
double immuno-labelled with CK 7 and Ki-67 using the optical brick technique (A–C,
1000). An unbiased counting frame (UCF) (red and green lines) is randomly
superimposed onto each uniform-randomly sampled ﬁeld of view. As the section is
scanned through the z-axis within the disector height (i.e. 15 mm), each labelled
cytotrophoblast cell (brown chromagen) that comes into sharp focus and does not
intercept the red forbidden line of the UCF (cells marked with an asterisk) is counted
as a ‘new event’ (A, no.1, 2, and 3) (B, no. 4 and 5) (C, no.6). The number of cyto-
trophoblast cells co-localised with Ki-67 (purple and brown chromagen) is also
counted (A, no. 2, C no. 5). Hence, for this ﬁeld of view, 6 cytotrophoblast cells are
counted, 2 of which are positive for Ki-67. The sum of the counts (per placenta) is
then multiplied by the disector height (i.e. 15 mm area of the UCF) generating
a numerical density.
K. Widdows et al. / Placenta 30 (2009) 735–738 737staining and efﬁciency of time; the protocol can be carried out in
one day taking approximately 8 h for completion.
The most striking observation of this protocol was the reduction
in the CK 7 primary antibody concentration and decreased incu-
bation time required to achieve full depth selective staining of
villous cytotrophoblast in a 25 mm section when compared with
a 5 mm histological section. Conversely, staining for Ki-67 in a thick
section required increased incubation time to ensure full depth
antibody penetration following antigen retrieval. The Ki-67 antigen
retrieval solution concentration was also increased along with the
addition of detergents EDTA and Tween (Sigma, UK). These obser-
vations illustrate the inﬂuence of antigen location, whether nuclear
or cytoplasmic, in determining the optimal protocol when staining
thick parafﬁn sections of human placental villi.
The order of the antibodies in the sequential double-labelling
protocol was inﬂuenced by antigen retrieval requirements. Since
cytokeratin 7 localised selectively to villous cytotrophoblasts only
with the omission of antigen retrieval, this protocol had to be
performed prior to the required antigen retrieval step for nuclear
localisation of Ki-67, necessitating CK 7 as the ﬁrst labelling
protocol. Signiﬁcantly, this indicates that antigen-retrieved anti-
bodies can be used in conjunction with antibodies that do not
require this step in a sequential double-labelling procedure (not
applicable to simultaneous double-labelling procedures), provided
the chromagen used to visualise the ﬁrst antigen canwithstand the
physical parameters of antigen retrieval in the second protocol.
Additionally, the colours of the ﬁrst and second chromagen and any
counterstain must all contrast sufﬁciently with each other to
ensure accurate identiﬁcation. This was achieved using a brown
chromagen, ImmPACT DAB, to visualise cytokeratin 7, a purple
chromagen Vector VIP for Ki-67 and a methyl green nuclear
counterstain (Vector Labs, UK). Sections were initially over-stained
with ImmPACT DAB to ensure crisp and localised staining of cyto-
trophoblasts following immersion in antigen retrieval solution;
conditions were optimized to those comparable to single stains in
5 mm sections. Since most of the purple chromagen, Vector VIP, was
lost due to its instability at high temperatures, it was used to
visualise Ki-67. Importantly, the high sensitivity of the ImmPRESS
polymer reporter enzyme kit gave superior staining to the routinely
Table 1
Stereological estimates of the total number of Ki-67 positive cytotrophoblast nuclei
in the term placenta.
Parameter (n¼ 5)
Numerical density of CT cells (mm3) 1.5 104 1.0 105
Numerical density of Ki-67 positive CT nuclei (mm3) 4.3 105 5.7 106
Total placental volume (cm3) 562 38
Total no. CT cells 8.6 1010 1.1 1010
Total no. Ki-67 positive CT nuclei 2.5 1010 4.6 109
% of Ki-67 positive CT nuclei 28.4 3.1
Data presented as the mean  SEM. CT, cytotrophoblast.
K. Widdows et al. / Placenta 30 (2009) 735–738738used avidin–biotin systemwhich was unable to withstand the high
temperature antigen retrieval required for Ki-67 (staining not
shown), and consequently staining was lost for both ImmPACT DAB
and Vector VIP. Whilst the increased sensitivity of the polymer kit
reduced antibody concentration and hence cost, it increased non-
speciﬁc background stainingwhichwasminimised using a high salt
wash buffer displaying no deleterious effect on the stability of the
antibodies or their chromagens.
Although the optical brick technique is far more efﬁcient in
terms of time and cost compared to the physical disector, bias
(inaccuracy) may be introduced into the ﬁnal stereological esti-
mate through tissue deformation of thick sections (shrinkage or
expansion for example by high temperature antigen retrieval),
especially when parafﬁn embedded. Correcting for tissue defor-
mation (Dolph-Petersen et al. [16] provide a detailed review on
estimating tissue deformation) however, is not always necessary
providing deformation is homogenous, (and comparable within
and between groups of placentas), since the cardinality of nuclei
will be preserved. Since the present aim was to assess the appli-
cability of the double-labelling technique for use in cytotropho-
blast number estimation using stereological analysis, the
comparative data shown in Table 1 was not corrected for tissue
deformation.
The ability to quantify both the total number of proliferating
(Ki-67 positive) and non-proliferating villous cytotrophoblast in
the human placenta has signiﬁcant potential for advancing future
stereological studies of trophoblast turnover and kinetics, since
alterations of which are hypothesised to underpin placental insuf-
ﬁciency syndromes of severe pre-eclampsia and IUGR [17].
However, it is acknowledged that Ki-67 identiﬁes all cycling cells
withholding the potential to divide [18], and that additional phase
labelling indices (e.g. BrdU for S phase and mitotic counts for M
phase) should be considered (in combinationwith CK 7) to quantify
the actual growth fraction of villous cytotrophoblast cells. In future
studies it will therefore be possible to address whether a steady
state exists between proliferation and fusion of villous cyto-
trophoblasts into the overlying syncytium; the dual immuno-
stereological approach will potentially allow the quantiﬁcation of
different villous cytotrophoblast phenotypes.
In summary, the development of this novel double-labelling
protocol provides a technical advance in the ﬁeld of stereological
analysis permitting the unbiased quantiﬁcation of the total number
of proliferating villous cytotrophoblast cells in the human placentausing the optical brick technique, thereby facilitating future
morphometric studies of the pathological placenta.Acknowledgment
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